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Abstract 
Recessive dystrophic epidermolysis bullosa (RDEB) is a debilitating genetic cutaneous 
blistering condition caused by loss-of-function mutations in COL7A1, encoding type VII 
collagen (C7), central in anchoring fibril (AF) formation at the dermal-epidermal junction 
(DEJ). Presently no curative treatments exist for RDEB. Reconstitution of COL7A1 expression 
in autologous primary keratinocytes (KC) and fibroblasts (FB) by ex vivo gene therapy was 
hypothesised to restore C7 expression and AF construction at the DEJ and ameliorate the RDEB 
skin phenotype.  
Feasibility of this approach was demonstrated using a therapeutic grade, self-inactivating-
lentiviral vector, encoding codon-optimised COL7A1 (LV-COL7) to transduce primary RDEB 
KCs and FBs. Expression and secretion of full-length de novo C7 was confirmed, with 
transduced cells exhibiting supranormal levels of protein expression and functional recovery in 
in vitro migration assays. A human:murine chimeric preclinical RDEB skin graft model was 
developed to assess functional correction mediated by the transduced cells in vivo. RDEB grafts 
lacking C7 expression exhibited severe blistering recapitulating the disease phenotype. Gene-
modified grafts, showed C7 deposition at the DEJ, with re-establishment of basement 
membrane zone integrity. Functional correction was confirmed by an abundance of de novo 
synthesised AF structures throughout the DEJ securing dermal-epidermal attachment. Gene-
corrected FBs were shown to mediate a superior therapeutic benefit. 
In addition, an alternative strategy was developed using zinc finger nucleases (ZFN) for the 
targeted editing of COL7A1 and site-specific restoration of endogenous C7 expression. 
Incorporation of ZFNs into non-integrating lentiviral vectors (NILV) resulted in a marked 
improvement of their cleavage activity. ZFN-mediated disruption of COL7A1 in KCs confirmed 
at both genomic and protein level initially enabled the in vitro modelling of RDEB, with 
observed regression of migration speeds. A dsDNA donor repair template was designed and 
codon optimised for co-delivery with the ZFNs. Sequencing across the ZFN binding site 
confirmed site-specific template insertion by targeted homologous recombination.  
In conclusion, gene correction of primary RDEB cells by LV-COL7 can mediate restoration of 
protein and structural defects in an RDEB model forming the proposal for therapeutic 
application in man. Furthermore, development of an alternative site-specific targeting strategy 
for correction of COL7A1 provides a promising insight into the realm of patient-tailored 
therapy.  
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Chapter 1  Introduction 
1.1  Epidermolysis bullosa: overview and classification 
Epidermolysis bullosa (EB), first described by Koebner H. et al in 1886 (Köbner, 1886) 
constitutes a clinically and genetically heterogeneous group of mechanobullous blistering 
disorders of the skin (Uitto et al., 2010), leading to tissue separation either spontaneously or 
following minor friction or trauma. A number of therapeutic approaches have been envisaged 
for the treatment of the disease although none have resulted in a cure with treatment 
predominantly revolving around pain management and palliative wound care.  
Almost eighty years later in 1962, Pearson classified EB into the three main types still used to 
date. According to the distinct ultrastructural level within which blistering occurs in patient 
skin, EB can be categorised as epidermolytic (simplex), lucidolytic (junctional) and dermolytic 
(dystrophic) EB with a fourth subtype recently added in 2008, Kindler syndrome (KS), carrying 
a unique clinical phenotype characterised by blistering arising in multiple levels within the skin 
(Pearson, 1962). 
Clinical symptoms are dependent on the type of EB, but predominantly include blistering of the 
skin, dystrophy of the nails and teeth, deformity of the limbs and erosions of the alimentary 
canal. Each of the aforementioned subtypes is further ordered on the basis of its severity; 
ranging from mild topical blistering in EB simplex (EBS) to whole body tissue separation and 
highly aggressive metastatic skin cancer with a low survival rate in dystrophic EB (DEB). At 
the molecular level, a range of genes have been reported to result in deleterious mutations 
carried over in a dominant or recessive inheritance pattern giving rise to dysfunctional proteins, 
the location of which directly corresponds to the position of ultrastructural cleavage (Table 
1.1).  
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Table 1.1 Summary of molecular and clinical features of EB. 
 
Key: AR, Autosomal Recessive; AD, Autosomal Dominant; HD, Hemidesmosome; AF, Anchoring Fibril; 
KC, Keratinocyte; Spl, Splice site mutation; Del, Deletion; NS, Nonsense mutation; MS, Missense 
mutation; Indels insertion/deletion, Gen, generalised; Loc, localised; PA, pyloric atresia; LO, late onset.  
(Construction of summary table based on published data (Fine et al., 1991, Fine et al., 2008, Fine et al., 
2014)). 
  
Type EBS JEB DEB KS 
Major Suprabasal Basal Gen. Loc. DDEB RDEB Gen. 
Subtype Loc. Gen. severe 
Gen. 
intermediate 
Severe, 
intermediate, PA, 
LO 
Inversa Gen. 
Gen. severe 
Gen. 
intermediate 
Loc. 
Gen.other 
 
Mode of 
inheritance AR, AD AR AD AR AR 
Onset Birth (some cases 12-18months) Birth Birth Birth 
Clinical 
features 
Blisters/erosions/crusts, nail 
dystrophy, keratoderma, mechanical 
fragility, oral cavity erosions, 
occasional growth retardation 
Blisters/erosions/crusts, 
dystrophic nails (may be 
absent) scarring, 
atrophy,exuberant granulation 
tissue, scarring alopecia, 
mechanical fragility, oral 
cavity erosions, mild 
scarring/microstomia/ankylogl
osia, dental abnormalities, 
defective enamel, cases of 
growth retardation, severe 
anaemia, gastrointestinal tract 
involvement 
Blisters/erosions/crusts, 
dystrophic nails (may be absent), 
milia scarring, atrophy, scarring 
alopecia (RDEB),, mechanical 
fragility, oral cavity, severe 
erosions/ scarring 
/microstomia/ankyloglosia, 
dental abnormalities, severe 
caries (RDEB), severe of growth 
retardation (RDEB), severe 
anaemia (RDEB), severe acral 
musculoskeletal deformities 
(RDEB), gastrointestinal and 
genitourinary tract involvement, 
ocular keratitis, squamous cell 
carcinoma 
Atrophic scarring, 
dystrophic or 
absent nails, 
granulation tissue, 
keratoderma, 
poikiloderma, 
photosensitivity, 
gingival 
hyperplasia, 
colitis, squamous 
cell carcinoma 
Level of skin 
cleavage Intraepidermal (epidermolytic) 
Intra lamina-lucida (lamina 
lucidolytic) Sub-lamina densa (dermolytic) Mixed 
Ultrastructural 
site of skin 
findings 
Basal layer, above level of HD 
attachment plaque, Basal 
keratinocytes, at interface between 
granular & cornified cell layer 
Lamina lucida Sub- lamina densa Mixed 
Other findings 
Dense, circumscribed clumps of 
keratin filaments, reduced 
integration of keratin filaments with 
HD, absent or reduced keratin 
filaments within basal KC 
Markedly 
reduced or 
absent HD, 
absent sub-
basal dense 
plate 
HDs may 
be normal 
or reduced 
in size & 
number 
Normal or 
decreased 
number of 
AFs, electron 
dense stellate 
bodies within 
basal layer 
Absent or 
rudimentary 
appearing AFs 
(reduced in 
RDEB-O) 
electron dense 
stellate bodies 
within basal 
layer 
Increased 
frequency of 
caries, 
pseudosyndactyly 
Mutational 
analysis 
TGM5, PKP1, 
DSP, ITGA6, 
ITGB4 
KRT5, KRT14, 
PLEC1, DST 
LAMA3, 
LAMB3, 
LAMC2 
LAMA3, 
LAMB3, 
LAMC2, 
COL17A1 
ITGA3, ITGA6, 
ITGB4 
COL7A1 FERMT1 
Types of 
mutations Spl, Del, NS, MS, In-frame Indels MS, NS Ins, Spl NS, Spl 
MS, NS, Del, 
Ins, Spl 
NS, Del, Spl, Ins, 
Indels 
Proteins 
affected 
Keratins 5 & 14, plectin, 
plakophilin-1, desmoplakin, bullous 
pemphigoid antigen-1, a6β4 integrin 
Laminin-332, type XVII 
collagen, a6β4 integrin, 
integrin a3 subunit 
Type VII collagen (C7) 
Fermitin family 
homolog 1 
(kindlin-1) 
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1.2  Structure of the human skin 
The human skin consists of three distinct layers starting from the subcutaneous fatty layer which 
lies below the dermis and ultimately the epidermis. Each of these is composed of distinct cell 
types conferring different properties to the skin (Figure 1.1). The epidermis is the most 
superficial layer acting as a protective barrier against chemical, natural such as UV, physical 
and a wide range of environmental insults while keeping essential body fluids in. The 
epidermis, comprised largely of keratinocytes, is subdivided into five distinct strata. The 
outermost layer is the stratum corneum comprised of terminally differentiated anucleated 
keratinocyte cells, key components of the skin barrier, creating a tough structure acting as a first 
line of defence. Below are the stratum granulosum, spinosum and basale predominantly 
composed of keratinocytes at earlier stages of differentiation. Additional cell populations 
including melanocytes, Langerhans’ cells and Merkel cells are situated amongst the 
keratinocytes and contribute to the functional and protective properties of the epidermis. The 
basal layer is attached to the underlying dermis of connective tissue through the basement 
membrane.  
The dermis consists mainly of fibroblasts and to a lesser extent mast cells and histocytes 
(monocytes/macrophages), and contributes largely towards water retention due to the large 
amount of produced macromolecules (polysaccharides and proteins). The dermis further 
functions as a supporting matrix via the production and association with two types of protein 
fibre, namely elastin and collagen, providing the bulk and tensile strength required (McGrath, 
2008). Below the dermis is the subcutaneous fat layer aiding in the protection and insulation of 
the underlying organs while also facilitating energy retention.  
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Figure 1.1 Schematic of human skin. 
Structure of the epidermis connecting to the underlying dermis at the basement membrane zone before 
interaction with adipose layer. Distinct keratinocyte morphology following differentiation through 5 
strata can be seen while dermis is largely populated by fibroblast cells. 
1.2.1  Human epidermis 
Keratinocytes, as part of their normal growth and differentiation cycle undergo a four-step 
process. Basal keratinocytes forming the deeper-most layer of the epidermis contain a dense 
network of keratin filaments providing intracellular cytoskeletal support. Keratins form the 
largest subgroup of intermediate filament proteins providing structural support to the epidermis 
accounting for up to 85% of the mass of a fully differentiated keratinocyte (Fuchs, 1995). Of the 
approximately 30 identified keratin filaments, 18 of those are expressed in skin. Classed into 
types I, acidic low molecular weight proteins keratins K9-20, and II, basic high molecular 
weight proteins K1-8, based on their keratin chain arrangement and biochemical properties are 
commonly co-expressed as heterodimeric pairs. Their structure is intended to have a 
cytoprotective function on the epithelial cells, which is highlighted by the fact that mutations in 
keratins leading to cytolysis can have detrimental effects on tissue integrity resulting in 
blistering disorders such as EBS. Mitotically active basal keratinocytes, interconnected by 
membrane junctions termed desmosomes, comprise of equal proportions of K5 and partner 
keratin K14 tightly regulating squamous cell differentiation (Nelson and Sun, 1983, Moll et al., 
(palms and soles) 
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1982). By modulating signalling pathways through the interaction with kinases, receptors and 
adaptors (Pallari and Eriksson, 2006) they are able to regulate events involved in protein 
synthesis, cell growth and differentiation (Koch and Roop, 2004, Alam et al., 2011). The levels 
of the K5/K14 pair gradually decresase with progression of keratinocytes to a more 
differentiated state while K1/K10 expression in turn increases with its synthesis only occurring 
in postmitotic keratinocytes (Coulombe et al., 1989). One of the main signals involved in the 
basal to suprabasal switch is coordinated by the Notch signalling pathway with Notch ligands 
DELTA1 and receptors located in the basal and spinous layers, respectively (Blanpain and 
Fuchs, 2009). This in turn leads to two key processes enabling progression of keratinocytes 
through the stages of epidermal stratification, delamination and asymmetric cell division. 
During asymmetric division, two resulting cells are generated, a committed suprabasal daughter 
cell and a proliferative basal cell (Lechler and Fuchs, 2005). Additional secreted factors 
promoting basal cell proliferation also come from the underlying dermal fibroblasts such as 
fibroblasts growth factor-7 (FGF-), FGF-10, insulin-like growth factors, epidermal growth 
factor (EGF) and transforming growth factor- α (TGF-α) (Hsu et al., 2014). 
In the suprabasal or spinous epidermal layers keratinocytes are in a postmitotic state although 
remain metabolically active producing K1/K10 cytoskeletal filaments and aggregating the 
cytokeratins together to form tonofibrils, mediating the development of desmosomes. Initiation 
of involucrin production, a substrate for transglutaminase-mediated enzymatic crosslinking, is 
additionally carried out within the spinous layer which will assist in the release of lipids in the 
intercellular spaces during later stages of differentiation (Rice and Green, 1979, Carroll et al., 
1993). 
Production of keratins ceases in the further differentiated granular layer where keratinocytes 
now switch to the production of filaggrin and loricrin, essential for epidermal homeostasis 
regulation. Keratohyalin granules within the granular layer contain the precursor of filaggrin, 
profilaggrin, which following proteolytic cleavage can assist in water retention and skin barrier 
function. Loricrin is produced for subsequent use by the terminally differentiated corneocytes 
aiding in their interconnection for the formation of a strong skin barrier. Keratin filaments also 
undergo reorganisation with dense packing to survive the subsequent lytic stage of the 
keratinocytes. Epidermal differentiation and development of distinct strata is additionally 
regulated by a calcium gradient which increases throughout the basal and spinous layers 
reaching a maximum in the granular layer. Calcium concentrations can induce terminal 
differentiation, resulting in metabolically inactive, flattened and anucleated cellular 
cytoskeletons known as squames comprising the stratum corneum, which will eventually be 
sloughed (Elias et al., 2002). This 10-20 µm thick layer forms the outermost protective barrier 
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of the skin often compared to a “brick and mortar” structure with high water impermeability 
achieved by the accumulation of lipid molecules secreted from exocytosis of lamellar bodies 
and the arrangement of the dead cells (Denda et al., 1994, Potts and Francoeur, 1991).  
Epidermal stem cells are crucial for the maintenance of tissue homeostasis for the continual 
self-renewal, turnover and repair following injury of the epithelial tissue. The typical turnover 
rate of keratinocytes is around 2 to 3 weeks for their progression from the basal to the cornified 
layer. Epithelial stem cells can be located in the outer sheath region of the hair follicle also 
known as the bulge, considered the deepest and most protected area of the skin. This specialised 
portion of the hair follicle, also termed a stem cell niche, provides the balanced 
microenvironment required to support stem cell maintenance and differentiation. The abundance 
of hair follicles on the body and therefore stem cell-containing bulge regions demonstrates the 
magnitude of the skin’s regeneration capacity.  
Their close proximity to sebaceous glands also allows for their migration upwards for 
differentiation into sebocytes, besides their downward migration for renewal of the hair follicle 
itself, facilitating the passing of hair through the follicles by the oils released. Generation of 
new hair is carried out by a subset of differentiated stem cells with a finite number of divisions, 
the transit-amplifying cells. The bulge cells will also periodically migrate to the basal epidermal 
layer thereby populating the region with transient amplifying cells. However bulge stem cells 
are not involved in normal maintenance of the epidermis, and will transiently contribute to 
interfollicular homeostasis only in injury (Ito et al., 2005). Transformation of oncogenic RAS 
gene in the bulge stem cells, coupled with inactivation of tumour suppressors p53, TGF-β or 
BRCA1 have been linked to development of aggressive squamous cell carcinoma (SCC) 
(Ratushny et al., 2012).  
Other major stem cell niches include the sebaceous gland and the basal interfollicular 
epithelium which as with the bulge derived stem cells can be characterised by the expression of 
K5, K14 and p63 (Blanpain and Fuchs, 2009). Of particular importance to the maintenance of 
epidermal homeostasis are the interfollicular keratinocytes which reside in the rete ridges which 
serve as a protective niche (Jones et al., 1995, Li et al., 1998). The high clonogenic capacity of 
these cells coupled with the ability to propagate them in vitro has allowed for the generation of 
skin grafts which have successfully become commonplace clinical treatment for burn patients 
(Green, 1991).  
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1.2.2  Basement membrane zone 
Located immediately below the epidermis, is a sheet of extracellular matrix (ECM) proteins that 
make up the basement membrane zone (BMZ) (Figure 1.2). Attachment to the BMZ is 
conferred by rivet-like structures in the basal keratinocyte layer known as hemidesmosomes 
(HDs). HDs, which are found on the inner surface of the keratinocyte basal pole, comprise of 
four single-span transmembrane proteins, the 180 kDa bullous-pemphigoid antigen (BPAG2, 
BP180, type XVII collagen), two α6β4 integrin subunits forming the core of the HD junction 
and CD151 protein arranged in a two-plaque structure (Tsuruta et al., 2008). The α6β4 integrin 
in turn interacts with the keratin intermediate filaments consisting of basal K5/K14 through the 
association with two members of the plakin family, plectin and dystonin (230 kDa BPAG1e, 
BP230) at the inner hemidesmosomal plaque (Fine et al., 2008, Shimizu, 1998). Association 
with the keratin cytoskeleton is a unique feature of α6β4 amongst integrins, which would 
typically interact with actin (Jones et al., 1998). In addition to HDs, a separate group of actin 
cytoskeleton-associated matrix adhesion proteins known as focal contacts are also found within 
the BMZ. Although not shown to be as crucial in mediating adhesion as HDs, their involvement 
has been associated with signalling pathways and regulation of cell migration (Tsuruta et al., 
2011).  
Type VII collagen (C7) is one of the main contributors of dermal-epidermal adhesion forming 
“wheat stack” shaped, centrosymmetrically banded semicircular loop structures known as 
anchoring fibrils (AFs), after antiparallel dimerisation of two fibrils at their carboxyl (C)-
terminus. These can be seen extending from their amino (N)-terminus which indirectly bind to 
hemidesmosomal α6β4 integrin via the bridging activity of laminin-332 in the lamina densa 
(Rousselle et al., 1997), where they protrude down to the papillary dermis encircling dermal 
type I and III collagen amongst other fibrous elements before terminating back in the lamina 
densa (Shimizu et al., 1997). 
Failure to generate functional C7 AFs at the DEJ results in the dystrophic form of EB (DEB). 
This can be caused by either missense or splice-site mutations, or small insertions/deletions 
resulting in nonsense or frame shift mutations in COL7A1 (Varki et al., 2007) with over 600 
distinct variants presently described (Human Gene Mutation Database).  
Subjacent to the HD below the basal keratinocyte membrane are the subbasal dense plate, a 40 
nm wide electron-lucent zone termed lamina lucida sparsely populated with laminins and a 
tightly packed electron-dense layer, the lamina densa composed of type IV collagen, laminin-
332, nidogen and perlecan (Adachi et al., 1997). Hemidesmosomal abnormalities with 
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mutations in either of collagen XVII, integrin α6β4 or laminin-332 can lead to blister formation 
in the lamina lucida below the HD, characteristic of JEB.  
One of the major proteins within the BMZ specifically found at the bordering region of lamina 
lucida and lamina densa is laminin-332 (previously known as laminin 5, Kalinin). Laminins 
comprise a family of trimeric glycoproteins with an α-chain, a β-chain and a γ-chain bound 
through disulfide bonds, confering structural integrity within the ECM via integrin and 
syndecan receptor-mediated interaction and binding of cell membrane and ECM molecules. The 
ECM of the BMZ, comprised mostly of laminins but also collagens, fibrin, fibronectin, perlecan 
and nidogen, although originally thought to only act as a supportive matrix with filtering 
properties has now been described extensively for its roles in the regulation of cell growth, 
division, differentiation, migration and apoptosis (Gumbiner, 1996, Aumailley and Smyth, 
1998). Approximately 15 different laminin isoforms have been discovered in the ECM with 
laminins-332 and -511 being specific to the BMZ (Miner and Yurchenco, 2004).  
Laminin-332 (containing α3, β3and γ2 chains) encoded for by gene LAMA3, LAMB3, LAMC2, 
in particular is known to interact with α6β4 and α3β1 integrins in HDs and focal contacts, 
respectively, and with thin anchoring filaments composed of type IV and type XVII collagen 
traversing the basal lamina. Upon secretion, laminin-332 is subjected to extensive proteolysis 
with specific cleavage of its subunits, each in turn acquiring binding, processing or regulatory 
properties. Both N-terminus of β3 and with lower affinity γ2 subunits of laminin-332 have been 
reported to directly interact with the N-terminus of type VII AFs (Chen et al., 1999, Tsuruta et 
al., 2008). It is widely accepted that dysregulation of laminin-332 directly correlates with 
progression to tumour formation through modulation of cell adhesion and migration. A recent 
report has described the development of SCC tumourigenesis through the support and signaling 
of laminin-332 and C7 (Waterman et al., 2007). Specifically, the individual VIII domain of the 
β3 subunit was shown to promote tumour progression following binding to C7 resulting in 
activation and upregulation of phosphoinositol-3-kinase (PI3K) thereby protecting the cell from 
apoptosis.  
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Figure 1.2 Basement membrane zone. 
Protein interactions within the basement membrane zone. Hemidesmosome (HD) structure at the basal 
pole of the keratinocyte attached to lamina lucida and densa region of the BMZ mediated by keratin 5/14 
and α6β4 integrin interaction. Adhesion to underlying papillary dermis conferred by non-collagenous 
(NC-1) domain of C7 interaction to laminin-332 and type IV collagen looping around interstitial 
collagens type I and III.  
1.2.3  Human dermis 
Located below all layers of the tightly packed epidermis and the BMZ is the dermis divided into 
two morphologically distinct regions, the uppermost papillary and lower, reticular, dermis. The 
two are distinguished by the arrangement and density of collagen fibres with a sparser 
distribution within the superficial papillary dermis. The dermis provides the skin with its tensile 
strength and flexibility while being home to a vast number of sweat glands, sebaceous glands, 
nerve endings, hair follicles and blood vessels providing nutrients to both dermis and epidermis. 
The dermis is populated by three main cell types, namely fibroblasts, macrophages and 
adipocytes, playing a crucial role in the synthesis of dermal proteins which provide the 
structural framework, phagocytosis of cellular and pathogenic debris and energy storage. Within 
the papillary region, finger like projections known as dermal papillae act to increase the contact 
surface area with the epidermis and in addition contain receptors sensitive to touch and pressure 
termed Meissner corpuscles amongst others signalling temperature, pain and itching. The 
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reticular region of the dermis is predominantly comprised of bundles of collagen and elastic 
fibres interspaced with sebaceous glands, sweat glands, blood vessels and hair follicles. Dermis 
contains glycosaminoglycans and specifically hyaluronic acid provides the dermis with its water 
retention properties maintaining the correct hydration and salt balance to the skin (Waller and 
Maibach, 2006).  
The collagen bundle fibres of the dermis comprise of type I and III collagen and to a lesser 
extent type V as well as fibril-associated collagens with interrupted triple helices (FACIT) 
collagens, types XII, XIV, XVI and VI which do not aggregate to form fibrils but can instead 
bind the surface of type I and III collagen (Ruggiero et al., 2005). Type III is crucial in the early 
developmental stages of the skin and colocalises with the most abundant collagen, type I 
although the ratio shifts during adolescence to a higher proportion of type I collagen (Cuttle et 
al., 2005). Their organisation is tightly regulated and can be arranged in both perpendicular and 
horizontal fashion.  
1.3  Molecular characterisation of Epidermolysis Bullosa subtypes  
Abnormalities in a number of proteins of the epidermis, BMZ and dermis can have a 
detrimental effect on the integrity of the skin structure resulting in tissue separation. Protein 
anomalies within the skin clinically manifest with epidermal blistering ranging from mild to 
life-threatening whole body tissue separation. The tendency is for the blistering severity to be 
augmented the deeper the cleavage occurs within the dermal-epidermal region. Out of the 
numerous skin diseases known, EB constitutes the largest heterogeneous group of incurable 
severe skin blistering disorders differentiated based on the level of cleavage within the skin 
(Figure 1.3). 
1.3.1  Simplex EB 
Epidermolysis bullosa simplex (EBS) is the most frequent type of EB characterised by fragility 
of the skin, leading to non-scarring blisters due to injury of the skin surface. The prevalence is 
about 1:17,000 in the UK. It is an autosomal dominant skin disease caused by mutations in 
keratin-5 and -14, resulting in the disruption of the intermediate filament network above the 
DEJ (Bolling et al., 2011, Rugg et al., 2007, Yasukawa et al., 2006). Its phenotype is 
predominantly mild with erosions confined to the hands and feet but in rare cases it may be fatal 
(Bruckner et al., 2011, Pfendner and Bruckner, 1993). 
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1.3.2  Junctional EB 
Two main types make up the junctional form of EB (JEB); generalised severe (lethal) and 
generalised (non-lethal) previously known as Herlitz and non-Herlitz, respectively. They differ 
in severity but share common genetic mutations. The onset of generalised severe JEB is at birth 
with blistering covering most of the body and mucosal membranes, leading to not only 
malnutrition due to irritation of the buccal cavity and digestive track but also scaring and in 
severe cases fusion of affected limbs. This disorder manifests at the level of the basal 
keratinocytes or HDs where separation of the basement membrane of the epidermis within the 
lamina lucida occurs. The two types differ in the extent of damage caused by a reduction of 
HDs and anchoring filaments, or their complete absence in lethal cases. JEB carries an 
autosomal recessive inheritance pattern and has been most commonly associated with mutations 
in four genes. LAMB3 mutations account for up to 70% of the cases, and to a lesser extent 
COL17A1, LAMC2 and LAMA3 (Aumailley et al., 2005, Varki et al., 2006). With the exception 
of the COL17A1 encoded protein collagen XVII which forms one of the structural components 
by interacting with α6β4 integrin to make up HDs (Charlesworth et al., 2003), the 
aforementioned genes encode proteins integral to the assembly of the laminin-332 heterotrimer, 
essential for the association of the epidermal to the dermal layer offering strength and stability 
to the structure (Aumailley et al., 2005). 
1.3.3  Kindler syndrome 
A more recently recognised EB subtype sometimes considered a distinct type of EB due to the 
variability in the location of blistering within the BMZ is Kindler syndrome. This rare 
autosomal recessive blistering disorder with only 250 cases reported arises from premature 
termination of translation of kindlin-1 protein caused by mutations in the FERMT1 gene 
(Jobard et al., 2003). Expression of kindlin-1 is localised to basal epidermal keratinocytes where 
it functions as a focal adhesion adaptor protein. Loss of the protein leads to disorganisation of 
keratinocytes affecting cytoskeletal architecture and anchoring to β1 integrin (Has et al., 2011). 
The disease is associated with epithelial microblister formation and soft tissue scarring, 
pigmentation anomalies (poikiloderma), photosensitivity and predisposition to epithelial skin 
carcinoma during the later stages of life (Bruckner-Tuderman and Has, 2014).  
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1.4  Dystrophic EB 
Dystrophic EB encompasses the most severe forms of cutaneous blistering disorders with a high 
mortality rate in the early years of life with no effective treatment currently available. It has 
been estimated to affect 6 per 1,000,000 patients worldwide with ~800 reported cases in the UK 
(Pfendner and Lucky, 1993a, Horn et al., 1997, McKenna et al., 1992). Patients suffering from 
DEB are challenged by lifelong skin fragility, susceptibility to shearing upon minimal friction 
and reduced epidermal barrier function resulting in vulnerability to mucosal membrane 
infections (Fine et al., 2008). Associated complications can present themselves in the form of 
joint contractures and growth retardation or more destructive outcomes such as mutilating 
scarring deformities of the limbs and life threatening skin carcinomas (Bruckner-Tuderman, 
2009, Burgeson, 1993, Fritsch et al., 2008, Kadler et al., 2007). 
 
 
Figure 1.3 Tissue cleavage sites in EB subtypes. 
Level of tissue cleavage by the three main types of Epidermolysis Bullosa (Simplex, Junctional, 
Dystrophic) and their key corresponding affected proteins.  
 
Dystrophic EB is subdivided into two types according to the current classification system based 
on its inheritance pattern. These can be either dominant (DDEB) or recessive dystrophic 
epidermolysis bullosa (RDEB). RDEB is further divided into several subtypes including severe 
generalised, (RDEB sev-gen), previously referred to as Hallopeau-Siemens type (RDEB-HS), 
generalized other (RDEB-O) (or non-Hallopeau-Siemens RDEB-non-HS), generalised 
intermediate and localised. The level of tissue cleavage in all major types and subtypes of DEB 
is identical, localised to the lamina densa of the DEJ. DDEB is the mildest of the dystrophic 
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types with blistering confined predominantly to the hands, elbows, knees and feet with 
relatively fast healing time but with significant scarring. RDEB-O shares common clinical 
manifestations with DDEB but affected areas can also include the trunk. RDEB-sev gen, on the 
other hand, is placed at the top of the severity scale associated with the demise of the individual 
by the third to fourth decade of life. It manifests in severe blistering affecting the whole skin 
surface of the body and further spreads to the ocular, nasal, oropharyngeal, gastrointestinal, 
genitourinary and musculoskeletal systems (Fine et al., 1991) with fusion of the tongue to the 
floor of the mouth, erosions of internal organ lining and mutilating scarring of the limbs causing 
fusion of fingers and toes known as “mitten” hand and feet deformity, a hallmark of this 
disorder (Pfendner and Lucky, 1993a). Dystrophic EB patients account for approximately 25% 
of all EB sufferers. Patients suffering from the recessive form of this disorder have been 
associated with a 70% chance of developing SCC by the age of 45 with a subsequent mortality 
rate of 90% (Ayman et al., 2002, Fine et al., 2009, Pfendner and Lucky, 1993a). 
The gene responsible for all three types of DEB is COL7A1 encoding the protein type VII 
collagen, alpha 1. It plays a critical role in the association of the epidermal layer to the 
underlying dermis by functioning as an AF between the external epithelia and the underlying 
stroma. To date, over 600 mutations including missense, nonsense, splicing, small insertions or 
deletions in the COL7A1 gene have been reported (Varki et al., 2007) (Figure 1.4). 
 
Figure 1.4 Proportion of mutations in COL7A1 gene. 
Frequency of mutation types reported at each exon of the COL7A1 gene with commonly found mutations 
in the UK marked by dotted line.  
  
 
33 
1.5  Type VII collagen 
Since its discovery in 1983 by Bentz et al. the COL7A1 gene has been extensively studied due 
to its direct correlation with DEB (Bentz et al., 1983).  
Chromosomal mapping of the human type VII collagen gene (COL7A1) was carried out  and 
was found to be at locus 3p21 in the short arm of chromosome 3 (Parente et al., 1991). The gene 
contains 9,287 base pairs and has 10 splice variants (Ensembl). It codes for 2,944 amino acids 
(a.a.) spanning over 118 exons, the largest number of exons in a single gene at the time of its 
discovery, but with relatively small intervening introns resulting in a moderately compact gene 
(Christiano et al., 1994b). At the amino acid level, the mouse C7 polypeptide exhibits 84.7% 
homology in the nucleotide sequence and 90.4% identity at the protein level when compared to 
human (Kivirikko et al., 1996).  
The protein product of the gene is C7 measuring at 295 kDa and is the main constituent of AFs 
securing the association of the epidermis to the underlying dermis. C7 is produced and secreted 
almost exclusively by basal keratinocytes and dermal fibroblasts, albeit at much lower 
abundance from the latter (Parente et al., 1991). The presence of this protein has also been 
detected by immunofluorescence in foreskin, placenta, skeletal muscles, chorioamnion, cornea, 
oral mucosa, cervix, kidney cortex, liver, lung, stomach, elastic cartilage and large intestine 
(Sakai et al., 1986). 
Type VII collagen along with type IV collagen belongs to the group of non-fibrillar collagens 
and is characterised by its heterogeneous supramolecular organisation (Christiano et al., 1994b). 
It is encoded by the COL7A1 gene, which features a large triple helical collagenous domain 
flanked by two non-collagenous domains on either terminus giving rise to monomeric 
polypeptide pro-α1 (VII) chains, the building blocks for the generation of functional AFs 
(Figure 1.5). 
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Figure 1.5 Schematic representation of the structural organisation of the type VII collagen pro-
α1(VII) polypeptide exons.  
The N terminus of the amino acid sequence codes for a 5’ UTR signal peptide which is followed by a 
non-collagenous domain (NC-1) spanning across 26 exons, approximately 145 kDa in size, and consisting 
of sub domains with homology to known adhesive molecules. These are a cartilage matrix protein (CMP) 
like domain, followed by nine consecutive fibronectin type III modules, a von Willebrand factor A 
domain and a cysteine, proline rich region. The triple–helical domain (84 exons) flanked by the two non-
collagenous regions is made up of Gly-X-Y repeats with a large 39 a.a. interruption forming a 
collagenous hinge region susceptible to proteolytic digestion with pepsin. The polypeptide ends with the 
second non-collagenous domain (NC-2) made up of seven exons and about 30 kDa in size containing a 
segment resembling the Kunitz protease inhibitor molecule. 
1.5.1  Non – Collagenous domain 1 (NC-1) 
The amino terminus of the pro-α1 (VII) chain initiates with the 5’ untranslated region (U) signal 
peptide and predicted signal peptidase cleavage site encoded by the first of 118 exons 
(Christiano et al., 1992, Christiano et al., 1994b).  
Exons 2-5 residing at the amino terminal of the non-collagenous domain 1 central region, were 
sequenced to reveal that the 85 amino acids shared a 38.8% homology with cartilage matrix 
protein. The major segment making up the NC-1 is comprised of nine consecutive repeat 
sequences. These submodules exhibit features of adhesive proteins which were verified by 
sequencing, displaying a 23.2% homology to fibronectin type III domains (FNIII) (Christiano et 
al., 1992). Each fibronectin type III like submodule is approximately 90 amino acids in size and 
encoded by two separate exons, which has also been characterised in other genes (Christiano et 
al., 1992). This includes the FNIII-like repeats in the a13 chain of VI and the a1 chain of XII 
collagen (Christiano et al., 1992, Chu et al., 1990). 
This is followed by a 123 amino acid segment encoded by three separate exons, found to be 
homologous to the A domains of von Willebrand factor (21.1%) (Christiano et al., 1992). These 
type-A-like motifs have been thought to be involved in its binding to collagen and platelet 
glycoprotein 1B (Mohri et al., 1989). 
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The final two exons of NC-1, 27 and 28, encode a cysteine, proline rich domain, 173 and 36 bp 
in size making up the 85 amino acid segment which has yet to be described in other protein 
sequences (Christiano et al., 1994b, Christiano et al., 1992). 
1.5.2  Triple helical domain  
The 1530 amino acid central segment of the pro-α1 (VII) makes up the collagenous triple 
helical domain consisting of numerous repeats of Gly-X-Y although including a number of 
interruptions within the amino acid sequence. Although it would be possible to have more than 
400 combinations of Gly-X-Y triplets, it appears that only a limited number of them occur with 
many of them never observed (Ramshaw et al., 1998). 
The most frequent combination found in the coding sequence is Gly – Proline – Hydroxylisine 
or Hydroxproline (Hyp), derived from posttranslational modification of Pro and Lys, which 
provides maximal stability to the triple-helical structure (Jones and Miller, 1991). The main 
factors providing the support to the helix are the close packing of the triple chain which is held 
together by hydrogen bonds combined with the high content of the imino acids Pro and Hyp 
(Ramshaw et al., 1998). Within the helix, each of the amino acids making up the triplet retains a 
distinct position with glycine securely buried avoiding contact with solvent, whereas residues Y 
and predominantly X being highly exposed to solvents (Jones and Miller, 1991, Ramshaw et al., 
1998). Usually, when residues X and Y are not occupied by imino acids which confer stability 
to the helix, but with a combination of the 20 standard amino acids, they have been shown to be 
involved in binding to other collagen molecules forming fibrils or other ECM molecules and 
may also play a role in recognition (Ramshaw et al., 1998). 
Most of the exons making up the uninterrupted regions of the triple helix were found to contain 
base pairs in numbers of multiples of nine, which is the required size to encode the stable amino 
acid triplet Gly-X-Y (Christiano et al., 1992) some of which are commonly found in the triple 
helix coding regions of fibrillar collagen and not usually associated with non-fibrillar collagen 
genes (Vuorio and de Crombrugghe, 1990). 
It has further been shown that the 19 interruptions, typical in non-fibrillar collagens, which may 
be due to insertions or deletions of the amino acid in the Gly-X-Y repeat sequence in the 
majority of cases correspond to exons which are not multiples of 9 bp (Chung and Uitto, 2010, 
Uitto et al., 2010). Eleven of these interruptions were caused by small 1 to 2 amino acid 
imperfections, while a further seven were due to insertions of up to 10 amino acids. The largest 
non-triple helical interruption in the collagenous sequence is 39 amino acid residues in length 
and located approximately at the centre of the domain, termed the hinge region, contributing 
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towards the flexibility of the protein structure. Its sequence reveals its distribution across three 
separate exons and its susceptibility to proteolytic cleavage by pepsin (Christiano et al., 1994a). 
The COL7A1 triple helix region exhibits further similarity in its pattern to fibrillar collagen 
genes as none of the codons in the coding region are split by introns as opposed to what is 
commonly observed in non-fibrillar collagens where the exons begin and end with split codons 
even in exons encoding uninterrupted Gly-X-Y repeats (Christiano et al., 1994b, Vuorio and de 
Crombrugghe, 1990).  
1.5.3  Non – Collagenous Domain 2 (NC-2) 
The carboxyl terminal of the pro-α1 (VII) chain ends with a second, much smaller in size non-
collagenous domain NC-2. It is perceived that upon secretion, this domain is responsible for the 
associations of the homotrimeric monomer into antiparallel dimers. This is then followed by the 
proteolytic removal of the NC-2 regions, which assists in stabilising the dimers by the formation 
of disulfide bonds (Greenspan, 1993, Rattenholl et al., 2002). The enzyme shown to be 
responsible for the cleavage of NC-2 is procollagen C-proteinase/BMP-12 (PCP) although the 
reason behind this processing is not known (Colombo et al., 2003, Rattenholl et al., 2002).  
The 30 kDa non-collagenous domain is distributed over seven exons, the first one being a fusion 
or junctional exon of the collagenous and NC-2 domains (Greenspan, 1993, Christiano et al., 
1994b). A cysteine residue Cys-2634 residing in the triple-helical domain closest to NC-2 has 
been suggested to interact with the first Cys-2802 or second cysteine Cys-2804 within the NC-2 
sequence forming intermolecular disulfide bonds stabilising the 60 nm overlap region observed 
in the anti-parallel dimer formation (Morris et al., 1986, Christiano et al., 1994a, Colombo et al., 
2003).  
The remaining exons together form a conserved motif which appears to be homologous to 
Kunitz-type serine protease inhibitors (Greenspan, 1993). This is thought to be responsible for 
directing the formation of pro-α1 (VII) dimers or possibly be involved in the regulation of the 
cleavage of NC-2, post dimerisation (Lunstrum et al., 1987). 
1.5.4  Organisation into anchoring fibrils (AFs) 
Three identical pro-α1(VII) chains associate through their carboxy-terminal ends and their 
collagenous domains, resulting in a homotrimer with a characteristic triple-helical 
conformation. Upon secretion into the extracellular space, newly synthesised homotrimers, 
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known as procollagens, assemble into 785 nm anti-parallel dimers through a 60 nm overlap of 
their carboxy-terminal sequences (Burgeson et al., 1990). Proteolytic cleavage at the C-terminus 
region where the triple-helical domain meets the NC-2 domain promotes the stabilisation of the 
dimer by intermolecular disulfide bonds, which further offers protection against collagenase 
digestion (Bachinger et al., 1990). This is followed by the highly organised lateral aggregation 
of multiple dimer molecules to form cross-striated, centro-symetric banded AF structures, 
containing large globular NC-1 domains at both ends of the structure (Bachinger et al., 1990, 
Villone et al., 2008) (Figure 1.6).  
 
Figure 1.6 Organisation of type VII collagen into anchoring fibrils.  
Three monomeric polypeptide chains of type VII α1 procollagen assemble into a triple helix. Antiparallel 
dimer formation by proteolytic cleavage of NC-2 domain of homotrimers. Lateral aggregation of mature 
dimers into AFs. (Schematic adapted from (Bruckner-Tuderman, 2009)). 
 
Type VII collagen is the major if not exclusive component of AFs (Sakai et al., 1986). They are 
specialised fibrous structures crucial to the preservation of the structural integrity of skin 
securing the connection between the epidermis and the underlying dermis at the BMZ. These 
can be seen extending from their amino (N)-terminus of the NC-1 homotrimer portion where it 
interacts with macromolecular components of the BMZ and indirectly binds to 
hemidesmosomal α6β4 integrin via the bridging activity of laminin-332 in the lamina densa 
(Rousselle et al., 1997, Villone et al., 2008). It was originally proposed that the opposite end of 
the dimer binds to basement membrane-like patches within the papillary dermis, termed 
anchoring plaques, also containing type IV collagen and laminin-332 therefore securing the 
lamina densa to the underlying connective tissue matrix (Uitto and Christiano, 1992). Rotary-
shadowed imaging has revealed the “trident” structure of the three NC-1 domain arms, 
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maximising the interactions of the AFs with the constituents of the lamina densa (Burgeson et 
al., 1990). 
More recent studies have described the existence of a second and possibly sole manner of 
attachment, whereby the AF heterodimers protrude down into the papillary dermis forming U-
shaped looped structures with both NC-1 ends inserted into the lamina densa resulting in 
physical entrapment of separate components of the dermal connective tissue, chiefly being type 
I and III collagen fibrils amongst other fibrous elements (Uitto et al., 1992, Uitto and 
Christiano, 1992, Villone et al., 2008).  
The flexibility of the AFs is believed to be due to the highly conserved discontinuities within 
the repeating Gly-X-Y sequence of each pro-α1 (VII) chain (Christiano et al., 1994a). 
Mutations in COL7A1 can cause abnormal or loss of function of C7 protein, leading to a 
reduced number, rudimentary structure, or entire absence of AFs at the DEJ, and morphological 
alteration of the skin (Dang and Murrell, 2008).  
Routine diagnosis for the distinction of the type of DEB involves transmission electron 
microscopy (TEM) of skin biopsy at birth and full sequence analysis of the gene. In suspected 
cases of DDEB sequencing is primarily limited to exons 73, 74 and 75 which have been linked 
to 75% of cases with full exome sequencing implemented if no mutation is identified. In RDEB, 
there is no such restriction as mutations could occur in any of the 118 exons always requiring 
the use of full exome sequencing, although there have been reports of hot-spot mutations in 
different ethnic groups (Murata et al., 2004). 
1.5.5  Type VII collagen involvement in SCC progression  
It has been well documented that the propensity of developing SCC above the age of 30 is 
substantially elevated in RDEB patients as opposed to those affected by other forms of EB with 
a mortality rate of 55% to as high as 80% in severe-generalised RDEB (Fine and Mellerio, 
2009, Fine et al., 2009). One of the explanations for SCC development has been the persistent 
wounding and scarring suffered by these patients, which can deplete basal stem cell progenitors 
and stimulate a pre-malignant microenvironment (Smoller et al., 1990, Goldberg et al., 1988). 
Additional factors affecting cell cycle regulation such as mutated p53, reduced expression of 
insulin growth factor-binding protein 3 and elevated matrix metalloproteinase (MMP-7) 
expression have been linked to SCC in RDEB patients (Martins et al., 2009).  
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Over the past decade there has been considerable interest in the elucidation of the involvement 
of C7 expression, or lack of, in the progression to SCC. It was originally postulated that the 
greater the disease severity and therefore the lower amounts of C7 present, the higher the risk of 
SCC development (Martins et al., 2009, Pourreyron et al., 2007). This hypothesis was 
questioned by evidence from RDEB patient keratinocytes assessed on a murine skin model, 
suggesting the requirement of the NC-1 domain of C7 for downstream activation of Ras-driven 
tumourigenesis. This was shown to be linked to the fibronectin-like domains of NC-1 associated 
with laminin-332 promoting cell invasion, whereas entirely absent C7 failed to mount an 
oncogenic response (Ortiz-Urda et al., 2005).  
More recent studies have demonstrated that contrary to Ortiz-Urda et al., patients lacking entire 
C7 expression or the NC-1 domain were still predisposed to malignant transformation. In 
addition, the SCC cases reported were shown to be Ras independent (Pourreyron et al., 2007). 
This observation was further supported by Rodeck et al. obtaining similar findings and Fine et 
al. indicating that dominant-DEB patients carrying an unaffected COL7A1 allele will seldom 
develop SCC (Rodeck and Uitto, 2007, Fine and Mellerio, 2009).  
Further in vitro work has linked C7 to SCC, with its loss resulting in an increase of migration 
and invasion. This was determined to be caused by deregulation of epithelial keratinocyte 
differentiation through upregulation of CXCL10-CXCR3-phopholipase C-β4 (PLC-β4) 
signaling (Martins et al., 2009). Similarly, cancer-associated fibroblasts play a role in cancer 
invasion by providing oncogenic signals, which in a paracrine fashion can promote tumor 
progression in RDEB keratinocytes (Ng et al., 2012).  
1.6  Current therapies for RDEB 
1.6.1  Conventional treatments for RDEB 
The current treatment options for RDEB are based on wound protection and pain management 
through the use of specially designed non-adherent dressings, which are secured with layers of 
gauze and elastic bandaging to provide padding and sturdiness (Kirkorian et al., 2014). The 
sloughing of the epidermis, the regular draining of blister fluid and erosions of the oesophagus 
limiting iron absorption result in a significant drop in haemoglobin levels also lead to the 
development of RDEB-associated chronic anaemia and therefore delay of wound healing. Iron 
and vitamin supplementation, nutritional support, and in severe cases gastrostomy are crucial as 
feeding may be incredibly cumbersome due to blistering along the entirety of the alimentary 
tract. In addition, balloon dilatation enabling the stretching of oesophageal strictures can 
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facilitate the passing of food (Pfendner and Bruckner, 1993, Pfendner and Lucky, 1993a, 
Pfendner and Lucky, 1993b). 
 A huge wealth of research is directed towards developing safer and more effective drug 
treatments to manage symptoms and prevent SCC progression. These include anti-itch, anti-
fibrosis, anti-inflammatory, anti-microbial and wound healing promoting drugs. Recalcitrant 
pruritus poses one of the major challenges in the management of RDEB causing wound 
breakdown and hence cutaneous damage. Coupled with the acute dryness of the skin making the 
wounded area itchy this evokes scratching which contributes to bacterial colonisation. Patients 
are typically treated with antibiotics and antifungals and bathed in low concentration bleach 
solutions to manage pathogenic infections while given antihistamines and moisturisers 
containing benzalkonium chloride and chlorhexidine dihychloride, topical emollients and 
steroids for the reduction of itching and moistening of the skin.  
The economic burden of this debilitating disorder is estimated at around £25 million per year in 
the UK with specialised dressings costing in the range of £250,000 per patient per year 
(www.debra.org.uk). 
RDEB has received a vast amount of interest from the scientific community worldwide with 
generous support from charities attempting to tackle this disorder at the molecular level via a 
wide array of therapeutic approaches. These come in the form of protein, cell and stem cell, and 
gene therapy amongst others, a number of which have displayed encouraging results.  
1.6.2  Replacement therapies for RDEB - recombinant protein therapy 
Protein replacement therapy for RDEB is currently gaining momentum with immediate 
prospects of initiating clinical trials aided by the commercial backing of Shire’s recent 
acquisition of Lotus Tissue repair specialising in the production of recombinant human C7 
protein (rC7). The call for this type of therapy was proposed in order to circumvent the potential 
side effects and safety concerns associated with grafting or injecting localised cell therapies or 
more invasive transplantation procedures in addition to minimising the complexity of 
administration for the clinicians. Since the first successful in vivo study of its kind for RDEB 
initiated in 2004 by Woodley et al. a number of publications have arisen, demonstrating the 
efficacy of recombinant C7 protein in restoring functional expression following intradermal, 
intravenous or topical administration (Remington et al., 2009, Woodley et al., 2004a, Woodley 
et al., 2013, Nystrom et al., 2013). These studies were all performed on mice which were either 
immunocompromised and wounded to assess healing (Woodley et al., 2004a, Woodley et al., 
 
41 
2013) or on RDEB recapitulating murine models expressing either none or 10% C7 at the BMZ 
(Remington et al., 2009, Nystrom et al., 2013). Recombinant human C7 was obtained by 
purification and precipitation of culture media from lentivirally transduced fibroblasts with full-
length COL7A1 cDNA (Woodley et al., 2004a).  
The principal study confirmed the deposition of human C7 in athymic nude mice following 
intradermal injection of 20 µg of rC7 (Woodley et al., 2004a). Expression persisted for 3 
months with an approximate 15% reduction overall. This was followed by intradermal 
injections of rC7 in RDEB skin equivalents grafted on mice further confirming functional 
correction of the disease with amelioration of subepidermal blistering accounted for by the 
assembly of human C7 AFs. Supporting evidence from two recent studies performing 
intradermal rC7 injections into Col7a1-/- null (Remington et al., 2009) or hypomorphic RDEB 
mouse models expressing 10% of wild-type (WT) C7 levels (Nystrom et al., 2013) came to 
similar conclusions demonstrating incorporation of the protein at the mouse DEJ and generation 
of AFs with signs of expression at distal sites from the injection with a significant improvement 
of the RDEB phenotype. An alteration to the protocol was carried out by Remington et al., 
2009, whereby a monomeric type VII procollagen, instead of the 900 kDa trimer, was injected 
which could potentially reduce the efficacy of AFs assembly in vivo.  
Although C7 is known to have a slow turnover (Burgeson, 1993), repeated and multiple site 
administration would be required clinically. It was estimated that an analogous dose in a 4 kg 
infant would be 100 mg of rC7 in 300 ml buffer over multiple time points (Bruckner-Tuderman, 
2009). A subsequent drawback of this therapeutic approach was the activation of an 
immunogenic response by the formation of circulating auto-antibodies against human C7 
(Remington et al., 2009, Woodley et al., 2004a, Woodley et al., 2007a). Although they did not 
appear to bind to the DEJ or prevent the formation of AFs in mice, it is unknown what effect 
they may have in humans as it could trigger the development of autoimmune blistering such as 
that seen in EB acquisita. In mice, treatment with anti-CD40L mAb appeared to impede anti-
human C7 antibodies (Remington et al., 2009).  
The small diffusion radius, most likely a consequence of the large size of C7 hampering its 
diffusion to neighboring wounded sites coupled with the requirement for multiple injections in 
severely affected individuals with whole body blistering, led to the assessment of a systemic 
administration approach. Intravenously injected protein has become commonplace for the 
targeted treatment of lysosomal storage disorders and haemophilia (Desnick and Schuchman, 
2012). A 60 µg dose of rC7 was intravenously injected in the tail veins of wounded 
immunocompromised mice or RDEB grafted models (Woodley et al., 2013). At a 2-week time 
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point post-injection, expression was confirmed at the wounded sites with acceleration of wound 
healing and functional correction of the blistering sustained for 2 months. Challenges such as 
the large size and likely proteolytic degradation of trimeric C7 before recruitment to the 
wounded sites have yet to be resolved.  
Lastly, Wang et al. demonstrated the potential of topical application of rC7 on murine skin 
wounds (Wang et al., 2013). It was shown that 30 µg of protein was sufficient for the 
acceleration of wound closure and re-epithelialisation while showing AFs formation at the DEJ 
for up to 2 months. Moreover, the introduced rC7 resulted in a decrease of fibrogenic TGF-β2 
expression and recruitment α-smooth muscle actin (α-SMA) myofibroblasts and an increase in 
antifibrogenic TGF-β3 expression, resulting in reduced scar formation. Due to the inability of 
rC7 to penetrate intact skin, this approach could only be usefull for deep SCC-type wounds.  
Although protein therapy may have a significant beneficial outcome in patients with the added 
benefit of being applicable to all recipients regardless of the COL7A1 mutation, challenges such 
as the short-lived expression, preparation of sufficient quantities of GMP-grade rC7 and 
potential risks developing an adverse immune response to the protein still remain. Nevertheless, 
a clinical trial is expected to initiate recruiting RDEB patients for the intradermal injection of 
rC7. A separate trial by Shire, aiming to deliver rC7 intravenously based on the encouraging 
murine data was about to commence, but has been put on hold due to severe adverse effects and 
toxicity encountered during testing in larger animal models (no details are available as of yet). 
1.6.3  Cell therapies for RDEB 
1.6.3.1 Epidermal grafting and intradermal administration of allogeneic cells 
The initial response to managing RDEB came in the form of cell therapy, employing techniques 
used for the treatment of burns’ patients. This involved skin grafting procedures using either 
allogeneic (Eisenberg and Llewelyn, 1998, McGrath et al., 1993) or autologous (Verplancke et 
al., 1997, Wollina et al., 2001) cultured keratinocyte skin sheets. The majority of the cases 
though resulted in poor graft take and a high incidence of skin infections.  
Although keratinocytes, being the main contributors of C7 expression would appear to be the 
ideal cell type to be used for treatment, their challenging culturing requirements, finite 
expansion capacity and the requirement for superficial application demonstrate the limits of 
their clinical use for RDEB. The focus has therefore shifted towards the use of dermal 
fibroblasts also known to contribute to C7 deposition at the DEJ. Moreover, their robustness in 
terms of ease of propagation and immunomodulatory capacities, allowing for use of allogeneic 
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cells without the risk of an adverse host immune response, make them a more suitable candidate 
(Haniffa et al., 2007).  
The hypothesis of ameliorating RDEB-associated skin blistering by delivery of allogeneic 
fibroblasts was primarily assessed in a hypomorphic mouse model established in the Bruckner-
Tuderman lab truly recapitulating the disease phenotype while expressing C7 at 10% of normal 
levels (Fritsch et al., 2008). An intradermal injection of WT mouse fibroblasts resulted in 
incorporation of C7 at the DEJ which peaked at 7 days post-injection raising the levels of C7 to 
25%-30% and was sustained throughout a 21-day observation period. A follow-up study from 
the same group was able to report long-term persistence of protein expression of >3 months 
although the cells displayed a gradual apoptotic tendency within the first month while only 
causing mild transitory inflammation (Kern et al., 2009). As the donor cells were derived from 
an EGFP+ transgenic mouse, fibroblasts could be traced confirming their clearance after 28 
days. Moreover, their results confirmed that the C7 expression observed was predominantly 
secreted by the injected fibroblasts and not due to paracrine signaling.  
Subsequent studies in man by Wong et al., 2008, demonstrated the potential of this application, 
as expression of C7 at the DEJ with subsequent improvement of dermal-epidermal blistering at 
the site of injection was achieved and remained stable for 3 months in most cases and 9 months 
in a single case with no observed clinopathological inflammatory response (Nagy et al., 2011). 
Fluorescent in situ hybridisation (FISH) for the detection of donor Y-positive cells in a female 
recipient demonstrated the clearance of the fibroblasts 2 weeks following intradermal injection. 
The limitation of this study was the requirement for the presence of some level of expression at 
the DEJ before therapy as it was ineffective in patients completely lacking C7. The positive 
effect seen was reported to be a result of upregulation of patients’ endogenous C7 stimulated by 
the allogeneic fibroblast injection giving rise to rudimentary AFs, although sufficient to provide 
amelioration of the blistering tendency of the select individuals (Wong et al., 2008). It was 
proposed that either an initial burst of C7 from the introduced fibroblasts or a paracrine effect 
exerted on the patients’ keratinocytes stimulating production of mutant protein may have 
contributed to the partial improvement seen. Indeed, this stimulation of endogenous C7 
expression by patients’ own cells has recently been associated with a heparin EGF-like growth 
factor induced by fibroblast injections, which in turn leads to an increase in expression of the 
AF forming protein predominantly by the keratinocytes (Nagy et al., 2011).  
The potential lack of major contribution to AF formation from the injected fibroblasts was 
further supported by a phase II double-blind randomised controlled trial demonstrating an equal 
increase in wound healing and COL7A1 mRNA expression following intradermal injections of 
both allogeneic fibroblasts and a 2% albumin suspension solution (Venugopal et al., 2013).  
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1.6.3.2 Bone marrow transplantation of allogeneic stem cells 
As RDEB is a systemic disease with patients suffering from total body epithelial and esophageal 
blistering, joint contractures and limb deformities, topical therapies may be considered 
insufficient in providing a cure. For this purpose a large amount of interest is currently focused 
on developing a systemic treatment. Bone marrow transplantation of allogeneic healthy donor 
stem cells can potentially provide a long-lasting curative effect, however limitations such as the 
invasiveness of the operation calling for myeloablative conditioning and stringency of HLA 
tissue typing have to be accounted for. Reports have confirmed the feasibility and success of 
this approach for congenital immunodeficiencies such as X-linked severe combined 
immunodeficiency disorder and X-linked adrenoleukodystrophy amongst others, which have 
considerably progressed the field (Cartier et al., 2009, Gaspar et al., 2011).  
Proof of principle studies carried out in a Col7a1-/- knockout RDEB mouse model, demonstrated 
the potential of a systemic therapy through the infusion of allogeneic BM cells (Tolar et al., 
2009). An enriched population of mouse allogeneic heamatopoietic stem cells positive for the 
signaling lymphocytic activation molecule (SLAM) CD150+ and negative for CD48- when 
delivered intravenously in newborn Col7a1-/- knockout irradiated mice resulted in amelioration 
of blistering and a prolonged life span by a number of weeks in 15% of the animals. These 
effects were only seen following a high dose of 8x106 cells and solely with the enriched cell 
population. Interestingly, administration of allogeneic mesenchymal, epidermal stem cell or 
transient amplifying cells alone were not sufficient for the alteration of the course of the disease.  
This is in contrast to the findings of Fujita et al., 2010, where mesenchymal stem cells (MSCs) 
were shown to migrate to the wounded skin and secrete type XVII collagen or differentiate into 
keratinocytes for the correction of JEB although did not provide a long-term effect (Fujita et al., 
2010). In addition, MSCs were shown to differentiate into type III collagen-producing 
fibroblasts as well as myofibroblasts following stimulation by IL-10 and IL-16 amongst others 
(Alexeev et al., 2011). Locally transplanted allogeneic MSCs into an RDEB Col7a1-/- mouse 
model demonstrated migration to the wounded skin and secretion of functional C7 following 
fibroblastic transition attributed to the environmental cues provided by the recipient dermal 
fibroblasts and ECM (Alexeev et al., 2011).  
A similar result was achieved in man where two RDEB patients were intradermally injected 
with unrelated adult allogeneic MSCs with significant improvement in wound healing after a 
12-week period with reulceration shortly after, probably due to MSC exhaustion (Conget et al., 
2010). The encouraging in vivo mouse data presented by Tolar et al., 2009, led to the first 
RDEB patient total bone marrow transplantation (BMT) studies (Wagner et al., 2010). 
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Allogeneic unfiltered marrow or umbilical-cord blood stem cells from an HLA-matched donor 
were infused into seven children patients following a myeloablative preconditioning regimen. 
An amelioration in blistering and partial restoration of C7 at the DEJ was observed within the 
first 100 days which was more noticeable in patients expressing a low amount of mutant 
rudimentary C7, suggesting a baseline expression may be necessary. Patients demonstrated a 
20% donor chimerism on average in the skin identified as CD45+ haematopoietic and CD45-
CD31- non-haematopoietic cells.  
Allogeneic BMT transplantation being a highly invasive and risky procedure is associated with 
a high incidence of failure due to graft rejection, graft versus host disease (GVHD) and 
complications during myeloablation. This was highlighted during this study with the death of 
two patients from the aforementioned causes. An approach capable of circumventing both 
allograft rejection and radiation related toxicity is embryonic-BMT (E-BMT). It has been shown 
that during the first trimester of human gestation the foetus can accept HLA-mismatched 
allogeneic antigens without the need for myeloablation. In the context of RDEB, Chino et al., 
2008, demonstrated the infusion of allogeneic GFP-expressing bone marrow cells (BMCs) into 
the embryonic circulation via the vitelline vein of RDEB mice resulted in their migration and 
differentiation into bone marrow derived fibroblasts (BMDFs) following appropriate matrix 
stimulation from the injured skin (Chino et al., 2008).  
One of the contributing factors thought to trigger recruitment of both allogeneic infused and 
autologous BM-derived cells to injured skin was discovered recently to be the high mobility 
group box 1 (HMGB1) protein (Tamai et al., 2011). It has been linked to the maintenance of 
tissue homeostasis during wounding and acceleration of healing through recruitment of BM-
derived epidermal progenitors while protecting surrounding uninjured tissue by 
immunosuppression. Specifically, Lin-/PDGFRα+ BM cells shown to be non-hematopoietic but 
of mesenchymal lineage are the key cells induced. HMGB1, although ubiquitously expressed, 
was found at high concentrations in the hypoxic environment of RDEB epidermal blisters. 
Topical administration of recombinant HMGB1 was shown to enhance mobilisation of the 
BMCs to skin wounds. E-BMT was associated with partial amelioration of the disease 
phenotype while survival was prolonged to 3 weeks post birth due to the small proportion of 
donor chimerism in the esophageal region impeding with solid feeding. E-BMT was further 
revealed to introduce immune tolerance to de novo expressed proteins, in this case GFP, 
signifying the potential of this approach for RDEB which would consecutively allow for protein 
and cell therapies to be used after birth without the risk of autoantibody production to C7 
(Chino et al., 2008).  
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The preferred scenario would comprise of autologous gene corrected foetal BMCs delivered to 
the affected embryo in utero which could lead to a one-off cure. The newest development in the 
field though has been the use of induced pluripotent stem cells (iPSCs) for the treatment of 
RDEB. The power of this strategy lies in the ability to derive autologous pluripotent stem cells 
from patient fibroblasts or keratinocytes offering an inexhaustible supply of dermal, bone 
marrow or other progenitor cells for downstream local or systemic therapeutic applications 
(Tolar et al., 2011, Itoh et al., 2013).  
Recent studies have demonstrated their capacity in treating RDEB through the delivery of 
autologous corrected Col7a1-/- mouse model iPSCs (Wenzel et al., 2014), or the use of gene 
editing tools such as transcription activator-like effector nucleases (TALENs) and adeno-
associated virus (AAV) AAV-DJ for the correction of RDEB patient derived iPSCs for grafting 
onto immunodeficient mice (Osborn et al., 2013, Sebastiano et al., 2014). As an alternative to 
gene editing, iPSCs can also be derived from the rare spontaneously-corrected patient cells 
which have undergone “natural gene therapy” known as revertant mosaicism as carried out by 
Umegaki et al., 2014, for JEB providing an unlimited supply of autologous skin cells 
(Umegaki-Arao et al., 2014). 
1.6.4  Gene therapies for RDEB 
Circumventing limitations of allogeneic cell rejection and HLA mismatch following topical or 
systemic therapies can be achieved through the correction of patients’ own cells. This is 
typically carried out by vector-mediated introduction of a healthy copy of the affected gene into 
the desired cell population for subsequent administration to the individual.  
1.6.4.1 Phage mediated gene therapy  
An efficient non-viral method of delivering foreign genetic material to target cells is by 
bacteriophage (Clark and March, 2006). Such a system based on the φC31 bacteriophage was 
developed for the delivery of COL7A1 (Ortiz-Urda et al., 2002). This was proposed to 
circumvent transient expression and low transfection efficiency in keratinocytes experienced 
with plasmid-based approaches and the transgene capacity limitations of viral vectors. Primary 
RDEB epidermal keratinocytes were co-transfected with a stably integrating transfer vector 
containing a specific 285 bp attb sequence and encoding COL7A1 cDNA driven by a CMV 
promoter and a φC31-integrase expression plasmid. Integration into the host genome is 
favoured at “pseudo-attP sites”. Following blasticidin selection for enrichment of the 
transfected cell population, protein analysis of both in vitro and ex vivo corrected human skin 
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equivalents grafted onto immunodeficient mice displayed restoration of adhesion at the DEJ 
with AFs formation.  
The same approach was applied to RDEB patient fibroblasts aiming for correction of a more 
robust cell type (Ortiz-Urda et al., 2003). This resulted in a highly C7-expressing population 
which demonstrated restoration of dermal-epidermal cohesion in a xenograft mouse model for a 
duration of 4 months with a very slight but noticeable spread of correction past the injection 
site. This study has also demonstrated the advantage of autologous gene therapy over allogeneic 
cell therapy by showing that endogenous C7 expression levels secreted by normal fibroblasts 
can fail to deliver sufficient protein to the BMZ, whereas overexpression following vector based 
correction can significantly enhance that (Ortiz-Urda et al., 2003).  
1.6.4.2 γ-retroviral mediated gene therapy 
Viral-based gene therapy strategies for the delivery of a WT COL7A1 gene into RDEB human 
patients’ cells have predominantly involved the use of conventional γ-retroviral vectors as gene 
delivery vehicles.  
Work carried out on a RDEB canine model demonstrated the use of two different retroviral 
vector backbones, pLZRS and pMSCV encoding full length 8.8 kb human COL7A1 cDNA 
driven by a Moloney murine leukaemia virus (MoMLV) promoter for the successful 
transduction of both human and canine RDEB keratinocytes (Baldeschi et al., 2003, Gache et 
al., 2004). Their use in skin equivalents revealed reversion of RDEB cell properties including 
proliferation, adhesion and migration, to those of WT cells. Overexpression of C7 in the 
retrovirally-transduced RDEB keratinocytes was estimated to be in the magnitude of 50 times 
that of WT cells (Gache et al., 2004). Efficiency was higher with the pMSCV vector thought to 
target a high proportion of epithelial progenitor cells due to the broad host range of the 
amphotropic MLV envelope.  
Gache et al. further highlighted the importance of this in a subsequent study where retroviral 
correction of keratinocytes obtained from a spontaneous RDEB canine model for the generation 
of epithelial skin sheets, showed persistent C7 protein expression for 2 years post-grafting in 
one of the animals (Gache et al., 2011). On the contrary, in a second animal expression 
disappeared after a 2-month period. This was attributed to the inefficient targeting of highly 
clonogenic keratinocyte stem cells, key in providing the auto-renewal capacity of the grafted 
tissue. The limitation of keratinocyte-based therapy is accentuated through this work as in a 
continuous tissue-healing environment, such as in RDEB, depletion of epidermal stem cell 
pools renders targeting of these populations highly infrequent (Gache et al., 2011).  
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Successful keratinocyte-based therapies, such as the one led by Mavilio et al. though has also 
shown the potential of this approach (Mavilio et al., 2006). Following correction of 
approximately 100% of keratinocytes obtained from JEB patients’ palm biopsies using a 
LAMB3-encoding MLV retroviral vector, cells were developed into skin sheets for grafting on 
patients’ legs. Epidermal regeneration was detected as early as 8 days post-transplantation and 
still maintained after 1 year. The long-term persistence of the graft was explained by the self-
renewing capacity of vector targeted epidermal stem cells, although transit amplifying 
progenitor cells were undetected after the first month due to epidermal turnover.  
To overcome limitations associated with the restricted 7-8 kb transgene capacity of retroviral 
vectors unable to efficiently accommodate the full-length 9 kb cDNA of COL7A1, a 
recombinant COL7A1 minigene containing intact NC1 and NC2 domains and a portion of the 
central domain was used for virus production (Chen et al., 2000). When cloned into a γ-
retroviral construct, it was able to efficiently transduce RDEB keratinocytes resulting in 
expression of a 230 kDa protein (700 kDa trimer) resistant to proteolytic degradation while 
retaining functionality showing increased proliferation, reduced cell motility and cell-
substratum adhesion. However, removing portion of the triple helical domain containing the 39 
a.a. hinge region may compromise the flexibility of the fibrils. An alternative approach for 
reduction of COL7A1 cDNA size while maintaining functionality can be achieved through 
trans-splicing (Murauer et al., 2011). In place of the 9.2 kb cDNA, a 3.3 kb transgene was 
incorporated into a retroviral vector encoding for exons 65 to 118 a.a. with a 3’ pre-trans-
splicing molecule in exon 64. Correction was achieved in vitro in patient cells with a mutation 
in exon 106 with no signs of truncated C7 produced.  
Moreover, the use of the strong γ-retroviral long terminal repeats (LTRs) to drive transgene 
expression have been associated with proto-oncogenic risks as described previously (Hacein-
Bey-Abina et al., 2008). An internal promoter can be used in their place, which not only 
enhances the vector biosafety, but can also confer tissue specific regulated expression. Titeux et 
al. demonstrated the use of self-inactivating (SIN) retroviral vectors encoding the full-length 
COL7A1 cDNA driven by either an endogenous COL7A1 promoter or the housekeeping 
elongation factor (EF1α) (Titeux et al., 2010). Transduction efficiency was estimated to be in 
the range of 30-80% following both primary keratinocyte and fibroblast transduction at a high 
multiplicity of infection (MOI). Although restoration of C7 was observed in both in vitro and ex 
vivo skin equivalent studies this was the first study to report the secretion of truncated C7 as 
assessed at the protein level. These shorter forms of C7 do not appear to hinder AFs formation 
to the extent that dermal-epidermal adhesion is compromised although it may be associated with 
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a drop in efficiency. Rearrangement was predicted to occur at the proviral stage in transduced 
cells during the retrotranscription process.  
Nevertheless, phase I clinical trials have now commenced for RDEB gene therapy using γ-
retroviruses for the correction of autologous patient keratinocytes and fibroblasts. Notable 
studies include those led by Marinkovich M.P. and Lane A. in Stanford, US, and Hovnanian A. 
in Toulouse, France. Two trials using the pLZRSE-COL7A1 γ-retroviral vector assessed in a 
preclinical study for the ex vivo correction of keratinocytes (Siprashvili et al., 2010), are now 
underway proposing the grafting of gene-corrected autologous keratinocyte sheets (LEAES) 
(NCT01263379), or intradermal injection of gene-corrected autologous fibroblasts (FCX-007), 
however, the latter has been held up until additional toxicology data has been generated. 
Similarly, based on preclinical data using a SIN-γ-retroviral vector (Titeux et al., 2010), is about 
to be launched in Europe in 2016 for the delivery of COL7A1-corrected keratinocyte and 
fibroblast grafts (Genegraft). 
1.6.4.3 Lentiviral mediated gene therapy 
The use of retroviral vectors in humans has raised concerns due to recognised adverse effects 
such as reversion to a virulent state or activation of oncogenes (Hacein-Bey-Abina et al., 2008, 
Hacein-Bey-Abina et al., 2003, Howe et al., 2008, Ott et al., 2006). To diminish the risk of 
recombination occurring as a result of viral incorporation, 3rd generation replication defective 
SIN lentiviral vector constructs have been designed based on the human immunodeficiency 
virus (HIV-1) stripped of all virulence factors (vpu, vpr, nef, vif) and Tat. Lentiviral vectors 
offer a range of advantages over their retroviral counterparts. These include i) reduced 
genotoxic potential secured by the integration in gene rich regions as opposed to nearby 
transcription sites, which can lead to insertional mutagenesis by the transactivation of proto-
oncogenes as suggested by integration mapping (Bushman et al., 2005, Mitchell et al., 2004, 
Montini et al., 2009) ii) the ability to produce concentrated virus with high titers by 
centrifugation and hence increased transduction efficiency; iii) the stability and sustained 
expression of the carrying transgene with negligible, if any, immune response; iv) larger insert 
capacity of 9 kb as opposed to 7-8 kb in retroviral vectors (Chen et al., 2002, Naldini, 1998), 
and v) potential to infect both dividing and non-dividing cells (Kuhn et al., 2002, Naldini et al., 
1996a, Sakoda et al., 1999). 
Furthermore, aiming to improve the safety profile of viral delivery as well as efficiency, a SIN-
lentiviral vector encoding full-length human COL7A1 cDNA was generated (Chen et al., 2002). 
The chosen modified murine leukaemia retroviral (MND) promoter driving the transgene 
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resulted in reduction of methylation and increase in expression. Viral transduction was shown to 
restore C7 expression in both RDEB keratinocytes and fibroblasts (Chen et al., 2002). 
Correction was sustained for 5 months in vitro with reversion of the RDEB phenotype and 2 
months in vivo with deposition of C7 and formation of AFs at the DEJ of skin equivalent 
grafted mice. Subsequent follow-up studies confirmed restoration of dermal-epidermal adhesion 
to be feasible either by a combination of gene corrected RDEB keratinocytes and fibroblasts or 
when corrected keratinocytes were grafted alone. On the other hand, gene corrected fibroblasts 
alone were demonstrated to express stable and sufficient enough levels to reconstitute dermal-
epidermal adhesion and functional correction following skin equivalent grafting in mice 
(Woodley et al., 2003).  
Furthermore, intradermal injection of gene-corrected RDEB fibroblasts in healthy nude mice 
showed expression of human C7 at the BMZ. For intradermal administration of fibroblasts to be 
clinically meaningful, multiple injections would have to be carried out considering the limited 
diffusion radius of the cells. Alternatively, fibroblasts could be delivered systemically by 
intravenous injection (Woodley et al., 2007b). Lentivirally-corrected fibroblasts appeared to 
promote wound healing after homing to the skin wounds in a murine model. Recruitment of the 
fibroblasts from the circulation was shown to only occur when the skin was injured suggesting 
the involvement of factors such as HMGB1.  
In a slightly different approach aimed at circumventing difficulties encountered with ex vivo 
gene correction, such as the harvesting and culturing of patient cells before gene modification, 
verification and subsequent transplantation, Woodley et al. explored the potential of using direct 
in vivo viral vector delivery to patient skin (Woodley et al., 2004b). As epidermal keratinocytes 
do not undergo continuous active division unless under epithelial remodelling following 
wounding, infection by retroviral vectors would not be possible. Instead, the minimal lentiviral 
vector previously used to correct both keratinocytes and fibroblasts in vitro was injected 
intradermally into RDEB skin equivalent immunodeficient mouse models. A single injection 
demonstrated sustained expression and reversion of blistering at the DEJ for at least 2 months. 
An exciting finding by these authors was the successful transduction and C7 expression of 
endothelial cells amongst dermal fibroblasts. This may open new avenues for the intravenous 
delivery of lentiviral vectors. Interestingly, there was no lentiviral integration detected in 
epidermal keratinocytes, presumed to be due to the depth of the injection into the underlying 
dermis, limiting diffusion of the vector through the BMZ and into epidermal progenitors.  
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1.6.5  Alternative therapeutic options 
A number of recurrent mutations are found in exonic regions 73, 74 and 80 which carry 
multiple Gly-X-Y collagenous repeats. It has been proposed that targeted knockout of 
sequences within that region would not interfere with functional C7 production (Turczynski et 
al., 2012). An exon-skipping strategy was therefore developed using antisense oligonucleotides 
complementary to the COL7A1 genomic sequence. The pre-mRNA exposed to the antisense 
oligonucleotides prevents normal splicing, in turn leading to the skipping of the dysfunctional 
exon in the mature mRNA. It has been suggested that in a clinical setting, antisense 
oligonucleotides can be administered in vivo intradermally, intravenously, intramuscularly or 
even topically. This strategy though will most likely only be feasible for those select exons, as 
skipping of sequence in non-collagenous domains would undoubtedly have a deleterious effect 
on the functionality of C7. An improvement to exon-skipping has recently been brought to light 
involving a novel premature termination codon (PTC) readthrough strategy (Cogan et al., 2014). 
Aminoglycosides such as geneticin, gentamicin and paromomycin when transiently delivered in 
an expression vector can mediate readthough of nonsense mutations and restore C7 expression.  
1.7  Lentiviral gene therapy  
Gene therapy can be termed as the process by which a therapeutic gene is introduced into a 
cellular target for the treatment of a medical disorder. This may involve the delivery of a portion 
or an entire gene for the replacement, modification or inactivation of the affected endogenous 
gene. In some instances the desired outcome may encompass the addition of de novo DNA 
sequence to a cell target for the institution of supplementary function by novel protein 
expression. An example of this can be seen in the breakthrough work currently underway for the 
expression of chimeric antigen receptors (CARs) on the surface of T-cells to combat malignant 
B-cells (Pule et al., 2003). 
Following extensive research and elucidation of the molecular basis of a number of genetic 
disorders, the potential of gene therapy was realised giving rise to its development as a 
prospective therapeutic tool. With work dating back to the early 70s for the treatment of 
hyperargininemia in three patients using a therapeutic transgene carrying papilloma viral vector 
formulated the first human gene therapy trial (Friedmann and Roblin, 1972, Terheggen et al., 
1975). Although no significant clinical benefit was demonstrated in contrary to the successful in 
vivo animal studies, this paved the way towards the development of improved transgene 
delivery systems. This resulted in the progression to using γ-retroviral vectors as the transgene 
vehicle, harnessing their ability to stably integrate into the host genome. A series of proof-of-
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principle studies in the early 90s using γ-retroviral vectors demonstrated their efficacy in 
transducing HSCs (Deisseroth et al., 1994, Brenner, 1993, Emmons et al., 1997), which led to 
the first approved clinical trial. This involved the reestablishment of adenosine deaminase 
(ADA) protein expression in CD34+ cells of severe combined immunodeficiency (SCID) 
patients using a γ-retroviral vector (Bordignon et al., 1993). Although no detrimental side 
effects were reported following therapy, the levels of ADA showed only a marginal increase 
which rapidly dissipated.  
This was succeeded by a large multicenter study involving twenty children patients suffering 
from interleukin receptor γ-chain (γc) deficient SCID-X1 (Hacein-Bey et al., 1996, Gaspar et 
al., 2004). A clinically significant result leading to restoration of immunological function with 
increase in T, B and NK cells was achieved by ex vivo delivery of the therapeutic γc gene into 
autologous bone marrow-derived CD34+ cells via a mouse leukaemia (MLV) retroviral vector 
(Cavazzana-Calvo et al., 2000). 
After a 3 to 6 year period post-treatment, serious adverse effects, namely splenomegaly and 
more importantly uncontrolled exponential clonal proliferation of mature T cells, associated 
with the vector were reported in five cases in both trials. This was later shown to have been 
caused by insertional mutagenesis proximal to the LMO-2 proto-oncogene promoter within 
chromosome 11 (Hacein-Bey-Abina et al., 2003, Howe et al., 2008). Despite this, the relative 
success of these studies boosted the field of gene therapy, which initiated the recruitment of a 
number of patients for subsequent clinical trials. An example of these included the use of γ-
retroviral vectors as a means of restoring gp91phox expression in CYBB gene deficient X-linked 
chronic granulomatous disease patients (X-CGD) (Moreno-Carranza et al., 2009) and was also 
successfully described as a method of conferring highly targeted anti-tumour activity achieved 
through the vector-mediated modification of autologous patient T-cells to express the α and β 
chains of the anti-MART-1 TCR obtained from a metastatic melanoma patient having 
undergone almost complete regression following adoptive cell transfer (Morgan et al., 2006).  
The outcomes of these studies were highly encouraging and demonstrated the potential of this 
therapeutic approach. Stable proviral integration into the host genome though was highly 
controversial at the time while still remaining a major concern in terms of biosafety as 
highlighted by the unanticipated events during the early gene therapy trials. This emphasised the 
need for a safer system with comparable efficiency giving rise to lentiviral vectors.  
The configuration of the vectors used in the aforementioned trials was initially based on 
oncoretroviruses of the Retroviridae family and most commonly on Moloney Leukaemia Virus 
(MLV). These γ-retroviral vectors have now been superseded by safer alternatives of the same 
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retroviral family based instead on a lentiviral backbone. Both vectors have a very similar 
backbone encoding the same structural, integration and envelope genes with the more complex 
lentiviruses carrying additional genes for the regulation of viral replication, assembly and 
infection (Dufait et al., 2012).  
1.8  HIV lifecycle  
1.8.1  Viral attachment 
These viruses belong to the family of enveloped single-stranded (SS) RNA viruses with 
chromosomal integration being an integral part of their life cycle (Figure 1.7). In their mature 
state as a virion they carry two copies of positive strand RNA in addition to enzymes principle 
for the initiation of reverse transcription and integration. A viral core is formed encapsidated by 
two distinct protein shells, and enveloped by host cell lipid membrane incorporating viral 
glycoproteins conferring selective tropism. The viral life cycle commences with the detection of 
specific cellular surface receptors now known to be predominantly CD4 on a subset of mature T 
lymphocytes and macrophages. Two distinct co-receptors were later identified required for viral 
entry into the host cell. Both belonging to the family of G protein coupled chemokine receptors, 
CXCR4 was typically found to be expressed on the surface of the majority of haematopoietic 
progenitor cells and largely on T cells while the human chemokine CCR5 was predominantly 
specific to macrophages (Dragic et al., 1996). The preference for co-receptor is used to define 
the host-cell specificity of the virus, which can be X4 or R5 tropic, and in some cases 
“dual/mixed” (Feng et al., 1996).  
1.8.2  Viral entry 
Host-cell attachment by the virion is succeeded by a complex process termed fusion, whereby 
the viral core is released into the cytoplasm and the particle is uncoated for the initiation of 
reverse transcription. This is mediated by the subunit components of the envelope complex, 
collectively known as glycoprotein 160 (gp160), consisting of trimeric forms of surface gp120 
non-covalently bonded to transmembrane gp41 forming an envelope spike. Association of 
gp120 to both CD4 receptor and either of the co-receptors institutes a conformational change in 
the envelope spike bringing viral and host-cell membranes in close proximity resulting in fusion 
(Weiss et al., 1996). 
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1.8.3  Reverse transcription 
Following entry and disassembly of the viral core proteins into the host-cell cytoplasm the 
reverse transcription complex (RTC) arises, which moderates the synthesis of viral dsDNA 
from the ssRNA genome forming the hallmark of retroviruses (Figure 1.8). Reverse 
transcriptase carries out two distinct enzymatic functions, with the N-terminal portion involved 
in RNA or DNA dependent DNA polymerisation, while the C-terminal portion confers RNase 
H activity to mediate cleavage of RNA when in an RNA-DNA duplex conformation with the 
exception of the polypurine tracts (PPTs) being resistant to degradation (Fuentes et al., 1995).  
For the initiation of reverse transcription, a host-derived lysine transfer RNA (tRNALys3) is 
employed as a primer complementary to the 5’ end of the viral RNA primer binding site (PBS) 
for synthesis of minus strand DNA (Kovaleski et al., 2006). Reverse transcription takes place in 
a 3’-5’ direction with synthesis of the DNA minus strand commencing with the R-U5 region 
while the viral RNA template undergoes degradation by RNase H activity with the exception of 
the PPT (Fuentes et al., 1995). This is proceeded by transfer of the R-U5 DNA-tRNA hybrid 
molecule to the 3’ end of the template mediated by the homology of the 5’ and 3’ R regions. 
Synthesis starts from the conserved PPT sequence, serving as a primer for the synthesis of the 
initial portion of the complementary DNA plus strand. The process is carried out by RNA 
dependent DNA polymerase, starting with synthesis of the U3-R-U5 region and including a 
PBS. Subsequent degradation of the tRNA results in hybridisation of the two complementary 
DNA PBSs which triggers the bidirectional completion of both DNA strands by DNA 
dependent DNA polymerase (Shaharabany and Hizi, 1991). This results in a complete viral 
dsDNA genome, carrying a U3-R-U5 sequence on both 5’ and 3’ ends termed LTR, capable of 
host integration following nuclear import.  
1.8.4  Nuclear import 
One of the defining features of lentiviruses making them so efficient at host-cell infection lies in 
their ability to enter the nucleus of not only dividing but also non-dividing cells unlike their γ-
retroviral counterparts such as MLV which can only pass the nuclear envelope during mitosis. 
The process is facilitated by the pre-integration complex (PIC), formed after the complete 
degradation of RNA following reverse transcription by the RTC (Miller et al., 1997). Owing to 
the large size of the PIC preventing entry via diffusion, a combination of viral elements, namely 
capsid (CA), central polypurine tract (cPPT), integrase (IN), matrix (MA) and Vpr which carry 
nuclear localisation signals (NLS) have been shown to interact with host importin and 
nucleoporin proteins facilitating nuclear import (Bukrinsky et al., 1993). 
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1.8.5  Proviral integration 
Following entry of the PIC into the host-cell nucleus, the viral genome undergoes a two-step 
chemical processing reaction by the catalytic activity of IN. The initial step, having commenced 
during the earlier stage of reverse transcription termed 3’ processing, involves the binding of IN 
to each LTR end of the viral dsDNA and cleavage of two nucleotides resulting in 3’ hydroxyl 
groups. When in the nucleus, the PIC can interact with chromosomal DNA to engage in viral 
DNA-strand transfer mediated by IN. Targeted cleavage of the chromosomal DNA is performed 
by IN resulting in 5’ overhangs that following nucleophilic attack by the 3’ hydroxyl groups 
resolve by ligation of viral and host DNA by endogenous cell-repair machinery (Kessl et al., 
2009).  
Lentiviruses like HIV-1 display a preference in their integration pattern for active 
genes(Mitchell et al., 2004, Schroder et al., 2002) as opposed to γ-retroviruses which highly 
favour integration at approximately 5 kb of either side of transcriptional start sites (Wu et al., 
2003). This suggests a difference in the process of target site selection between retroviruses 
accounted for by sequence recognition, engagement with the PIC machinery, and response to 
transcriptional activity (Vandegraaff and Engelman, 2007). For HIV-1, cellular cofactor cellular 
lens epithelium-derived growth factor (LEDGF)/p75 has been demonstrated to facilitate the 
targeting of the virus to gene rich regions by direct binding of IN and chromatin (Maertens et 
al., 2004).  
1.8.6  Transcription 
The integrated dsDNA viral genome can at this stage be termed provirus and utilises host 
machinery such as RNA polymerase II (RNA pol II) for the production of viral transcripts. 
Transcription initiates at the strong promoter region of U3-R junction located at the 5’ LTR and 
terminates when it recognises the polyA signal at the 3’ LTR. A number of transcription factor 
binding sites have additionally been located in the LTR, facilitating interactions with factors 
Specific protein (Sp) and nuclear factor κB (NFκB), further modulating transcription (Jones et 
al., 1986, Nabel and Baltimore, 1987). Synthesis of viral proteins Tat and Vpr act in turn as 
modulators and enhancers of viral transcription.  
1.8.7  Nuclear export 
Unlike cellular pre-mRNA where complete splicing of introns has to take place before 
processing and nuclear export of mature mRNA (Legrain and Rosbash, 1989), in the case of 
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HIV-1, a mixture of fully spliced and partially spliced viral mRNA can enter the cytoplasm 
(Cullen, 1992). This process is facilitated by the RNA-binding Rev protein encoded for by fully 
spliced mRNA also encoding regulatory factors Tat, Nef, Vpr and Vpu. Structural components 
required for assembly of the virion such as Gag, Pol, and Env, are sequestered to the cytoplasm 
at later stages of the replication cycle in response to elevated concentrations of translated Rev 
which is imported into the nucleus (Blissenbach et al., 2010). The presence of a Rev response 
element (RRE) in all fully and partially spliced mRNAs permits Rev to coordinate spliceosome 
assembly and nuclear translocation (Feinberg et al., 1986). The transcripts are then exported via 
the host-cell chromosome maintenance region 1 (Crm1) pathway serving as templates for 
translation (Malim and Cullen, 1993).  
1.8.8  Translation viral assembly and budding 
Following translation by host ribosomal subunits, viral assembly is almost exclusively executed 
by Gag. Proteolytic cleavage of the Gag p55 precursor by pol encoded viral protease gives rise 
to mature Gag protein subdomains Matrix (MA), Capsid (CA), Nucleocapsid (NC) and p6 
(Gottlinger et al., 1989). During translation, the N terminus of Gag undergoes myristoylation, 
triggering the transporting and anchoring of Gag to the cell membrane through the action of MA 
which is also involved in the coating of the inner surface and stabilisation of the virion (Bryant 
and Ratner, 1990). CA protein p24 in turn facilitates the protein-protein interactions leading to 
the assembly of the immature conical shell containing the viral core.  
Recognition of the HIV-1 packaging signal (Ψ), composed of a distinct 4-hairpin secondary 
structure, is mediated by the NC protein leading to the incorporation of two strands of capped 
and polyadenylated full-length RNA genome into the budding virion along with the remaining 
viral proteins and two copies of host tRNALys3. p6 in turn is responsible for the incorporation of 
Vpr into the virion via interactions with p55 Gag (Paxton et al., 1993).  
Env glycoprotein gp160 is transported to the cell membrane independently where it is inserted 
into the virus particle forming an integral part of the HIV-1 life cycle. The involvement of p6 is 
seen again during the final stages where it recruits cellular factors for the budding of the virion 
and the “pinching” off of the particle from the host cell. A series of structural and 
conformational rearrangements of the viral proteins signifies maturation of the viral bud into an 
infectious particle (Briggs and Krausslich, 2011). 
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Figure 1.7 HIV-1 lifecycle in host mammalian cell.  
Attachment of HIV-1 virus to cell surface of T-cell followed by fusion of host and viral membranes and 
release of viral proteins into the host cell cytoplasm. Using host machinery and viral reverse transcriptase, 
the two strands of viral RNA are reverse transcribed into dsDNA. The PIC facilitates nuclear import 
where following the binding of integrase to the 5’ and 3’ LTR the viral dsDNA integrates into host 
chromosomal DNA. Using host machinery, a mixture of fully spliced and partially spliced viral 
transcripts are generated and enter the cytoplasm. Fully spliced mRNA encodes regulatory factors Tat, 
Nef, Vpr and Vpu which can enter the cytoplasm. Translation is mediated by host ribosomal units and 
viral assembly is orchestrated by viral Gag. The synthesized viral proteins and two strands of capped and 
polyadenylated full-length viral RNA are enveloped by host cell membrane in which gp160 is inserted. 
Following budding of the immature virus, p6 facilitates the pinching off of the viral particle and release 
from the host cell. Structural and conformational rearrangements of the viral proteins result in maturation 
of the viral particle. LTR: long terminal repeat; PIC: pre-integration complex; gag, pro, pol: HIV 
structural polyproteins; Tat, Rev, Nef, Vpr, Vif, Vpu: HIV regulatory elements. 
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Figure 1.8 Reverse transcription of HIV-1.  
Host-derived lysine transfer RNA (tRNALys3) anneals to the 5’ end of the viral RNA PBS for synthesis of 
minus (-) DNA strand. Reverse transcription takes place in a 3’-5’ direction with synthesis of DNA (-) 
strand commencing with the R-U5 region. Viral RNA template degraded by RNase H activity with the 
exception of the PPT. Transfer of the R-U5 DNA-tRNA hybrid molecule to the 3’ end of the template by 
the homology of the 5’ and 3’ R regions. Synthesis of plus (+) strand starts from the conserved PPT 
sequence and initiates with synthesis of U3-R-U5 region including a PBS, followed by degradation of the 
tRNA. Hybridisation of the two complementary DNA PBSs triggers the bidirectional completion of both 
DNA strands. A complete viral dsDNA genome is generated, carrying a U3-R-U5 sequence on both 5’ 
and 3’ ends termed LTR. gag, pol, env: HIV-1 structural genes; LTR: long terminal repeat; PBS: primer 
binding site; PPT: polypurine tract; tRNA: transfer RNA; U3 or U5: untranslated 3’ or 5’ region; 
1.9  Development of lentiviral vectors 
The insertional mutagenesis reported in the SCID-X1 trials with an estimated 1 in 105 chance of 
random integration into transcriptionally active genes coupled with the presence of a potential 
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100-1000 proto-oncogenes in the human genome (Hacein-Bey-Abina et al., 2003) prompted the 
optimisation of the vector. This came in the form of a SIN lentiviral vector based on HIV-1, 
which allowed to combat a number of the caveats exposed with γ-retroviral vectors (Naldini et 
al., 1996b). One of the benefits of lentiviral vectors over their γ-retroviral counterparts can be 
primarily seen in their integration profile with a preference for gene-rich regions as opposed to 
transcriptional start sites, promoter and regulatory regions. Modification of endogenous 
retroviral promoters within the LTR region known for their ability to drive expression of genes 
at over 100 kb downstream (Hacein-Bey-Abina et al., 2003) was a key step in reducing potential 
transcriptional activation of oncogenes.  
The basic principle for the generation of lentiviral vectors involves the use of a packaging cell, 
typically human embryonic kidney (HEK) 293T cells, to assemble the vector following 3-
plasmid co-transfection with a packaging plasmid, a transfer plasmid and an envelope plasmid 
(Naldini et al., 1996a). Since its initial development, the current vector system has undergone a 
series of modifications aiming to improve its safety profile, classed as generations. The major 
alterations were made in the packaging plasmid as the first generation lentiviral vector 
contained all structural gag, pol, regulatory tat, rev and accessory vif, vpr, vpu and nef viral 
genes with the exception of env.  
Advances in the field later revealed that a number of these genes had no detrimental effect on 
infectivity or vector yield resulting in their removal and giving rise to the second generation. 
Accessory genes vif, vpr, vpu and nef were therefore removed, attenuating the packaging 
system, majorly benefiting vector safety by significantly reducing the risks of recombination 
which could potentially result in a functional virulent particle (Zufferey et al., 1998). Aiming to 
broaden the host-cell tropism of HIV-1, the envelope is frequently substituted with that of 
vesicular stomatitis virus (VSV) in a process termed pseudotyping. VSV glycoproteins (VSV-
G) interact with a ubiquitously expressed cell surface marker gp96 enabling viral entry in a wide 
host range (Burns et al., 1993). Similarly, use of envelope glycoproteins from Rabies virus and 
Venezuelan Equine Encephalitis virus envelopes have been reported to confer neuronal tropism, 
essential for the treatment of neurodegenerative disorders (Trabalza et al., 2013).  
Currently in use, is the 3rd generation system further reducing safety concerns of RCL formation 
by employing a split-genome packaging plasmid whereby the rev gene is provided in trans to 
gag and pol. This method allows for the sustained yet restricted to the packaging cell expression 
of Rev (Dull et al., 1998). Additionally, a series of modifications were made to the transfer 
plasmid making it self-inactivating, by disrupting promoter function of the 5’ LTR which is 
replaced with a tat-independent constitutive promoter while still ensuring sufficient expression 
(Dull et al., 1998). This was made possible by adapting the 3’ LTR U3 enhancer/promoter 
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region by deletion of 133 bp of the TATA box and binding sites required for the sequestration 
of transcription factors. During reverse transcription the 3’LTR deletion is transferred and 
acquired by the 5’LTR rendering the integrated provirus transcriptionally inactive (Miyoshi et 
al., 1998).  
As a means of enhancing gene expression and viral titres, a post transcriptional regulatory 
element derived from woodchuck hepatitis virus (WPRE) shown to have promoter activity, was 
also added to the vector (Schambach et al., 2005, Zufferey et al., 1999). Owing to the 
inactivation of the viral LTR in the SIN vectors, transgene expression requires the use of an 
internal promoter, the choice of which is application dependent and typically selected with cell 
and tissue specificity in mind. Commonly used promoters which have already been approved 
for clinical trials can be of either viral or human origin, such as Spleen focus-forming virus 
(SFFV) and Cytomegalovirus (CMV), or phosphoglycerate kinase (PGK) and EF1α, 
respectively, allowing for stable transgene expression in both progenitor and differentiated cells. 
These promoters vary considerably in their strength of expression with cellular EF-1α known to 
drive the strongest transgene expression while viral CMV the weakest. Interestingly, when 
assesed in differentiated cell populations, the opposite was observed suggesting promoter 
selection can be optimised to the intended target cell (Hong et al., 2007). The PGK promoter, 
although not necessarily the strongest in terms of transgene expression, is highy desirable as it 
can drive robust and long-term expression and, importantly, has been reported to be active in 
most cell types and lineages (Qin et al., 2010).  
Although the use of lentiviral vectors has been traditionally described for the stable integration 
of a transgene to achieve long-term permanent correction, sustained transient gene expression 
can also be attained independent of proviral integration. This was demonstrated with the 
development of non-integrating lentiviral vectors (NILV) also known as integration-deficient 
lentiviral vectors (IDLVs). Modification of the pol portion of the gag-pol polyprotein encoding 
the IN enzyme via a 64 bp deletion (∆64V) of the catalytic domain, abolishes proviral 
integration with a 4-log unit drop in infectious titre and therefore background integration over 
WT virus yet generating the same levels of viral DNA (Leavitt et al., 1996). The non-integrated 
proviral forms persist as circular vector episomes which can support transgene expression 
(Matrai et al., 2011). This not only offers the advantage of a transient effect that can be diluted 
out in proliferating cells but can provide stable expression without the risks of chromosomal 
integration in quiescent cells. Examples of applications necessitating transient expression 
include the delivery of gene editing machinery such as sequence specific nucleases which are 
typically required for a “hit-and-run” approach. NILVs can be described as one of the safest 
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viral-mediated gene-transfer systems albeit the low levels of background integrations reported 
(Leavitt et al., 1996). 
 
1.10  Zinc Finger Nucleases as a highly targeted gene-editing tool 
Zinc finger nucleases (ZFNs) comprise one of the largest families of eukaryotic DNA binding 
motifs coupled to a nuclease domain capable of introducing double-stranded breaks (DSBs) in 
targeted regions of the genome. This provides researchers with a valuable genome editing tool 
for the modelling of genetic diseases both in vitro and in vivo. Their potential as a clinical 
application has further been realised by their use as a gene correction tool. DSBs are known to 
promote homologous recombination (HR) which can be exploited by the provision of 
homologous healthy donor sequence.  
1.10.1  Zinc finger protein structure and their development 
Zinc finger proteins (ZFP) generally refer to relatively small protein structural motifs that 
coordinate zinc ions through the interaction of histidine and cysteine residues and can bind 
DNA. Six classes of ZFPs have been discovered and characterised according to the protein 
domain and backbone shape into respective fold group. By far the most common of the ZF 
domains conferring DNA binding in eukaryotes and the more specifically the human genome is 
based on the Cys2-His2 conformation also known as the Cys2-His2–like fold group. 
Crystallographic studies performed at 1.6 Å resolution (Elrod-Erickson et al., 1996, Pavletich 
and Pabo, 1991), have revealed the precise structure of the Zif268-DNA complex variant, a 
mammalian transcription factor encoded by the EGR1 gene in humans, revealing its simple, 
modular structure (Elrod-Erickson et al., 1998).  
Each individual finger comprises of approximately 30 amino acids in a short two-stranded 
antiparallel β sheet and single α helix conserved ββα configuration (Elrod-Erickson et al., 1998). 
A small hydrophobic core retains the helix and sheets together along with a zinc ion coordinated 
by the conserved β sheet region cysteines and α helix histidines (Elrod-Erickson et al., 1998). A 
proportion of the amino acids at the N-terminal portion of the α helix typically interact with a 
three base pair subsite, usually guanine-rich (GCG/TGG/GCG), in the major groove of the 
double helix with variable selectivity (Elrod-Erickson et al., 1998).  
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It has been elucidated that the sequence specificity of the ZFPs relies chiefly on base contacts 
with amino acids located at the start of the ZF α helix at positions 1, 2, 3, and 6 with residues 1, 
3, and 6 directly contacting the 3’, central and 5’ DNA base. This has formed the basis for 
generating a multitude of ZFPs with a broad range of sequence specificities by altering the four 
key amino acids while maintaining the remaining ones as a consensus backbone (Pavletich and 
Pabo, 1991, Kim and Berg, 1996, Desjarlais and Berg, 1993, Shi and Berg, 1995, Elrod-
Erickson et al., 1998). This permits for the modular assembly of variable ZFP structural motifs 
against custom sequences making it a highly attractive framework. A highly conserved linker 
sequence was later used for the construction of synthetic ZFPs recognising sequences of DNA 
triplets, 9-18 bp in length (Liu et al., 1997) (Figure 1.9).  
 
 
Figure 1.9 Zinc-finger nuclease structure.  
Zinc-finger protein (ZFP) modules recognising nucleotide triplets are linked together up to a maximum of 
six constituting a ZF arm recognising a total of 18 bp of genomic DNA sequence. A ZF arm is 
synthesized for each strand of the genomic region to be targeted with an intervening 5 bp spacer region. 
The assembled ZFPs are coupled to a FokI endonuclease on their C-terminus end, modified to confer 
cleavage only upon formation of a heterodimer. Zinc-finger nucleases are delivered as a pair in order to 
create double-stranded breaks (DSBs) in a predetermined region of the genome.  
 
Improvements have been made in the methods of assembly of multiple zinc fingers as not all 
combinations are as efficient at targeting the specified chromosomal DNA sequence. 
Techniques such as the “modular assembly” approach whereby a preselected library of ZF 
modules based on rational design has enabled the generation of ZFPs against all 64 possible 
nucleotide triplets (Beerli and Barbas, 2002, Segal et al., 1999, Kim et al., 2010, Sander et al., 
2011, Gupta et al., 2012, Joung and Sander, 2013). Oligomerised pool engineering (OPEN) has 
been a further development in the selection of ZF arrays based on randomised libraries which 
unlike the “modular assembly” takes into account interactions between neighbouring ZFs in a 
context-dependent manner (Maeder et al., 2008). Although kits for the in-house production of 
ZFP modules are available, their construction remains challenging with commercially available 
ones remaining the preferred choice. Companies such as Sangamo Biosciences (Richmond, CA, 
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USA) in partnership with Sigma-Aldrich (St. Louis, MO, USA) have developed a proprietary 
platform for the construction and validation of ZFPs (CompoZr™) using a combination of the 
aforementioned approaches, offering a vast database of available custom designed modules (Gaj 
et al., 2013).  
1.10.2  Zinc Finger Nuclease complexes for induction of DNA breaks 
The main purpose for the rapid advancement in the field is due to the capacity to couple a 
variety of effector domains to the zinc finger modules conferring nuclease, recombinase, 
transposase, and activator or repressor activity. The establishment of the currently used zinc 
finger nuclease (ZFN) platform was achieved by the fusion of the FokI cleavage domain, a type 
IIS restriction enzyme derived from Flavobacterium okeanokoites, to the carboxyl terminus of 
the modular ZFP monomers. FokI requires dimerisation for it to cleave dsDNA with the 
advantage of increasing specificity at the target site by involving two inverted ZFNs spanning a 
maximum of 36 nucleotides. A high frequency of off-target cleavage and therefore cytotoxicity 
was reported due to the formation of homodimers. This led to the artificial modification of the 
WT FokI domain to solely cut DNA upon the formation of obligate heterodimers within a 5-7bp 
spacer region, increasing the safety profile of ZFNs (Miller et al., 2007, Szczepek et al., 2007). 
Creating targeted chromosomal disruptions which result in precise endogenous gene knockouts, 
is an invaluable strategy permitting the modelling of diseases in vitro and generation of animal 
models and determining how genotype influences phenotype.  
ZFN-induced double stranded breaks are lethal to the cell and are therefore repaired by either of 
two mechanisms by the endogenous cell machinery; primarily by non-homologous end joining 
(NHEJ) and at a lower frequency by HR. NHEJ is a mutagenic process resulting by the simple 
ligation of the DSB, inevitably introducing insertions/deletions (indels) in the sequence and 
disrupting the function of the gene. Assuming the availability of an unaffected allele, 
homology-directed repair (HDR) takes place correcting the DSB and hence the functionality of 
the gene. Induction of a DSB by ZFNs has been reported to significantly increase the frequency 
of HDR (Moehle et al., 2007) and occurs preferentially during the S/G2 phase (Genovese et al., 
2014). This process has been harnessed predominantly for the repair of point mutations but also 
for the site-directed integration of therapeutic genes by the provision of a recombinant donor 
template sequence bearing locus-specific homology arms (Figure 1.10). 
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Figure 1.10 Homologous directed repair after delivery of donor template to ZFN treated 
mammalian cells.  
Co-delivery of three non-integrating lentiviral vectors (NILVs), two of which encode the left and right 
portion of the zinc-finger FokI complex under the control of a spleen focus-forming virus (SFFV) 
promoter and a third one carrying a dsDNA sequence to be used as a donor template. After viral entry 
into the cell and uncoating ZFNs and donor template are reverse transcribed to cDNA which in the case 
of the ZFNs sequence will be translated into active ZFNs which locate the target site and cleave genomic 
DNA upon heterodimerisation of their FokI portions. The cell will repair the double-stranded break 
(DSB) predominantly by non-homologous end joining (NHEJ) but upon availability of template sequence 
it will stimulate the homologous recombination (HR) pathway and seal the break via homologous 
directed repair (HDR).  
 
1.10.3  ZFNs and their use in the clinic 
The potential of ZFN-induced genome engineering has gained momentum over the past decade 
and has been demonstrated in a range of model organisms, namely plants, insects, roundworms 
and humans (Urnov et al., 2010). Additionally, both ex vivo and in vivo genome editing tactics 
by the delivery of ZFNs have been reported as a treatment option against haemophilia B in mice 
and HIV in humans (Tebas et al., 2014, Li et al., 2011). The haemophilia study involved the in 
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vivo delivery of ZFNs targeting intron 1 of human factor IX gene via an AAV8 vector 
accompanied by a donor vector to stimulate HDR in a humanised mouse model for haemophilia 
B. The authors successfully demonstrated that at week 10, a population of cells in the range of 
1-3% had undergone HDR and the circulating levels of human factor IX were directly 
correlated averaging around 2-3% (Li et al., 2011).  
Genome editing tools have made a substantial breakthrough in search of a treatment for HIV-1 
with clinical trials led by Sangamo Biosciences currently underway (NCT00842634 and 
NCT02388594). The miraculous clearance of the viral load in the HIV-positive “Berlin patient” 
who underwent allogeneic hematopoietic stem and progenitor cell (HSPC) transplantation from 
a donor homozygous for the CCR5∆32 mutation (Hutter et al., 2009, Hutter and Thiel, 2011) 
has propelled research forward in generating targeted CCR5 gene knockout cells, a key co-
receptor for CCR5 tropic HIV-1 entry into T-cells. A chimeric adenoviral vector Ad5/F35, with 
selective tropism to cells of the haematopoietic lineage, expressing ZFNs targeting a coding 
region upstream of the known CCR5∆32 mutation was established and employed for the 
modification of primary CD4(+) T cells (Maier et al., 2013, Perez et al., 2008). Preclinical 
studies in a NOD/Shi-scid/IL-2Rγnull (NSG) mouse model of HIV-1 infection showed the 
efficient reduction of HIV-1 viral load after engraftment with the ZFN-modified CD4(+) T cells 
(Perez et al., 2008). A follow-up study revealed the progression of the vector to clinical scale for 
the ex vivo stable modification of autologous primary human T cells in a cohort of twelve 
patients with no adverse effects reported (NCT00842634) (Perez et al., 2008). Parallel studies 
by Sangamo BioSciences are now entering the phase II clinical trial stages (NCT01252641 and 
NCT01044654). The ZFN construct used by Perez et al. and Maier et al. is also being tested in 
parallel for delivery to CD34+ HPSCs by nucleofection aiming to overcome potential host 
immunogenic responses associated with adenoviral vectors, with results showing high levels of 
CCR5 disruption when transplanted into NSG mice (Holt et al., 2010).  
1.10.4  ZFNs for the in vitro modelling and treatment of genetic diseases 
ZFNs have also been employed for the correction of a number of diseases in a preclinical in 
vitro setting with measurable success. Some of these studies have included work on X-linked 
severe combined immunodeficiency disorder (X-SCID) by plasmid delivery of IL2Rγ specific 
ZFNs (Urnov et al., 2005) and improving T-cell immunotherapy by the targeted knockout of the 
endogenous αβ T-cell receptor (TCR) using ZFNs delivered by either the Sleeping Beauty (SB) 
transposon system (Torikai et al., 2012) or by NILV (Provasi et al., 2012) and subsequent 
expression of tumour specific TCRs for the development of an allogeneic adoptive T cell 
therapy.  
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More recently, there has been a move towards the correction of patient-derived iPSCs as a 
regenerative medicine approach, for their obvious advantages of unlimited proliferation, 
multilineage differentiation and potential for autologous transplantation. Their use has been 
reported in sickle cell anaemia with plasmid-mediated ZFN transfer against mutated β-globin 
alleles (Zou et al., 2011a, Sebastiano et al., 2011); α1-antitrypsin deficiency by the PiggyBac 
delivery of ZFNs and donor for the biallelic correction of the A1AT gene and subsequent 
differentiation into liver cells (Yusa et al., 2011); and X-CGD via NILV-ZFN site-specific HR 
targeting of a gp91phox minigene to the “safe harbour” AAVS1 locus (Zou et al., 2011b). 
Advances have also been made in the modelling and understanding of mutations associated with 
Down’s syndrome (Jiang et al., 2013) and Parkinson’s disease (Soldner et al., 2011) by ZFN-
mediated gene knockout. 
1.10.5  Modes of delivery of ZFN to mammalian cells 
1.10.5.1 DNA plasmid/mRNA 
As seen from the studies mentioned previously, the route and mode of ZFN delivery has been 
extensively variable. Therefore, one of the key areas of interest in the field still remains the 
search for an improved method of delivery (Genovese et al., 2014). Typically the custom ZFNs 
are delivered to target cells by transient cationic lipid-based transfection or electroporation in 
the form of plasmid DNA or mRNA, with the advantage of the latter being rapid expression and 
prevention of undesirable nuclease integration. The permissiveness of certain cell types to such 
delivery methods, which are also often associated with high toxicity in primary cell types, added 
to the prolonged and uncontrolled cDNA expression leading to potential off-target cutting 
further illuminates the caveats of this approach. A shift has been made towards the use of viral 
vectors as an alternative delivery approach (Lombardo et al., 2007).  
1.10.5.2 Adeno-Associated Viruses (AAV) 
Viral vectors based on both adenoviruses and AAV, commonly used in gene therapy trials, have 
recently made an appearance in the gene editing field. The transgene capacity of up to 4.2 kb in 
AAV vectors is sufficient for the packaging of both ZFN monomers while large enough to also 
accommodate a donor construct, making it an attractive delivery platform for both in vitro and 
in vivo application. Ellis et al. proved the efficiency of such a system by incorporating a donor 
substrate alongside both ZFN arms separated by a 2A cleavage domain in a recombinant AAV 
(rAAV) type 6 serotype. The obvious advantage is the minimisation of delivered viral particles 
to the cell which have been shown to cause significant toxicity. Additionally, delivery of all 
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three constructs as a single vector was demonstrated to substantially increase gene targeting and 
correction efficiency, most likely due to the minimisation of vector transduction competition 
(Ellis et al., 2013). 
1.10.5.3 Non-integrating Lentiviral Vectors (NILV) 
NILVs based on HIV-1 are favourable as a ZFN delivery platform due to their capacity to 
induce a permanent and heritable genome modification following HDR. Contrary to the widely 
used integrating lentiviral system, NILVs remain as linear or circular DNA strands in an 
episomal state; fundamental for the “hit-and-run” effect desired from ZFNs. That enables them 
to circumvent the potentially deleterious clinical consequences of transgene integration into the 
host chromosome. Although these vectors have been designed to entirely ablate host genomic 
integration, reports in the literature have revealed a low frequency of illegitimate background 
integrase-independent insertions (Banasik and McCray, 2010), which could potentially 
compromise their use in the clinic. Although the levels are practically negligible, it has been 
suggested that they can be further reduced by the deletion of the cPPT in the vector (Kantor et 
al., 2011). For successful targeted sequence cleavage both ZFN monomers have to be delivered 
in equal proportion. As with AAV, various groups have attempted the delivery of both ZFNs in 
a single vector with relative success (Joglekar et al., 2013, Yi et al., 2014, Lombardo et al., 
2007). However, the process of reverse transcription resulted in recombination events in tandem 
repeat regions of the closely positioned ZFN monomers leading to significantly diminished 
nuclease activity. Codon optimisation has now been employed to address the issue (Joglekar et 
al., 2013).  
As previously noted, the ability to target primary cells has been the main limitation of plasmid 
transfection. Pseudotyping, thereby offering an interchangeable viral envelope to the vector, 
which can confer cell specific tropism, is a powerful tool unique to this platform. Typically 
VSV-G is used with the added advantage of its broad host cell tropism and stability during viral 
concentration steps by ultracentrifugation, but others such as the native HIV-1 envelope has 
been used for the efficient and selective transduction of unstimulated CD4+T cells and 
subsequent disruption of CCR5 (Yi et al., 2014). NILVs can therefore be used as a delivery 
vehicle for practically any cell type of any lineage, both dividing and non-dividing. The 
drawbacks of using viral vectors predominantly revolve around their challenging manipulation 
and complex production, although they still remain a safe and highly efficient mode of delivery 
to otherwise non-permissive cell types.  
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1.10.5.4 ZFN proteins 
The most recent development aiming to enhance nuclease delivery has been the use of purified 
recombinant ZFN proteins which can easily permeate cell membranes due to the ZFP domains 
carrying a net positive charge, and induce targeted gene disruption. The main limitations 
associated with internalisation of highly charged proteins are the requirement of a relatively 
high starting protein concentration and that entry into the cell is likely to occur in a non-specific 
manner. Fusing targeting ligands such as transferrin to the ZFN proteins has been shown to 
significantly enhance the targeted delivery of the nucleases and at lower concentrations (Chen et 
al., 2013). Added benefits include their almost immediate effect, yet short half-life of 
approximately 4 hr within the host cell, thereby reducing potential integrations and off-target 
cleavage. Additionally, this method overcomes cell-type dependency and proves a safer option 
as the host cells are not exposed to any foreign genetic material. Encouraging data has been 
published on the delivery of ZFN in protein form for the targeting of the CCR5 gene (Gaj et al., 
2012). 
1.10.6  Emergence of newer systems 
A plethora of gene editing tools have been developed since the realisation of ZFNs’ potential, 
namely meganucleases, TALENs and clustered regularly interspaced short palindromic repeats 
(CRISPR). All function in a similar manner comprising of a DNA binding motif associated with 
a nuclease. Each comes with their advantages and limitations, as do ZFNs, but none of the 
systems has been coined as the definitive one yet. The major drawbacks with ZFNs have been 
their challenging assembly in a lab setting, the stringency in the selection of compatible ZFP 
modules with a suggested functional obtainable ZFN pair per ~100 bp DNA sequence (Kim et 
al., 2009) and their reported off-target cleavage (Gabriel et al., 2011). In an attempt to combat 
off-target effects, ZFN nickases have been generated carrying a mutation in one of the FokI 
subunits only allowing for a single-strand break (SSB) to occur therefore increasing their safety 
profile although inevitably lowering the efficiency of HDR (Kim et al., 2012, Wang et al., 2012, 
Ramirez et al., 2012).  
TALENs derived from the Xanthomonas spp. bacterium similar to ZFNs can bind and cleave 
genomic sequence via a FokI endonuclease domain coupled at their carboxyl termini 
responsible for DSB generation. Each DNA binding domain is composed of 33 - 35 tandem 
amino acid repeats forming the scaffold with amino acid repeats at positions 12 and 13 known 
as repeat variable diresidues (RVDs) governing the single nucleotide specificity (Kim and Kim, 
2014). Approximately 20 such binding domains are required for targeted recognition of 
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genomic sequence. The off-target effects tend to be much lower with TALENs, primarily due to 
their design being such that each TALEN is specific for one nucleotide as opposed to the ZFN 
specific triplet. This therefore allows for a greater design flexibility and can be directed towards 
anywhere within the genome thereby permitting the selection of unique target sequences. 
Furthermore, in comparison to ZFNs they are slightly less challenging in terms of production 
within the lab and can be designed at a lower cost. Their overall size though, approximately 
three times that of ZFNs, and their highly repetitive nature restricts their delivery and can lead 
to rearrangement events when cloned into a NILV platform due to reverse transcriptase 
mediated template switching (Holkers et al., 2013).  
CRISPRs make up a novel group of genome editing tools belonging to a separate family to 
ZFNs and TALENs. Originating from bacteria, the CRISPR system is directly involved in the 
acquired immunity against pathogenic viral and plasmid DNA by fragmenting it and 
incorporating it in the form of “spacers” into short genomic loci. Of the three CRISPR/Cas 
systems, type II is the most widely used for genome editing and functions by processing the 
DNA fragments into short CRISPR RNA (crRNA) which act as guides for the targeting of 
specific sequences and anneal to transactivating crRNAs (tracrRNA) which in turn sequester 
Cas proteins mediating DNA cleavage (Jinek et al., 2012). A requirement for the recruitment of 
Cas9 is a conserved dinucleotide-containing protospacer adjacent motif (PAM) sequence, 
typically (NGG) for Streptococcus pyogenes derived Cas9, upstream of the crRNA-binding 
region. Synthetic crRNA/tracrRNA combined structures have been designed and coined short-
guide RNA (sgRNA). These typically 20 bp sequences can be designed against virtually any 
portion of the genome with target sites averaging one per 8 bp accounting for a PAM sequence 
availability, and delivered in conjunction with Cas9 as a single plasmid or vector (Jinek et al., 
2012). As with ZFNs and TALENs they can induce a DSB at the target site, which can be used 
for disease modelling by introduction of indels through NHEJ, or HDR upon the provision of a 
donor template sequence.   
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1.11  Project aims 
Although several therapeutic approaches are currently in development to combat RDEB, there is 
no successful treatment that can provide a cure for the affected individuals. This study proposes 
a method for genetically correcting patients’ cells to restore the functionality of the DEJ. 
Possible target cells include keratinocytes, fibroblasts, mesenchymal cells and bone marrow 
stem cells. I plan to use a state-of-the-art lentiviral vector as a delivery system, to introduce a 
full-length codon optimised COL7A1 gene into autologous RDEB patient cells the hypothesis 
being that ex vivo gene corrected cells can then be re-infused into the patient either by skin 
grafting, intradermal injection or systemically. Using a 3rd generation COL7A1 expressing 
lentiviral vector, I aim to assess its efficiency in restoring C7 expression and function in both 
RDEB primary keratinocyte and fibroblast primary cells and cell lines initially in vitro (Figure 
1.11). To obtain an accurate estimation of the corrective potential of the vector, in vivo studies 
will be carried out which entails the development of a suitable RDEB animal model. 
A secondary approach I wish to investigate alongside gene addition is the use of a targeted gene 
editing strategy to help overcome limitations associated with the large size of the transgene 
approaching the upper limit of vector capacity. By designing highly specific nucleases against a 
distinct region of a gene permits its targeted knockout by NHEJ or correction of the endogenous 
sequence by HDR. For this approach I aim to use ZFNs as the genome-editing tool of choice 
delivered via a NILV system thereby improving efficiency of delivery of genetic material to 
primary skin cells otherwise non-permissible to normal transfection. Harnessing both processes 
of the endogenous cell repair machinery following ZFN-mediated DSBs, will primarily allow 
for the in vitro modelling of RDEB through generation of monoallelic and biallelic knockouts, 
while further enable the quantification of HDR upon provision of an exogenous donor repair 
template. To our knowledge this is the first study to assess the disruption and subsequent 
restoration of the human COL7A1 gene using ZFN gene-editing machinery. Besides providing 
us with a repeatable method of obtaining an unlimited supply of RDEB cell lines with specific 
mutations, it could potentially result in a personalised clinical treatment by autologous, site-
specific correction of a wide range of missense, nonsense and splice site mutations via healthy 
donor template delivery (Figure 1.11).  
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Hypothesis 
i) Delivery of a full length COL7A1 transgene to primary RDEB cells by lentiviral 
vector will restore C7 protein expression and reinstate functionality to the 
diseased cells. 
ii) Grafting lentivirally corrected primary RDEB cells into a human:murine 
chimeric skin graft model will lead to AF formation at the DEJ and ameliorate 
the disease phenotype.  
iii) In vitro RDEB cell models can be generated by the NHEJ activity of ZFNs 
targeting COL7A1 delivered to keratinocytes by NILVs. Co-delivery of a 
homologous donor template can mediate site-specific repair of genomic 
disruptions by HDR. 
Objectives 
i) Develop a gene addition strategy based on a lentiviral vector platform for the 
restoration of C7 expression and function to autologous human RDEB patient 
cells. 
ii) Develop a human:murine chimeric RDEB skin graft model to investigate the in 
vivo restorative potential of ex vivo lentivirally corrected RDEB cells. 
iii) Design a state-of-the-art gene editing strategy for the site-specific manipulation 
of the endogenous COL7A1 genomic sequence aiming to generate targeted 
DSBs and consequently correction of individual patient mutations. 
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Figure 1.11 Gene modification strategies for the correction of autologous RDEB cells.  
Autologous RDEB patient keratinocytes or fibroblasts isolated from 6 mm biopsy for correction by: i) 
gene addition using LV-COL7 vector for delivery of a full-length WT COL7A1 transgene or ii) by 
targeted gene editing of COL7A1 mutations using site-specific nucleases co-delivered with a homologous 
donor repair template. 
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Chapter 2  Materials and Methods 
2.1 Materials 
2.1.1  Reagents 
DNA  
10X TAE: 400 mM Tris-acetate and 10 mM EDTA  (Thermofisher, Waltham, MA USA) 
1Kb Plus DNA ladder  (Thermofisher) 
Branched PEI - Polyethylenimine (PEI)  (Sigma-Aldrich, Dorset, UK) 
Deoxynucleotide (dNTPs)  (NEB, Ipswich, MA, USA) 
Gel Loading Dye, Purple (6X) (NEB) 
Lipofectamine® 2000  (Thermofisher) 
Platinum® Quantitative PCR SuperMix-UDG with ROX  (Thermofisher) 
Sodium acetate (3M) pH 5.5  (Sigma-Aldrich) 
Taq DNA Polymerase  (Roche, Welwyn Garden City, UK) 
UtlraPure™ Agarose  (Thermofisher) 
 
Protein analysis 
Amersham Full-Range Rainbow Markers  (GE LifeSciences, Buckinghamshire, 
 UK) 
Amersham Hybond-P PVDF Membrane    (GE LifeSciences)  
Ammonium persulfate (APS) (Sigma-Aldrich) 
cOmplete Protease Inhibitor Cocktail Tablets (Roche) 
Dithiothreitol (DTT) (Thermofisher) 
Phenylmethanesulfonyl fluoride (PMSF)  (Sigma-Aldrich) 
Ponceau S Solution  (Santa Cruz, Dallas, TX, USA) 
Sodium Dodecyl Sulphate (SDS) (Sigma-Aldrich) 
Triton™ X-100  (Sigma-Aldrich) 
Trizma Base (Sigma-Aldrich) 
Whatman 3MM chromatography paper  (Sigma-Aldrich) 
30% Acrylamide/Bis (37.5:1) solution  (Bio-Rad, Hertfordshire, UK) 
 
Cell culture 
Ascorbic acid  (Sigma-Aldrich) 
Dimethyl sulfoxide (DMSO)  (Sigma-Aldrich) 
Dulbeco’s Modified Eagle Medium (DMEM)  (Thermofisher) 
DMEM: Nutrient Mixture F-12 (DMEM/F12) (Thermofisher) 
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Foetal Calf Serum (FCS) (Seralab, West Sussex, UK) 
Mitomycin C  (Sigma-Aldrich) 
NB Collagenase and Neutral Protease (SERVA, Heidelberg, Germany) 
Opti-MEM®  (Thermofisher) 
Penicillin Streptomycin (Pen Strep)  (Thermofisher) 
Phosphate-buffered saline (PBS)  (Thermofisher) 
Trypan Blue solution 0.4%  (Thermofisher) 
Trypsin-EDTA (0.05%), phenol red   (Thermofisher) 
Trypsin-EDTA (0.25%), phenol red  (Thermofisher) 
 
Mouse studies / Immunofluorescence 
Antifade 1,4-diazabicyclo-[2.2.2]octane (DABCO) (Sigma-Aldrich)  
Antisedan 5 mg/ml  (Pfizer, Surrey, UK) 
DAPI 5mg/ml (Sigma-Aldrich) 
Dormitor 1 mg/ml  (Olenco) 
DPX mountant (Sigma-Aldrich) 
Eosin Y 1% solution (Sigma-Aldrich) 
Haematoxylin Solution, Gill No.1 (Sigma-Aldrich) 
Mowiol 4-88  (Merk Millipore, Hertfordshire, UK) 
Paraformaldehyde 16% Solution (VWR, Leicestershire, UK) 
Pig plasma in Sodium Citrate unfiltered, 500ml  (Seralab) 
ProLong Gold Antifade Mountant  (Thermofisher) 
Thrombin from human plasma  (Sigma-Aldrich) 
Tissue-Tek® O.C.T.™ Compound (Sakura, Alphen aan den Rijn  
 The Netherlands) 
Vetalar V 100 mg/ml  (Pfizer)  
Vetergesic 0.3 mg/ml  (Alstoe, York, UK) 
 
Bacterial Culture 
Ampicillin  (Sigma-Aldrich) 
JM109 Competent Cells (Promega, Manheim, Germany) 
Kanamycin  (Sigma-Aldrich) 
LB medium (capsules)  (MP Bio, Santa Ana, CA, USA) 
LB-Agar Medium (capsules)  (MP Bio) 
One shot Stbl3 Chemically Competent E. coli (Thermofisher) 
S.O.C. Medium  (Q-BioGene, Carlsbad, CA, USA) 
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2.1.3  Kits 
BigDye® Terminator V3.1 Cycle Sequencing Kit  (Thermofisher) 
Bio-Rad protein assay  (Bio-Rad) 
ECLplus™  (GE Healthcare, Hatfield, UK) 
Mix-n-Stain™  (Biotium, Cambridge Biosciences, 
 Cambridge, UK) 
Oris™ Cell Migration Assay  (Platypus Technologies, Madison WI, 
 USA) 
ProteoExtract®  (Merk Millipore) 
QIAamp DNA Mini Kit  (QIAGEN, Manchester, UK) 
QIAprep Spin Miniprep; Maxiprep; Gigaprep Kit  (QIAGEN) 
QIAquick Gel Extraction Kit  (QIAGEN) 
QIAquick PCR Purification Kit  (QIAGEN) 
QuikChange II XL Site-Directed Mutagenesis Kit  (Agilent Technologies, Cheshire, UK) 
Surveyor Mutation Detection assay  (Transgenomic, Omaha, NE, USA) 
pCR®4-TOPO® (Thermofisher) 
ZR-96 Quick-gDNA™  (Zymo Research, Cambridge 
 Biosciences, Cambridge, UK)  
2.1.4  Buffers 
0.5M Tris/HCL buffer, pH 6.8: 6.07 g Trizma Base (MW 121.44) was dissolved in 80 ml dH2O 
and adjusted to pH 8.8 with 5 N HCL (~2 ml) and made up to 100 ml. The buffer was stored at 
RT. 
1.5M Tris/HCL buffer, pH 8.8: 18.21 g Trizma Base (MW 121.44) was dissolved in 80 ml 
dH2O and adjusted to pH 8.8 with 5 N HCL (~3 ml) and made up to 100 ml. The buffer was 
stored at RT. 
10% ammonium persulfate (APS): 0.1 g APS was dissolved in 1 ml dH2O and kept for up to a 
week at RT. 
10% sodium dodecyl sulphate (SDS): 1 g SDS was dissolved in 100 ml dH2O. The buffer was 
stored at RT. 
10X running buffer: 0.25 M Tris, (MW 121.44) 30.3 g; 1.92 M Glycine, (MW 75.07) 144 g; 
1% SDS, 10 g. Make up to 1 litre with dH2O. Diluted with dH2O to 1X for use. The buffer was 
stored at RT. 
10X wash buffer: 0.5% Tween-20 in 10X PBS. Diluted with dH2O to 1X for use. The buffer 
was stored at RT. 
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5X Sample buffer: 10% SDS, 1g; 30% Glycerol, 3 ml; 10% β-mercaptoethanol, 1 ml; 0.001% 
bromophenol blue, 1 mg. Made up to 10 ml with 0.5M Tris/HCL, pH 6.8, aliquoted and stored 
at -20°C. 
Blocking solution: 5% dried skimmed milk (Marvel) in 1X wash buffer. 
Diluent 1: 3% BSA in 1X wash buffer. 
Diluent 2: 3% dried skimmed milk (Marvel) in 1X wash buffer 
Eosin working solution: 1 part of eosin stock solution + 3 parts of 80% ethanol + 0.5 ml glacial 
acetic acid was mixed in 100 ml of dH2O. 
LB medium: 20 capsules per 1 L of dH2O, autoclaved at 121°C for 15 min. Typical content per 
1 L: 10 g Tryptone, 5 g Yeast Extract, 10 g NaCl. 
LB-agar medium: 40 capsules per 1 L of dH2O, autoclaved at 121°C for 15 min. Typical 
content per 1 L: 10 g Tryptone, 5 g Yeast Extract, 10 g NaCl, 15 g Agar. 
Lysis buffer base: 50 mM Tris/HCL, pH 8.0, (MW 121.4); 150 mM NaCl, (MW 58.44), 5 mM 
EDTA (Ethylenediaminetetraacetic acid, MW 380.2) 
Lysis buffer: 50 mM Tris/HCL, pH 8.0, (MW 121.4); 150 mM NaCl, (MW 58.44), 5 mM 
EDTA (Ethylenediaminetetraacetic acid, MW 380.2), 1:25 dilution of stock cocktail protease 
inhibitor (cOmplete cocktail tablets); 1 mM PMSF 
Mowiol mountant: 6 ml glycerol and 2.4 g (10%) of Mowiol 4-88 and 6 ml water were 
combined and mixed in a 50 ml falcon tube by vortexing and placed on a roller for 2 hrs. 12 ml 
of 200 mM Tris-HCL at pH 8.5, was added to the falcon tube and was incubated at 50°C for ~3 
hrs with occasional mixing. The solution was passed through a 0.45 µm sterile filter and stored 
in 2 ml aliquots at -20°C. Prior to use, antifade 1,4-diazabicyclo-[2.2.2]octane at 2.5% (w/v) 
concentration (DABCO) was added to the Mowiol mountant and allowed to dissolve for 30 min 
at RT to prevent photobleaching. Mowiol with antifade was kept at 4°C for up to a week.  
PEI transfection reagent: For preparation of 10 mM PEI, 50 ml of PBS was adjusted to pH 4.5 
using HCL. 10.3 g of polyethylenimine was weighed into a 50 ml falcon tube and 31 ml of PBS 
pH 4.5 was added. The solution was placed in a 75°C water bath and vortexed every 10 min 
until completely dissolved. The PEI was aliquoted and stored at -80°C. 
Rainbow ECL full-range Molecular Weight Markers: Stock Rainbow molecular weight 
markers were aliquoted at 10 µl per vial and stored at -20°C. 
Separating gel: (all volumes calculated for production of x2 6% 10 ml gels) dH20, 5.35 ml; 
1.5M Tris/HCL pH 8.8, 2.5 ml; 30% Acrylamide/Bis, 2 ml; 10% SDS, 0.1 ml; 10% APS, 0.075 
ml; TEMED, 0.0075 ml. 
S.O.C (Super Optimal Broth): liquid medium was prepared by adding 31 g of powder per 1 L 
of dH2O and autoclaved at 121°C for 15 min. The final composition per L: 20 g Tryptone, 5 g 
Yeast Extract, 0.5 g NaCl, 5 g MgSO4.7H2O, 20 mM Glucose.  
 
77 
Stacking gel: dH20, 3.05 ml; 0.5M Tris/HCL pH 6.8, 1.25 ml;  30% Acrylamide/Bis, 0.65 ml; 
10% SDS, 0.05 ml; 10% APS, 0.0375 ml; TEMED, 0.0075 ml. 
Stripping buffer: 2% SDS and 100 mM of β-mercaptoethanol in 62.6 mM Tris-HCL, pH 6.7 
(stock β-mercaptoethanol at 14.3 M, add 70 µl of stock β-mercaptoethanol into 10 ml stripping 
buffer base). 
Transfer buffer: 0.025 M Trizma Base (MW 1221.33), 6 g; 0.019M Glycine (MW 75.07), 29.6 
g; 20% methanol, 400 ml. Dissolve in 2 L dH2O 
Trituration buffer: (For 700ml) 100 mM CaCl2 (10.29 g) + 70 mM MgCl26H20 (9.96 g) + 40 
mM Sodium Acetate anhydrous (2.3 g). The pH was adjusted to pH 5.5 and the buffer was 
passed through a 0.45 µm sterile filter. 
2.1.5  Culture media 
Complete media (DMEM/10% FCS): DMEM; 10% FCS; 1% Pen/Strep. 
Keratinocyte media: 3 parts of DMEM medium to 1 part of HAM/F12 medium; 10% FCS; 1% 
Pen/Strep. 
Complete keratinocyte media: 3 parts of DMEM medium to 1 part of HAM/F12 medium; 10% 
FCS; 1% Pen/Strep; 1% RM+. 
RM+: Hydrocortisone 0.4 g/ml; Choleratoxin 10
-10 M; Transferrin 5 g/ml; Lyothyronine 2x10-11 
M; Adenine 1.8x10-4 M; Insulin 5 g/ml; EGF 10 ng/ml. 
N.B. Lyothyronine was initially dissolved in 1 part of HCL and 2 parts of ethanol; Adenine was 
dissolved in NaOH pH 9; Insulin was dissolved in 0.05 M HCL. 
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2.1.6  Antibodies 
Table 2.1 List of primary antibodies used in this study. 
 
Antibodies 
 
 
 
 
 
 
Target/ lineage specificity 
 
 
 
Dilution 
 
 
 
Supplier 
 
 Keratin 10 Suprabasal keratinocytes 1:10 In-house 
Desmoglein I Cell-cell junctions Human 
specific 
1:100 Fitzgerald 
Industries 
mAb-C7-LH7.2 C7 protein Human specific 1:500 Sigma-Aldrich 
mAb-C7-LH7.2 C7 protein Human specific 1:25 Flow Santa Cruz 
Calbio-C7-pAb C7 protein Human/Mouse specific 1:200 IF 1:500 WB Calbiochem 
Chen-C7 C7 protein Human/Mouse specific 1:2,000 IF 1:2,500 WB Prof. M. Chen 
Purified C7-pAb C7 protein Human specific 1:1,250 Abnova 
C7-1002.3 C7 protein Human specific 1:100 Accurate Chemical 
C7-C12207 C7 protein Human/Mouse specific 1:200 Assay 
Biotechnologies 
C7-SAB4500390 C7 protein Human/Mouse specific 1:200 Sigma-Aldrich 
C7-sc20774 C7 protein Human/Mouse specific 1:100 Santa Cruz 
C7-sc8928 C7 protein Human/Mouse specific 1:100 Santa Cruz 
Keratin 14 Basal and suprabasal 
Human/Mouse keratinocytes 
1:1,000 Covance 
MTCO2 Mitochondrial Complex IV 
subunit II Human specific 
1:250 Abcam 
Involucrin Suprabasal keratinocytes 
Human specific 
1:15,000 Sigma-Aldrich 
Vinculin Loading control 1:250,000 Sigma-Aldrich 
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Table 2.2 List of secondary antibodies used in this study. 
 
Antibodies 
 
 
 
 
 
 
 
 
Conjugate 
 
 
 
Dilution 
 
 
 
Supplier 
 
 
Goat Anti-Mouse (IgG) AlexaFluor 488 1:500 Invitrogen 
Goat Anti-Mouse (IgG) AlexaFluor 568 1:500 Invitrogen 
Goat Anti-Rabbit (IgG) Alexa Fluor 568 1:500 Invitrogen 
Anti-Mouse (IgG) Biotin 1:100 Sigma-Aldrich 
Streptavidin AlexaFluor 488 1:200 Thermo Fisher 
Anti-Mouse (IgG) HRP 1:3,000 GE Healthcare 
Anti-Rabbit RG-96 IgG HRP 1:7,000 Sigma-Aldrich 
Goat Anti-Mouse Cy3 1:500 Abcam 
Goat Anti-Rabbit Cy3 1:500 Abcam 
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2.1.7  Mammalian and murine cells 
Table 2.3 List of WT mammalian and murine cells. 
Cell ID Cell Type Immortalisation 
HEK-293T Human Embryonic Kidney Cell (Line) SV40 large T antigen 
NTERT Human Keratinocyte (Line) 
Human telomerase reverse 
transcriptase (hTERT) 
HaCaT Human Keratinocyte (Line) Spontaneously transformed 
NIKS Human Keratinocyte (Line) Spontaneously transformed 
WT KC Human Keratinocyte (Primary) - 
WT FB Human Fibroblast (Primary) - 
3T3-SWISS Mouse Fibroblast (Line) Spontaneously transformed 
 
 
Table 2.4 List of RDEB human patient and murine model cells. 
Patient 
ID 
Mutation 
c.DNA level 
Mutation 
Protein 
level 
Exon/ 
Intron 
Type of 
Variant 
Variant 
effect 
EB type / 
subtype 
RDEB 
EBKC 
cell line 
(+/-) c.1732C>T 
p.Arg578X 
(p.R578X) 
13 
Base 
substitution 
nonsense 
(stop codon) 
RDEB 
(+/-) c.2716C>T 
p.Gln906X 
(p.Q906X) 
21 
Base 
substitution 
nonsense 
(stop codon) 
RDEB 
RDEB 
patient 
(CK) 
(+/+) c.425A>G 
p.Lys142Ar
g (p.K142R) 
3 
Base 
substitution 
missense, 
splicing 
change 
RDEB 
RDEB 
patient 
(EB8) 
(+/-) c.1732C>T 
p.Arg578X 
(p.R578X) 
13 
Base 
substitution 
nonsense 
(stop codon) 
RDEB 
(+/-) 
c.2710+2T>C 
(IVS20+2T>C) 
- 
Intron 
20 
Base 
substitution 
splicing 
change 
NHS-
RDEB 
RDEB 
patient 
(BT) 
(+/-) c.5798G>A 
p.Arg1933G
ln 
(p.R1933G) 
70 
Base 
substitution 
missense or 
in-frame 
deletion 
RDEB 
(+/-) c.8440C>T 
p.Arg2814X 
(p.R2814X) 
114 
Base 
substitution 
nonsense 
(stop codon) 
RDEB-O 
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2.1.8  Mouse Strains 
NMRI-Foxn1nu were obtained from Charles River. 
NSG, or NOD scid gamma (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) were obtained from the Institute 
of Child Health, UCL. 
2.1.9  Primers  
Table 2.5 List of PCR, qPCR and SDM primers used.  
Primer name Primer sequence 
HIV packaging signal Psi forward CAGGACTCGGCTTGCTGAAG 
HIV packaging signal Psi reverse TCCCCCGCTTAATACTGACG 
HIV packaging signal Psi probe FAM-CGCACGGCAAGAGGCGAGG-TAMRA 
Human albumin forward GCTGCTATCTCTTGTGGGCTGT 
Human albumin reverse ACTCATGGGAGCTGCTGGTTC 
Human albumin probe VIC- CCTGTCATGCCCACACAAATCTCTCC-TAMRA 
SDM ex4 COL7A1 template 
primer Left forward 
GCACCTGTCCCAGGTGTGTATTCTGATCACAG
ACGGG 
SDM ex4 COL7A1 template 
primer Left reverse 
CCCGTCTGTGATCAGAATACACACCTGGGACA
GGTGC 
SDM ex4 COL7A1 template 
primer Right forward 
TGTGTATTCTGATCACAGATGGCAAATCGCAG
GACCTGGTGGACACAG 
SDM ex4 COL7A1 template 
primer Right reverse 
CTGTGTCCACCAGGTCCTGCGATTTGCCATCTG
TGATCAGAATACACA 
M13 forward GTAAAACGACGGCCAG 
M13 reverse CAGGAAACAGCTATGAC 
LV-ZFN arm forward GACCCTGCGCCTTATTTG 
LV-ZFN arm reverse CCACATAGCGTAAAAGGAGC 
COL7A1 ex4 template forward AATTCTCCATGTGGCTGACC 
COL7A1 ex4 template forward AATTCTCCATGTGGCTGACC 
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2.1.10  Parental plasmids 
pMD2.G: CMV driven Vesicular Stomatitis Virus envelope glycoprotein (VSV-G) expressing 
plasmid (Addgene). 
pCMVR8.74: 2nd generation gag-pol-tat-rev expressing lentiviral packaging plasmid driven by 
CMV promoter (Addgene). 
pCMV-dR8.74 D64V: 2nd generation integrase mutant gag-pol-tat-rev expressing lentiviral 
packaging plasmid driven by CMV promoter for generation of non-integrating lentiviral vectors 
(NILV) (Addgene). 
pRSV-Rev: 3rd generation REV expressing lentiviral plasmid driven by RSV promoter 
(Addgene). Requires co-transfection with pMDLg/pRRE. 
pMDLg/pRRE: 3rd generation gag-pol expressing lentiviral packaging plasmid driven by CMV 
promoter (Addgene). Requires co-transfection with pRSV-Rev. 
pCCL-LV-SPINK5: 3rd generation HIV-1 SIN lentiviral transfer plasmid with SPINK5 
transgene flanked by BamHI restriction enzyme recognition sites expressed from constitutive 
PGK promoter. Native HIV-1 U3 region in the 5’ LTR replaced with Tat independent CMV 
promoter.  
coCOL7A1: Codon optimised COL7A1 cDNA for the removal of cryptic splice acceptor/donor 
sites, reduction of repetitive codon usage, addition of a Kozak consensus sequence for the 
initiation of translation and addition of flanking BamHI restriction enzyme recognition sites 
subcloned into cloning plasmid (GeneArt). 
pRRL-PGK-GFP 3rd generation HIV-1 SIN lentiviral transfer plasmid with GFP transgene 
expressed from constitutive PGK promoter. Native HIV-1 U3 region in the 5’ LTR replaced 
with Tat independent RSV promoter. 
PZFN1: CompoZr™ Knockout Zinc Finger Nucleases targeting exon 4 of COL7A1 left arm 
(Sigma-Aldrich) 
PZFN2: CompoZr™ Knockout Zinc Finger Nucleases targeting exon 4 of COL7A1 right arm 
(Sigma-Aldrich) 
pHR’SIN.cPPT-SW: SIN 2nd generation lentiviral backbone including a MCS flanked by a 
SFFV promoter upstream and Woodchuck hepatitis virus post-transcriptional regulatory 
element (WPRE) downstream.  
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COL7A1 in2-ex7 donor template: A portion of the COL7A1 cDNA sequence spanning intron 2 – exon 
7 was synthesised including a 5’ EcoRI and 3’ XhoI restriction site. 2 base substitutions in intron 4 were 
introduced giving rise to a KpnI restriction digestion site to allow for distinction from endogenous 
COL7A1 sequence. The sequence was synthesised and provided in a cloning vector by GeneArt.  
2.1.11  Generated plasmids 
pCCL-PGK-COL7A1: The pCCL-LV-COL7 3rd generation lentiviral vector with the U3 
region in the 5’ LTR replaced with a CMV promoter was generated by releasing the SPINK5 
transgene from the parental pCCL-LV-SPINK5 promoter using BamHI restriction enzymes and 
retaining the PGK promoter and subcloning the codon optimised COL7A1 transgene (GeneArt) 
with BamHI compatible ends.  
NILV-ZFN left: Parental DNA plasmid PZFN1 was first digested with EcoRI and Klenow 
fragment to fill in 5’ overhangs and create a blunt end and then with XhoI leaving a sticky end. 
The digested ZFN-FokI portion was gel extracted and purified. The parental pHR’SIN.cPPT-
SW vector was linearised at the multiple cloning site with BamHI followed by 5’ overhang 
filling using Klenow fragment and with XhoI leaving a compatible sticky end with the ZFN-
FokI insert. Ligation was performed at a 1:3 backbone:insert ratio and colonies were verified by 
Sanger sequencing using LV-ZFN arm forward and reverse primers. (Provided by Dr. D. 
Almarza).  
NILV-ZFN right: Performed as described with NILV-ZFN left but using PZFN1. Colonies 
were verified by Sanger sequencing using LV-ZFN arm forward and reverse primers. (Provided 
by Dr. D. Almarza).   
NILV-OriginalTemp: Performed as described with NILV-ZFN left but using COL7A1 in2-ex7 
donor template and subcloned into the modified pHR’SIN.cPPT-W vector lacking the SFFV 
promoter. Colonies were verified by Sanger sequencing using COL7A1 ex4 template forward 
and reverse primers. (Provided by Dr. D. Almarza). 
NILV-SDMTemp: The NILV-OriginalTemp was modified by site directed mutagenesis for the 
introduction of 3 silent mutations in the left ZFN binding region using SDM ex4 COL7A1 
template primer Left forward and reverse primers and an additional 4 silent mutations in the 
right ZFN binding region using SDM ex4 COL7A1 template primer Right forward and reverse 
primers to prevent unwanted template cleavage. Colonies were verified by Sanger sequencing 
using COL7A1 ex4 template forward and reverse primers. 
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2.1.12  E. coli bacterial competent cell strains 
Stbl3 genotype:  
F-mcrB mrrhsdS20(rB-, mB-) recA13 supE44 ara-14 galK2 lacY1 proA2 rpsL20(StrR)xyl-5 λ-
leumtl-1 
JM109 genotype:  
endA1, recA1, gyrA96, thi, hsdR17 (rk –, mk +), relA1, supE44, Δ(lac-proAB), [F´, traD36, 
proAB, laqIq ZΔM15] 
2.2  Methods 
2.2.1  Growth of E. coli bacterial cells 
Escherichia coli (E. coli) competent Stbl3 or JM109 cells were grown in LB broth in a bacterial 
cell shaker set to 37°C and shaking at 250 rpm. E. coli cells transformed with plasmids 
containing an antibiotic resistance gene were cultured in LB broth containing either ampicillin 
(50 µg/ml) or kanamycin (100 µg/ml). E. coli colonies were selected by growing transformed 
competent cells on LB agar plates containing either ampicillin (50 µg/ml) or kanamycin (100 
µg/ml) in a 37°C incubator. Transformed competent cells were stored in LB broth containing 
15% (v/v) glycerol at -80°C. 
2.2.2  Preparation of JM109 competent cells 
A glycerol stock of JM109 cells was used to inoculate 10 ml LB broth and cultured in a 
bacterial shaker at 37°C, 250 rpm for 24 hrs. The culture was transferred to 500 ml LB broth 
and cultured for ~3 hrs until OD600 reached 0.45 - 0.55 nm measured on a spectrometer. At that 
point the flask of cells was placed in ice water and chilled for 2 hrs and the cells were then 
collected by centrifugation 2,500 g for 20 min at 4°C. The bacterial cell pellet was resuspended 
in 20 ml of ice-cold trituration buffer, then further diluted to 500 ml in the same buffer and 
incubated on ice for 45 min. The cells were collected by centrifugation at 1,800 g for 10 min 
and the pellet was resuspended in 40.6 ml ice cold trituration buffer. 80% autoclaved glycerol 
was added drop wise with gentle swirling to a final concentration of 15% (9.37 ml for total of 
50 ml culture). The cells were aliquoted (200 µl) in 1.5 ml Eppendorf® tubes and chilled on dry 
ice. The cells were stored at -80°C until further use.  
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2.2.3  Bacterial transformation 
200µl of chemically competent E. coli Stbl3 cells (Invitrogen) or E. coli JM109 cells (in-house) 
were kept on ice, 10-50 ng of plasmid DNA was added and cells were incubated on ice for 30 
min. Cells were then heat shocked at 42°C for 45 seconds and put directly on ice for 2 min. 
S.O.C (Super Optimal Broth, Q-BioGene) media was added and the cells incubated at 37°C for 
1 hr with shaking at 250 rpm. Cells were centrifuged at 3,000 g for 2 min and resuspended in 
500 µl LB with antibiotics. 100 µl was then streaked onto LB agar plates containing the 
appropriate antibiotic, ampicillin (50 µg/ml) or kanamycin (100 µg/ml) and incubated at 37°C 
overnight. Individual bacterial colonies were selected and grown for 8 hr in 3 ml LB broth with 
the appropriate antibiotic at 37°C agitated at 250 rpm. A small volume was stored long term in 
8% glycerol at -80°C. 
2.2.4  Isolation of primary keratinocytes and fibroblasts from skin biopsies 
A 6 mm RDEB skin biopsy was obtained with authorisation from the National Research Ethics 
Services, Westminster (07/H0802/104) and with written informed consent from patients. Excess 
connective tissue was removed using a sterile blade and the sample was incubated in neutral 
protease NB (1 unit/ml) (SERVA Electrophoresis GmbH, Germany) at 37°C for 3 hrs until the 
epidermis peeled off. The epidermis was fragmented and incubated in a falcon tube containing 
0.25% trypsin in EDTA at 37°C for 3 – 4 hrs with agitation every 30 min. The suspension 
containing the digested tissue was neutralised with DMEM/10% FCS and vigorously vortexed 
to obtain a single cell suspension and filtered through a sterile cell strainer (100 µM) into a 
falcon tube. The resulting suspension was then centrifuged at 850 g for 10 min and the cell 
pellet was resuspended in complete keratinocyte media and cultured at 37°C in a 10% CO2 
incubator with the addition of irradiated 3T3 cells (1x106 cells/25 cm2). The remaining dermis 
was fragmented and treated with collagenase NB6 (SERVA Electrophoresis GmbH) (0.45 
units/ml). The resulting cell suspension was seeded into a T25 flask and cultured at 37°C in a 
5% CO2 incubator.  
2.2.5  Irradiation of mouse 3T3 cells 
3T3 murine fibroblast cells were irradiated at a dose of 600 Grays (Gy) or 60 rads (1 Gy = 100 
rads) using an irradiator containing a 137Caesium source. The irradiation time was calculated 
using a reducing factor of 15%, i.e. the water-based dose x 15%. 60 Gy should take 27 min + 2 
seconds. Accounting for the 15 % reducing factor, the final time was 23 min and 30 seconds 
(1410 seconds). 
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2.2.6  Culture of mammalian cell lines 
HEK-293T cells were routinely cultured using DMEM/10% FCS at 37°C in a 5% CO2 
incubator and passaged when reaching confluence by washing once with 1X PBS and detaching 
the cells using 0.05% trypsin in EDTA. The trypsin was neutralised with DMEM/10% FCS and 
cells were collected by centrifugation at 400 g for 5 min. The cells were resuspended in the 
appropriate volume of DMEM/10% FCS, counted and seeded accordingly.  
2.2.7  Culture of human keratinocytes 
Primary human keratinocytes (passage p0) were cultured with complete keratinocyte media in 
T25 flasks with the addition of 1x106/25 cm2 irradiated 3T3 cells providing a supporting feeder 
layer for the colonies to grow. Media was changed every 2-3 days and additional 3T3 cells were 
added every 3-4 days. When the keratinocytes reached 70 – 80% confluency, cells were 
passaged to prevent stratification. Flasks were washed once with 1X PBS and 1 ml of 0.25% 
trypsin in EDTA was added. Flasks were primarily incubated for 3 min at RT for the 
detachment of the 3T3 feeder layer, washed again with 1X PBS and inoculated with a further 3 
ml of trypsin. Flasks were incubated at 37°C until keratinocytes were completely detached. The 
trypsin was neutralised with complete keratinocyte media and the suspension was centrifuged at 
400 g for 5 min for the collection of the cells. The pellet was resuspended and counted before 
re-plating at a density of 5x105/25 cm2 in a new flask with fresh feeder cells added. Human 
keratinocyte cell lines were cultured as described above but with the omission of the 3T3 feeder 
layer. Keratinocytes were cultured at 37°C in a 10% CO2 incubator.  
2.2.8  Culture of human fibroblasts 
Primary human fibroblasts were routinely cultured using DMEM/10% FCS at 37°C in a 5% 
CO2 incubator and passaged using 0.25% trypsin in EDTA when reaching confluence. 
2.2.9  Freezing and recovery of cells 
All cells were suspended in either DMEM 10%/FCS or complete keratinocyte media, counted 
and collected by centrifugation. The cell pellets were resuspended in the appropriate volume of 
cold freezing media containing 90% FCS + 10% Dimethyl Sulphoxide (DMSO4) to obtain a 
final concentration of 2x106 cells/ml and 1 ml volumes were transferred to individual cryovials. 
These were wrapped in 3 layers of paper tissue and stored for 24 hrs at -80°C and then 
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transferred to a LN2 tank for long-term storage. Cells were recovered from LN2 by thawing the 
cryovials in a 37°C water bath for ~1 min before transferring the 1 ml volume to a 50 ml falcon 
tube containing pre-warmed DMEM 10%/FCS. The suspension was centrifuged at 400 g for 5 
min and the pellet was resuspended in 5 ml of the appropriate media, cells were counted and 
plated accordingly.  
2.2.10  Restriction endonuclease DNA digestion  
PCR products from genomic DNA or plasmid DNA were digested in a final volume of 20 µl 
containing 1X buffer (NEB), 0.1mg/ml BSA according to the requirement of each enzyme and 1 
or 2 restriction enzymes (<10% final volume) assuming buffer compatibility. The reaction was 
incubated for 2 hrs at 37°C. In cases where the buffer system was incompatible between the 2 
restriction enzymes, a QIAquick PCR Purification step intervened.  
2.2.11  Filling in of 5’ DNA overhangs  
Blunt-end cloning steps requiring filling of 5’ DNA overhangs were generated by using the 5’-
3’ polymerase activity of the DNA polymerase I Large (Klenow) fragment. The restriction 
digestion reaction from the previous step generating the 5’ overhangs was heat inactivated or 
PCR purified and 1 unit (U) of enzyme per microgram of DNA and 200 µM of dNTPs were 
added to a final volume of 30 µl. The reaction was incubated at 25°C for 15 min, followed by 
heat inactivation of the enzyme at 75°C for 20 min.  
2.2.12  Exonuclease removal of 3’ DNA overhangs 
Blunt-end cloning steps requiring removal of 3’ DNA overhangs were generated by using the 
3’-5’ exonuclease activity of the DNA polymerase I Large (Klenow) fragment. The restriction 
digestion reaction from the previous step was heat inactivated or PCR purified and 1 unit (U) of 
enzyme per microgram of DNA was added to a final volume of 30 µl. The reaction was 
incubated at 25°C for 15 min, followed by heat inactivation of the enzyme at 75°C for 20 min.  
2.2.13  Dephosphorylation of 5’ DNA termini 
DNA plasmids were incubated with 1 U of calf intestinal alkaline phosphatase (CIAP) 
(Promega) and 1X CIAP buffer in a final volume of 30 µl prior to ligation to prevent re-ligation 
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of linearised cloning vehicle DNA by removing phosphate groups from both 5´-termini. The 
reaction was incubated for 30 min at 37°C.  
2.2.14  Agarose gel electrophoresis 
0.7% - 2% UltraPure agarose was dissolved by heating in 1X TAE and allowed to cool before 
adding 0.5 µg/ml ethidium bromide. The agarose was cast in gel trays and allowed to set. DNA 
samples were loaded with the addition of a 6X purple loading dye and a 1 kb Plus DNA ladder 
was run alongside as a size reference. Electrophoresis was carried out at 80 – 120 V and gels 
were visualised under ultraviolet light using a UviDoc gel documentation system.  
2.2.15  Agarose gel purification of digested DNA fragments  
Digested DNA fragments were separated by gel electrophoresis on a 0.7% - 1.5% 1X TAE 
agarose gel containing ethidium bromide and exposed to UV light using a UviDoc gel system. 
The desired DNA fragments were excised using a sterile scalpel and gel slices of up to 400 mg 
were purified using the QIAquick Gel Extraction Kit according to the manufacturer’s 
instructions and eluted in 35 – 50 µl of dH2O. 
2.2.16  Ligation of digested DNA fragments 
Digested plasmid backbone (100 – 200 ng) was ligated to insert DNA at a 1:1 – 1:5 molar ratio 
with 1:3 typically resulting in the majority of clones using 4 U T4 DNA ligase and 1X T4 DNA 
ligase buffer with ATP (NEB) in a total volume of 20 µl. Ligations were performed at 16°C 
overnight and the ligated product was transformed into competent E. coli Stbl3 or JM109 cells 
without exceeding >10% of the total transformation volume.  
2.2.17  Introduction of silent mutations by site directed mutagenesis 
SDM of the donor template (10.2 kb) required HPLC purified primers of the region to be 
modified used at a quantity of 125 ng. This equated to 10.2 pmole of the 37 bp SDM ex4 
COL7A1 template Left forward and reverse primers. A PCR reaction was set up using 1X Pfu 
PCR buffer, 10 ng template DNA, 125 ng of each left or right primer set, 200 µM dNTPs, 3 µl 
quick solution and 1 µl Pfu Turbo (2.5 U) polymerase in a final volume of 50 µl. The PCR cycle 
was set to 1 cycle at 95°C for 1 min, 18 cycles of 95°C for 50 seconds, 60°C for 50 seconds 
68°C for 10 min 20 seconds, 1 cycle of 68°C for 7 min and the reaction was cooled to 37°C on 
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ice. 1 µl of DpnI (10 U) was added to digest non-nicked parental circular plasmid by incubating 
for 1 hr at 37°C. Mutated molecules were transformed into competent E. coli for nick repair. 
Successfully mutated sequences were confirmed by Sanger sequencing using COL7A1 ex4 
template forward and reverse primers. The second set of silent mutations was introduced by 
repeating the assay on the mutated clone DNA using 7.9 pmole of the 48 bp SDM ex4 COL7A1 
template Right forward and reverse primers. 
2.2.18  Genomic DNA extraction 
Individual cell pellets from ~1x105 cells were lysed with the addition of proteinase K and lysis 
buffer diluted in PBS at 56°C for 10 min and DNA was precipitated with 100% ethanol. DNA 
was collected using silica resin columns (QIAGEN DNA mini kit) according to the 
manufacturer’s instructions and eluted in 30 µl of dH2O. Clones grown in 96-well plates were 
extracted by directly lysing clones in the 96-well plate and extracting genomic DNA using the 
ZR-96 Quick-g-DNA kit.  
2.2.19  TOPO-TA cloning 
PCR products from the ZFN COL7A1 ex4 template amplicons were purified using the 
QIAquickPCR purification kit and ligated into the pCR®4-TOPO®. 4 µl of product was 
combined with 1 µl salt solution and 1 µl pCR®4-TOPO® vector in a final volume of 6 µl and 
incubated at RT for 5 min. 2 µl of the reaction were transformed into competent cells and grown 
on ampicillin selection LB agar plates. 6-8 colonies were picked the following day for DNA 
extraction and Sanger sequencing using the M13 forward and reverse primers.  
2.2.20  96-well sequencing reaction and DNA precipitation 
For the detection of genomic disruptions in NILV-ZFN transduced keratinocytes a PCR was 
carried out in a 96-well plate by adding 2 µl BigDye® Terminator V3.1 Ready Reaction Mix, 2 
µl of 2.5X sequencing buffer, 4 µl of DNA template and either 2 µl 1.5 µM Fwd SDM or Rev 
SDM primer in a 10 µl reaction. The amplification cycles were 96oC for 1 min, followed by 25 
cycles of rapid thermal ramp (1oC/second) to 96oC; 96oC for 10 seconds; rapid thermal ramp to 
50oC; 50oC for 5 seconds; rapid thermal ramp to 60oC; 60oC for 4 min; rapid thermal ramp to 
4oC and hold. 
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Following the BigDye® Terminator V3.1 Cycle Sequencing reaction, the PCR product was 
precipitated in a 96-well plate by centrifuging the plate at 250 g for 1 min followed by the 
addition of 1 µl 125 mM EDTA, 1 µl 3M sodium acetate and 25 µl 100% ethanol. The plate was 
centrifuged at 250 g for 1 min at 4°C and incubated at RT for 15 min. The plate was then 
centrifuged at 850 g for 30 min at 4°C and the supernatant was removed by inverting the plate 
and centrifuging at 250 g for 1 min on paper towels. 35 µl of 70% ethanol was added to the 
plate and centrifuged at 1,900 g for 15 min at 4°C. Supernatant was removed as before and the 
plate was air dried for 10 min. The plate was covered with a plate seal and stored at -20 before 
dispatching for sequencing.  
2.2.21  Cell sorting by limiting dilution and FACS 
Keratinocyte clones were manually diluted to obtain single colonies by diluting the bulk 
population to 0.85 cells/100 µl of complete keratinocyte media and seeding in multiple 96-well 
plates. Alternatively, automated cell sorting was carried out using a BD FACSARIA III (BD 
Biosciences) using FACSDiva software with cells collected in conditioned media. 
2.2.22  Plasmid DNA preparation 
E.coli transformed cells expressing the plasmid of choice were gown in 200 – 400 ml volumes 
for large-scale plasmid DNA preparation. Extraction was performed using Maxi-Prep or Giga-
Prep kits (QIAGEN) carried out to the manufacturer’s guidelines. DNA concentration in the 
eluent was measured using a Nano-Drop spectrophotometer. The measurements were taken with 
a 0.2 mm path length at a wavelength of 269 nm (A260). Confirmation of plasmids was carried 
out by restriction digestion of unique restriction sites (NEB) and subjected to 0.7 - 2% agarose 
gel electrophoresis at 100V. 
2.2.23  Lentiviral vector production 
HEK-293T cells were seeded at a density of 2.0 – 2.3x107 per T175 cm2 flask (12 flasks) for 
small scale productions and grown overnight to obtain an ~80% confluency the following day. 
For a single T175 cm2 flask, a mixture of DNA plasmids was prepared by combining 25 µg of 
transfer plasmid (pCCL-PGK-COL7A1/pRRL-PGK-GFP), 32.5 µg of gag-pro-pol packaging 
plasmid pCMV-dR8.74 (for integrating lentivirus) or 32.5 µg of pCMV-dR8.74 D64V (for non-
integrating lentivirus), 17.5 µg of envelope plasmid (pMDG.2) and 25 µg pRSV-Rev (for 3rd 
generation lentivirus) in 5 ml of Opti-MEM and passed through a 0.22 µm filter. 2 µM PEI (1 µl 
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of the prepared stock solution) was added to 5 ml of Opti-MEM and passed through a 0.22 µm 
filter. For large scale productions, cells were seeded at a density of 130x106 cells/5-layer flask 
and transfected with 180 µg of transfer plasmid (pCCL-PGK-COL7A1/pRRL-PGK-GFP), 90 
µg of gag-pro-pol packaging plasmid (pMDLg/pRRE), 55 µg of envelope plasmid (pMDG.2) 
and 45 µg pRSV-Rev in 25 ml of Opti-MEM and added to 25 ml of Opti-MEM containing 5 µl 
of PEI. The DNA plasmid and PEI mix were combined and incubated for 20 min at RT to form 
a DNA-PEI complex. The flasks were washed once with Opti-MEM and the complex was 
added (10 ml/230 ml) and topped up with an additional 2 ml of plain Opti-MEM. The cells were 
incubated with the transfection mix for 4 hrs in a 37°C 5% CO2 incubator. The transfection mix 
was then replaced with 20 ml/250 ml complete DMEM/10% FCS. 24 hrs later the media was 
replaced with 17 ml/250 ml complete DMEM/10% FCS. 48 hrs later the media was harvested 
and centrifuged at 3,300 g for 10 min to precipitate cell debris before passing through a 0.22 µm 
sterile filter. For small scale productions, the filtrate was loaded in polyalomer tubes and 
concentrated by ultracentrifugation in a Sorvall Discovery SE or a Beckman Coulter LE-80 for 
2 hrs at 100,000 g. The final viral pellets were resuspended in plain reduced serum Opti-MEM 
and left on ice for 30 min before aliquoting and storing at −80°C until further use. Second 
harvest was performed at 72 hrs. For large scale productions, the first harvest was concentrated 
by overnight spin at 7,500 g and the supernatant was discarded and the volume of the second 
harvest was added to the flasks and centrifuged for a further 6 hrs at 8,500 g on an Avanti J-26S 
Series high speed centrifuge (Beckman Coulter). The final viral pellets were resuspended in 
plain reduced serum Opti-MEM and left on ice for 30 min before aliquoting and storing at 
−80°C until further use. 
2.2.24  Vector titration 
HEK-293Ts were seeded at a density of 1x105 cells/well of a 24-wel plate and allowed to attach 
overnight. 24 hrs later, concentrated viral stocks were serially diluted 5-fold and used to 
transduce cells in a minimal culture volume of 300 µl DMEM/10% FCS. The volume was 
topped up to 1 ml DMEM/10% FCS 6 hrs later and incubated for 72 hrs. The cells were then 
harvested and analysed for vector expression by flow cytometry and qPCR. Viral titre was 
calculated off dilutions resulting in 1-10% of transgene expression to ensure 1 viral copy per 
cell. The titre was calculated using the formula [Titre (TU/ml) = (vector 
expression/100)*1000*number of cells seeded / volume of virus added].  
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2.2.25  Viral vector transduction of keratinocytes and fibroblasts 
Primary fibroblasts cultured in DMEM/10% FCS and seeded in 24-well plates or primary 
keratinocytes and keratinocyte cell lines seeded in T25 flasks with lethally irradiated 3T3 cells 
and grown in complete keratinocyte media were transduced 24 hrs later by one or two rounds of 
exposure to LV-GFP or LV-COL7 vectors at MOI 1-50. Viral and culture volumes were 
adjusted to ensure viral volume accounted for ≤10% of the total culture volume. Virus 
supernatant was added to the wells/flasks in minimum volume (300 µl in 24-well / 1.5 ml in 6-
well / 3 ml in T25) and topped up to optimal culturing volume after 6 hrs and kept on cells 
overnight. The culture media was replaced with fresh media the following day. Cells were 
propagated by subculturing in larger format culture plates/flasks. NTERT keratinocyte cell line 
was seeded at 2x105 cells/well of a 6-well plate and transduced with NILV-ZFN left, NILV-
ZFN right (MOI of 100 for each) and NILV-template (MOI of 200) in 1.5 ml complete 
keratinocyte media and topped up to 3.5 ml after 6 hrs. Medium was changed and cells 
propagated the following day.  
2.2.26  Flow cytometry for detection of GFP 
Transduced or transfected cells expressing GFP were harvested and collected by centrifugation 
at 400 g for 5 min in FACS tubes. The cells were washed once with 2% FCS/PBS and pelleted. 
The supernatant was aspirated and 400 µl of 2% FCS/PBS was added. The proportion of green 
fluorescent protein (GFP) positive cells and GFP intensity were detected by flow cytometry 
using a CyAn™ ADP Analyzer (Beckman Coulter, High Wycombe, UK). Forward and side 
scatter were used to exclude debris and aggregates and eGFP fluorescence was measured by 
filter 530/30 nm. In all cases, 10,000 eGFP+ cells were collected. Transduced cells were 
identified by eGFP fluorescence. Data were collected using Summit 4.4 (Beckman Coulter). 
Analysis was performed using FlowJo v7.6.5 (TreeStar, Stanford University, San Francisco, 
CA).  
2.2.27  Flow cytometry for detection of C7 
Primary keratinocytes and fibroblasts derived from subjects with RDEB were transduced with 
clinical grade LV-COL7 encoding lentiviral vector. Briefly, 1x105 cells were seeded in 24-well 
plates and transduction was carried out at MOI 5 with LV-COL7. For expression analysis, cells 
were fixed in Fix & Perm® Medium A (Life Technologies, Paisley, UK) for 20 min at RT in the 
dark. The cells were then washed with 2-3 % FCS/PBS, in 2 ml, twice; spun down at 550 g for 
4 min at RT. The cell pellets were resuspended in Fix & Perm® Medium B with mAb-C7-LH7.2 
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antibody at a 1:25 dilution (Santa Cruz Biotechnologies, Heidelberg, Germany), and incubated 
at 4°C overnight in the dark. The cells were washed with 2 %FCS/PBS, twice and pelleted at 
16,600 g for 4 min. The cell pellets were resuspended in Fix & Perm® Medium B with Alexa 
488 goat or rabbit anti-mouse 2ry antibody at a 1:200 dilution, and incubated at RT for 1 hr 30 
min in the dark. The cells were washed with 2% FCS/PBS twice, resuspended in 0.5 ml 2% 
FCS/PBS and analysed using flow cytometry. 
2.2.28  Quantitative PCR (qPCR) 
For the detection of integrated proviral copies in lentivirally transduced cells, genomic DNA 
was extracted with QIAamp DNA mini kit. The qPCR reaction was set up using 100 ng DNA 
template, 0.9 µM of each Psi and Albumin forward and reverse primers (Eurofins, MWG), 0.2 
µM fluorescently labelled probes (Applied Biosystems) and 1X Platinum Quantitative PCR 
SuperMix-UDG w/ROX in a 25 µl reaction volume. The reaction was run for 1 cycle at 50°C 
for 2 min, 1 cycle at 95°C for 10 min, 40 cycles at 95°C for 15 seconds and 60°C for 1 min on a 
ABI Prism 7000 sequence detection system (Applied Biosystems) Integrated copy number was 
calculated with the aid of standard curves generated using serially diluted plasmid encoding 
both viral packaging Psi and endogenous housekeeping Albumin sequences.  
2.2.29  p24 ELISA  
The HIV-1 p24 levels measured in pg/ml in viral supernatants harvested after lentiviral 
production were analysed by ELISA to assess the physical HIV-1 titre of the NILVs. Samples 
were diluted 1:100,000 and 1:1,000,000 times in Opti-MEM and the ELISA was performed 
according to manufacturer’s instructions. Briefly, the viral supernatants were diluted and then 
lysed before adding to pre-coated with anti-p24 antibody wells in duplicate. An internal kit 
standard curve was prepared by serially diluting p24 antigen and loaded in duplicate alongside 
samples. The plate was sealed and incubated in a 37ºC incubator overnight. The plate was 
washed and incubated with a biotin conjugated anti-p24 antibody for 1 hr at 37ºC. The plate was 
then washed and incubated with streptavidin-peroxidase solution for 30 min at RT after which 
stop solution was added the absorbance was read at 450 nm using a FLUOstar OPTIMA (BMG 
Labtech, Offenburg, Germany) and the concentration of p24 calculated in relation to the p24 
antigen standards. A physical titre was derived using the following conversion factor: i: (2x103 
molecules) x (24x103 Da of p24 per Physical Particle (PP)) = 48x106 ii: 48x106 /Avogadro’s 
constant = (48x106) / (6x1023) = 8x10-17 g of p24 per PP iii. There is approximately 1 PP per 
1x10-16 g of p24 iv.1x104 PP per pg of p24 v. 100 Transducing Units (TU) per 1000 PP. 
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2.2.30  Detection of mismatches by nuclease S CEL-I assay 
Clones treated with NILV-ZFNs and NILV-template were amplified for detection of 
mismatches by Nuclease S (CEL-I enzyme) + Enhancer. An initial PCR reaction containing 1X 
PCR buffer, 200 µM dNTPs, 0.5 µM of each forward and reverse ZFN primers, 0.5 U Taq 
polymerase (Roche) and 200 ng of extracted genomic DNA in a final volume of 50 µl was 
performed by heating to 95°C for 5 min, followed by 30 cycles of 95°C for 30 seconds, 64°C 
for 30 seconds and 72°C for 30 seconds, 1 cycle of 72°C for 5 min and kept at 4°C. 10 µl of the 
PCR reaction from each sample was subjected to a hybridisation reaction by heating to 95°C for 
10 min and then gradually cooling to 85°C at -2°C/second, then 85°C to 25°C at -0.1°C/second 
and kept at 4°C. For the detection of sequence mismatches the SURVEYOR Nuclease S 
reaction was performed by adding 1 µl of enhancer, 1 µl of 0.15 M Mg2Cl and 1 µl of Nuclease 
S enzyme to the 10 µl PCR reaction and incubated at 42°C for 60 min. Internal kit positive and 
negative controls (Ctrl C and Ctrl G) were carried out alongside. The reaction was run on a 
1.5% agarose gel and bands corresponding to the expected sizes of uncleaved product (372 bp) 
or (445 bp) and cleaved product (211, 161 bp) or (245, 200 bp) according to the PCR primer 
sets used were detected.  
 
Figure 2.1 Schematic of the Surveyor nuclease CEL-I assay for the detection of ZFN activity.  
The region of interest to which the ZFN arms bind and cleave is PCR amplified in the bulk cell 
population expected to carry mismatches in some alleles. The single or double-stranded breaks 
(SSB/DSB) in the genome are repaired by the NHEJ introducing indels into the sequence (depicted by 
black x). Heteroduplex formation is carried out by the denaturing and re-annealing step from 95oC – 4oC 
between mutated and WT amplicons. Cleavage then occurs by digestion with the CEL-I mismatch 
detecting endonuclease assay resulting in fragments of three varying lengths. The ratio of cleaved to 
uncleaved product seen by gel electrophoresis can be used as a rough measure of the ZFN-mediated 
cleavage efficiency.  
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2.2.31  High-throughput next generation sequencing 
DNA extracted from polyclonal NTERT population transduced with NILV-ZFNs was analysed 
by NGS using COL7A1 ex4 template forward and COL7A1 ex4 template reverse primers. 
These were coupled to flanking NGS-adapter sequences using the NEBNext Multiplex Oligos 
for Illumina kit (NEB) as per the manufactirer’s instructions. Sample sequencing was carried 
out on an Illumina MiSeq genome sequencer (Illumina, San Diego, CA, US). Set up and data 
analysis was performed by Dr. C. Deakin.  
2.2.32  In situ immunofluorescence staining  
Both LV-COL7 transduced and untransduced primary RDEB fibroblasts (minimum 1x105 
cells/per coverslip in 24-well plate) were fixed in 4% neutral buffered formalin, washed once 
with 1X PBS and permeabilised with 0.1% Triton X-100 in PBS. Cells were incubated with 
blocking solution (1% BSA in PBS) for 20 min at RT, and then incubated overnight at 4°C with 
30 µl mAb-C7-LH7.2 or Calbio-C7-pAb primary antibodies. A piece of Parafilm® was placed 
on top of each coverslip to prevent it from drying out. After washing, cells were incubated with 
goat anti-mouse or goat anti-rabbit AlexaFluor-568, or Cy3 conjugated 2ry antibodies and DAPI 
(4',6-Diamidino-2-Phenylindole). The slides were mounted on superfrost polylysine coated 
slides (VWR) with Mowiol or Prolong gold. Micrographs were imaged using a Leica DMLB 
upright microscope (Leica Microsystems CMS GmbH, Wetzlar, Germany) and a Leica SP2 
laser confocal microscope (Leica, Milton Keynes, UK) and processed using Image J (Wayne 
Rasband (NIH)) and Inkscape 0.48. 
2.2.33  SDS-PAGE immunoblotting 
Transduced and untransduced cell pellets, or cultured media supernatant from cells grown for 
48 hr in the absence of serum and supplemented with 50 µg/ml ascorbic acid, and concentrated 
using ProteoExtract® Protein Precipitation kit according to the manufacturer’s guidelines 
(Merck Millipore, Hertfordshire, UK), were resuspended in cell lysis buffer. Samples were 
lysed by pipetting the cells up and down repeatedly until the cell pellet dissolved completely, 
and then incubated for 20 min on ice. The samples were then centrifuged at 12,400 g for 10 min 
to pellet the insoluble cell debris at 4°C. The total protein concentration in the supernatant was 
determined using a Bio-Rad protein assay kit (BIO-RAD, Hertfordshire, UK). Briefly, 4 µl of 
sample supernatant was diluted 1:50, 1:100 and 1:500 times in lysis buffer base and loaded in a 
96-well flat-bottomed plate. A standard curve was formulated using 40 µg/ml of BSA serially 
diluted 2-fold to 2.5 µg/ml. BCA reagent was added at a 1:5 concentration to all samples and 
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absorbance was at an OD 595 nm. Samples from cell lysate were normalised and further diluted 
in 5X sample buffer and 3 µl fresh DTT (1 M) was added to a final sample volume of 35 µl and 
were heated at 95°C for 3 min and then kept on ice. A 6% sodium dodecyl sulphate 
polyacrylamide separating SDS-PAGE gel was made with a stacking gel above containing the 
comb. Samples were loaded and subjected to electrophoresis at 100 V in 1X running buffer. 
After electrophoresis, proteins were transferred to polyvinylidene fluoride membranes (PVDF) 
in ice-cold 1X transfer buffer at 120 V. The membrane was then washed in 1X washing buffer 
and blocked in 5% milk in 1X washing buffer for 1 hr at RT with shaking. The membrane was 
washed once and incubated with anti-C7 antibody (overnight) or anti-vinculin mAb (cl.V284, 
Sigma-Aldrich, Dorset, UK) (1 hr at RT) in diluent 1 with shaking. The membranes were then 
washed three times and further incubated with mouse anti-rabbit secondary antibody conjugated 
with HRP 1:7,000 or secondary HRP conjugated anti-mouse 1:3000 in diluent 2 and signals 
were detected using the ECLplus system. For re-probing, the membrane was stripped in 1X 
stripping buffer at 58°C for 30 min with agitation and then washed three times with 1X washing 
buffer. The blots were developed and fixed manually on x-ray film. Total protein amounts in the 
samples from concentrated culture medium supernatants loaded on the SDS-PAGE were 
checked by Ponceau S (Sigma-Aldrich, Dorset, UK) staining of the PVDF membrane following 
protein transfer. 
2.2.34  In vitro wound healing scratch assay 
Keratinocytes were seeded at a density of 1.2x106 cells per well of a 6-well plate and incubated 
overnight at 37°C with complete keratinocyte media. 22 hrs later the media was aspirated and 
the cells were treated with mitomycin C (10 µg/ml) in DMEM/10% FCS for 2 hrs at 37°C. 
Following the incubation period, a straight vertical scratch from top to bottom and a horizontal 
scratch from left to right were made in the well using a P200 pipette tip held at a 90° angle. The 
well was washed 3 times with 1X PBS to remove the detached cells and 3.5 ml of complete 
keratinocyte media was added to each well. A hole was made on the lid of the plate with a 
sterile needle to allow for the CO2 supply to be connected. The plate was placed on a 
mechanical stage in a 37°C chamber with supply of 5% CO2 and the field was imaged using a 
Zeiss Axiovert time-lapse microscope (Zeiss, Germany) at 3 different locations of the vertical 
and horizontal scratch using a 4X objective. Images were captured every 15 min for a total of 35 
hrs. The data was processed using Volocity 6.1.1 software (PerkinElmer, Coventry, UK). The 
extent of scratch closure was quantified by measuring the area of the scratch occupied at each 
time point of the migration assay, using a custom thresholding macro (Dr. Vernay B.) on 
ImageJ (Wayne Rasband (NIH)) and expressed as percentage change. The area under the curve 
 
97 
(AUC) was calculated for each triplicate of each sample and analysed by one-way ANOVA. 
Multiple comparisons were statistically analysed by Tukey’s post-test.  
2.2.35  In vitro two-dimensional migration assay 
The assay was performed as described previously (Syed et al., 2012, Syed et al., 2013) with 
some modifications. Briefly, an Oris 96-well black plate (Oris migration assay kit, Cambridge 
Bioscience, Cambridge, UK) was used and Oris cell seeding stoppers were inserted according to 
the manufacturer’s instructions. LV-COL7 transduced and untransduced RDEB primary 
fibroblasts were seeded at a density of 2.5x104 cells/well in each well of an Oris 96-well 
migration assay plates using serum-free DMEM. The plate was then incubated overnight at 
37°C and 5% CO2. The next day, the cell seeding stoppers were removed and the cells were 
treated with mitomycin C (10 µg/ml) in DMEM/10% FCS for 2 hrs at 37°C. The wells were 
washed in 1X PBS and 100 ml of fresh medium was added and the plate was further incubated 
and the cells were allowed to migrate for ~72 hrs in the migration zone. Micrographs were 
captured using 4X magnification of an inverted microscope (Olympus, Japan). Cells in the 
migration zone were counted using ImageJ (Rasband, W.S., ImageJ, US National Institutes of 
Health, USA. http://imagej.nih.gov/ij/) from four independent replicates. Data was analysed by 
one-way ANOVA. Multiple comparisons were statistically analysed by Tukey’s post-test.  
2.2.36  Bioengineered skin equivalent preparation and grafting on immunodeficient 
mice 
A fibrin matrix populated with live fibroblasts was used as the dermal component of the 
bioengineered skin. The methods for preparing and grafting bioengineered skin in nude mice 
have been previously described (Larcher et al., 2007). In brief, 1 ml of fibrinogen solution (from 
cryoprecipitate from porcine plasma) was added to 5.5 ml of DMEM/10% FCS containing 
7.5x105 human dermal fibroblasts. Immediately afterwards, 0.5 ml 0.025 mmol/l CaCl2 with 11 
U of bovine thrombin was added. Finally, the mixture was poured in two 35 mm wells (in 6-
well culture plates) and allowed to solidify at 37 °C for 1 hr and then supplemented with 3 ml 
complete keratinocyte medium overnight. The procedure was repeated a number of times 
depending on the final number of wells or grafts to be prepared. Human keratinocytes (1.2×106 
cells per well) were then seeded on the fibrin matrix and left submerged in complete 
keratinocyte medium for 72 hrs to form the epidermal layer of the bioengineered skin. When 
confluent, bioengineered skins were manually detached from tissue culture wells and grafted 
onto immunodeficient mice. All animal procedures were approved by the local ethical 
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committee and performed in accordance with the United Kingdom Animals Scientific 
Procedures Act (1986). Grafting was performed under sterile conditions using 6-week-old 
female nude (NMRI-Foxn1nu (outbred) (Charles River) or 6-week-old male or female NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ mice (NSG, Institute of Child Health, UCL). In brief, mice were 
aseptically cleansed and anaesthetised according to ASPA regulations and full thickness 35 mm 
diameter circular wounds were then created on the dorsum of the mice. Bioengineered 
equivalents were detached from the 6-well culture plate and placed orthotopically on the wound. 
The mouse skin removed to generate the wound was de-vitalised by three repeated cycles of 
freezing and thawing and used as a biological bandage and fixed with sutures to protect and 
hold the skin substitute in place during the take process. Dead mouse skin was sloughed off, 
generally within 15–20 days after grafting, and regenerated human skin became visible. 8-
weeks after grafting, mice were given an overdose of anaesthesia and analgesics, and either the 
complete graft including mouse skin bordering regions for the LV-COL7 studies or 3 mm punch 
biopsies for the TALEN studies were taken, snap frozen in LN2, embedded in OCT and 
cryosectioned at 7 µm for histological and immunohistochemical examinations. A central 
portion of the human graft was placed in TEM fixative for ultrastructural imaging. 
2.2.37  Immunofluorescent and histological staining of bioengineered grafted tissue  
Immunofluorescence staining was performed on frozen graft tissue sections following 10 min 
fixation with ice-cold 50% acetone/ 50% methanol (7 µm thickness). Sections were blocked for 
1 hr at RT with 3% FCS in 1X PBS before incubation with primary antibodies (Table 1) mAb-
C7-LH7.2, anti-desmoglein-1, anti-involucrin, anti-keratin 10, anti-MTCO2 diluted in 1X PBS 
overnight at 4oC. 24 hrs later the slides were washed three times with 1X PBS and incubated 
with secondary antibodies Alexa Fluor goat anti-mouse 488 (Invitrogen, UK), goat anti-rabbit 
Cy3 (Life Technologies, Paisley, UK), strep 488 diluted in 3% BSA/PBS was followed for 1 hr 
at RT. Sections were stained with DAPI (5mg/ml) and sealed with coverslips using mowiol 
(Calbiochem, Nottingham, UK) or ProLong Gold antifade agent (Life Technologies, Paisley, 
UK) mounting reagents. Sections were also stained by haematoxylin and eosin (H&E) 
histochemical technique. Briefly, slides were re-hydrated in a series of 3 x 2 min incubations in 
100% and 70% ethanol and water followed by a 10 min incubation in haematoxylin (Sigma-
Aldrich). The slides were rinsed in hot tap water and differentiated by one dip in acid ethanol 
(2% HCL in 70% ethanol) and rinsed in water. The slides were stained with 1% eosin (Sigma-
Aldrich) for 2 min and dehydrated in 3 x 2 min incubations in 70% and 100% ethanol. The 
slides were cleared by 2 x 5 min incubations in xylene before mounting with DPX. Staining was 
visualised and imaged using a Leica DMLB upright microscope (Leica Microsystems CMS 
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GmbH, Wetzlar, Germany) and a Zeiss Axiophot 2 (Zeiss, Oberkochen, Germany) and 
processed using Image-Pro 6.2 (MediaCybernetics, Rockville, MD, USA) or on an Olympus 
upright BX51 RT slider Diagnostic Spot microscope (Olympus, Tokyo, Japan) and analysed 
using Spot advanced 4.6 and processed using Image J (Wayne Rasband (NIH)) and Inkscape 
0.48. Confocal imaging was carried out on a Zeiss LSM 510 Meta laser confocal microscope 
(Zeiss, Oberkochen, Germany). Post processing was carried out using ImageJ.  
2.2.38  Preparation of skin grafts for transmission electron microscopy (TEM)  
For TEM, the central piece (approximately 3 x 3mm2) of each skin graft was dissected out, and 
fixed with half strength Karnovsky’s fixative (2% (v/v) paraformaldehyde, 2.5% (v/v) 
glutaraldehyde in 0.1 M phosphate buffer (pH 7.4)) for 3-5 hrs at RT and kept at 4°C until 
further processing. After the initial fixation, tissue samples were rinsed several times in PBS 
and post-fixed with 1.3% osmium tetroxide in double distilled water for 2 hrs at RT. Samples 
were then washed, en bloc stained with 2% uranyl acetate in 50% ethanol and dehydrated in a 
graded series of ethanols. Tissue samples were further equilibrated with propylene oxide before 
infiltration with TAAB epoxy resin, embedded and polymerised at 70°C for 24 hrs. Ultrathin 
sections (70-90 nm) were prepared using a Reichert-Jung Ultracut E ultramicrotome (Eeichert-
Jung, Vienna, Austria), mounted on 150 mesh copper grids (Gilder, Grantham, UK), contrasted 
using uranyl acetate and lead citrate and examined on a FEI Tecnai 12 (FEI Co., Hillsboro, 
Oregon, USA) transmission microscope operated at 120 kV. Sample processing and embedding 
was performed by L. Glover. Images were acquired with an AMT 16000M camera (Advanced 
Microscopy Techniques, Corp., Woburn, MA, USA). Morphological examination and 
anchoring fibril scoring of the TEM slides was blinded and performed by Dr. J.R. McMillan 
ultrastructural microscopy specialist. 
2.2.39  Statistical analysis 
Keratinocyte migration assays data was analysed by calculating the area under the curve (AUC) 
accounting for % scratch closure against time for each of the replicates of every sample. The 
AUCs were compared against the group by one-way ANOVA and multiple comparison analysis 
of the means was performed by Tukey’s post-test. Fibroblast migration values measured by cell 
bodies at the end-point  were analysed by one-way ANOVA and compared by Tukey’s post-
test. Error bars on flow cytometry data from LV-COL7 trnasduced keratinocytes and fibroblasts 
represent standard deviation (SD) amongst triplicates. All statistical analysis was performed on 
GraphPad Prism v.6.  
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Chapter 3  Restoration of C7 expression in RDEB cells 
using COL7A1 expressing lentiviral vector  
Experimental therapies for the management of RDEB through restoration of C7 protein 
expression have included protein replacement, cell and gene therapy and bone marrow 
transplantation, previously demonstrated to reinstate functionality in epithelial cells and 
ameliorate blistering. One of the hurdles faced in these studies has however, been the transient 
expression of C7 and the immunological risks of delivering allogeneic cells or recombinant 
protein.  
In this study, I investigated the use of an autologous gene therapy strategy for the correction of 
RDEB patient cells. This approach involved delivery of a full-length functional copy of 
COL7A1 to both RDEB patient primary keratinocytes and fibroblasts using the HIV-1 based 
lentiviral vector. Viral transfer presents the most efficient method of gene delivery to primary 
cells, allowing for safe and permanent integration of large transgenes in both dividing and non-
dividing cells. Based on this, a full-length codon optimised COL7A1 cDNA (8.9 kb) sequence 
was designed and incorporated into a 3rd generation HIV-1 lentiviral vector backbone. The 
employed lentiviral platform has been approved for use in clinical trials for other diseases 
including the skin disease Netherton syndrome (NCT01545323).  
For the evaluation of the capacity of the COL7A1 expressing vector in transducing RDEB cells, 
primary patient keratinocytes and fibroblasts isolated from RDEB skin lacking functional C7 
expression were transduced and examined for vector integration using molecular techniques. It 
was next assessed whether introduction of a functional copy of the COL7A1 gene could 
ultimately lead to the restoration of C7 expression in both RDEB cell types. This was examined 
by in situ immunofluorescence staining analysis and immunoblotting for the detection of vector-
derived full-length C7 protein expression. Furthermore, as a means of detecting an associated 
functional improvement in gene-corrected cells, an in vitro wound healing assay allowing for 
the monitoring of C7 dependent cell migration was employed.  
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3.1  HIV-1 lentiviral vector carrying codon-optimised COL7A1 
transgene under the control of internal PGK promoter 
The development of the RDEB gene therapy strategy employed in this study involved the use of 
a 3rd generation self-inactivating (SIN) HIV-1 lentiviral vector. A large deletion in the 3’LTR of 
the viral genome ensures only a single round of reverse transcription, leading to transcriptional 
inactivation of the provirus after its incorporation into the host cell rendering it replication 
incompetent. Furthermore, replacement of the native HIV-1 5’LTR with a chimeric 
Cytomegalovirus (CMV) or Rous sarcoma virus (RSV) enhancer/promoter to drive transcription 
in turn results in independence from the powerful transcriptional activator tat crucial in the 
replication of HIV-1. The two 3rd generation transfer plasmids available, pCCL (CMV) and 
pRRL (RSV) therefore allowed for packaging using both 2nd generation gag-pro-pol 
(pCMVR8.74) and 3rd generation tat mutated gag-pro-pol (pMDLg/pRRE) plasmids (Dull et al., 
1998).  
The SIN lentiviral vector was generated by co-transfection of the COL7A1 transgene bearing 
transfer plasmid, the HIV-1 packaging plasmids and a viral envelope. Although a portion of the 
preliminary in vitro studies was carried out using 2nd generation SIN HIV-1 packaging plasmids 
where rev is provided in cis with gag-pro-pol as a single plasmid the platform was then 
switched to the safer 3rd generation SIN lentiviral packaging system where a further split in the 
packaging system allows for rev to be delivered in trans (RSV-Rev). This was employed to 
reduce the risk of recombination events and RCL formation. Packaging gag-pro-pol and 
regulator of virion expression rev genes were provided in trans as separate plasmids driven by a 
CMV promoter. The rev responsive element (RRE) maintained in the gag-pro-pol ensures its 
expression is rev dependent. The envelope plasmid of choice used to pseudotype the vector was 
from the Vesicular Stomatitis virus glycoprotein (VSV-G) (pMD2.G), selected for its broad 
host-cell tropism permitting the infection of a wide range of host cell types (Figure 3.1). For the 
construction of the transfer plasmid, a full-length COL7A1 cDNA was codon optimised by the 
replacement of inhibitory sites, cryptic splice sites, poly(A) sites and RNA instability motifs and 
introduction of a Kozak sequence to increase translational initiation (Fath et al., 2011).  
The newly designed codon-optimised COL7A1 transgene sequence was synthesised and 
subcloned into a 3rd generation lentiviral transfer plasmid pCCL-PGK-COL7A1 by GeneArt. 
The human phosphoglycerate kinase (PGK) promoter, a relatively strong endogenous 
housekeeping promoter known to outperform CMV in transcriptional activity, was selected to 
drive stable and constitutive expression of COL7A1 in almost all cell types including fibroblasts 
(FB), keratinocytes (KC), haematopoietic, mesenchymal cells or iPSCs. A cPPT region was 
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incorporated in the pCCL-PGK-COL7A1 transfer plasmid as an initiation signal of reverse 
transcription and facilitation of nuclear import of HIV-1 cDNA through a central DNA flap as 
was a WPRE element shown to increase titre and expression of intronless transgenes via 
increased nuclear export. These sites were flanked by modified HIV-1 LTRs ∆U3-R-U5 
enhancer/promoter regions at both 5’ and 3’ ends of the provirus (Figure 3.1). Sequence fidelity 
of the synthesised plasmid was confirmed by direct Sanger sequencing of the whole construct. 
Restriction enzymes BamHI and NotI were also used to confirm plasmid size and transgene 
orientation (Figure 3.2). 
 
  
Figure 3.1 2nd and 3rd generation SIN lentiviral packaging plasmids.  
Provirus map: pCCL transfer plasmid backbone; CMV: cytomegalovirus; psi (ψ) encapsidation signal; 
LTR: Long Terminal Repeat 5’ or 3’ HIV R: HIV R region; HIV delta U3: self-inactivating (SIN) ΔU3 
region with a deletion; RRE: Rev responsive element; cPPT cts: central polypurine tract – central 
terminal sequence; PGK, Phosphoglycerate kinase promoter; COL7A1: human collagen VII gene 
(cDNA); WPRE: mutated woodchuck hepatitis virus posttranscriptional regulatory element; gag/pro-pol: 
HIV structural polyproteins; tat & rev: essential HIV regulatory element; polyA: polyadenylation tail; 
RSV: Rous sarcoma virus; VSV-G: Vesicular stomatitis virus glycoprotein. 
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Figure 3.2 Confirmation of LV-COL7 plasmid by restriction digestion analysis. 
pCCL-PGK-COL7A1 plasmid was digested with NotI and BamHI and checked on a 1.5% agarose gel. 
Undigested 15,926 bp band shown in first lane with second supercoiled band below. NotI single digestion 
linearises the pCCL-PGK-COL7A1 plasmid. BamHI digestion gives rise to two fragments 8,856 bp and 
7,070 bp. Double digestion with NotI and BamHI shows the predicted three bands at sizes 8,856 bp, 
5,544 bp and 1526 bp. 
3.2  Production of PGK-COL7A1 expressing lentiviral vector  
Production of SIN-lentiviral vectors was performed by transfecting human embryonic kidney 
(HEK) 293T cells with either the pCCL-PGK-COL7A1 transfer plasmid or the control pRRL-
PGK-GFP transfer plasmid. Both transfer plasmids were co-transfected with the HIV-1 
packaging plasmids encoding vector components pCMVR8.74 or pMDLg/pRRE, RSV-Rev and 
the pMD2.G using the cationic polymers polyethylenimine (PEI) for lentiviral production of 
LV-COL7 and LV-GFP (Figure 3.3 A). Small scale (12 x 175 cm flasks) and large-scale (6 x 5-
layer flasks) productions were performed to obtain sufficient volumes of viral stocks. 
Ultracentrifugation of viral supernatants (340-fold for small-scale or 1000-fold for large-scale) 
was implemented for the concentration of the viral preparations (see Methods 2.2.23).  
The viral titres for both concentrated LV-COL7 and LV-GFP vector preparations were 
evaluated by real-time quantitative PCR (qPCR) and flow cytometry following transduction of 
HEK-293Ts with serial dilutions of each virus. C7 expression based titres for LV-COL7 ranged 
from 1x106 to 5x107 TU/ml with an average of 5x106 TU/ml and 8x107 to 5x108 TU/ml with an 
average of 3x108 TU/ml for LV-GFP (Table 3.1). Physical titres calculated by measuring HIV-
1 p24 in the viral supernatants were in the range of ~7x108 IP/ml for LV-COL7 and ~5x108 
IP/ml for LV-GFP. There was a notable reduction in functional titres attained with the LV-
COL7 vector compared to those of the LV-GFP vector, most likely due to the large COL7A1 
transgene size approaching the maximal insert capacity of the vector backbone, encumbering 
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packaging into fully functional virions as supported by the similar p24 levels to LV-PGK. In an 
attempt to improve viral titres, the commercial transfection reagent Lipofectamine 2000 was 
used and compared against PEI. The results showed no obvious differences in the resulting 
titres between the two reagents (Table 3.1). 
 
Table 3.1 Titration by qPCR of LV-GFP and LV-COL7 vectors produced using two different 
transfection reagents. 
 
Figure 3.3 Transfection and transduction efficiency of LV-GFP vector in HEK-293T cells. 
HEK-293T cells were transiently co-transfected with 3rd generation pRRL-PGK-GFP or pCCL-PGK-
COL7A1 transfer plasmids and 2nd or 3rd generation accessory, packaging and envelope plasmids to 
produce pseudo-viruses. (A) Representative images of pRRL-PGK-GFP expression 2 days post 
transfection (n=5) (a). Representative images of transduction of HEK-293T cells (n=5) with concentrated 
LV-GFP pseudo-virus at 5-fold decreasing concentrations (b & c). The images are representations of a 
single experiment performed repeatedly and reproducibly. (B) LV-GFP infected HEK-293T cells were 
harvested and transduction efficiency and titre were assessed by measuring the percentage of GFP 
positive cells using flow cytometry. For accurate titre calculation values in the range of 2%-10% were 
used. Scale bar = 100 µm. 
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3.3  Transduction efficiency of LV-COL7 vector in primary RDEB 
keratinocytes and fibroblasts 
Primary keratinocytes isolated from the RDEB patient (CK) were transduced with LV-COL7 
vector at a multiplicity of infection (MOI) of 5. The viral transduction efficiency and transgene 
integration were assessed by pro-viral copy number (VCN) per cell using qPCR and further 
confirmed for C7 protein expression by flow cytometry. At 3 days post transduction the average 
VCNs per cell were in the range of 0.09-0.24. The percentage of C7 expressing cells measured 
at 2 weeks post transduction was 18% (Figure 3.4 A, B). The reason for assessing C7 following 
a 2-week culturing period was to dilute out plasmid DNA contamination during viral 
preparation. Transduced cells demonstrated a higher intensity of C7 expression over 
endogenous WT levels as seen by their corresponding mean fluorescence intensity (MFI) values 
(Figure 3.4 B). The transduced cells were maintained in culture and propagated for up to 2 
months with no significant decrease of C7 expression. 
Figure 3.4 Flow cytometry analysis of LV-COL7 transduced primary RDEB keratinocytes for 
confirmation of C7 expression. 
RDEB (CK) keratinocytes transduced in three separate wells with LV-COL7 vector were stained for 
intracellular C7 expression 2 weeks post viral exposure. Untransduced (UT) RDEB and wild-type (WT) 
keratinocytes cultured alongside in triplicate representing experimental controls were run in parallel. (A) 
Flow cytometry shows positive C7 expression in LV-COL7 transduced RDEB (CK) and WT 
keratinocytes, but not in the UT cells. Isotype staining confirms specificity of secondary antibody. (B) 
Triplicate values of flow cytometry data were plotted against each other. Error bars represent SD amongst 
triplicates.  
A 
B 
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It has previously been reported that although both keratinocytes and fibroblasts secrete C7 
protein, approximately 90-97% of the protein is secreted by the keratinocytes with fibroblasts 
only accounting for 3-10% of total C7 production (Woodley et al., 2003). However, the slower 
turnover, relatively long life span in vitro and easier ex vivo manipulation of primary 
fibroblasts compared to the challenging to culture primary keratinocytes which 
differentiate after the first few passages, make fibroblasts a more suitable candidate for 
gene therapy applications. Studies on allogeneic fibroblasts have reported successful 
delivery by both intradermal and intravenous routes highlighting their versatility (Woodley 
et al., 2004b, Woodley et al., 2007b, Wong et al., 2008).  
In this study, primary fibroblasts were isolated from 2 RDEB patients’ skin biopsies (CK and 
EB8) (see Methods 2.2.4) and transduced with LV-COL7 at an MOI of 5. Intracellular C7 
expression was measured by flow cytometry 2 weeks post transduction with average 
efficiencies in the two patients’ cells calculated to be in the range of 9.3% - 12.8% with 
untransduced RDEB patient samples representing the negative control (Figure 3.5 A, B). In 
addition, transduced cells exhibited a higher level of C7 expression than that of endogenous C7 
in healthy donor cells as seen by the MFI values due to the constitutive nature of the PGK 
promoter (Figure 3.5 C). Transgene integration was further confirmed by qPCR 2 weeks post 
transduction with a VCN/cell of 0.12-0.14.  
These data demonstrate that despite the relatively low titres of the LV-COL7 vector, a modest 
fraction of primary RDEB keratinocytes and fibroblasts were transduced, resulting in genomic 
integration of the codon optimised COL7A1 transgene and C7 protein expression.  
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Figure 3.5 Intracellular C7 expression in LV-COL7 transduced RDEB fibroblasts. 
RDEB patient (CK) and (EB8) fibroblasts transduced in triplicate with LV-COL7 vector were stained for 
intracellular C7 expression 2 weeks post viral exposure. (A) Flow cytometry showing C7 expression in 
LV-COL7 transduced RDEB (CK) and wild-type (WT) fibroblasts. No signal detected in untransduced 
(UT) sample. RDEB (CK) samples were transduced in triplicate wells. WT or UT samples were cultured 
alongside in triplicate wells. (B) Corresponding percentages of average C7 expression from flow 
cytometry analysis of LV-COL7 transduced RDEB (CK) fibroblasts versus WT and RDEB UT samples 
and corresponding mean fluorescence intensity (MFI) (C). LV-COL7 transduction of RDEB patient 
fibroblasts shows transgene expression by positive staining of C7 protein. Error bars represent SD of 
triplicate sets of the two patient samples.  
 
 
It has been reported that transduced cells can exhibit distinct morphological alteration such as 
elongation of the cell bodies and increased protrusions (Chen et al., 2002). In addition, use of a 
high MOI may potentially be toxic to the cells. To examine this, the cell proliferation rate 
calculated by total cell-counts was assessed on RDEB fibroblasts transduced with increasing 
concentrations of LV-COL7 vector at MOIs ranging from 1 to 50 (Figure 3.6). RDEB 
fibroblasts were seeded at a density of 1x105 cells 24 hrs prior to transduction with six different 
MOIs (1, 2, 10, 20, 25 & 50) and the cells were counted after 6 days. The results showed a 
modest increase of cell proliferation at lower MOIs of 1 and 2, while a slight decrease in cell 
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viability was observed above an MOI of 10. This effect was exacerbated at higher MOIs of 20 
and 25 with a 3-fold drop and at an MOI of 50 with a 13-fold drop in the number of viable cells 
suggesting an increased level of vector-mediated cytotoxicity at high MOIs. To balance the 
transduction efficiency and cytotoxicity, MOIs of 5 and 10 were used for further studies.  
 
Figure 3.6 Cell proliferation and viability following escalated dose of LV-COL7 transduction 
RDEB fibroblasts (FB) were seeded and transduced with a range of MOIs of LV-COL7 virus (1-50) to 
evaluate cell viability after 6 days of culture. A significant decrease in the total number of viable cells 
was observed upon increase of MOI in RDEB fibroblasts, indicating vector related cytotoxicity. The 
values depicted in the graft represent data from a single experiment.  
3.4  Restoration of C7 protein expression in RDEB keratinocytes 
and fibroblasts transduced with LV-COL7 vector 
3.4.1  Confirmation of C7 expression in gene modified RDEB cells by in situ 
immunofluorescence staining 
The LV-COL7 mediated restoration of C7 expression in the transduced RDEB keratinocytes and 
fibroblasts was examined by in situ immunofluorescence staining using a specific anti-human 
C7 antibody (see Methods 2.2.32) 
This was initially evaluated in an RDEB EBKC keratinocyte cell line (RDEB EBKC) 3 days 
post LV-COL7 or LV-GFP transduction with untransduced RDEB EBKCs used as a negative 
control. Healthy donor cells or RDEB EBKCs either untransduced or LV-COL7 transduced, 
were seeded on coverslips and stained for C7 using the mouse mAb anti-C7 antibody (mAb-C7-
LH7.2). Positive staining was visualised in the LV-COL7 transduced RDEB EBKC and the 
control healthy donor population, whereas there was complete absence of C7 expression in 
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untransduced cells, suggesting vector-mediated restoration of C7 expression in RDEB 
keratinocytes. The LV-COL7 transduced cells exhibited intense cytoplasmic staining throughout 
the intracellular space at a much higher level than that of endogenous C7 expression seen in 
healthy donor keratinocytes (Figure 3.7 a-c). RDEB EBKC cells transduced with the LV-GFP 
vector were used in parallel as a control and showed strong expression of GFP protein (Figure 
3.7 d).  
 
Figure 3.7 Restoration of C7 protein expression in RDEB keratinocytes transduced with LV-COL7  
An untransduced (UT) RDEB EBKC cell line was transduced with LV-COL7 at an MOI of 5. At 3 days 
post transduction, cells were reseeded on coverslips. The cells were fixed and stained with C7 antibody in 
situ. The results showed C7 expression (red) in WT untransduced cells (a) and LV-COL7 transduced 
RDEB EBKCs (c). In contrast, there was no C7 expression in UT EBKC (b). RDEB EBKC cells 
transduced with LV-GFP were used as a transduction control (d). Nuclei were counterstained with DAPI 
(blue). The images depicted are from representative fields of the stained coverslips allowing for 
qualitative assessment of protein expression. Scale bars = 25 µm. 
 
In a similar fashion, LV-COL7 transduced RDEB patient (CK) and (EB8) fibroblasts (see 
materials Table 2.4) were also evaluated for vector-mediated C7 expression by in situ 
immunofluorescence staining. The cells transduced with LV-GFP vector were run in parallel 
representing the negative control. The results revealed pronounced LV-COL7 derived C7 
protein expression in both RDEB (EB8) and (CK) fibroblasts demonstrated by intense 
cytoplasmic staining. The detected expression levels surpassed those of endogenous C7 
expression in normal donor cells indicating transgene overexpression by the PGK promoter. 
Untransduced RDEB fibroblasts showed a complete absence of C7 expression (Figure 3.8). 
Collectively, the results showed restoration of C7 protein expression in an RDEB keratinocyte 
cell line and two separate RDEB primary fibroblast samples following transduction with the 
LV-COL7 vector with expression levels superseding those of normal donor cells. 
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Figure 3.8 Restoration of C7 protein expression in primary RDEB fibroblasts transduced with LV-
COL7.  
In situ immunofluorescence staining for C7 expression (red) and nuclear stain DAPI (blue) of either 
healthy primary (WT) (a), RDEB patient (CK) or (EB8) untransduced (UT) (c, e) or LV-COL7 
transduced fibroblasts (d, f). Control transductions performed using LV-GFP encoding vector (b). C7 
expression is restored after LV-COL7 transduction at MOI 5 showing intense cytoplasmic staining. These 
are representative fields of the stained areas from triplicate coverslips. Scale bar = 50 µm. 
3.4.2  Confirmation of C7 protein production in gene modified RDEB cells by 
Western blot  
To further confirm whether the C7 protein expressed by the LV-COL7 transduced RDEB 
keratinocytes and fibroblasts was formed and secreted as full-length C7, cell lysates and culture 
media from the transduced RDEB cells were subjected to SDS-PAGE under reducing conditions 
for separation of C7 in its monomeric form. The full-length C7 monomer of 290 kDa was 
further detected by Western blot analysis (see Methods 2.2.33).  
3.4.2.1 Antibody specificity against full-length C7 protein 
Three polyclonal antibodies detecting C7, two of which were sourced commercially (Calbio-
C7-pAb and purified C7-pAb) and one kindly provided by Prof. M. Chen (C7-Chen) were 
tested for their specificity. Cell lysates from normal donor keratinocytes (WT) and untransduced 
(UT) RDEB EBKCs were used to evaluate the specificity, and examine possible background 
staining and non-specific banding. All three antibodies were shown to specifically detect full-
length C7 at 290 kDa in WT cells, with no corresponding band could be visible in UT RDEB 
EBKCs (Figure 3.9). However, the Calbio-C7-pAb antibody displayed besides the C7 290 kDa 
band, a high frequency of additional larger and smaller non-specific bands on the immunoblot. 
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The purified C7-pAb on the other hand, showed greatly reduced non-specific banding when 
compared to the Calbio—C7-pAb, with the major additional band appearing at ~150 kDa in all 
samples (Figure 3.9). The C7-Chen antibody was an affinity-purified polyclonal antibody 
against the NC-1 domain of C7 and when assessed by Western blot, showed a clear highly 
specific band at 290 kDa in WT keratinocytes. However, upon high protein loading, a small 
number of faint bands were also visible with the most distinct one at 150 kDa similar to the 
Calbio-C7-pAb and purified C7-pAb. The untransduced RDEB EBKC sample though revealed 
a complete absence of any bands (Figure 3.9). Background staining in all three antibodies was 
relatively low and did not interfere the results. Based on these findings, unless otherwise 
specified, the C7-Chen antibody was used for further studies. 
 
 
 
 
 
 
 
 
 
Figure 3.9 Antibody assessment for detection of C7 expression in WT and RDEB keratinocytes. 
Cell pellets from WT or RDEB EBKC keratinocytes were harvested and lysed under reducing conditions 
and subjected to 6% SDS-PAGE. Blots were probed with either of three antibodies; Calbio-C7-pAb 
(Calbiochem); purified C7-pAb (Abnova); or Chen-C7 (Chen/Woodley) for detection of C7 expression at 
290 kDa. All three antibodies recognised the full length C7, with the Chen-C7 showing the highest 
specificity for the protein and least amount of non-specific banding. These blots are representations of a 
single experiment. 
3.4.2.2 Expression of full-length C7 in LV-COL7 transduced RDEB keratinocytes 
LV-COL7-mediated restoration of C7 was initially assessed in the RDEB EBKC keratinocyte 
cell line for evaluation of C7 expression and durability. Western blot analysis of cell lysates of 
LV-COL7 transduced RDEB EBKCs revealed full-length C7 protein detected at 290 kDa, 
expressed at similar levels to those of endogenous C7 in WT cells. The corresponding band was 
entirely absent in untransduced RDEB EBKCs, indicating protein restoration in LV-COL7-
transduced cells (Figure 3.10 left panel). Expression in the transduced RDEB EBKCs appeared 
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to remain stable over a 22-day period during which time the cells underwent 7 passages. As C7 
is a secreted protein, culture media was also harvested from LV-COL7-transduced RDEB 
EBKCs 13 days post-transduction. The cells were cultured in the absence of serum but with the 
supplementation of ascorbic acid for a 48-hour period prior to harvesting the media, previously 
shown to promote C7 secretion (Titeux et al., 2010). Culture media from untransduced RDEB 
EBKCs and a normal keratinocyte cell line (NIKS) were used as controls. The media samples 
were concentrated by protein precipitation prior to running on Western blot under reducing 
conditions. Strong full-length C7 expression was detected in the media samples of both LV-
COL7-transduced and NIKS cells (Figure 3.10 right panel). Protein loading per well was 
normalised by Bradford assay allowing for the addition of equal protein amounts of each 
sample. In addition, the consistently appearing non-specific ~150 kDa band when staining with 
all anti-C7 antibodies was used as an internal indicator of sample loading in cases where 
staining of endogenous housekeeping protein was not available.   
 
 
Figure 3.10 Expression of C7 in cell lysate and culture media of RDEB keratinocyte line post LV-
COL7 transduction.  
RDEB EBKC keratinocyte cell line was transduced with LV-COL7 and assessed for C7 expression over 
time in cell lysate and culture media supernatant (S/N) by Western blot on 6% SDS-PAGE. (Left) C7 
expression detected at 290 kDa in cell lysates show of WT keratinocyte cell-line (NIKS) and RDEB 
EBKC LV-COL7 keratinocytes at days 13 and 22 days post transduction (dpt). There was no C7 seen in 
RDEB EBKC untransduced (UT) cells. (Right) culture media S/N after ascorbic acid supplementation 
(50 µg/ml) and serum starvation for 48 hrs show C7 expression at 290 kDa only in NIKS and RDEB 
EBKC LV-COL7. Protein loading was normalised by Bradford assay. The results show long-term C7 
expression in LV-COL7 transduced RDEB EBKC cell lysates and supernatants. Immunoblot was stained 
with Calbio-C7-pAb. 
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Following the assessment of the keratinocyte cell line, primary RDEB patient (BT) 
keratinocytes were next evaluated for C7 expression by Western blot (Figure 3.11 left). The 
results revealed strong C7 expression in the LV-COL7-transduced RDEB (BT) keratinocytes 
with a similar band intensity level to that of normal donor keratinocytes. As a transduction 
control, LV-COL7-transduced RDEB EBKCs were used alongside (Figure 3.11 left). However, 
the RDEB (BT) untransduced keratinocytes also showed strong expression of a protein band at 
290 kDa band which corresponded to C7 (Figure 3.11). As this patient according to the 
genotype data carries two heterozygous mutations, with one causing an amino acid change in 
exon 70 (p.Arg1933Gln) and the other a PTC in exon 114 (p.Arg2814X) it is therefore possible 
that full-length C7 is expressed from one allele and detected by the C7-Chen antibody specific 
to the early NC-1 domain of C7. Furthermore the late stage mutation in the other allele resulting 
in truncation of a few amino acids may also be detected as there would be a minimal difference 
in overall protein size. Subsequent in vivo experiments using untransduced patient (BT) cells 
were carried out to confirm the functionality of the C7 protein detected through formation of 
AFs. Primary fibroblast cell lysate of the same RDEB patient (BT) was run alongside to detect 
whether a similar phenomenon occurred (Figure 3.11 right). The immunoblot showed the 
presence of a faint band at 290 kDa corresponding to C7, albeit at much lower levels to that 
seen in normal donor fibroblasts or RDEB (BT) keratinocytes suggesting detection of the 
endogenous mutant C7. 
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Figure 3.11 C7 expression in primary RDEB patient (BT) keratinocytes and fibroblasts. 
Primary keratinocyte (KC) and fibroblast (FB) cell lysates from RDEB patient (BT) either untransduced 
(UT) or LV-COL7 transduced were assessed for C7 expression by Western blot on 6% SDS-PAGE. 
(Left) There was C7 protein detected at 290 kDa in the positive primary normal donor keratinocyte 
control WT KCs and LV-COL7 transduced RDEB EBKC but not in the untransduced (UT) RDEB EBKC 
negative control. Strong expression of full-length C7 was detected in both UT and LV-COL7 transduced 
primary patient (BT) keratinocytes. (Right) A faint band corresponding to C7 at 290 kDa was seen in UT 
RDEB patient (BT) fibroblasts, compared to the strong expression detected in primary WT positive 
control fibroblasts. Protein loading was normalised by Bradford assay. Vinculin (VCL) was used as an 
internal loading control. These are representative blot images of duplicate experiments.  
3.4.2.3 LV-COL7 mediated C7 restoration in gene modified primary RDEB fibroblasts 
The expression of full-length C7 was next evaluated in LV-COL7-transduced primary RDEB 
patient (CK and EB8) fibroblast cell lysates and culture media by Western blot with the 
untransduced cells used as negative controls. The results confirmed expression of full-length C7 
at 290 kDa in both transduced patient cells transduced with an MOI of 5 or 10 of LV-COL7 
with protein levels similar to those of normal donor endogenous C7.  
There was no significant difference in C7 expression upon doubling of the MOI. Apart from the 
major full size C7 protein band, there were multiple smaller protein bands detected on the 
immunoblot, likely the result of increased protein loading. No detectable bands were observed 
in untransduced cell lysates (Figure 3.12 A). Secreted full-length C7 expression was also 
assessed in media harvested from the culturing of cells. The results confirmed the presence of 
C7 protein secreted from the LV-COL7-transduced RDEB (CK) fibroblasts although it appeared 
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as three similarly sized bands slightly smaller than 290 kDa possibly caused due to degradation 
during sample processing (Figure 3.12 B).  
The results therefore confirmed that the C7 expression seen by in situ immunofluorescence 
staining corresponded to full-length 290 kDa C7 as detected by Western blot analysis of both 
primary RDEB keratinocytes and fibroblasts transduced with LV-COL7. 
 
Figure 3.12 Restoration of protein expression in RDEB patient (EB8) & (CK) fibroblasts following 
LV-COL7 transduction.  
Primary RDEB patient fibroblasts from patients (EB8) and (CK) were transduced with LV-COL7 at MOI 
5 or 10 and assessed for C7 expression 2 weeks post transduction by Western blot of cell lysates and 
culture media supernatant (S/N) run on a 6% SDS-PAGE. (A) Reconstitution of C7 expression visualised 
at 290 kDa in both LV-COL7 transduced patient (EB8) and (CK) fibroblasts and both MOIs as well as in 
positive control normal donor primary WT fibroblasts. Complete absence of C7 expression in both RDEB 
patient (EB8) & (CK) untransduced samples. Loading was normalised by Bradford assay and vinculin 
used as internal loading control. (B) Detection of extracellular C7 expression in S/N of LV-COL7 
transduced RDEB (CK) and WT fibroblasts. No protein band seen in RDEB (CK) UT S/N sample. 
Protein loading was normalized by Bradford assay and membrane counterstained in Ponceau S stain as 
loading control. The results demonstrate restoration of C7 expression in primary patient fibroblasts 
transduced with LV-COL7. These are representative blot images of duplicate experiments. 
 
Due to the relatively low viral titres of LV-COL7 (~5x106 TU/ml), large volumes of the viral 
preparation are required for the transduction of cells with a meaningful MOI which can in turn 
lead to vector related cytotoxicity. Typically, the viral suspension volume did not exceed the 
10% total culture volume. In an attempt to increase transduction efficiency while at the same 
time avoiding potential cytotoxicity, the viral dose was divided and used to transduce RDEB 
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patient (BT) fibroblasts at two instead of a single time point. RDEB (BT) fibroblasts were 
exposed to either a single or a double round of infection with LV-COL7 maintaining the total 
MOI at 2 and propagated for a period of 62 days. Cell lysates collected at three different time 
points (32, 42 and 62 days) were assessed for C7 expression by Western blot and qPCR-based 
pro-viral copy number. Transduction efficiency calculated by VCN/cell at 3 days post-
transduction was shown to be 6.19% in cells infected with two rounds of virus, compared to 
3.55% after a single time point. These results were corroborated by Western blot pointing 
towards a slight increase of C7 expression in RDEB fibroblasts transduced with two rounds of 
LV-COL7 at all three collection time points over those infected with a single dose albeit at a 
total MOI of 2 in both cases (Figure 3.13). This is most likely due to the use of a lower volume 
of viral supernatant on the cells, minimising possible adverse effects on proliferation and vector 
related cytotoxicity. Furthermore, there was no notable decrease of C7 expression in the 
transduced cells over the 2-month culture period suggesting stable and constitutive transgene 
expression mediated by the PGK promoter (Figure 3.13). 
Figure 3.13 Durability of C7 expression in RDEB corrected fibroblasts in vitro. 
Primary patient (BT) fibroblasts were transduced with a single or double round of LV-COL7 and assessed 
for protein expression and durability over 62 days by Western blot. (A) C7 protein band detected at 290 
kDa of normal donor primary WT and RDEB (BT) fibroblast cell lysates harvested at 32, 42 and 62 days 
post transduction (dpt) with LV-COL7 at single (MOI 2) or double (MOI 1x2) round of transduction. No 
expression seen in LV-GFP (MOI 2) transduced RDEB (BT) fibroblast negative control. Immunoblot was 
stained using Calbio-C7-pAb. Vinculin (VCL) used as internal loading control. (B) Densitometry of C7 
bands from Western blot image using ImageJ pixel intensity analysis confirms slight increase in C7 
expression when a double round of transduction is carried out over single at a total MOI of 2 in all three 
harvest dates. These are representative blot images of a single experiment.   
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3.5  Functional correction in LV-COL7 transduced RDEB 
keratinocytes and fibroblasts 
3.5.1  Improved cell migration in RDEB keratinocytes transduced with LV-COL7 
Lack of C7 expression has been associated with functional alterations such as changes in cell 
migration and invasion compared to normal human keratinocytes thought to be due to aberrant 
laminin-332 organisation altering α6β4 signaling, caused by lack of C7 protein deposition 
(Murauer et al., 2011, Martins et al., 2009, Nystrom et al., 2013, Woodley et al., 2008, Chen et 
al., 2002). In vitro cell migration assays offer a way to evaluate the propensity and closure 
speed of an artificially created wound. Several cell migration assays have been previously 
developed for the functional assessment of C7 loss in RDEB keratinocytes and with an 
adaptation of a 2D scratch assay utilised in this study (Martins et al., 2009) (see Methods 
2.2.34).  
Normal donor keratinocyte, untransduced or LV-COL7-transduced RDEB EBKCs were plated 
at a concentration of 1.2x106 cells/well in a 6 well plate format and a scratch was made through 
the centre of the well to create a “wound” area. Cell migration and closure of the wound area 
was monitored by time-lapse imaging over 15 minute intervals for 35 hrs and calculated by 
measuring the unoccupied surface area of the well after setting a threshold on the edges of the 
scratch (Figure 3.14). All cells were pre-treated with the DNA crosslinker mitomycin C at 10 
µg/ml for 2 hrs to ensure the sole measurement of migration while eliminating the cell 
proliferation variable.  
The migration values revealed a significant level of variation amongst the three groups 
(p≤0.01), with complete wound closure completed within 15-35 hrs. Multiple comparison 
analysis showed a significant decrease in wound closure in untransduced RDEB EBKC cells 
with a large portion of the scratch still remaining unoccupied after 35 hrs, compared to WT 
healthy keratinocytes which filled the open wound space entirely within 15 hrs (p≤0.001) 
(Figure 3.14 A & B). A lag in migration speed compared to the WT healthy keratinocytes was 
noticed during the initial 5 hr period in both untreated and gene-corrected RDEB EBKC cells. 
However, throughout the remaining period, the LV-COL7-transduced RDEB EBKCs showed a 
significant acceleration in migration speed compared to the untransduced cells (p≤0.05) 
although with complete scratch closure only achieved at 25 hrs, it was significantly slower than 
WT cells (p≤0.05) (Figure 3.14 A & B). The data therefore suggest a partial functional 
recovery in the RDEB EBKCs following LV-COL7 transduction as a result of the vector-
mediated C7 expression.  
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Figure 3.14 Effect on RDEB keratinocyte migration following restoration of C7 protein expression. 
Primary healthy WT donor, RDEB EBKC transduced with LV-COL7 and untransduced RDEB EBKC 
(UT) keratinocytes were seeded in a 6-well plate, treated with mitomycin C to halt proliferation and a 
scratch was made to compare cell migration over 35 hrs at 15-min intervals by time-lapse microscopy. 
(A). RDEB EBKC UT cells show reduction in cell migration speed over healthy WT cells with scratch 
zone still open by 30 hrs. RDEB EBKCs transduced with LV-COL7 demonstrate intermediate cell 
migration speed with scratch closure by 25 hrs. Scale bar = 300 µm. The values of percentage closure 
calculated using a custom macro on ImageJ measuring proportion of empty space within the edges set by 
a threshold, were plotted against imaging time points over a 35 hr period (mean±SD, n=3). Statistical 
analysis was carried out on values collected from 5 – 35 hrs. The area under the curve (AUC) was 
calculated for each replicate of the 3 samples and their means were compared by one-way ANOVA and 
found to be significant between the groups (**p≤0.01). Tukey’s post-test was used for multiple 
comparison analysis within the group and showed percentage of scratch closure was increased in RDEB 
EBKC transduced with LV-COL7 compared to UT EBKC (*p≤0.05), although still lower than that of 
WT keratinocytes (*p≤0.05).  
0 5 10 15 20 25 30 35 40
0
25
50
75
100
EBKC UT
EBKC LV-COL7
Healthy WT KC
Time point (hours)
Pe
rc
en
ta
ge
 o
f s
cr
at
ch
 r
em
ai
ni
ng
 o
pe
n 
(%
)
*** **
Healthy WT KC vs. EBKC LV-COL7, *p≤0.05 
EBKC LV-COL7 vs. EBKC UT, *p≤0.05 
EBKC UT vs. Healthy WT C, ***p≤0.001 
 
119 
3.5.2  Normalisation of RDEB fibroblast migration following correction by LV-
COL7 
In vitro functional recovery was next evaluated in primary RDEB patient (CK) and (EB8) 
fibroblasts using the cell migration assay previously described (Syed et al., 2013) (see Methods 
2.2.35). Both untransduced and LV-COL7-transduced fibroblasts were seeded at a density 
of 4x104 cells/well in a 96-well plate containing a cell seeding stopper occupying a 2 mm 
area in the centre of each well. 24 hrs post seeding, the cells were treated with mitomycin 
C at a concentration of 10 µg/ml for 2 hrs before the stoppers were removed exposing the 
artificially created migration zone. The cells were continuously cultured for 72 hrs and 
were then fixed, counterstained with DAPI and imaged. The number of cells within the 2 
mm migration zone were quantified and plotted against each other (Figure 3.15 A & B).  
 The results demonstrated that untransduced patient (CK) fibroblasts exhibited a noticeable 
reduction in migration speed compared to WT healthy cells (p≤0.01) displaying a similar 
pattern in “wound” closure to that seen previously in the RDEB EBKC keratinocyte data. Upon 
transduction of the RDEB (CK) fibroblasts with LV-COL7, a significant improvement in 
migration speed over the untransduced sample was observed (p≤0.05) suggesting functional 
recovery by attaining a similar migration rate to that of in WT donor cells (p>0.05). 
However the migration rate of RDEB (EB8) fibroblasts revealed an inverse response RDEB 
(CK), with an increased migration speed of untransduced cells compared to WT donor cells 
(p≤0.05). Following LV-COL7 transduction though, the number of cells detected in the 
migration zone was reduced compared to those in the untransduced sample (p≤0.05) with 
normalisation of the (EB8) cell migration rate exhibiting comparable speeds to those of WT 
donor cells (p>0.05). This points towards patient-to-patient variation with normalisation of 
migration speed following LV-COL7 transduction in both patients’ cells. 
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Figure 3.15 Effect of loss and restoration of C7 expression on RDEB patient (CK) and (EB8) 
fibroblasts.  
Primary RDEB patient (CK) and (EB8) fibroblasts either untransduced or following LV-COL7 
transduction were assessed for cell migration alongside normal donor fibroblasts. Cells were seeded in a 
96-well plate with 2 mm stoppers and treated 24 hrs later with mitomycin C for 2 hrs halting 
proliferation. Stoppers were removed and cells were continuously cultured for 72 hrs and then fixed and 
counterstained with DAPI. The migration zone was imaged at 0 hrs (T=0) and after 72 hrs (T=72). The 
number of cells within the migration zone were quantified and plotted against each other. One-way 
ANOVA analysis comparing the RDEB (CK) group and WT fibroblasts or RDEB (EB8) group and WT 
fibroblasts showed significant variation in the values in both cases (**p≤0.01) and (*p≤0.05). Tukey’s 
post-test showed a decreased migration rate in UT RDEB (CK) fibroblasts compared to WT fibroblasts 
(p≤0.01) but regained migration speed after cells were transduced with LV-COL7 ((A) upper panel, (B) 
green bars with normalisation to WT levels (ns p>0.05)). Increased migration was observed in UT RDEB 
(EB8) fibroblasts compared to WT donor cells (*p≤0.05), which decreased back to a similar speed to that 
of donor cells after LV-COL7 transduction ((A) lower panel, (B) red bars (ns p>0.05)).  
 
There has been conflicting evidence published regarding the effect on migration speed 
following loss of C7 protein. Although a previous study (Chen et al., 2002) has reported a 
significant increase in COL7A1 deficient RDEB cells measured by an in vitro colloidal 
gold assay, more recently published reports revealed an inverse effect whereby wounds 
generated on RDEB mouse models showed delayed re-epithelialisation and maturation of 
the granulation tissue (Nystrom et al., 2013). This disparity was noticed in the data 
generated in this study. The cause of variation amongst individual patients remains 
unknown. However, the results obtained from both RDEB EBKC keratinocytes and RDEB 
(CK) and EB8 fibroblasts clearly point towards functional improvement of the RDEB 
phenotype following LV-COL7 transduction confirmed by the normalisation of migration 
rates.   
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3.6 Discussion 
This work has demonstrated a feasible strategy for the restoration of C7 expression and 
function in RDEB cells by a viral vector-mediated gene addition/replacement approach. 
This was achieved by the design and production of a state-of-the-art clinically-compliant 
3rd generation SIN lentiviral vector based on HIV-1, stripped of virulence factors and with 
packaging and nuclear import accessory proteins delivered in trans, therefore eliminating 
the potential of generating replication competent lentiviruses. Within this system the codon 
optimised COL7A1 cDNA transgene, was packaged and delivered to RDEB patient 
keratinocyte and fibroblast cells. Use of degenerate codons throughout the transgene was 
employed for the removal of major cryptic splice sites and minimisation of repetitive 
sequence predominantly found in the triple-helical collagenous coding region of COL7A1. 
This can otherwise have a deleterious effect on C7 expression through transgene 
rearrangement during viral packaging and aberrant splicing of the expressed protein, with a 
reported detection of 25-33% of abnormal C7 in retrovirally transduced RDEB keratinocytes 
and fibroblasts (Titeux et al., 2010). 
Concentrated batches of therapeutic lentiviral vectors carrying a functional copy of 
COL7A1 were produced and confirmed for their infectivity resulting in a modest titre of 
~5x106 TU/ml. The infectivity range however was 2-log lower than that of the LV-GFP 
vector. The most plausible explanation for the variation between the viral titres is the 
increased size of the COL7A1 transgene hampering its packaging into functional lentiviral 
particles having a maximal transgene capacity of 8-9 kb (Siprashvili et al., 2010, Titeux et 
al., 2010). This was further corroborated by p24 levels of the LV-COL7 viral preparations, 
demonstrating a 10-15 fold higher physical titre when compared to the functional titre 
obtained from titration on HEK-293Ts. This however may also be a result of sequences 
within the transgene resulting in aberrant splicing of primary transcripts (Moiani et al., 
2012).  
However, restoration of the otherwise null C7 expression was achieved following LV-
COL7 transduction of the COL7A1-deficient patient keratinocyte and fibroblast 
populations using a range of MOIs of 2-10 exhibiting robust and sustained over-expression 
of the de novo full-length C7 protein. Moreover, from the immunoblots presented, there 
was no immediate evidence of truncated C7 protein expressed in the transduced cells 
suggesting the advantage of codon optimisation. Expression levels in the transduced cells 
superseded those of endogenous C7 of WT cells mediated by the strong constitutive 
activity of the PGK promoter demonstrated by both in situ immunofluorescence staining 
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and Western blot, despite transduction efficiency not exceeding ~25%, presumably owed to 
the low vector titre and the resilient nature of primary keratinocytes to infection. Limited 
by the maximum viral supernatant volume used during transduction having to fall below 
10% of the total culturing volume, use of a high MOI would not be feasible as a means of 
compensating for the reduced titre as it is associated with a high-level of cytotoxicity. 
Instead, dividing the viral dose over two time points as demonstrated in primary RDEB 
fibroblasts, resulted in a slightly increased transduction efficiency measured by C7 
expression while ensured a reduction in the viral load. Alternatively, an indirect method for 
the improvement in the percentage of LV-COL7 transduced cells, would be the 
incorporation of a selectable surface marker co-expressed with COL7A1. This would 
permit for the enrichment of gene-corrected clones thereby circumventing the requirement 
of a high, potentially cytotoxic MOI.  
Furthermore, cell migration assays also demonstrated that following LV-COL7 
transduction of RDEB cells, the impaired migration rates were normalised in both 
keratinocytes and fibroblasts, indicating functional recovery due to restoration C7 
expression. 
It is believed that the observed C7 over-expression may be sufficient in providing functional 
restoration in skin. Both gene-modified keratinocytes and fibroblasts were subsequently used in 
in vivo experiments delineated in the following chapter to ultimately assess whether the 
restoration achieved in vitro could achieve meaningful reversion of the RDEB phenotype. 
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Chapter 4  Functional evaluation of gene modified RDEB 
cells in in vivo human:murine chimeric skin graft model 
Following confirmation of C7 protein expression and recovery of migration in RDEB cells 
transduced with LV-COL7 vector in vitro, the functional restoration of C7 as assessed by its 
ability to form AFs at the DEJ thereby ameliorating the RDEB-associated blistering and 
separation phenotype was examined. Previous studies have suggested that C7 expression levels 
as low as 10% of normal endogenous levels reported in some RDEB patients were sufficient for 
the formation of rudimentary AF structures conferring a certain level of attachment and 
blistering amelioration (Wagner et al., 2010, Fritsch et al., 2008). Added to the slow turnover of 
C7 protein, it could be argued that even a low proportion of corrected RDEB keratinocytes 
and/or fibroblast overexpressing C7, may be adequate in providing a therapeutic and long-
lasting effect by restoring adhesion at the DEJ. Therefore, despite the modest LV-COL7 
transduction efficiency of 18% in keratinocytes and 12% in fibroblasts, it was expected that C7 
expression would be visualised in vivo and present with a certain degree of functional 
amelioration. 
Although Col7a1-/- mice have previously been generated by others (Fritsch et al., 2008, 
Heinonen et al., 1999), these strains have a limited lifespan and are unsuitable to address 
whether LV-COL7-transduced human fibroblasts and keratinocytes can confer functional 
correction and restore dermal-epidermal integrity in vivo. 
In this study, a pre-clinical human:murine chimeric skin graft model was used. This model was 
developed based on a previously described method (Larcher et al., 2007) which allows for the 
grafting of a bioengineered skin equivalent (SE) comprised of human keratinocytes and 
fibroblasts onto immunodeficient mice giving rise to full-thickness human skin. Optimisation of 
the model by altering the recipient mouse strain was also assessed in this study to evaluate 
whether this could lead to an increased grafting success rate. Rigorous assessment to confirm 
the human origin of the grafted tissue and the ability of the epithelial cells to progress through a 
normal differentiation cycle was also carried out. This method therefore allowed for the 
development of a robust in vivo RDEB disease model recapitulating the skin blistering 
phenotype in which the proposed autologous gene correction strategy could be tested. This was 
executed by replacing unmodified RDEB keratinocytes and/or fibroblasts during preparation of 
the bioengineered SEs with LV-COL7 gene-corrected cell combinations. The grafts were 
primarily assessed for the deposition of C7 at the DEJ secreted from the gene corrected cells 
using immunofluorescence analysis, while the functionality of C7, evaluated by its capacity to 
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form fully functional AFs and ultimately restore adhesion to the DEJ, was investigated by 
morphological and ultrastructural imaging.  
4.1 Histological features of bioengineered human skin grafts  
4.1.1 Identification of the human skin graft and distinction from mouse tissue using 
human-specific tissue markers 
Prior to testing the pre-clinical RDEB mouse model, unique markers permitting the distinction 
between the human and mouse skin structure of the grafts were identified and tested. 
Skin samples from a healthy human donor and a mouse were embedded in OCT and 7 µm thick 
frozen sections were obtained. Firstly, tissues were stained with haematoxylin and eosin (H&E) 
for the morphological examination of the skin. An easily distinguishable thicker epidermal 
compartment was observed in human tissue with multiple tightly organised cell layers. The 
lower compartment comprised of larger and more spherical basal keratinocytes formed the 
apical side of the basement membrane zone (BMZ) whereas differentiating keratinocytes 
formed the stratum spinosum and granulosum located the intermediate epidermal compartments 
and terminally differentiated keratinocytes made up the stratum corneum in the uppermost 
epidermal compartment lacking a nucleus and flatter in morphology (Figure 4.1 a). Mouse 
epidermis on the contrary, appeared very thin with 2 to 3 layers of keratinocytes and a less 
pronounced cornified layer (Figure 4.1 b). Furthermore a higher density of hair follicles could 
be seen in the murine epidermis compared to human skin.  
Subsequently, species-specific antibodies for the detection of human mitochondrial (MTCO2) 
and desmosomal (Desmoglein-1) proteins were further used for identification of the human 
origin of the skin and distinction from mouse tissue. Immunofluorescence staining for MTCO2 
revealed intense cytoplasmic staining of the entire epidermis and of dermal fibroblasts in human 
tissue (Figure 4.1 c). In contrast, there was no such staining in the mouse epidermis, although 
faint signal was detected at the section edge and surrounding the hair follicles from 
autofluorescence from the 2ry antibody (Figure 4.1 d). Desmoglein-1 staining showed strong 
expression in the human epidermis with a membranous localisation of the staining, whereas no 
such staining pattern was observed in mouse tissue (Figure 4.1 e, f). These results suggested the 
distinction between human and mouse skin can be robustly recognised using a combination of 
epidermal cyto-architectural staining of the epidermis by H&E, and by species-specific 
mitochondrial and desmosomal staining.  
 
125 
 
Figure 4.1 Morphological staining of skin by H&E and species-specific antibodies differentiates 
between human and mouse tissue. 
Biopsies from healthy human (a, c, e) or WT mouse (b, d, f) were cryo-sectioned at 7 µm thickness and 
stained by H&E for morphological assessment and IF for human proteins: complex IV subunit II 
mitochondrial marker (MTCO2) and desmoglein-1. Histological staining shows distinct multilayered 
thick epidermis in human skin (a) compared to a thin epidermal layer populated by hair follicles in mouse 
skin (b). There was positive staining for MTCO2  (red) in human epidermal keratinocytes and dermal 
fibroblasts (c), with no staining following a similar pattern in mouse tissue (d). Desmoglein-1 staining 
(green) showed positive signal in the stratum granulosum of the human epidermis (e), but not in mouse 
tissue (f). Nuclei were stained with DAPI (blue). Scale bar = 100 µm. 
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4.1.2  Detection of human C7 protein in bioengineered human grafts  
A series of commercially available antibodies against C7 were tested in search of a highly 
species-specific option for the accurate determination of the human origin of C7 (Figure 4.2). 
Both human and mouse tissue were stained with 8 separate antibodies against C7 by 
immunofluorescence and the results were analysed. 4 antibodies showed positive staining at the 
DEJ (Calbio-C7-pAb, mAb-C7-LH7.2 and C7-Chen) including SantaCruz sc8928 displaying 
faint staining. The Calbio-C7-pAb and C7-Chen antibodies detected both human and mouse C7 
protein due to recognition of homologous epitopes and were therefore not used for the study. In 
contrast, mAb-C7-LH7.2 showed strong and defined staining at the DEJ of human skin with no 
cross-reactivity to mouse C7 (Figure 4.2).  
The mAb-C7-LH7.2 antibody was further tested in human and mouse tissue from separate 
donors and similar results were obtained showing strong signal localisation of C7 at the DEJ 
and with weaker punctate cytoplasmic staining of dermal fibroblasts. In contrast, no such 
staining was observed in mouse skin (Figure 4.3). These results confirmed the mAb-C7-LH7.2 
antibody specificity showing no cross-reactivity between human and mouse tissue (Figure 4.3). 
The antibody was therefore utilised for all subsequent immunofluorescence staining for the 
detection of human C7 expression. 
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Figure 4.2 Detection of species-specific C7 expression in human and mouse tissue. 
Evaluation of species-specific antibodies against C7 protein in human and mouse sample tissue using 8 
antibodies, 7 were commercially sourced and 1 was from Prof. M. Chen. The top panel shows antibodies 
that exhibited limited or no detection of either human or mouse C7 at the DEJ (red). Background 
expression seen in 2nd, 3rd and 4th lanes, with diffuse staining of the epidermis. Bottom panel shows 
antibodies resulting in strong detection of C7 at the DEJ of human and mouse tissue. mAb-C7-LH7.2 was 
the only antibody to show human specific staining with no cross-reactivity to mouse C7. Scale bars = 100 
µm.  
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Figure 4.3 Human specific C7 recognition in skin using mAb-C7-LH7.2 immunofluorescent 
staining. 
Healthy human donor (left panel) or mouse (right panel) 7 µm thick skin sections were stained against 
human C7 using mAb-C7-LH7.2 antibody and imaged at two different magnifications. Positive staining 
for C7 (green) is detected in human skin at the dermal-epidermal junction (DEJ) (a, c). There was no 
staining in mouse skin, indicating no detection of mouse C7 or cross reactivity with mouse tissue (b, d). 
Nuclei were stained with DAPI (blue). Scale bars = 100 µm. 
4.1.3  Epidermal differentiation markers in human and mouse skin 
To allow confirmation of the maturation of bioengineered human grafts on the human:murine 
chimeric mice models, verification of natural keratinocyte progression through all stages of 
differentiation was carried out. A panel of proliferation and differentiation markers were tested 
on healthy human skin, and compared to mouse skin (Figure 4.4). The results showed strong 
expression of the early differentiation marker involucrin, localised within the stratum 
granulosum of human but not mouse tissue. (Figure 4.4 a, b). Keratin intermediate filament 
marker, keratin 10, a protein mainly expressed in both stratum spinosum and granulosum was 
expressed in the uppermost suprabasal layers of the epidermis in the human skin, while mouse 
tissue exhibited autofluorescence at the tissue edge with a dissimilar signal localisation and 
expression pattern to human skin (Figure 4.4 c, d). In addition, the cytoskeletal intermediate 
filament protein and marker of keratinocyte proliferation, keratin 14, showed strong expression 
in basal keratinocytes of the human skin with reduced intensity in the stratum spinosum and 
granulosum. Staining was also detected in the mouse epidermis and around the hair follicle 
(Figure 4.4 e, f).  
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Taken together, these results indicate a clear morphological distinction and specific epidermal 
protein expression between human and mouse skin. The specific anti-human C7 antibody could 
furthermore provide robust and high quality staining, while a panel of differentiation markers 
was shown to successfully detect distinct keratinocyte strata. The above staining procedures 
and antibody combinations will therefore be used for distinguishing bioengineered human SEs 
from mouse tissue, evaluation of epidermal maturation and, ultimately, for the detection of the 
human origin of C7 expression. 
 
Figure 4.4 Epidermal maturation and differentiation markers in human and mouse tissue.  
Healthy human donor (n=2) (a, c, e) and mouse (n=3) (b, d, f) skin tissue were sectioned at 7 µm 
thickness and stained with a panel of epidermal markers including early terminal differentiation marker 
involucrin (a, b) spinous layer specific keratin 10 (c, d) and basal cytokeratin marker keratin 14 (e, f). 
Compartmentalised staining of all three epidermal proteins was seen in human skin while mouse skin 
demonstrates faint non-specific expression. Nuclei were stained with DAPI (blue). The images shown are 
from representative fields of multiple tissue sections. Scale bar = 100 µm. 
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4.2  Development of an in vivo pre-clinical RDEB human:murine 
chimeric skin graft model  
4.2.1  Formation of bioengineered RDEB skin equivalents  
For the in vivo assessment of vector-mediated functional correction, a robust RDEB mouse 
model recapitulating the disease characteristics was required. Since the Col7a1-/- knockout 
murine models available in Germany and the US are lethal, they would not be suitable for 
testing the gene therapy approach that we proposed. For this reason, a human:murine chimeric 
skin graft model using a nude NMRI-Foxn1nu athymic mouse strain was selected to generate a 
pre-clinical gene therapy model for RDEB (Larcher et al., 2007). In this model, a bioengineered 
SE composed of normal donor or RDEB patient keratinocytes and fibroblasts either 
untransduced or transduced with LV-COL7 was grafted onto the dorsal back region of an 
immunocompromised mouse strain (see Methods 2.2.36).  
Preliminary experiments were carried out to validate the model by using a combination of 
immortalised human keratinocytes (NIKS) (see materials Table 2.3) either untransduced or 
transduced with LV-GFP and primary healthy donor fibroblasts. A supporting scaffold was 
formulated from coagulant factors extracted from porcine plasma cryoprecipitate, 7.5x105 
fibroblasts and thrombin. 1.2x106 keratinocytes were seeded on the surface of the semi-solid 
gel-like fibrin matrix the following day  (Figure 4.5 A). The bioengineered fibroblast and 
keratinocyte comprised SEs were cultured until keratinocytes reached the desired confluency 
and then grafted on the dorsal region of the back of the NMRI-Foxn1nu athymic mice (Figure 
4.5 B). 6 weeks post-grafting, the murine dorsal region was examined under UV light for GFP 
expression with the results confirming the persistence of the grafted cells localised in the central 
portion of the grafted tissue (Figure 4.5 C).  
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Figure 4.5 Human:murine chimeric skin graft model.  
Bioengineered skin equivalents (SEs) were generated by using a fibrin scaffold containing human 
keratinocytes and fibroblasts and transplanted onto immunodeficient mice for formation of a full 
thickness human graft. (A) 3D fibrin gel comprised of porcine plasma cryoprecipitate, human thrombin 
and either normal donor or RDEB patient keratinocytes and fibroblasts untransduced or transduced with 
LV-COL7 or LV-GFP generated in vitro. (B) Grafting of SEs onto NMRI-Foxn1nu athymic or NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. (C) 6-weeks post grafting, full-thickness skin of human origin is 
visible. Confirmation of grafting by GFP expression of LV-GFP transduced human keratinocytes.  
 
 
 
 
 
 
133 
4.2.2 Human:murine chimeric skin graft model for the in vivo assessment of RDEB 
gene therapy  
A pilot experiment was performed using bio-engineered skin grafts generated by using a 
combination of NIKS or RDEB EBKC keratinocytes either untransduced or LV-COL7 
transduced, and primary or RDEB patient (BT) fibroblasts untransduced or following LV-COL7 
transduction. 8-week post grafting, the grafts were harvested and cryosectioned for analysis. 
Immunofluorescent staining using the mAb-C7-LH7.2 antibody demonstrated C7 expression at 
the DEJ of the LV-COL7 transduced RDEB cell combination at comparable levels to control 
grafts generated from NIKS and primary fibroblasts (Figure 4.6 d, g). On the contrary, there 
was no deposition of C7 detected at the DEJ of skin grafts generated from the combination of 
untransduced EBKC and RDEB fibroblasts (Figure 4.6 a). H&E staining revealed a distinct 
thickening of the epidermis in all grafts with visible stratification and formation of a cornified 
layer resembling that of human skin (Figure 4.6 c, f, i, j). Furthermore, the graft generated from 
the combination of untransduced RDEB keratinocytes and fibroblasts exhibited a blister-like 
morphology with subepidermal cleavage at the DEJ recapitulating the RDEB phenotype, 
whereas no discernible tissue cleavage or blistering could be detected in the LV-COL7 
transduced RDEB or healthy donor cell (Figure 4.6 c, f).  
These results have demonstrated the use of a human:murine chimeric skin graft model for the  
in vivo modelling of RDEB and for the functional assessment of C7 expression in gene 
corrected cells. 
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Figure 4.6 Assessment of C7 expression and graft morphology using LV-COL7 transduced 
keratinocytes in pre-clinical human:murine chimeric skin graft RDEB model. 
Bioengineered human skin equivalents generated by the combination of healthy donor primary 
keratinocytes and fibroblasts (WT KC/FB) (n=2) or RDEB EBKC keratinocytes cells with or without 
LV-COL7 transduction (n=4) and RDEB patient (BT) fibroblasts (n=2), were grafted onto NMRI-
Foxn1nu athymic nude mice (n=8) and harvested 8 weeks post grafting. H&E staining shows thick 
epidermis with attachment of DEJ in LV-COL7 transduced RDEB keratinocyte graft (f) and WT KC/FB 
graft (i) while a distinct blistering phenotype was seen in the untransduced (UT) RDEB cell combination 
(c). Immunofluroscence staining using mAb-C7-LH7.2 antibody shows positive C7 expression (red) at 
the DEJ of grafts generated from LV-COL7 transduced RDEB EBKC and patient (BT) fibroblasts (d) and 
WT KC/FB combination (g), with a similar staining pattern to that of human skin control (j). No 
expression of C7 was seen at the DEJ of graft generated from the UT RDEB cell combination (a). Images 
of 2ry antibody control staining revealed no background staining (b, e, h, k). Scale bars = 100 µm. 
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A major hurdle encountered in this study was the relatively high occurrence of graft rejection in 
the NMRI-Foxn1nu mouse strain with up to 50% of the bioengineered SEs failing to engraft 
(personal communication with Dr. F. Larcher confirmed similar observations) (of the 12 NMRI-
Foxn1numice grafted 7 mice showed graft rejection). This may be due to the presence of 
circulating B-cells in this strain. Therefore, the NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse 
strain was selected (Shultz et al., 2005). A loss-of-function mutation in the Prkdc gene causes a 
knockdown of the T cell receptor (TCR) and the B cell immunoglobulin gene (IG), preventing 
their development and maturation, resulting in the scid phenotype. In addition, a null mutation 
in IL2rg inhibiting the production of a number of interleukins including IL-15, results in a 
disruption of signalling with NK cells, preventing their development. Using the NSG strain as 
the recipient of the bioengineered SEs showed an increase of grafting success rate to 80% (15 
out of 17 NSG grafted mice had human skin graft growing). Therefore, the NSG-based 
human:murine chimeric skin graft model was utilised for all subsequent in vivo work.   
4.3  Functional recovery of C7 in RDEB skin grafts genetically 
corrected by LV-COL7  
4.3.1  Restoration of C7 expression in graft generated by LV-COL7 corrected 
RDEB patient fibroblasts  
Primary cells obtained from either healthy donors or RDEB patients with or without LV-COL7 
transduction were used for evaluation of the efficacy of the gene therapy strategy in the in vivo 
human:murine skin graft model.  
Firstly, to test whether gene corrected RDEB fibroblasts alone would be sufficient for the 
functional recovery of C7 in RDEB skin, indicated by the formation of robust AFs, primary 
fibroblasts from RDEB patient (CK) were transduced with LV-COL7 at an MOI of 10. Both 
untransduced RDEB patient (CK) fibroblasts or LV-COL7 transduced patient (CK) fibroblasts 
were formulated into bioengineered SEs as previously described with the combination of 
primary untransduced RDEB (CK) keratinocytes. Control SEs were prepared alongside using a 
combination of primary healthy donor keratinocytes and fibroblasts. The bioengineered SEs 
were then grafted onto 6 to 8-week old NSG mice (total number of 8) in duplicate for healthy 
donor and RDEB untransduced control groups and quadruplicate for the LV-COL7 transduced 
group. 2-3 weeks post grafting, the devitalised mouse skin used as a biological bandage had 
sloughed off and revealed a noticeably thicker epidermis resembling that of human skin. 8-
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weeks post grafting, the grafts were harvested with attention to preserve portion of the 
bordering mouse tissue and snap frozen for cryosectioning. 
Graft morphology was evaluated by staining frozen sections of each graft with H&E. The 
results revealed a distinct border between mouse and human tissue (Figure 4.7 a-c). The skin 
grafts examined from each group showed a noticeably thicker epidermis than that of the 
bordering mouse tissue, comprising of 10-12 keratinocyte cell layers, while there was also a 
thickened cornified layer and absence of hair follicles in the human grafts. Staining of the grafts 
with a panel of human specific antibodies (described in section 4.1.1) further corroborated these 
findings. Clear boundaries of where mouse and engineered human skin grafts fused were easily 
distinguished in all grafts. Blistering, visualised as sub-epidermal tissue separation was apparent 
in the graft generated from non-gene corrected cells, whereas intact adhesion of the DEJ was 
seen in healthy donor and LV-COL7 gene corrected grafts (Figure 4.7 b). Immunofluorescence 
staining with human specific antibodies desmoglein-1 and MTCO2 showed positive staining 
restricted to the human graft with no signal detected in the bordering mouse tissue (Figure 4.7 
g-i, j-l). The staining patterns of both MTCO2 and desmoglein-1 were comparable to those 
observed in the previous section (4.1.3), with cytoplasmic staining of keratinocytes and 
fibroblasts for MTCO2 and suprabasal membranous epidermal staining for desmoglein-1.  
7 out of the 8 grafted mice presented with full-thickness skin of human origin confirmed by 
desmoglein-1 and MTCO2 expression. The single case that failed however, displayed positive 
staining of MTCO2 in a portion of the fibroblasts in the dermis. This suggested that on this 
occasion, mouse keratinocytes may have migrated into the wound during the graft take process 
and replaced the human keratinocytes, resulting in a mixed cell population in the graft with 
human fibroblasts in the dermis and mouse keratinocytes in the epidermis. 
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Figure 4.7 Confirmation of bioengineered human SEs grafted on NSG mice by H&E and human 
specific antibody staining. 
Harvested grafts were stained for H&E and human specific desmosomal and mitochondrial markers 
desmoglein-1 and MTCO2. H&E staining shows a defined border (dotted line) between mouse (ms) and 
bioengineered human (hu) skin (a-c) with thickened epidermis and loss of hair follicles (b). Human 
specific anti-C7 antibody (green) is expressed in healthy and gene corrected graft (d, f) but not in the 
untransduced graft (e). MTCO2 (red) stained both epidermis and dermis in all grafts but not in the mouse 
portion of the tissue (g-i). Desmoglein-1 (green) shows a defined epidermal human/mouse tissue border 
in all grafts (j-l). Splitting at the DEJ of the untransduced graft is depicted (stars). Nuclei were stained 
with DAPI (blue). Scale bars = 100 µm.  
 
Examination of the H&E stained morphology of the DEJ under low-magnification, revealed 
visible tissue cleavage in the graft generated using untransduced RDEB cells (Figure 4.7 b). On 
the contrary, this phenotype was not observed in the grafts generated using healthy or 
transduced fibroblasts (Figure 4.7 c). To determine whether this was a LV-COL7 mediated 
effect, suggesting the secretion and deposition of functional C7 at the DEJ, grafts were stained 
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with mAb-C7-LH7.2 antibody. The results showed an overexpression of C7 protein throughout 
the DEJ of the graft generated using LV-COL7 transduced RDEB fibroblasts similar to that in 
healthy donor cell graft (Figure 4.8 a&d, c&f). The intensity of C7 expression allowed for its 
detection in fibroblasts in the dermis as cytoplasmic staining seen predominantly in the 
transduced graft and to a lesser extent in the healthy control graft. The epidermis appeared 
securely attached to the underlying dermis with no visible indication of separation or blistering. 
In contrast, the graft generated using the untransduced RDEB cell combination showed no 
discernible C7 expression at the DEJ, with sub-epidermal tissue separation from the dermis, 
closely resembling RDEB patient skin (Figure 4.8 b&e).  
 
 
Figure 4.8 Restoration of C7 expression at the DEJ of the transduced graft mediated by LV-COL7 
gene correction of RDEB patient fibroblasts. 
Harvested grafts were cryosectioned and stained for human C7 at the DEJ. The morphology showed a 
blistering phenotype (asterisks) with dermal-epidermal cleavage (dotted line) in the graft generated with 
untransduced RDEB patient keratinocytes and fibroblasts (b, e), whereas, there was no such phenotype in 
grafts generated by healthy donor  (a, d), or LV-COL7 transduced RDEB fibroblasts containing grafts (c, 
f). Immunofluorescence staining using human specific anti-C7 antibody (green) shows strong C7 
expression at the DEJ of healthy donor (a, d) and LV-COL7 transduced graft (c, f). In contrast, no C7 
expression is seen in untransduced graft. These results indicate the restoration of C7 expression in the 
grafts with COL7 gene corrected cells.  The disappearance of the blistering phenotype in the gene 
corrected graft suggested the re-establishment of dermal-epidermal adhesion after C7 restoration. Nuclei 
were stained with DAPI (blue). Scale bars = 100 µm. 
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The grafts were also examined for epidermal proliferation and differentiation markers 
involucrin, keratin 10 and keratin 14 (Figure 4.9). A fully developed epidermis staining positive 
for all three markers in grafts generated using healthy donor, RDEB patient untransduced or 
LV-COL7 transduced fibroblasts suggested normal differentiation and maturation of the grafts 8 
weeks post grafting (Figure 4.9 d-f, g-i, j-l). Although all grafts, irrespective of the cell 
combinations, showed a differentiated and matured epidermis, extensive tissue separation and 
blister formation between basal keratinocytes and the underlying dermis was clearly observed in 
the untransduced RDEB graft. These data clearly indicate that LV-COL7 transduction of the 
fibroblasts alone can lead to restoration of C7 expression and amelioration of tissue cleavage at 
the DEJ. 
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Figure 4.9 Expression of epidermal maturation and differentiation markers in grafts generated 
from primary RDEB patient (CK) keratinocytes and fibroblasts. 
Differentiation and maturation of the harvested grafts were assessed by H&E and with epidermal protein 
specific antibodies against involucrin and keratins 10 and 14 proteins. No tissue cleavage seen in LV-
COL7 fibroblast transduced graft suggesting vector-mediated restoration of adhesion (b). Positive and 
negative controls represented by healthy donor graft (a) and untransduced RDEB graft (c). Staining of 
grafts with involucrin (red) (d-f) and keratin 10 (green) (g-i) as markers of keratinocyte differentiation 
and keratin 14 (red) (j-l) as a keratinocyte proliferation marker. All grafts were positively stained for 
these markers indicating maturation of the harvested grafts. Tissue separation/cleavage in RDEB 
untransduced combination depicted by dotted lines at DEJ. Nuclei were stained with DAPI (blue). Scale 
bars = 100 µm. 
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4.3.2  Assessment of C7 function in an in vivo human:murine skin graft model  
It was previously described (Section 3.4.2.2), that RDEB (BT) keratinocytes showed full-length 
C7 expression by Western blot.  It was speculated that detection of the 290 kDa protein band 
corresponding to C7 by the Chen-C7 antibody, was due to the amino acid substitution mutation 
in one allele, or the late stage truncation of the other allele potentially resulting in expression of 
the full-length C7 protein although rendered non-functional. To confirm this, bioengineered SEs 
were generated using RDEB keratinocytes and fibroblasts from patients (BT) and (EB8) 
transduced with LV-COL7 at an MOI of 5 and 10, respectively, and grafted onto NSG mice 
(n=2) to measure the combined effect on the level of C7 expression and functional restoration to 
the DEJ following gene correction in both cell types. Untransduced RDEB patient (BT) 
keratinocytes and fibroblasts were used in parallel as negative control (n=1). The skin grafts 
were harvested after 8 weeks and examined.  
It was immediately noticed during sample processing that the epidermis in the untransduced 
negative control graft separated from the underlying dermis without exerting any external force, 
whereas not such phenomenon occurred with the LV-COL7 gene corrected graft. This 
observation indicated that the full-length endogenous C7 expression of patient BT cells did not 
appear to confer a functional effect in the adhesion of the DEJ.  
The graft morphology and expression of human specific protein markers were also examined. 
The results demonstrated a thickened epidermis and distinct dermal morphology lacking mouse 
hair follicles in the human grafts (Figure 4.10 a&b). A distinct boundary between mouse and 
human skin confirmed by positive staining of MTCO2, desmoglein-1 and human C7 solely 
within the human grafts was also detected (Figure 4.10 c-h). Morphological H&E staining also 
revealed RDEB-like severe splitting of the DEJ in the graft generated using untransduced cells 
confirming the lack of functional adhesion conferred by the patient cells (Figure 4.10 a&b). 
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Figure 4.10 Verification of human origin of bioengineered SEs grafted on NSG mice by 
morphological and species specific staining. 
Grafts were stained with antibodies against human specific mitochondrial (MTCO2) and desmosomal 
(desmoglein-1) markers or H&E across the human:murine tissue junction. H&E staining of grafts 
generated from either untransduced (a) or LV-COL7 transduced fibroblast RDEB patient cells (b) 
showed defined border (dotted line) between mouse (ms) and bioengineered human (hu) skin. Blistering 
at the DEJ of untransduced graft (a) is depicted (stars). Human specific anti-C7 antibody (green) showing 
expression in transduced graft (d) with weak expression in untransduced graft (c). No cross-reactivity 
seen beyond border into mouse tissue. MTCO2 (red) stained positive in human region of epidermis and 
dermis in both grafts (e, f). Defined epidermal human/mouse tissue border detected by human specific 
desmoglein-1 (green) (g, h). Nuclei were stained with DAPI (blue). Scale bars = 100 µm. 
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Human-specific C7 expression was further evaluated using the mAb-C7-LH7.2 antibody, which 
revealed strong C7 protein expression in the gene corrected graft with intense staining in basal 
keratinocytes at the DEJ region and in a portion of the dermal fibroblasts (Figure 4.11 b). 
Positive C7 staining was also observed along the BMZ of the untransduced graft with no signal 
detected in the dermis, consistent with previous Western blot results showing C7 expression in 
patient BT keratinocytes (Figure 4.11 a). From the results combined demonstrating severe sub-
epidermal tissue separation but positive C7 expression at the DEJ of the untransduced graft, it 
can be concluded that the endogenous C7 protein in the RDEB patient (BT) keratinocytes was 
in fact non-functional. Restoration of tissue separation following LV-COL7 transduction of the 
cells in the gene corrected graft further illustrated the efficacy of the in vivo model for the 
functional assessment of C7. 
 
Figure 4.11 Restoration of C7 expression in graft generated by the combination of LV-COL7 
transduced keratinocytes and fibroblasts.  
Grafts comprised of RDEB cells either untransduced or transduced with LV-COL7 were examined for the 
expression of human C7. The morphology shows a blistering phenotype with dermal-epidermal cleavage 
(dotted line) in the untransduced graft (a), whereas secure attachment of DEJ is seen in grafts generated 
with LV-COL7 transduced RDEB cells (b). Immunofluorescence staining using human specific anti-C7 
antibody (mAb-C7-LH7.2) (green) shows strong C7 expression at the DEJ of transduced LV-COL7 graft 
(b). Weaker C7 expression is visible in untransduced graft although non-functional as confirmed by 
severe dermal-epidermal separation. The results indicate the restoration of C7 following LV-COL7 gene 
correction of both RDEB keratinocytes and fibroblasts and amelioration of tissue cleavage. Nuclei were 
stained with DAPI (blue). Scale bar = 100 µm.  
 
The grafts were further stained with epidermal protein markers to assess epidermal maturation 
in the grafted tissue. Keratinocyte differentiation was confirmed by positive staining of keratin 
10 (Figure 4.12 e&f) and involucrin (Figure 4.12 c&d) in the suprabasal and cornified layers. 
Keratin 14 was predominantly expressed by the basal keratinocytes with diffuse staining in 
suprabasal layers (Figure 4.12 g&h). The positive staining of all three epidermal markers, and 
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the organised layering and well-formed stratum corneum seen by H&E (Figure 4.12 a&b), 
suggested that the human grafts underwent proliferation and maturation during the 8-week 
period on the NSG mice.  
 
Figure 4.12 Expression of maturation and differentiation markers in patient (BT) & (EB8) 
bioengineered skin grafts.  
Grafts were stained for H&E and epidermal differentiation and maturation markers involucrin and 
keratins 10 and 14. The non-gene corrected graft generated from untransduced RDEB patient (BT) cells 
(a) shows tissue splitting at the DEJ  (stars/dotted line), whereas no tissue separation is seen in the LV-
COL7 transduced graft (b). Epidermal differentiation confirmed by involucrin (red) (c, d), keratin 10 
(green) (e, f) and keratin 14 (red) (g, h) in both grafts suggesting epidermal proliferation and maturation 
occurred. Nuclei were stained with DAPI (blue). Scale bars = 100 µm. 
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4.4  Anchoring fibril formation in gene corrected grafts confirmed by 
transmission electron microscopy 
4.4.1  Amelioration of tissue cleavage through functional C7 anchoring fibril 
formation in graft generated from LV-COL7 gene corrected fibroblasts 
Immunofluorescent staining of the harvested graft generated from the combination of 
untransduced RDEB patient keratinocytes and LV-COL7 transduced RDEB patient fibroblasts 
showed the restoration of C7 expression at the DEJ. To evaluate whether this vector-mediated 
C7 expression could form functional AFs, the skin graft was further examined at the 
ultrastructural level by transmission electron microscopy (TEM). 
Fixed and resin embedded graft tissue was processed into ultrathin 100 nm thickness sections 
and examined by TEM (see Methods 2.2.38). Low magnification micrographs were initially 
acquired to allow for the visualisation of the basal keratinocytes and underlying fibroblasts 
(Figure 4.13). At first glance, extensive tissue cleavage was observed in the graft generated 
from untransduced RDEB patient keratinocytes and fibroblasts, which appeared to have been 
restored following gene correction of the RDEB patient fibroblasts alone.  
 
Figure 4.13 Ultrastructural morphology of grafts generated from RDEB patient (CK) cells imaged 
by TEM.  
Morphological assessment of graft DEJ was performed by low power magnification (x1,200) TEM. 
Extensive sublamina densa split (stars) in graft generated from untransduced RDEB patient (CK) 
keratinocytes and fibroblasts with separation between epidermis and underlying dermis (middle). No 
blistering or separation was visible in LV-COL7 transduced RDEB (CK) fibroblast graft (right) or 
healthy donor graft (left), highlighting vector-mediated restoration of adhesion. Dermal-epidermal 
junction (DEJ); Fibroblasts (FB); Keratinocytes (KC); Melanosome (MN); yellow squares depict area of 
DEJ imaged at high magnification in figure 4.14. Scale bar = 6µm. 
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Upon closer inspection of a select portion of the DEJ at high magnification, an abundance of 
rope-like structures throughout the DEJ of the LV-COL7 fibroblast transduced graft could be 
clearly seen, which were, according to their location and morphology, confirmed to be type VII 
collagen AFs (Figure 4.14 C). The healthy control graft exhibited a similar AF structure with 
normal cross-banding and with the NC-2 domain extending 200 nm into the dermis looping 
around dermal type I and III collagen fibres (Figure 4.14 A). In both gene corrected and healthy 
grafts, the AF morphology could be described as thick, looped and arching and in some areas of 
the gene corrected graft, their numbers appeared increased over those seen in the healthy 
control. The NC-1 domain of C7 was closely associated with the hemidesmosomes of the basal 
keratinocytes, which appeared to be large in size, well-formed with sub-basal dense plates. The 
AFs in most cases could be seen extending from the DEJ down to the papillary dermis and 
looping round dermal collagens bundles before re-attaching to the DEJ.  
In instances where the whole AF could not be seen, it was most likely due to the oblique 
sectioning of the specimen, suggesting the continuation of the fibril may be on a different plane 
of view. There was a an abundance of plasmalemmal vesicles within the finger-like protrusions 
of the basal keratinocytes in close proximity to the BMZ assisting in the deposition of mature 
C7 protein to the DEJ. More importantly, in both healthy control and gene corrected grafts there 
was no indication of blistering or tissue cleavage at the DEJ. Instead, there was a robust lamina 
densa throughout and dense AF distribution, demonstrating functional correction at the DEJ and 
restoration of dermal-epidermal adhesion in the gene corrected graft.  
In contrast, the graft comprised of untransduced RDEB patient keratinocytes and fibroblasts 
resulted in a severe blistering phenotype (Figure 4.14 B). There was an extensive sublamina 
densa split with complete separation of the epidermis from the underlying dermis. The 
hemidesmosomes appeared reduced in number, slightly smaller and in some cases appeared to 
be internalised. There were no clear discernible AFs attached at the DEJ, which is in line with 
the lack of type VII collagen expression observed by immunofluorescence (Section 4.3.1). This 
graft appeared to truly recapitulate the RDEB disease phenotype with loss of AFs leading to 
tissue separation at the DEJ.  Visualisation of the keratinocytes in a number of areas within all 
three healthy, uncorrected and gene corrected grafts suggested a possible migratory phenotype, 
a sign of a wounded environment, i.e. keratinocyte protrusions extending deep within the dermis 
as a way of increasing the surface area of attachment. Additionally, an elevated amount of 
plasmalemmal vesicles and slightly reduced number of hemidesmosomes also suggested 
reorganisation of the wound-bed taking place. Increased activity was also apparent within the 
dermis, with instances of lamina densa reduplication and with a somewhat disorganised type I 
and III dermal microfilbril bundle arrangement.  
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Figure 4.14 Functional correction of DEJ through LV-COL7 mediated restoration of type VII 
collagen anchoring fibrils in gene corrected fibroblast graft. 
Grafts were examined for anchoring fibril (AF) formation at the DEJ by high-powered TEM. Healthy 
donor graft (A), showed intact DEJ with numerous large hemidesmosomes. Thick, cross-banded type VII 
AFs (arrows) extend ~200 nm into the dermis looping round type I and III collagen. High proportion of 
C7 protein depositing plasmalemmal vesicles were visible. Untransduced graft generated from RDEB 
patient (CK) keratinocytes and fibroblasts (B) showed extensive tissue cleavage at the DEJ with lamina 
densa reduplication. Complete absence of type VII collagen fibrils resulting in separation of epidermis 
from underlying dermis. Gene corrected graft generated from LV-COL7 transduced RDEB (CK) 
fibroblasts and untransduced RDEB (CK) keratinocytes (C) showed restoration of dermal-epidermal 
adhesion by formation of several thick, looping, arching and cross-banded type VII collagen AFs at the 
DEJ. Anchoring fibril (AF), collagen type I and III (C), dermal–epidermal junction (DEJ), 
hemidesmosome (HD), keratin filament (KF), lamina densa (LD), lamina lucida (LL), melanin (MN), 
plasmalemmal vesicle (PV). Images taken at x13,000 and x30,000 magnification. Scale bar =300nm. 
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4.4.2  Anchoring fibril formation in graft generated using a combination of LV-
COL7 transduced RDEB keratinocytes and fibroblasts  
Grafts generated using RDEB patient (BT) and (EB8) keratinocyte and fibroblast combinations, 
with or without LV-COL7 transduction were processed and examined by TEM. At the 
ultrastructural level, the gene corrected graft showed strong attachment at the DEJ with no 
visible blistering or tissue separation under low magnification (Figure 4.15). The epidermis 
appeared to be well formed with large hemidesmosomes at the basal keratinocyte layer and an 
increased amount of plasmalemmal vesicles. Within the dermis there appeared to be slight 
collagen remodelling, characteristic of wound-bed healing. At the DEJ there was solid lamina 
densa formation with distinguishable AFs extending from the hemidesmosomes and looping 
through the dermis anchoring round type I and III collagen fibres. Their morphology could be 
characterised as cross-banded, looping and arching although were reduced in number and 
slightly thinner compared to the AFs restored in the previous fibroblast transduced CK patient 
combination (Figure 4.16 B). In the graft generated from untransduced RDEB patient (BT) 
cells there was relative undulation of the DEJ and a high proportion of hemidesmosomes 
although a large sublamina densa split was immediately apparent (Figure 4.16 A). It is arguable 
whether AFs could be detected in the field of view although if any, they can only be described 
as short, rudimentary, very thin, rarely arching and wispy. More importantly, these AFs did not 
appear to confer sufficient anchoring in order to prevent tissue separation and blistering at the 
DEJ.  
These results provided strong evidence of functional restoration of the RDEB phenotype upon 
correction of patient cells with LV-COL7. The vector-mediated C7 expression observed 
following immunofluorescent staining of grafts was directly linked to a functional correction 
through de novo formation of AFs securing the DEJ. The quality and abundance of the AFs 
detected was equal or in some cases exceeded that of healthy donor cell controls thought to be 
due to transgene overexpression. Grafting of corrected fibroblasts alone did not appear to 
perform inferiorly to using a combination of both corrected fibroblasts and keratinocytes. 
Although this may be due to patient variation it can be speculated that correction of fibroblasts 
alone being the more robust cell-type are sufficient for functional correction of the DEJ and 
phenotypic reversion of RDEB aberrations. 
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Figure 4.15 Ultrastructural morphology of grafts generated from patient (BT) and (EB8) cell 
combination imaged by TEM.  
Morphological assessment of structural integrity of DEJ in grafts generated from either untransduced or 
LV-COL7 transduced RDEB patient (BT) and (EB8) keratinocytes and fibroblasts by low power TEM 
(x1,200). Sublamina densa split (star) in untransduced RDEB graft showing separation between 
epidermis and underlying dermis (left). No blistering or separation visible in graft generated from both 
RDEB keratinocytes and fibroblasts transduced with LV-COL7 (right), highlighting vector-mediated 
restoration of adhesion. Dermal-epidermal junction (DEJ); Fibroblasts (FB); Keratinocytes (KC); yellow 
squares depict area of DEJ imaged at high magnification in figure 4.16. Scale bar = 6µm. 
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Figure 4.16 Restoration of anchoring fibril formation following LV-COL7 mediated correction of 
RDEB patient keratinocytes and fibroblasts.  
Grafts were examined by high-powered TEM for detection of type VII collagen anchoring fibrils (AFs) 
following transduction of RDEB patient (BT) keratinocytes and (EB8) fibroblasts with LV-COL7.The 
graft generated from untransduced RDEB patient cells (A) showed blistering (stars) at the DEJ. Possible 
rudimentary AFs present, although conferring no visible functional effect. Undulation of keratinocyte 
protrusions suggesting wounded migratory phenotype. The gene corrected graft combination (B) showed 
restoration of dermal-epidermal adhesion. Looping, arching and cross-banded type VII collagen AFs 
extending ~200 nm into the dermis looping round type I and III collagen visible providing attachment at 
the DEJ. High proportion of C7 protein depositing plasmalemmal vesicles seen above lamina lucida. 
Anchoring fibril (AF), collagen type I and III (C), dermal–epidermal junction (DEJ), hemidesmosome 
(HD), keratin filament (KF), lamina densa (LD), lamina lucida (LL), melanin (MN), plasmalemmal 
vesicle (PV). Images taken at x13,000 and x30,000 magnification. Scale bar =300nm. 
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4.5  Discussion 
A chimeric human:murine RDEB skin graft mouse model was established for the investigation 
of C7 expression and functional correction of the RDEB phenotype mediated by LV-COL7 in 
an in vivo setting. Although the two published RDEB murine models can truly recapitulate the 
disease phenotype with lack of C7 expression and with neonates developing large haemorrhagic 
subepidermal blisters on the trunk and extremities, life expectancy is limited to approximately 1 
week due to the severity of their phenotype (Heinonen et al., 1999, Fritsch et al., 2008). In 
search of a more robust alternative, the technique developed by Larcher et al. was investigated 
and successfully utilised for the culture of bioengineered human grafts on immunodeficient 
murine hosts allowing for the generation of the chimeric human:murine RDEB models.  
Following initial experimentation with the proposed NMRI-Foxn1nu hairless mouse strain 
facilitating the process of grafting, a high incidence of graft rejection was encountered possibly 
to be due to residual functionality of NK and B-cells. Instead, replacement of the NMRI-
Foxn1nu with the NSG mouse strain resulted in a marked increase in the grafting success rate. 
The NSG strain lacks T-cells, B-cells, and NK cells and such profound cellular and humoral 
immunodeficiency has proven an excellent model of studies requiring human cell engraftment 
(Shultz et al., 2005).  
The model robustly replicated the disease phenotype with full thickness human skin displaying 
tissue cleavage and blistering at the DEJ. Lack of C7 protein expression by 
immunofluorescence directly translated to absence of AFs at the ultrastructural level and hence 
disruption of BMZ integrity. To assess whether the phenotype could be reversed using the LV-
COL7 therapeutic vector, both RDEB primary patient keratinocyte and fibroblast cells were 
transduced ex vivo and confirmed to express C7 in vitro prior to formulating into a skin 
equivalent matrix. Eight weeks post grafting onto immunocompromised NSG mice and 
obtaining full thickness human skin tissue, confirmed through the meticulous detection of 
human specific protein, samples were processed revealing restoration of C7 expression and 
deposition of protein at the DEJ. Use of a validated anti-human C7 specific antibody exhibiting 
no cross-reactivity in mouse, ratified the human, and hence LV-COL7 derived origin of the 
detected C7.  
In line with the in vitro protein assays showing overexpression of C7 albeit the modest overall 
transduction efficiency, corrected grafts similarly exhibited intense expression of secreted C7 
with cytoplasmic staining visible even in individual gene-corrected fibroblasts. Although the 
therapeutic potential of the LV-COL7 vector was immediately realised in the corrected grafts by 
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histological staining indicating phenotypic reversion of the associated disease characteristics, 
functional correction was further affirmed following detection of type VII collagen AFs. 
TEM examination clearly depicted thick rope-like AFs populating the DEJ which abrogated the 
blistering phenotype and restored adhesion of the epidermis to the underlying dermis. 
Importantly, this was confirmed in both conditions in which either a combination of gene-
corrected keratinocytes and fibroblasts, or gene-corrected fibroblasts alone were used for 
grafting. However, the observed overexpression of C7, suggested that gene correction of a 
single C7 contributing skin cell type, in this case fibroblasts, is capable of conferring a 
sufficient level of functional correction. On the contrary, endogenous C7 expression levels of 
allogeneic healthy donor fibroblasts alone may not have been adequate in providing sufficient 
anchoring as they only contribute for approximately 10% of total C7 secretion in skin.  
Keratinocytes, being the major contributors of C7 to the DEJ in healthy skin, are not anticipated 
to confer as long a lasting therapeutic benefit as fibroblasts if grafted alone. The ~47 day 
turnover from basal, to the terminally differentiated keratinocytes of the cornified layer (Iizuka, 
1994), implies that unless a modest portion of stem cell keratinocytes were to be gene-corrected 
during LV-COL7 exposure, the transduced cells would rapidly be replaced by uncorrected ones. 
This effect would in fact be further accelerated due to C7 expression restricted to the basal 
keratinocytes (Ryynanen et al., 1992). Moreover, the extensive damage of the wound bed in 
blistered regions of RDEB patient skin would most likely hinder the graft “take” process if 
applied as skin sheets. Furthermore, transport of C7 protein secreted from the keratinocytes 
through the basement membrane and into the dermal compartment would be delayed and 
incomplete (Ryynanen et al., 1992). Bioengineered grafts comprised of LV-COL7 transduced 
RDEB keratinocytes alone were therefore not assessed for their therapeutic ability.  
However, the potential of keratinocytes can not be denied, as demonstrated in a study where a 
retroviral vector was used to deliver dog C7 protein to canine RDEB cells (Gache et al., 2011). 
The corrected cells were grafted on the RDEB dogs in the form of epithelial sheet and showed 
persistence of expression for up to 2 years with ectopic expression of C7 also seen in the 
suprabasal layer. Further investigation revealed that the sustained expression was due to the 
transduction of highly clonogenic cells. 
Fibroblasts on the other hand, circumvent a number of the drawbacks associated with 
keratinocytes, chiefly being the slower turnover in vivo ensuring sustained expression over a 
prolonged post engraftment period. This further suggests that fibroblasts remain within 
originally transplanted locations secreting C7 into the extracellular space which is in turn 
sequestered by BMZ proteins and contributes to AF formation (Chen et al., 1999, Chen et al., 
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1997). In addition, the ease of their in vitro manipulation, allowing for up to 30 cell passages 
with no specialised culturing requirements enables their propagation to attain large cell numbers 
without undergoing growth arrest and differentiation (Krueger, 2000).  
In line with reports having previously shown restoration of C7 expression and improvement in 
DEJ of murine RDEB models using gene corrected keratinocytes (Murauer et al., 2011, Gache 
et al., 2004), fibroblasts (Woodley et al., 2003, Woodley et al., 2007b, Ortiz-Urda et al., 2003, 
Goto et al., 2006) or a combination of the two (Titeux et al., 2010, Chen et al., 2002), I was also 
able to provide definitive evidence of functional AF formation from RDEB cells corrected using 
a clinical grade LV-COL7 vector highlighting the therapeutic potential of an autologous gene 
therapy approach. 
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Chapter 5  Genome editing as a tool for establishing an in 
vitro RDEB model and correcting mutations in COL7A1 
Over 600 mutations including missense, nonsense, splicing, small insertions or deletions in 
COL7A1 have been reported to cause RDEB (Varki et al., 2007). Current gene therapy 
strategies rely on the addition of a full-length, WT copy of COL7A1 cDNA into RDEB patients’ 
cells carrying mutations in the COL7A1 gene. A gene addition approach carries complications 
such as the large size of the COL7A1 gene, spanning 8.9 kb in its cDNA form making 
packaging into current viral vectors systems and subsequent delivery to target cells a 
challenging task (Chen et al., 2000, Chen et al., 2002, Titeux et al., 2010). The potential of a 
targeted gene editing approach, whereby individual mutations can be corrected for the 
restoration of endogenous C7 expression instead of introducing an exogenous full-length copy 
of COL7A1 cDNA sequence is very appealing.  
To date, there has only been a single report on the use of gene editing by TALEN technology, as 
a tool for the in vitro correction of a homozygous PTC mutation in RDEB fibroblasts (Osborn et 
al., 2013). The results of the study prove the feasibility of a site-specific genome editing 
approach for the correction of COL7A1 mutations. In addition, as one aspect of gene editing 
involves the introduction of monoallelic or biallelic mutations, it allows for the targeted 
disruption of WT COL7A1. In this way, RDEB cell models can be generated enabling the 
functional characterisation of the disease thereby bypassing the challenge of obtaining and 
culturing precious primary RDEB patient cells. Ultimately, genome editing enables the 
exploration of an alternative strategy for the correction of COL7A1 in autologous RDEB cells 
and restoration of endogenous C7 expression beyond traditional viral-mediated gene addition.  
In this chapter, a ZFN-mediated genome editing approach was developed for RDEB. The 
efficiency of site-specific targeting of COL7A1 using ZFNs was primarily investigated using a 
WT keratinocyte cell line. Considering the resilient nature of keratinocytes to infection, the 
ZFN platform was packaged into a lentiviral platform and used to transduce the target cells. To 
ensure transient expression of the ZFNs within the target cell, the integrase defective HIV-1 
packaging plasmid was utilised for the generation of NILVs. Cleavage efficiency following 
ZFN delivery using either a DNA plasmid or viral-based delivery platform was assessed and the 
genomic disruption and protein knockdown levels in vitro were examined. This aspect of gene 
editing resulting in site-specific genomic disruptions by non-homologous end joining (NHEJ) 
allowed for the in vitro modelling of RDEB.  
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This was followed by an evaluation of the corrective capacity of the ZFN system by harnessing 
the homologous directed repair (HDR) pathway through co-delivery of healthy donor template. 
This was determined through the detection of template sequence within the target cell genome 
by direct Sanger sequencing. Lastly, a proof of principle study assessing in vivo restoration of 
the DEJ anchoring, mediated by RDEB fibroblasts having undergone correction of COL7A1 by 
TALEN gene editing was assessed in the human:murine chimeric skin graft model.  
5.1  Targeted disruption of COL7A1 by DNA plasmid-based ZFN 
delivery 
ZFNs specific to exon 4 of human COL7A1 were designed with the intention of targeting a 
cluster of known patient mutations in the proximal genomic region while preserving ZFN-
induced gene disruption within 100 bp from the target mutation site for optimal efficiency 
(Elliott et al., 1998). The ZFNs were custom-synthesised by Sigma (CompoZr® technology) 
with each ZFN monomer annealing to an 18 bp sequence of exon 4; 5’-
TCCCAGGTCTGCATCCTG-3’ on the top strand and 5’-TCCTGGGACTTCCCGTCT-3’ on 
the complementary strand with a 5 bp spacer sequence 5’-ATCAC-3’ in between and constructs 
were subcloned into DNA delivery plasmids. The ZFN activity was estimated to be ~13.5% in 
human K562 cells as assessed by the supplier.  
The ZFN activity was firstly measured in a keratinocyte cell line (HaCaT). 2.5x106 cells were 
nucleofected with 3 µg of the ZFN DNA plasmid pair using the Amaxa™ Nucleofector™. A 
plasmid encoding eGFP nucleofected in parallel was used as a positive control. The ZFN 
activity assessed by the detection of disruptions presented as insertions/deletions (indels) in the 
COL7A1 genomic sequence created by NHEJ following the delivery of ZFN DNA plasmid pair 
was examined by surveyor nuclease CEL-I assay (see Methods 2.2.30). CEL-I nuclease 
digestion of DNA extracted from the polyclonal HaCaT ZFN-nucleofected population presented 
with a cleaved product at (161 and 211 bp) compared to DNA from the GFP nucleofected 
population, suggesting disruption of the COL7A1 DNA sequence due to NHEJ (Figure 5.1). In 
order to confirm the ZFN cleavage efficiency, the nucleofected HaCaT population was sorted 
into single cells by FACS. Individual clones were propagated and sequenced across the ZFN 
binding region in COL7A1. The data revealed a single base pair deletion in 1 out of 8 clones 
tested.  
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Figure 5.1 CEL-I assay for the detection of ZFN-mediated cleavage in HaCaT keratinocytes.  
Exons 3-5 of COL7A1 were amplified by PCR based heteroduplex reaction and products were examined 
by CEL-I assay for mismatch detection. A cleaved product was seen at 211 bp and 161 bp in HaCaT 
keratinocytes nucleofected with the left and right ZFN DNA plasmid (lane 2) and in the positive (+ve) kit 
control (lane 1), whereas there was no digested band in GFP nucleofected sample representing the 
negative control (lane 3). 
 
5.2  Disruption of COL7A1 in keratinocytes by lentiviral-based ZFN 
delivery - generation of an in vitro RDEB cell model 
5.2.1  Improvement of ZFN delivery efficiency by incorporation of ZFN sequences 
into a non-integrating lentiviral platform  
Delivery of plasmid DNA to keratinocytes or stem cells through transient transfection or by 
electroporation remains a challenging and inefficient method as demonstrated with the ZFNs, 
which is sometimes associated with a significant level of cytotoxicity. Therefore, lentiviral 
vectors were used to improve the efficiency of ZFN delivery. Both left and right ZFN DNA 
sequences described in section 5.1, were separately subcloned into the 2nd generation lentiviral 
transfer plasmid (pHR’SIN.cPPT-SW) containing a spleen focus-forming virus (SFFV) 
promoter using EcoRI /BamHI blunt end sites and an XhoI sticky end site. Positive clones were 
confirmed by restriction enzyme digestion and DNA sequencing. Vectors were pseudotyped 
with VSV-G (pMD2.G) and packaged using the HIV-1-based NILV system by co-transfecting 
the HEK-293T host cells with the Δ64 mutated gag/pro-pol plasmid (pCMV-dR8.74-D64V) 
(Figure 5.2). Left and right ZFN sequence-bearing transfer plasmids were packaged into 
separate NILV constructs. Viral titres were determined by quantifying the HIV-1 p24 antigen 
concentrations by ELISA (see Methods 2.2.29). The viral protein p24 levels (ng/ml) 
corresponding to a physical titre were converted to an estimated functional titre (IP/ml) 
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assuming a range of 10 to 100 TU per pg of p24. Viral preparations were concentrated by 340-
fold and average viral titres converted from p24 protein levels were 4.17x108-9 IP/ml for NILV-
ZFN Left and 2.68x108-9 IP/ml for NILV-ZFN Right.  
 
Figure 5.2 Schematic of 2nd generation NILV transfer and packaging system. 
NILV-ZFN transfer, packaging and envelope plasmids. U3: untranslated 3’ end; HIV1R: human 
immunodeficiency virus 1 reverse; U5: untranslated 5’ end; ψ: psi packaging signal; RRE: rev response 
element; cPPT: central polypurine tract; SFFV: spleen-focus forming virus promoter; ZFN: Zinc Finger 
Nuclease transgene; WPRE: woodchuck hepatitis posttranscriptional regulatory element; ∆U3: deletion in 
untranslated 3’ end; CMV: cytomegalovirus promoter; gag/pro-pol: HIV-1 structural and accessory 
polyproteins; Δ64: substitution of aspartic acid to valine in HIV-1 integrase; tat: HIV-1 trans-activating 
regulatory protein; rev: HIV-1 accessory protein; polyA: polyadenylation tail; VSV-G: vesicular 
stomatitis virus glycoprotein. 
 
5.2.2  Efficiency of NHEJ-mediated cleavage in keratinocytes transduced with 
NILV-ZFNs  
To assess the NILV-ZFN cleavage efficiency, the keratinocyte cell line, NTERT, encoding a 
WT copy of the COL7A1 gene, was seeded at a density of 2x105 cells/well of a 24-well plate 
and co-transduced with left and right NILV-ZFNs at MOIs of 20 or 100, respectively. Owing to 
the high viral titres, the virus volume added fell below the 10% threshold of the total cell 
culturing volume, and therefore, no obvious cytotoxicity or impaired cell growth was observed 
in transduced cells. Subsequent experiments were therefore carried out using the cells 
transduced with an MOI of 100.  
2nd	  generation	  pHR’SIN.cPPT-­‐SW	  transfer	  plasmid 
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The transduced cells were propagated for 7 days and DNA was extracted and amplified by PCR for the 
genomic region covering exon 4 and incorporating the ZFN cut site by PCR. PCR products were further 
run using the heteroduplex hybridisation program and subjected to CEL-I assay. The results revealed two 
additional faint bands corresponding to the expected sizes of the cleaved heteroduplex in the NILV-ZFN 
transduced population, suggesting ZFN-mediated cleavage and NHEJ activity in the targeted region. In 
contrast, no additional bands were detected in untransduced or NILV-GFP-transduced cell controls 
(Figure 5.3).  
 
 
Figure 5.3 CEL-I assay confirming NHEJ in bulk population of NILV-ZFNs transduced NTERTs.  
Bulk populations of untransduced NILV-GFP or NILV-ZFN NTERTs were PCR amplified across the 
ZFN cut site region and allowed to form heteroduplexes before digesting with CEL-I nuclease. Lanes 
Ctrl C and Ctrl C+G show internal kit negative and positive controls respectively; Lanes NTERT UT 
and NTERT NILV GFP represent untransduced (UT) or NILV-GFP transduced experimental negative 
controls; Lane NTERT NILV ZFN represents bulk population of NILV-ZFN transduced NTERTs at 
MOI of 100. The results showed the expected digested products at 211 bp and 161 bp in the positive 
control and at 416 bp and 217 bp in cells transduced with NILV-ZFNs, but not in the UT or NILV-GFP 
transduced NTERTs. 
 
 
To further investigate the mutation frequency mediated by ZFNs in the NILV-ZFN transduced 
NTERT cells, a set of barcoded primers specifically amplifying the region of interest within 
exon 4 of COL7A1 were designed. DNA extracted from the untransduced and NILV-ZFN 
transduced NTERTs were PCR amplified and analysed by high throughput next generation 
sequencing (NGS) using an Illumina MiSeq genome sequencer (see Methods 2.2.31). 
Approximately 1.6x106 raw reads were passed through a series of deconvoluting filtering steps 
allowing for the removal of ~4x105 unmatched reads with the post-filtered fraction containing 
solely matched reads. Sequence alignment against the endogenous COL7A1 sequence ultimately 
resulted in detection of 18.3% of mismatches caused by NHEJ-mediated indels while 81.7% of 
the cells were unaffected. Analysis of the untransduced population resulted in a non-specific 
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background readout of 0.3% (Table 5.1). Although not to be used as a reliable method of 
quantification, the obtained NGS data confirm the qualitative result of the CEL-I assay 
demonstrating the functionality of the NILV-ZFNs through the detection of genomic disruptions 
in COL7A1. These data further point towards an improved efficiency of ZFN delivery by NILV 
over plasmid DNA nucleofections.   
 
Table 5.1 Mutation analysis by high-throughput sequencing of polyclonal NILV-ZFN transduced 
NTERT population. 
 
 
5.2.3  Assessment of NILV-ZFN cleavage frequency in single cell clones  
To further confirm and quantify the NILV-ZFN cleavage activity seen in the polyclonal 
transduced NTERT population, single cells were manually sorted by limiting dilution cloning. 
A total of 48 single clones were expanded from the polyclonal population. DNA sequences 
amplified for the exon 4 region of COL7A1 were examined for the detection of indels across the 
ZFN cut site by Sanger sequencing. 36 out of 48 clones were unaffected, while 10 out of 48 
clones (20.8%) presented with monoallelic disruption and 2 out of 48 clones (4.2%) showed 
biallelic disruption at the ZFN target site (Figure 5.4). Of the 10 clones exhibiting monoallelic 
disruption, clone cl3 & cl26 were selected, identified to have a 2 bp deletion within the ZFN cut 
site. Both clones, showing biallelic disruption, cl4 and cl15, were selected and when sequenced, 
were shown to have deletions at the ZFN cut site of 2 bp and 4 bp, respectively (Figure 5.4).  
CEL-I digestion was carried out on PCR hybridised heteroduplex products of the selected 
clones to further verify the single and double stranded breaks in COL7A1 (Figure 5.5). Both 
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clones (cl3 & cl26) which showed monoallelic disruption carried heterozygous mutations which 
resulted in the two expected shorter fragments after CEL-I-mediated mismatch cleavage. The 
results from cl4, which had presented with biallelic disruption, also revealed the additional 
smaller cleaved fragments upon CEL-I digestion suggesting it was a heterozygous mutant clone. 
The sequencing data confirmed cl4 had a compound heterozygous mutation, as in addition to 
the 2 bp deletion seen in both alleles, a single base mismatch in one allele was also detected. 
The biallelic disruption detected in cl15 only revealed a single undigested PCR product 
confirming the Sanger sequencing data, which showed a matching homozygous mutation in 
both alleles. The heteroduplex PCR product of cl15 was spiked by hybridisation with that of 
unmodified NTERT clone (cl1) carrying the WT COL7A1 sequence which confirmed the 
mutation seen by the digestion of the hybridised cl15+cl1 PCR product (Figure 5.5).  
 
 
 
Figure 5.4 Detection of NILV-ZFN induced mutations by Sanger sequencing. 
Individual NILV-ZFN treated NTERT clones were sequenced along the ZFN cut site for the detection of 
indels. Untransduced WT NTERT cells (cl1) show intact endogenous COL7A1 sequence; NILV-ZFN 
transduced NTERTs show monoallelic disruption in COL7A1 (cl3); biallelic disruption with compound 
heterozygous mutations (cl4) and a homozygous mutation (cl15) in COL7A1. The sequencing results of 
the individual NTERT clones confirmed NHEJ mediated heterozygous and homozygous mutations 
following NILV-ZFN transduction. Mutations highlighted by red borders; asterisk: single-nucleotide 
changes.  
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Figure 5.5 Detection of mutations in selected clones of NILV-ZFN transduced NTERTs by CEL-I 
nuclease assay.  
NILV-ZFN treated NTERT clones detected to have undergone NHEJ were subjected to CEL-I assay for 
further detection of mismatches caused by indels. Wild-type (WT cl1) or NILV-ZFN transduced NTERT 
KC clones were PCR amplified for a region of the ZFN cut site and after heteroduplex hybridisation the 
product was digested with CEL-I. WT clone (cl1) shows single full-length product (372 bp) suggesting 
no mutation in the region, whereas heterozygous mutant NILV-ZFN transduced clones (cl3) & (cl26) and 
compound heterozygous mutant (cl4), show cleaved product at 211 bp and 161 bp suggesting NHEJ-
induced mismatches in the sequence. Homozygous mutant clone (cl15) showed no cleaved product as the 
incurred DSB resulted in identical deletions in both alleles. Hybridisation of cl1 with cl4 or cl15 showed 
appearance of cleaved product, confirming NHEJ in cl15.  
5.2.4  NILV-ZFN treated NTERT clones result in significant C7 disruption 
As there was no donor template provided to support homologous recombination for repair of the 
NILV-ZFN-induced genomic break, the mutations introduced during the error-prone NHEJ 
pathway are expected to result in frameshifts and PTCs in COL7A1 with a functional impact on 
C7 protein expression. To examine whether C7 expression was affected following NILV-ZFN 
treatment, cell lysates from clones cl1, cl3, cl26, cl4 & cl15 were subjected to 6% SDS-PAGE 
and probed with the Chen-C7 antibody. The results showed a marked decrease of C7 protein 
expression in cl3 & cl26 carrying a heterozygous null mutation and complete absence of protein 
bands in the compound heterozygous mutant cl4 and homozygous mutant cl15 compared to WT 
NTERT cl1 C7 expression levels (Figure 5.6). The reduction in C7 protein expression levels 
was corroborated by in situ immunofluorescence staining in clones using mAb-C7-LH7.2. The 
results showed an approximately 50% reduction and 100% reduction of C7 levels in 
monoallelic and biallelic disruption respectively (Figure 5.7).  
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Figure 5.6 Disruption of C7 expression following NILV-ZFN. 
C7 protein levels were assessed in cell lysates from NTERT clones following transduction with NILV-
ZFNs by Western blot. Primary keratinocytes (KC) and untransduced wild-type NTERTs (WT NTERT) 
representing the positive controls show positive C7 expression at 290 kDa while RDEB EBKCs 
representing the negative control demonstrate complete lack of expression. NILV-ZFN transduced 
NTERTs with monoallelic disruption of COL7A1 (NTERT cl3 & cl26) show ~50% reduction of C7 
expression compared to WT NTERTs, and complete absence of C7 expression in NTERT clones (cl4) 
and (cl5) with biallelic disruption of COL7A1. Vinculin was used as a loading control.  
 
Figure 5.7 C7 expression in NTERTs following NILV-ZFN mediated disruption of COL7A1.  
In situ immunofluorescence staining for C7 expression was performed in NTERT clones treated with 
NILV-ZFNs. Top left panel indicates wild-type (WT) NTERT positively expressing C7 (red). The top 
right panel show absence of C7 staining in RDEB EBKCs representing the negative control; the middle 
panel depicts partial C7 expression in monoallelic disrupted clones (cl3 & cl26) compared to WT 
NTERTs and the lower panel shows biallelic disrupted clones (cl4 & cl15) with abrogation of C7 protein 
expression. Nuclei were counterstained with DAPI (blue). Scale bar = 25 µm. 
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Taken together, these data demonstrated transduction of NTERTs with NILV-ZFNs targeting 
exon 4 of COL7A1 could induce DSBs in the region, with a frequency of 25%. There appeared 
to be a direct correlation between the ZFN-induced genomic disruptions in the target gene and 
protein expression level, resulting in partial or complete C7 knockdown following monoallelic 
and biallelic disruption respectively. 
5.2.5  Alteration of migration speed in cells transduced with NILV-ZFNs 
The functional change in the ZFN-treated clones were examined by in vitro “wound-healing” 
scratch assay (Figure 5.8). Previous studies (Section 3.5.1) have demonstrated that lack of C7 
expression can affect cell migration. In order to assess whether the NILV-ZFN treated NTERTs 
exhibit a similar effect, monoallelic and biallelic disrupted clones were seeded in 6-well plates 
at a density of 1.2x106 cells and treated with mitomycin C for 2 hrs to induce cell cycle arrest 
(see Methods 2.2.34). A scratch was made in the confluent cultures and the open ‘wound’ area 
closure time was monitored by time-lapse microscopy over a 10 hr period. Representative 
images from three separate time points suggest a reduced “wound” closure speed in the affected 
clones, cl3 and cl4, over WT cl1. The AUC of each clone was further calculated and analysed. 
The results when statistically compared by one-way ANOVA showed significant variation in 
migration values within the group (p≤0.001). Multiple comparison analysis revealed 
monoallelic disrupted cl3 partially expressing C7 to have a noticeable decrease in migration 
over WT cl1 (p≤0.05) with full scratch closure at ~9 hrs. The effect was exacerbated in biallellic 
disrupted cl4 NTERTs lacking C7 expression, with scratch closure time (~10 hrs) being 
significantly reduced to that of WT cl1 (p≤0.001). Migration speed was also found to be 
reduced in cl4 when compared to cl3 (p≤0.01) (Figure 5.2 A & B). 
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Figure 5.8 Assessment of migration in NTERT keratinocytes following NILV-ZFN transduction 
causing downregulation of C7. 
NTERT cells with COL7A1 knock out (cl4) or knock down (cl3) were treated with Mitomycin C and the 
rates of cell migration were assessed by an in vitro scratch assay over 10 hrs. Images were captured by 
time-lapse microscopy at 15 min intervals and representative images at 0, 3 and 9 hrs are shown (A). WT 
represents NTERTs with WT COL7A1 sequence and normal C7 expression; cl3 represents NTERTs with 
monoallelic COL7A1 gene disruption and partial C7 expression and cl4 represents NTERTs with biallelic 
COL7A1 disruption and lack of C7 expression. The percentage of non-occupied open “wounded” areas 
were dynamically analysed over a 10 hr period (B). Error bars were calculated based on standard error of 
the mean (n=3). Area under the curve (AUC) values of each replicate of each clone were calculated for 
each clone and analysed statistically. The results showed significant differences in migration rates 
amongst the 3 NTERT populations (**p<0.001, one-way ANOVA). Multiple comparison analysis by 
Tukey post-test was further used and results showed a decreased migration rate compared to WT NTERT 
cells (cl1) in both COL7A1 knockdown (cl3) (*p≤0.05) and knockout (cl4) cells (**p≤0.001).  
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5.2.6  Restoration of C7 expression in NILV-ZFN COL7A1 knockout cells following 
transduction with LV-COL7 
The RDEB cell model generated by NILV-ZFN mediated knockout of COL7A1 was further 
tested for the RDEB lentiviral-based gene addition strategy using LV-COL7. NILV-ZFN clone 
4 (cl4) carrying compound heterozygous mutations resulting in absence of C7 expression was 
transduced with LV-COL7 viral vector at an MOI of 1.6. The transduced cells were assessed for 
C7 protein expression by in situ immunofluorescence staining using Calbio-C7-pAb. The results 
revealed positive staining for C7 in the LV-COL7 vector transduced cl4 cells, but not in 
untransduced cl4 cells. (Figure 5.9 B). The percentage of positively stained cells were counted 
in three individual optical images and the results showed 15.23% ± 5.7% cells to be positively 
expressing C7. C7 expression was further assessed by Western blot and full-length C7 was seen 
in cl4 cells transduced with LV-COL7, WT NTERT and cl3 clones and primary keratinocytes 
(Figure 5.9 A). In contrast, no C7 expression could be detected in either untransduced cl4 cells 
or in LV-GFP control vector transduced cl4 cells. However, a very faint band at 290 kDa was 
noticed in both untransduced and LV-GFP transduced NILV-ZFN cl4 cells. Supported by 
previous examination of cl4 at genomic and protein level confirming the absence of C7 
(sections 5.2.3 and 5.2.4), the weak signal seen is most likely a result of minor spillage from the 
neighbouring C7 positive well. The proviral copy number confirming genomic integration was 
also assessed by quantitative PCR and the results showed a 0.021 VCN/cell, indicating 2.1% 
transduction efficiency in the cl4 cells transduced with LV-COL7 at MOI 1.6. 
These results, therefore suggest that NILV-ZFN generated COL7A1 knockout cells can be 
utilised as an in vitro RDEB cell model for the in vitro functional assessment of the disease, 
while can also offer a platform for the investigation of alternative gene therapy approaches. 
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Figure 5.9 Restoration of C7 expression in NILV-ZFN cl4 cells transduced with LV-COL7. 
NILV-ZFN cl4 cells carrying heterozygous biallelic mutations in COL7A1 were transduced with LV-
COL7 at an MOI of 1.6. The C7 protein expression was examined by Western blot and in situ 
immunofluorescence staining. The Western blot results representing results from a single experiment (A) 
showed restoration of a 290 kDa C7 protein in LV-COL7 transduced NILV-ZFN cl4 cells. Positive 
controls included primary healthy donor keratinocytes, NTERT cells expressing WT COL7A1 (WT); 
NTERT cells carrying the heterozygous COL7A1 mutation (cl3) generated by NILV-ZFNs. Negative 
controls included RDEB EBKC (RDEB KC UT) and NTERT cells carrying the compound heterozygous 
mutation in COL7A1 (cl4), either untransduced or transduced with LV-GFP. Faint expression in 
untransduced cl4 was due to sample overflow from neighbouring well. Non-specific band at 76 kDa was 
used as internal loading control. In situ immunofluorescence staining (B) shows C7 expression (red) in 
NILV-ZFN COL7A1 knockout cl4 cells transduced with LV-COL7. There was no C7 expression in 
untransduced NILV-ZFN cl4 cells. These images depict a single representative field of the stained area. 
Scale bar = 50 µm.  
5.3  Gene editing in COL7A1 by homologous recombination-
mediated repair following co-delivery of NILV-ZFNs and homologous 
donor template 
5.3.1  The design and subcloning of a homologous donor template  
ZFNs when co-delivered with exogenous template sequence, present the ability to edit and 
correct mutations within targeted genomic regions by triggering the HDR pathway. To test this 
function, a homologous donor template was designed bearing a portion of the WT COL7A1 
sequence spanning exons 3 to 7 while preserving introns 2 to 7 (Figure 5.10). The donor 
template was designed taking into consideration the optimal length of the homology arms with a 
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recommended span of ~400-800 bps on either side of the ZFN cleavage site acknowledging that 
most efficient repair occurs within the first 100 bps (Hasty et al., 1991, Thomas et al., 1986, 
Elliott et al., 1998, Ran et al., 2013). To enable detection of the template sequence upon 
integration, a KpnI restriction site was included within intron 4 of the donor template sequence 
to allow for confirmation of HDR. EcoRI and XhoI restriction sites were further added at the 5’ 
and 3’ ends of the donor template sequence, respectively, to allow for subcloning into the 
pHR’SIN.cPPT-SW lentiviral transfer plasmid (Figure 5.10). The designed donor template was 
commercially synthesised (GeneArt) and subsequently subcloned into the modified lentiviral 
pHR’SIN.cPPT-W plasmid lacking an SFFV promoter (NILV-OriginalTemp). The viral 
preparations employed the Δ64 integrase defective packaging plasmid for production as a NILV 
as previously described (Section 5.2.1). 
  
Figure 5.10 Donor template design. 
The donor template was designed spanning exons 3 to 7 including introns 2 to 7 of COL7A1. (a) C7 
protein monomer; (b) synthesised recombinant 1.8 kb donor template sequence spanning intron 2-7 with 
addition of KpnI digestion site; (c) exons 3-5 of recombinant donor template sequence indicating ZFN 
binding sites (yellow), ZFN cleavage site (red) and the addition of KpnI restriction site (blue). Capitals 
highlighted in grey: exons; lower case: introns; green: known mutations; bold underlined: PCR primer 
sites. 
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In an attempt to avoid ZFN-mediated cleavage of the donor template containing the ZFN 
binding sites, silent mutations were introduced in the ZFN recognition sequence of the template 
to protect from unwanted cutting. Site-directed mutagenesis (SDM) was performed by using 
complementary primers containing the desired base substitutions (see Methods 2.2.17). 7 
individual silent mutations were introduced over a distance of >40 bps, with 3 nucleotide 
substitutions in the left and an additional 4 in the right ZFN recognition regions, in a two-step 
SDM reaction process using two sets of mutagenic primers. Positive colonies were checked by 
Sanger sequencing and the correctly modified clones showing incorporation of all 7 silent 
mutations were used for preparation of virus (NILV-SDMTemp). Titres of concentrated viral 
preparations for both NILV-OriginalTemp and NILV-SDMTemp vectors were assessed by p24 
ELISA assay and converted to a biological titre (see Methods 2.2.29). The viral titre range was 
from 4.82x107-8 to 2.81x108-9 IP/ml.  
 
 
Figure 5.11 ZFN binding site modification of donor template sequence by site directed mutagenesis 
Original template sequence was modified by introducing silent mutations by site directed mutagenesis 
(SDM) to the ZFN binding site to prevent unwanted cleavage. The sequences show a correctly modified 
clone with 7 introduced silent mutations in exon 4 of the donor template sequenced using forward (SDM 
ex4 COL7A1 template forward) and reverse primers (SDM ex4 COL7A1 template reverse) when 
compared against WT COL7A1 reference sequence (WT). Marked dots indicate base substitutions, 
resulting in degenerate codons encoding same amino acid as the endogenous sequence. 
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5.3.2  Integration of donor template into “recipient” genomic DNA by HDR 
pathway following NILV-induced DSBs 
To examine the efficiency of the donor template to integrate into recipient genomic DNA 
following ZFN cleavage through the process of HDR, both the NILV-OriginalTemp and NILV-
SDMTemp were tested. As there was no RDEB patient keratinocytes available with a mutation 
spanning exon 4, NTERT cells carrying a WT copy of COL7A1 with normal levels of 
endogenous C7 expression were selected for a proof-of-principle study. Although this implies 
that NILV-ZFN/template transduced cells successfully undergone HDR could not be detected 
on account of C7 expression restoration, the unique KpnI restriction site incorporated in the 
donor template was used to confirm template integration.  
WT NTERT cells were seeded at a density of 2x105 cells /well of a 24-well plate and co-
transduced the following day with NILV-ZFN (Left) and NILV-ZFN (Right) at an MOI of 100 
of each and with either NILV-OriginalTemp or NILV-SDMTemp at an MOI of 200. There was 
no noticeable toxicity observed the following day. ZFNs and donor template NILVs were co-
delivered at the same time-point to ensure the template sequences were reverse transcribed and 
readily available by the time the ZFNs have undergone translation and mediated cleavage.  
DNA extracted from the transduced cells was assessed for template integration by KpnI 
digestion of the PCR amplified product of the targeted genomic region. A very faint band was 
observed by gel electrophoresis, suggesting donor template integration in a small portion of the 
transduced cells (Figure 5.12 A). This was confirmed in NTERTs transduced with both NILV-
OriginalTemp and NILV-SMDTemp templates. The transduced cells were further propagated 
for about 14 days to dilute out transient expression of the NILVs and were then sorted as single 
cell clones by limiting dilution (see method 2.2.21). 103 clones from cells transduced with 
NILV-ZFNs + NILV-OriginalTemp and 85 clones from cells transduced with NILVs + NILV-
SDMTemp were picked and expanded for DNA extraction. The region spanning exons 3 to 5 
was amplified and sequenced for detection of the novel KpnI site and the SDM modifications. 
The results revealed 1 (cl13) out of 103 NILV-ZFNs + NILV-OriginalTemp clones contained 
the KpnI site and 1 (cl8) out of 85 NILV-ZFNs + NILV-SDMTemp transduced clones 
contained both the KpnI site and the SDM modifications. The template integration efficiencies 
were 0.97% and 1.17%, respectively. In both cases the integration of the template sequence was 
monoallelic. It was noticed, that the frequency of NHEJ dropped significantly compared to the 
values obtained by NILV-ZFN transduction alone. This may be due to viral competition during 
co-introduction of cells with three separate vectors, NILV-ZFN left, NILV-ZFN right and a 
NILV-template. 
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The positive clones cl13 & cl8 were further analysed by restriction digestion of KpnI. The 
results confirmed the presence of the expected band sizes corresponding to the digested 
template in both NILV-OriginalTemp and NILV-SDMTemp transduced clones (Figure 5.12 B). 
A substantial amount of undigested product was observed in these samples compared to 
digestion of the positive control template plasmid. This is unlikely due to inefficient activity of 
the enzyme, but rather, a result of the monoallelic presence of the KpnI site in these clones.  
 
Figure 5.12 Confirmation of template integration in NILV-ZFN + NILV-template transduced 
NTERTs by KpnI digestion  
PCR amplicons from polyclonal cells or single cloned cells transduced with NILV-ZFNs + NILV-
OriginalTemp or NILV-SDMTemp were examined for template integration using KpnI digestion. (A): 
PCR products from polyclonal NTERT cells transduced with NILV-ZFNs + NILV-OriginalTemp or 
NILV-SDMTemp shows faint band at 245 bp corresponding to digested product, compared to 
untransduced NTERTs and undigested negative controls. (B): PCR products from single cell clones cl13 
transduced with NILV-ZFNs + NILV-OriginalTemp and cl8 transduced with NILV-ZFNs + NILV-
SDMTemp digested with KpnI showing digested products at 200 bp and 245 bp. Control sample included 
positive control pHR’SIN.cPPT-TempW template plasmid and WT NTERT clone cl1 digested with KpnI 
and negative control undigested pHR’SIN.cPPT-TempW template plasmid. The results showed both 
polyclonal cells and single cell clones contained the novel KpnI site, suggesting integration of donor 
template into the recipient NTERT cell genome following co-transduction with ZFN and template NILVs.  
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5.3.3  SDM modification in the donor template eliminates unwanted cleavage 
mediated by NILV-ZFNs 
Sanger sequencing of exons 3-5 of the COL7A1 sequence in cells transduced with NILV-ZFNs 
+ NILV-OriginalTemp or NILV-SDMTemp confirmed the presence of the novel KpnI sequence 
in both cl13 and cl8 clones within intron 4. The introduced SDM modification sites were further 
detected in cl8 (Figure 5.13).  
 
Figure 5.13 Confirmation of HDR-mediated template integration by SDM and KpnI site detection 
in NTERT clones using Sanger sequencing.  
Amplicons of the COL7A1 exon 3-5 genomic region using both SDM ex4 COL7A1 template-forward and 
reverse primers were sequenced. The results show the novel KpnI restriction site in both clones cl13 & 
cl8, but not in WT COL7A1 reference sequence (WT). In addition, cl8 transduced with NILV-SDMTemp 
also shows incorporation of silent mutations introduced by SDM.  
 
 
The PCR amplicon sequence traces indicated both clones cl13 and cl8 had monoallelic sequence 
variation. To further clarify the mutation sites, subcloning of the PCR amplicons into the TA 
vector TOPO® TA was carried out (see Methods 2.2.19). This allows for the two alleles to be 
individually subcloned into the vectors enabling the reliable detection of nucleotide changes in 
each allele. Positive clones were assessed by sequencing and results showed matched donor 
template sequences in NILV-ZFNs + NILV-SDMTemp transduced cl8 with incorporation of 
SDM modifications and the KpnI site ~145 bp upstream of the ZFN cut site in one allele 
F 
F 
R 
WT 
R 
WT 
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(Figure 5.14). A single base pair deletion at the ZFN cut site was detected in the other allele of 
cl8, but without additional donor template sequence. In clone cl13, transduced with NILV-ZFNs 
+ NILV-OriginalTemp, one allele showed incorporation of the KpnI site, although importantly, 
a 7 bp deletion at the ZFN cut site and approximately 9 nucleotide substitutions, typically G>A 
were also detected in that same allele. In the other allele, there was a 10 bp deletion upstream of 
the ZFN cut site within the right ZFN binding region and no detection of additional donor 
template sequence (Figure 5.14). The sequence variation observed in cl13 is likely to be caused 
by cleavage of the unmodified donor template by the NILV-ZFNs as the same phenomenon was 
not observed in cl8 transduced with NILV-SDMTemp. This highlights the requirement for the 
modification of the ZFN binding sites in the donor template sequence.  
It was also noticed that during sequence analysis of both TOPO subcloned cl13 and cl8, a third 
allele with no sign of integrated template sequence or any additional mutations was detected. It 
is possible that this was a result of cross contamination from a second clone.  
 
Figure 5.14 Identification of template integration sequences in NILV-ZFNs + NILV-template clones 
after TOPO-TA subcloning.  
PCR amplicons from NILV-OriginalTemp cl13 (left) and NILV-SDMTemp cl8 (right) were subcloned 
into a TOPO TA vector and sequenced across exons 3-5 and aligned against WT COL7A1 genomic 
sequence (WT). Results demonstrate successful monoallelic HDR in both clones with KpnI sequence and 
SDM silent mutations based on template sequence (T). However, a number of mutations were detected in 
cells transduced with NILV-ZFNs + NILV-OriginalTemp, indicating the importance of modification ZFN 
binding site sequence in the donor template. Yellow: ZFN binding domain; red: ZFN cut site; green: KpnI 
site; orange: mismatches/deletions compared to reference; blue: SDM modifications; dots: alignment 
mismatches; WT: WT COL7A1 sequence; 1, 2, 3: individual alleles; T: integrated template sequence.  
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The results obtained from KpnI digestion experiments and single clone sequencing analysis 
demonstrated the successful integration of donor sequences mediated by the HDR pathway 
following ZFN induced genomic DSBs. Furthermore, the NILV delivery of ZFNs and template 
resulted in a notable improvement over plasmid DNA nucleofections. Moreover, incorporation 
of silent mutations in the homologous ZFN binding regions of the donor template sequence 
could successfully eliminate unwanted donor template cleavage by ZFNs.  
5.4  Restoration of C7 expression at DEJ of in vivo human:murine 
RDEB skin graft model following COL7A1 gene editing in RDEB 
fibroblasts 
With a slightly enhanced targeting efficiency over ZFNs, TALENs known to have a available 
target binding site every ~35 bp of DNA, can be manufactured with relative ease within the 
laboratory and when coupled to an obligate heterodimeric Fok1 nuclease domain can be utilised 
for precise genome editing. This strategy was employed for the site-specific correction of a 
COL7A1 mutation in RDEB fibroblasts (Osborn et al., 2013). The authors had constructed 
plasmid DNA vectors containing specific TALEN sequences targeting an exon 14 PTC found in 
COL7A1 of primary RDEB patient fibroblasts which were co-transfected with WT donor 
template for site-specific repair of the mutation. Positive clones were selected by puromycin 
resistance and monoallelic correction verified by sequencing of integrated template was further 
confirmed by Western blot and in situ immunofluorescence staining. The results showed 
restoration of C7 expression in the RDEB fibroblasts.  
In support of this study, I investigated the in vivo functional potential of these cells in Prof. J. 
Tolar’s lab (University of Minnesota, US). To assess whether the TALEN-corrected RDEB 
fibroblasts could deposit functional C7 at the DEJ and contribute towards the amelioration of 
subepidermal tissue cleavage, a human:murine chimeric skin graft model (see Methods 2.2.36 
and Section 4.2) was used. Healthy donor, RDEB patient unmodified or TALEN-corrected 
fibroblasts and RDEB keratinocytes were used to generate bioengineered SEs. These were then 
grafted onto the dorsum of 6-week old athymic NMRI-Foxn1nu mice and allowed to develop 
over an 8-week period. A 3 mm biopsy of the fully stratified human skin was harvested at week 
8 post-transplant. The morphological characterisation by H&E staining and immunofluorescent 
analysis using a combination of human specific (mAb-C7-LH7.2) and mouse/human specific 
(Calbio-C7-pAb) C7 antibodies was carried out to confirm the grafting procedure (Figure 5.15).  
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The results revealed restoration of C7 expression and deposition of the protein at the DEJ of the 
TALEN-corrected graft, solely contributed to by the fibroblasts (Figure 5.15 i-k). On the 
contrary, no signal was observed in the RDEB unmodified patient cell combination (Figure 
5.19 e-g). The healthy donor cell combination was used as a control to verify the effectiveness 
of the procedure showing strong human C7 deposition at the DEJ (Figure 5.15 a-c). The 
specificity of the antibodies in detecting human C7 by mAb-C7-LH7.2 or both human and 
mouse C7 by Calbio-C7-pAb was confirmed in human and mouse tissue stained controls 
(Figure 5.15 m-o & q-s) and in the previous chapter (Section 4.1.2 Figure 4.2). Skin 
morphology was analysed by H&E staining with the results showing a distinctly thickened 
epidermis in all grafts closely resembling a human-like structure (Figure 5.15 d, h, l). 
Furthermore, when focusing on the DEJ, strong dermal epidermal attachment was observed in 
the healthy donor combination (Figure 5.15 d), whereas the epidermis appears to have 
completely separated from the underlying dermis in the unmodified patient sample due to tissue 
cleavage at the DEJ (Figure 5.15 h). Upon TALEN-mediated correction of the fibroblasts 
mediating HDR from a donor repair template, deposited C7 appears to have sufficiently restored 
the integrity of the BMZ therefore postulating the abundance of fully functional anchoring 
fibrils (Figure 5.15 l).  
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Figure 5.15 Correction of RDEB patient fibroblasts by TALENs leads to deposition of human C7 at 
the DEJ.  
Bioengineered skin equivalents (SE) were grafted onto athymic NMRI-Foxn1nu mice and 3 mm punch 
biopsies were harvested after 8 weeks for detection of human C7 by immunofluorescent staining. (a-d) 
represents SE seeded with healthy donor keratinocytes (KC) and fibroblasts (FB) (n = 2); (e-h) SE seeded 
with RDEB patient unmodified KC and FB (n = 2); (i-l) SE seeded with RDEB patient unmodified KC 
and TALEN corrected RDEB FB (n = 4); (m-p) represents control mouse skin tissue; (q, r) control 
human skin tissue. Antibodies that recognise either human only (green, α-H, mAb-C7-LH7.2) (a, e, i ,m, 
q) or both human and mouse C7 (red, α-H+M, Calbio-C7-pAb) (b, f ,j, n, r) were used to differentiate 
between human and mouse derived C7. Merged images reveal co-localisation of staining (yellow) in 
grafts where the C7 is of human origin (c, k, s). The results depict restored C7 expression in the RDEB 
TALEN-corrected FB graft which was otherwise absent in unmodified RDEB grafts. H&E staining for 
morphological assessment of grafted tissue (d, h, l) against mouse (p) and human control skin (t). 
Blistering and tissue separation at the DEJ is apparent in the RDEB uncorrected graft (stars) (h). Scale bar 
= 100 µm. 
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5.5  Discussion 
This work has highlighted the potential therapeutic use and possible improvement of available 
gene editing machinery for RDEB. This was shown by initially selecting a genomic target site 
within exon 4 of COL7A1 to introduce a DSB using a pair of sequence specific ZFNs. 
Preliminary experiments delivering the ZFNs as plasmid DNA resulted in modest cleavage 
which was greatly increased by subcloning of the ZFN sequences into a NILV platform 
overcoming the notoriously hard to transfect nature of keratinocytes. Although there is a direct 
correlation between ZFN dose and cleavage efficiency, ZFNs delivered to target cells at high 
concentrations have been associated with an increased level of genotoxicity and hence 
cytotoxicity due to off-target effects (Bohne and Cathomen, 2008). This effect is greatly 
exacerbated when delivered to keratinocytes in plasmid DNA form, reported to decrease 
survival by 63.5% at concentrations of 1 µg/ml, while only achieving a ~7% genomic disruption 
efficiency (Hoher et al., 2012).  
In this study, I showed ZFNs delivered by NILV led to a 25% knockdown of COL7A1 with no 
noticeable detriment to target cell survival. This implies that NILV-based delivery is highly 
efficient and can greatly increase ZFN-mediated cleavage without negatively impacting cell 
survival. By harnessing the error-prone NHEJ endogenous cell repair mechanism, it allowed for 
the generation of COL7A1 knockouts in both monoallelic and biallelic fashion resulting in 
either partial or entire loss of C7 protein expression. Functional assessment of the knockout 
clones by evaluation of the migration rate by an in vitro “wound healing” assay revealed the 
similarity of the knockout cells to RDEB patient cells. The first part of this study, therefore, 
demonstrated the successful modelling of the RDEB disease phenotype in a keratinocyte cell 
line for potential use in downstream applications assessing correction efficiency.  
The significance of this result is highlighted by the fact that RDEB patient sample availability is 
scarce and the isolated primary cultures can be particularly challenging to propagate. Therefore, 
using the ZFN technology an infinite supply of RDEB-like cells can be generated carrying a 
wide range of user-defined mutations. This scenario was tested using the full COL7A1 knockout 
model developed here for the assessment of C7 restoration by gene addition. Using the 
previously described LV-COL7 vector, C7 was successfully restored to the developed RDEB 
cell model in line with initial results obtained from transduction of RDEB patient primary 
keratinocytes.  
A discrepancy was noticed in the untransduced cl4 biallelic disrupted cells, showing faint 
protein expression by Western blot at 290 kDa corresponding to C7.  This was not believed to 
be true expression as the clone was extensively characterised during previous assessment at both 
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genomic and protein level. As the clone carried a compound heterozygous mutation it was 
hypothesised that one allele could potentially result in a missense mutation with full-length non-
functional C7 expression. The Chen-C7 antibody detecting the NC-1 domain could therefore 
still detect the protein. Alternatively, the possibility of two different clones being present in the 
population could explain the expression. As both these scenarios would have resulted in a 
significantly stronger band while also would have been detected during initial assessment by 
three independent assays, it can be extrapolated that this was a case of technical error causing 
contamination from the neighbouring C7 expressing sample during loading of the SDS-PAGE.  
Ultimately, a strategy for the potential correction of patient mutations and restoration of 
endogenous C7 expression in autologous cells using ZFNs was developed based on prompting 
cells to undergo repair of DSBs by homologous recombination as opposed to the error prone 
NHEJ. This was achieved through the provision of a 1.8 kb donor template sequence with ~880 
bp of homologous arms to the WT COL7A1 genomic sequence flanking the ZFN cut-site. At 
first, the use of primary RDEB patient (CK) keratinocytes with a homozygous mutation at c.425 
A>G in exon 3, 99 bp from the ZFN cut site and within the optimal range of the donor template 
for HDR efficiency to occur was proposed. Sequencing though of endogenous COL7A1 in the 
(CK) keratinocytes isolated for detection of the homozygous c.425 A>G mutation showed 
sequence variation with the specified mutation detected in only a single allele hampering their 
use for this study. Similarly, NILV-ZFN transduced cl13, cl26, cl4 and cl15, which would have 
allowed for the detection of C7 restoration following HDR, could not be used due to the 
disruption of the ZFN binding sites by the initial exposure to the NILV-ZFNs hence hampering 
generation of a second DSB.  
Therefore this study was performed on WT NTERT cells with template integration relying upon 
detection of the introduced unique KpnI restriction site. An added concern when co-delivering 
ZFNs alongside the donor template included the potential cleavage of the template by the ZFNs 
as the targeted binding sites are conserved in both endogenous and template sequence (Porteus, 
2006). By introducing silent mutations in the ZFN recognition sequences of the template while 
maintaining the peptide sequence, unwanted cleavage could be eliminated. This was shown to 
be the case in clones detected to have undergone template integration, with intact template 
sequence observed when transduced with the SDM construct. On the contrary, a substantial 
number of deletions and substitutions were detected at the target site when the unmodified 
template was provided instead. Homologous recombination by both SDM and unmodified 
template sequences resulting in repair of the ZFN introduced DSBs was confirmed to be 
monoallelic at a frequency of ~1%. This is in line with the observation that HDR occurs at a 30-
fold lower frequency to NHEJ (Coluccio et al., 2013). Low levels of HDR in keratinocyte cell 
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lines have also been reported by others in the field with a 50% drop when applied to primary 
keratinocytes (Coluccio et al., 2013). Moreover, their study investigated the possibility of 
improving donor template delivery by adenoviral vectors, although they noticed an increase of 
NHEJ while NILV template delivery appeared to promote homologous recombination.  
NILVs, however, have been reported to sustain a low level of background integration upon 
delivery (Nightingale et al., 2006, Leavitt et al., 1996). This has been estimated to be in the 
range of 10-2 to 10-4 times less than integrating vectors. Delivery of NILV donor template alone, 
has demonstrated background integration levels of <2% in permissive cell lines which upon co-
delivery with NILV-ZFNs otherwise showed >35% efficiency of HDR (Lombardo et al., 2007). 
This effect was significantly reduced in less permissive primary cells with background 
integration only accounting for 0.005%. An analogous response is expected in keratinocytes 
considering the low efficiency of transduction.  
Owing to the endogenous C7 expression in the NTERT cells treated in this study, and therefore 
inability to assess restoration at the protein level as with RDEB cells, an accurate measurement 
of off-target integration was not possible. Moreover, with ZFNs and template delivered as three 
separate NILVs, detection of potential integration events based on viral sequence would prove 
inaccurate. Delivery of ZFNs and template as a single construct has been hypothesised as a 
means of increasing the efficiency of the system (Lombardo et al., 2007).  
The study presented here, has been the first to employ ZFNs for the gene editing and 
development of a therapeutic strategy for COL7A1 RDEB mutations. Although the ZFN 
platform theoretically shows potential for the correction of patient specific point mutations the 
low frequency of HDR is a limiting factor. It has been suggested that target cells may be more 
prone to undergo homologous recombination in the S/G2 phase, which should be considered as 
a way of improving the frequency of repair (Mohrin et al., 2010).  
A study being carried out in parallel by our collaborators showed confirmation of a COL7A1 
patient mutation by TALEN-mediated gene editing (Osborn et al., 2013). The repetitive 
sequence in the DNA binding region of TALENs hampers their incorporation into viral delivery 
systems resulting in rearrangements (Holkers et al., 2013). This, therefore, limits their delivery 
by either plasmid DNA or mRNA with the caveats being reduced efficiency and increased 
cytotoxicity. To increase the proportion of HDR corrected cells the template had to encode a 
puromycin resistance gene to allow for selection. I was given the opportunity to assess the 
performance of these cells in vivo on the chimeric human:murine skin graft model. Analogous 
to the observations concluded to previously (Section 4.3.1), deposition of C7 contributed from 
corrected fibroblasts alone was able to restore dermal-epidermal adhesion and reverse the 
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RDEB phenotype. What renders this study particularly promising, is that endogenous corrected 
C7 expressed at low levels was shown to be sufficient in providing a significant therapeutic 
benefit, therefore highlighting the clinical potential of autologous gene editing tools. This is a 
step forward in the development of a personalised therapy approach for RDEB, which can be 
caused by a substantial number of potentially easily targeted mutations.  
	   181 
Chapter 6  Discussion 
This project has demonstrated a potential ex vivo gene therapy approach for the correction of 
autologous RDEB patient cells by gene addition and editing strategies. A full-length codon-
optimised copy of COL7A1 was efficiently delivered to primary RDEB cells by therapeutic 
lentiviral vector resulting in restoration of C7 protein expression and functional correction of 
dermal-epidermal adhesion in a preclinical human:murine chimeric RDEB skin graft model. In 
addition, gene-editing using ZFNs against COL7A1 was implemented for the targeted knockout 
of the gene enabling the in vitro modelling of RDEB. A proof-of-concept evaluation for the site-
specific repair of COL7A1 mutations mediated by ZFN triggered HDR was also investigated.  
6.1  Proposal of an autologous gene therapy for RDEB 
The selected strategy in contrast to delivery of allogeneic cells aimed to overcome the 
limitations encountered by others, chiefly clearance of cells within a period of 2 weeks (Wong 
et al., 2008). In vivo mouse studies have previously demonstrated dose dependent functional 
restoration of the DEJ using healthy donor fibroblasts in RDEB skin equivalents and persistence 
of up to 16 weeks (Woodley et al., 2003). The study led by Wong et al. (Wong et al., 2008), 
forming the first clinical trial to intradermally inject allogeneic fibroblasts for RDEB 
demonstrated a two-fold increase in C7 expression levels at the injection site visualised by 
immunofluorescence. Importantly, although expression levels were sustained yet decreased over 
3 months, cells were undetectable after 2 weeks.  
A separate trial showed a similar result with detection of intradermally injected allogeneic 
fibroblasts on day 7 with clearance by day 28 (Petrof et al., 2013). These observations led the 
authors to investigate further, which revealed expression was in fact a result of upregulation of 
patients’ own endogenous mutant C7, as confirmed by the rudimentary AFs seen by TEM. It 
has been postulated that both an initial boost of C7 from the allogeneic fibroblasts coupled with 
the slow turnover of the protein, and an autocrine effect exerted on recipient keratinocytes by 
inflammation-induced HB-EGF, may have indirectly led to increased synthesis and secretion of 
endogenous C7 (Wong et al., 2008, Nagy et al., 2011). Furthermore, upregulation of C7 was 
only displayed in patients with baseline expression of mutant protein. Allogeneic fibroblast 
death and eventual clearance was most likely mediated by a host immune response with 
reported transient increase of haematopoietic cell marker CD45, dendritic cell marker CD11c, 
dermal macrophage marker CD68 and IgM (Wong et al., 2008).  
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The limitations associated with allogeneic cell delivery therefore provide a strong rationale for 
the development of an autologous therapy for RDEB. This poses a more elegant strategy and is 
expected to offer sustained benefit without eliciting an allo-immune response. As C7 is 
expressed by both fibroblasts and keratinocytes in the skin, this allows for the potential 
correction of either cell type providing a range of options for their clinical application. 
Autologous keratinocytes can be corrected and cultured to produce skin sheets for superficial 
grafting as has been previously carried out in a JEB human trial with promising results (Mavilio 
et al., 2006).  
A phase I clinical trial has recently commenced to investigate correction of RDEB keratinocytes 
using the LZRSE-Col7A1 retroviral vector and transplantation of autologous epidermal sheets 
in RDEB patients (LEAES) (NCT01263379). The extensive damage to the dermal wound bed 
in RDEB patients though hampers graft take and skin infections are commonplace (Ryynanen et 
al., 1992). The use of keratinocytes for the treatment of RDEB may therefore be restricted to 
milder abrasions or as a combination therapy. Fibroblasts on the other are a better candidate 
being a more robust cell type, offering easier propagation and maintenance in vitro. Moreover, 
they offer broader potential administration routes with delivery possible intradermally (Kern et 
al., 2009, Wong et al., 2008, Petrof et al., 2013, Woodley et al., 2003), intravenously (Woodley 
et al., 2007b) or in a supporting matrix for deeper wounds, typically following surgical excision 
of SCCs.  
6.2  Overcoming the obstacles of gene transfer to epithelial cells 
using 3rd generation lentiviral vectors 
Keratinocytes and to a lesser extent fibroblasts are known to be resilient to transfection which 
would allow for the introduction of foreign DNA into their nucleus. It has been proposed that 
the most efficient way of introducing genetic material into keratinocytes is via a virus (Deng et 
al., 1997, Di Nunzio et al., 2008). For that reason, a lentiviral vector delivery system was used, 
known to attain a high efficiency of infection in a range of cell types, for the delivery of full 
length COL7A1 cDNA. The configuration selected was based on the 3rd generation pCCL SIN-
lentiviral vector, currently approved and used in a number of clinical gene therapy trials for the 
treatment of Netherton syndrome, X-CGD, ADA and WAS (NCT01545323, NCT02234934, 
NCT01380990, NCT01347242).  
Selection of a lentiviral system also offered a number of benefits over its γ-retroviral 
counterpart, the key ones including their potential to infect both dividing and non-dividing cells 
enabling the targeting of post-mitotic, highly differentiated cells, and their safer integration 
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profile with preference for gene rich regions, although have been considered to be potentially 
more disruptive to the host cell genome than γ-retroviruses (Maruggi et al., 2009). Furthermore 
and with relation to the COL7A1 cDNA, lentiviruses can accommodate and efficiently package 
transgenes of up to 9 kb with retroviruses restricted to 7-8 kb. Development of this transfer 
plasmid was undertaken with safety in mind, stripping it of all virulence factors and replacing 
the otherwise strong LTR promoter, capable of activating genes several kb downstream, with a 
CMV promoter (Zufferey et al., 1998). The full-length 8.9 kb COL7A1 transgene has previously 
been successfully incorporated into an MLV retroviral vector (Titeux et al., 2010), although 
their integration profile, favouring regions proximal to transcription start sites and growth 
controlling genes with the potential upregulation of oncogenes, is a high-risk concern (Titeux et 
al., 2010, Maruggi et al., 2009, Wu et al., 2003). In addition, improvement of the vector 
throughout the generations enabling tat independent transcription and delivery of accessory 
plasmids in trans greatly reduced the likelihood of RCL formation (Dull et al., 1998).  
Although pseudotyping of the viral particles with foreign envelopes can be used to confer cell 
specific tropism, preservation of the ubiquitously targeting VSV-G envelope as was carried out 
for this study allows for sufficient transduction of skin cells while it also offers the advantage of 
withstanding concentration by ultracentrifugation (Burns et al., 1993).  
Expression of the COL7A1 transgene by a human promoter such as PGK which was selected for 
LV-COL7, reduces the potential methylation and hence transgene silencing. Significant fold 
decrease in transgene expression due to methylation induced silencing of the driving promoter 
has been seen when using CMV and SFFV promoters over PGK (Herbst et al., 2012). The 
constitutive nature of this promoter also allowed for sustained expression of the COL7A1 
transgene, which led to a desirable overexpression of C7 protein. Other groups have opted for 
the synthetically modified MND promoter, containing the U3 region of a modified MoMuLV 
LTR believed to reduce viral promoter methylation, or the stronger EF1α promoter which when 
tested against the endogenous COL7A1 promoter, demonstrated a significant increase in 
expression levels (Chen et al., 2002, Titeux et al., 2010).  
The rationale behind selecting the PGK promoter was its enhanced ability in also transducing 
heamatopoietic progenitor cells (Salmon et al., 2000) and mesenchymal cells (McGinley et al., 
2011), making this system applicable for future direction into the systemic correction of RDEB. 
Although the EF1α promoter has been reported to have a slight advantage over PGK in 
expression levels when incorporated into a SIN configuration, addition of a WPRE sequence 
upstream of the 3’ LTR has been shown to rescue the negative effect (Salmon et al., 2000). A 
further consideration for the selection of the PGK promoter over the EF1α was the size 
difference with PGK being 672 bp shorter, therefore allowing more space for the large COL7A1 
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transgene and hence more efficient packaging into viral particles. In the minimal SMPU-C7 
vector utilised by Chen et al., in order to compensate for the reduced transgene capacity of γ-
retroviral vectors, the WPRE sequence had to be removed and a minimal Ψ packaging signal 
was used, reducing HIV-derived sequences to 774 nucleotides (Chen et al., 2002). In the LV-
COL7 vector used in this study, a mutated version of WPRE (WPREmut6) was included. This 
retained the ability of enhanced transgene expression through an increase of nuclear and 
cytoplasmic mRNA levels by improving transcript termination, while abrogating synthesis of 
woodchuck hepatitis virus X protein (WHX), a transcriptional activator associated with liver 
tumor development (Zanta-Boussif et al., 2009). For the improvement of transduction 
efficiency, a cPPT sequence was included to facilitate nuclear translocation of the PIC.  
The LV-COL7 vector when prepared using the 4-plasmid transient co-transfection protocol with 
the PEI cationic polymer and concentrated by ultracentrifugation, exhibited a 2-log drop in 
functional titres (5x106) compared to the same vector backbone containing the reporter 
transgene eGFP in place of COL7A1. It was suspected this was predominately caused by the 
increased transgene size rather than vector configuration or technique. It is however also 
plausible that despite removal of major cryptic splice acceptor and donor sites within the 
transgene, residual sites may still result in aberrant mRNA transcript formation through 
alternative splicing (Moiani et al., 2012). In support of the inefficient packaging of the COL7A1 
transgene into functional LVs, when p24 viral antigen levels were measured in the viral 
supernatants, HIV viral capsid protein concentrations were found to be similar to those of LV-
GFP vector. As levels of p24 provide a measure of physical titre rather than functional titre, and 
the similarity seen between LV-COL7 and LV-GFP suggests an accumulation of empty vectors 
in the LV-COL7 preparation. These findings are in line with observations by Kumar et al. 
showing proviral length can be extended to 18 kb in VSV-G pseudotyped lentiviral vectors, 
suggesting no absolute packaging limit although the increase in transgene size was seen to be 
directly associated with a semi-logarithmic drop in titres (Kumar et al., 2001). This was linked 
primarily to interference with viral encapsidation and also limitations during nuclear export of 
proviral RNA.  
However, it is also possible that the RNA genome undergoes successful packaging, but the 
error-prone nature of reverse transcriptase and its frequent dissociation from the template lead to 
mutations or disruption during viral DNA synthesis, affecting proviral integration and gene 
expression (Urbinati et al., 2009, Matrai et al., 2010). Furthermore, it’s noteworthy to mention 
that reducing the length of the vector backbone has minimal effect on the increase of functional 
titres as does reducing the proviral integration sequence length (al Yacoub et al., 2007). In 
addition, alteration of transfer plasmid DNA amount or ratio to packaging plasmids similarly 
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had little effect. Modifications to the concentration protocol have been suggested to 
dramatically increase viral yield by 80% by reducing centrifugal speed to 20,000xg as opposed 
to the typical 100,000xg combined with the addition of a sucrose cushion (al Yacoub et al., 
2007). In this study viral preparations were harvested following ultracentrifugation at 100,00xg 
and 340-fold concentration for optimal recovery.  
6.3  Lentiviral vector caveats- in search of optimisation strategies  
In this study, the overall efficiency of transgene delivery in primary RDEB keratinocytes and 
fibroblasts using the LV-COL7 vector measured by C7 expression, ranged between ~10-20% 
following single or double rounds of transduction. When directly paralleled to other studies, 
performance of LV-COL7 appeared to be modest. Transduction efficiencies of 95% were 
attained at an MOI of 25 (7.5 ± 0.8x107 TU/ml) using an MND driven SMPU-C7 minimal 
lentiviral vector (Chen et al., 2002) and 30-80% when cells were transduced over two time 
points at an MOI of 20 (1x107 TU/ml – 5x108 TU/ml) using an EF1α driven pCMS-COL7A1 
retroviral vector with the supplementation of polybrene (Titeux et al., 2010). However, despite 
the lower titre and reduced transduction efficiency of LV-COL7, robust and sustained 
expression of full-length C7 was achieved, which was able to form fully functional AFs and 
restore adhesion at the DEJ of a chimeric human:murine skin graft model. The reasons for the 
lower transduction efficiency of LV-COL7, may be due to the viral vector utilised although 
expression levels following transduction with LV-GFP using comparable MOIs were ~90-
100%. Alternatively, this could potentially be a discrepancy in the measurement of protein 
expression and hence transduction efficiency according to the assay and conditions used. 
With the increased transgene size being the most logical explanation for the reduced 
transduction efficiency, a previous study attempted to manipulate the COL7A1 cDNA sequence 
to create a minigene and improve the viral vector titer as originally carried out for the 14 kb 
DMD cDNA (Dunckley et al., 1993, Vincent et al., 1993). For the COL7A1 minigene, 678 non-
critical amino acids from the central collagenous region including the 39 amino acid hinge 
region were removed while preserving the triple-helical assembly of the gene (Chen et al., 
2000). Although it was shown to express a shorter 230 kDa form of C7 with similar 
functionality to WT cells in vitro, it may, when assessed in vivo, result in a dysfunctional 
translated protein lacking structural integrity and flexibility, or even elicit an immunogenic 
response to the shorter product from the host. Furthermore, as reducing the size of the viral 
backbone is unlikely to result in an increase in titre and hence transduction efficiency, it was 
hypothesised that including a selectable marker could instead allow for enrichment of 
transduced cells thereby increasing the yield of gene-corrected cells.  
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Preliminary experiments were carried out introducing a self-cleavable CD34 epitope 
downstream of the COL7A1 transgene for co-expression following transduction (data not 
shown). This could potentially allow for FACS based sorting of the transduced population 
resulting in a highly expressing heterogeneous population. However, considering the observed 
overexpression of C7 protein levels over endogenous C7 seen in both LV-COL7 transduced 
RDEB keratinocytes and fibroblasts mediated by the constitutive PGK promoter, such 
additional manipulation may be superfluous. Moreover, this is further supported by data 
suggesting expression of as low as 10% of WT C7 levels at the DEJ can confer adequate 
dermal-epidermal adhesion and maintain skin integrity (Fritsch et al., 2008, Wagner et al., 
2010).  
A crucial optimisation strategy applied to the LV-COL7 vector used in this study differentiating 
it from other RDEB gene therapy reports, has been the use of a codon optimised COL7A1 
transgene sequence to ensure the production of functional C7. Previous reports have 
documented the appearance of truncated forms of C7 following retroviral delivery of full-length 
COL7A1 cDNA to both RDEB fibroblasts and keratinocytes (Titeux et al., 2010). These 
aberrations were further noticed at the genomic level with detection of shorter proviral forms 
suggesting rearrangements were most likely caused during retrotranscription. The presence of 
Gly-X-Y repeats in the triple helical collagenous region of COL7A1 can trigger intramolecular 
template switching of the reverse transcriptase, a mechanism native to retroviruses facilitating 
their genetic variability in the host (Cocquet et al., 2006). It was hypothesised that codon 
optimisation of the transgene would abrogate those effects. The COL7A1 transgene was 
therefore commercially codon optimised for the removal of cryptic splice sites, replacement of 
repetitive sequence using degenerate codons and was further coupled to a Kozak consensus 
sequence ensuring more efficient initiation of translation of full-length COL7A1.  
Protein analysis of transduced RDEB fibroblasts and keratinocytes did not reveal truncated 
forms of C7 in the bulk population suggesting full-length expression. However, studies carried 
out in our lab showed the presence of shorter C7 protein forms at 230 kDa in ~6% of transduced 
keratinocyte clones (data not shown). Sequencing of the entire incorporated COL7A1 transgene 
in clones expressing abnormal C7 using overlapping primers, showed deletions in all three 
colonies clustered around exons 31-40 within the Gly-X-Y rich triple helical domains shown to 
contain tandem repeats. This suggested that aberrations in COL7A1 following LV-COL7 
transduction of cells still occurred despite codon optimisation of the transgene, albeit at a 
significantly reduced frequency compared to reports of ~20% rearrangement when using WT 
endogenous COL7A1 sequence (Titeux et al., 2010). It was speculated that codon optimisation 
of those specific regions could have inadvertently introduced repetitive sequences. Replacing 
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those defined regions with endogenous non-codon optimised sequence may help in reducing 
aberrant clone formation even further. In addition, a functional assessment of the aberrant 
clones carried out in our lab, also demonstrated that these clones performed equally to 
uncorrected RDEB patient cells in terms of attachment, proliferation and migration indicating 
that patients receiving a mixed population of transduced cells containing such clones would not 
suffer any detrimental effects.  
In an effort to decipher the reason behind transgene rearrangement, a retrotranscription 
independent, non-viral, transposon based delivery platform was investigated which instead 
relies on a “cut and paste” mechanism of chromosomal integration upon recognition of inverted 
terminal repeat sequences (ITRs) at either end of the transposon by the transposase. I generated 
a COL7A1 carrying PiggyBac (PB) transposon vector with the advantage of this platform being 
its unlimited cargo capacity (data not shown). Although C7 expression was successfully 
restored in RDEB keratinocytes after transposition of PB-PGK-COL7A1-IRES-GFP by the 
Super PiggyBac transposase, true integration events only accounted for <2% of the population 
following 3 weeks of culture. As this platform still appears to be in the early stages of 
development, it could therefore not be used to attain meaningful data on C7 rearrangement.  
6.4  Determining the functional properties of de novo synthesised C7 
Despite having confirmed the synthesis and secretion of full-length C7 expression by LV-COL7 
transduced RDEB cells, the actual functionality of C7 cannot be inferred solely based on these 
data. For this purpose, a semi-quantitative in vitro functional assay simulating the process of 
wound healing by measuring cell migration over an artificially created scratch was employed. 
RDEB keratinocytes lacking C7 expression revealed a significantly reduced migration rate over 
WT cells. Following gene correction of the RDEB keratinocytes however, the rate of migration 
appeared to recover suggesting normalisation of the migratory phenotype although still 
remained below those of WT cells. As all cells had been pre-treated with mitomycin C, the 
proliferation variable was removed from the measurement. There appeared to be a lag in 
migration during the first 5 hrs in untransduced and LV-COL7 transduced RDEB keratinocytes, 
which then proceeded with the transduced sample showing significant variation and accelerated 
migration until complete closure of the scratch. This was speculated to be due to the moderately 
low transduction efficiency with <20% of cells secreting C7, perhaps being insufficient in 
exhibiting an immediately detectable effect. This migration pattern was further supported in the 
subsequent study which showed NTERT clones having undergone ZFN-mediated COL7A1 
knockdown resulted in a regression of migration speed compared to WT levels upon 
monoallelic disruption which was significantly augmented in biallelic disrupted clones.  
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Interestingly, when migration was analysed in RDEB fibroblasts, there was variation amongst 
the two tested untransduced patient cells demonstrating both reduced and increased migration 
speeds compared to WT. Importantly though, LV-COL7 transduction resulted in normalisation 
of the values in both cases.  
This increased migration propensity has been linked to early SCC development in RDEB 
keratinocytes (Martins et al., 2009). The RDEB patient (EB8), whose fibroblasts exhibited 
increased migration has not displayed clinical evidence of SCC, however a predisposition to 
malignancy can not be ruled out. There have been contradicting reports concerning the effect on 
in vitro wound closure of keratinocytes in the absence of C7 expression. Originally described by 
Chen et al. (Chen et al., 2002), RDEB keratinocytes appear to migrate in an inverse fashion to 
the findings of the study presented here with WT keratinocytes having a lower migration index 
value. This though might instead be explained by their choice of protocol involving the 
treatment and coating of the cell-culture surface with type I collagen prior to seeding and 
performing a colloidal gold migration assay. On the other hand, the assay performed here, 
involves culturing keratinocytes in untreated tissue culture dishes to confluency before 
performing the scratch assay, therefore allowing for the secretion and deposition of endogenous 
extracellular matrix proteins (collagens, laminin, fibronectin).  
Nystrom et al. similarly to the observations in my study, demonstrated from both in vitro and in 
vivo data a significant reduction in migration speed of Col7a1 hypomorphic mouse 
keratinocytes, expressing 10% of normal C7 levels, when compared to wild type keratinocytes 
(Nystrom et al., 2013). This was proposed to have been mediated by a direct interaction of C7 
with the laminin-332/integrin α6β4 complex known to influence directional migration of 
keratinocytes (Pullar et al., 2006, Sehgal et al., 2006, Tsuruta et al., 2011). It has been suggested 
that RDEB cells overexpress α6β4 (Nystrom et al., 2013). That, in turn, not only alters laminin-
332 organisation but is also associated with an activation of E-cadherin, which tightens cell–cell 
contact thereby delaying migration (Hintermann et al., 2005). Hence, the reduced migration 
speed in the RDEB cells and the ZFN-knockout clones observed can be most likely attributed to 
the alteration in α6β4 signaling mediated by the knockout and lack of C7 protein deposition 
leading to aberrant laminin-332 organisation and E-cadherin activation. 
The variability in the RDEB fibroblast migration data, as well as the disparity in the published 
reports illustrates the limitations of this in vitro assay in obtaining an accurate representation 
and confirmation of functional correction following treatment. Therefore it can only be stated 
that restoration of C7 following LV-COL7 transduction of RDEB cells results in normalisation 
and functional recovery of migration.  
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6.5  Development of a RDEB human:murine chimeric model allows 
for in vivo evaluation of gene corrected cells 
Acknowledging the limitations of in vitro assays shown to hinder true functional evaluation of 
the de novo synthesised C7, adopting a procedure for the generation of a chimeric 
human:murine RDEB skin graft model previously described (Larcher et al., 2007), allowed for 
the examination of the functionality of the secreted C7 in vivo. RDEB patient keratinocyte and 
fibroblast cells either untransduced or having undergone gene correction by LV-COL7 were 
used to generate bioengineered SEs which were then grafted onto immunodeficient mice. Initial 
validation of the grafting method was carried out on hairless NMRI-Foxn1nu mice as suggested 
by the authors of the aforementioned study, although a high rate of graft rejection (~50%) with 
mouse skin re-epithelialisation overtaking human graft growth was observed, presumably due to 
fully functional circulating B-cells in the NMRI-Foxn1nu strain. This was circumvented by using 
the NSG strain, greatly increasing the grafting success rate (>80%), confirmed by the clearly 
defined borders between mouse and human skin. Both dermis and epidermis of the harvested 
tissue 8 weeks post grafting showed distinctive human specific staining confirming maturation 
and differentiation of the graft and formation of a multilayered stratified epidermis with 
apparent cornification. Importantly, the mouse model truly recapitulated the disease phenotype 
with lack of functional C7 expression at the DEJ which was supported by lack of AFs at the 
ultrastructural level resulting in severe tissue separation.  
In vivo assessment of the corrective capacity of the LV-COL7 vector allowed for the 
demonstration of the restorative potential for both skin cell types opening a number of possible 
therapeutic avenues in patients. Deposition of C7 at the DEJ of gene corrected grafts resulting in 
amelioration of the blistering and reversion of the RDEB phenotype was seen using both a 
combination of gene corrected keratinocytes and fibroblasts and with fibroblasts alone. There is 
compelling evidence to consider autologous keratinocyte gene therapy as a treatment for RDEB. 
In this study keratinocytes were gene-corrected and shown to contribute to restoration of the 
DEJ in vivo. Pre-clinical data in mice that led to the (LEAES) (NCT01263379) trial 
demonstrated graft persistence and C7 expression with the transplanted cells undergoing up to 
12 epidermal turnover cycles (Siprashvili et al., 2010). This however implies the need for 
efficient transduction of epidermal stem cells and keratinocyte progenitors as supported by 
studies in canine RDEB (Gache et al., 2011). Moreover, continuous tissue damage in EB 
patients leads to gradual loss of transit amplifying progenitor cells and exhaustion in epidermal 
stem cell pools (Mavilio et al., 2006), which would significantly reduce their availability for 
transduction. Grafting using gene-corrected keratinocytes alone in this study was therefore not 
attempted. 
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The exclusive effect of fibroblasts, considered to be the main contributors of therapeutic C7 in 
skin (Kern et al., 2009, Goto et al., 2006) was therefore explored for restoration of dermal-
epidermal adhesion. There was clear evidence of complete reversion of the diseased phenotype 
with overexpression of C7 protein at the DEJ which following secretion into the dermal ECM is 
sequestered by BMZ macromolecules such as laminin-332, type IV collagen and fibronectin 
resulting in the generation of thick centrosymetrically banded AFs. Although C7 expression 
levels at the DEJ of the gene-corrected grafts were supranormal, there is evidence to suggest 
potential saturation of C7 binding to laminin-332 and type IV collagen BMZ components 
(Woodley et al., 2003). As previously shown, C7 has a high affinity for both of these BMZ 
proteins (Chen et al., 1999, Chen et al., 1997). As the levels of expression of both laminin-332 
and type IV collagen are unaffected in RDEB patients and therefore are a limiting factor for C7 
binding (Woodley et al., 2003), overexpression of C7 is unlikely to cause adverse effects. 
Moreover, staining of the grafts for keratinocyte differentiation markers confirmed that C7 
expression from the transduced fibroblasts did not disrupt epidermal morphology. The 
epidermis in gene corrected grafts similar to WT grafts showed precise localisation of keratins 
10 and 14 and involucrin. The de novo synthesised C7 therefore appears to be functionally 
indistinguishable from WT C7.  
6.6  Fibroblasts demonstrate desirable characteristics making them 
suitable therapeutic candidates. 
Fibroblasts present a much more versatile and robust target cell due to their ease of handling, 
propagation and expansion and moreover their potential routes of administration (Goto et al., 
2006). Furthermore, they provide mechanical strength through the active production of ECM 
constituting the structural supporting framework. Their mesenchymal origin implies that the 
appropriate stimulation, such as epithelial stress caused by inflammation or tissue injury, can 
trigger their proliferation and orchestrate the reorganisation of the wounded epithelium. More 
recently, they have been linked to the modulation of immune-cell behavior through the 
production of cytokines, chemokines and prostanoids (Flavell et al., 2008). 
The slow turnover of both fibroblasts and C7 protein allows for multiple intradermal injections 
at sites of injury offering long term correction albeit clearance of allogeneic fibroblasts within a 
few weeks of injection (Kern et al., 2009, Petrof et al., 2013, Wong et al., 2008, Woodley et al., 
2003). Assessment of allogeneic fibroblast injections in RDEB mice has demonstrated 
allogeneic derived C7 in vivo to have a turnover of >100 days despite clearance of the cells 28 
days post injection. Cell clearance was reported to be due to proliferation arrest and eventual 
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apoptosis although the mild inflammation observed may have been a contributing factor (Kern 
et al., 2009). Examination of the harvested graft tissue by human specific staining of the 
chimeric human:murine RDEB model tested here, confirmed the presence of the LV-COL7 
transduced primary RDEB fibroblasts after 8-weeks of in vivo culture suggesting increased 
persistence or potentially active proliferation. In addition, although biopsies were not harvested 
at earlier time points, staining for C7 at the DEJ at 8 weeks, revealed intense C7 expression 
superseding endogenous levels. Although this is in part due to the constitutive PGK promoter 
activity driving high levels of transgene expression, it also supports the hypothesis that the 
activity of the grafted cells has not been majorly compromised. A concern with fibroblast 
therapy is hypertrophic scar formation caused by the excessive synthesis of ECM proteins from 
the injected cells (Kern et al., 2009). As this is a recurrent complication in RDEB patients, 
markers of fibrosis such as α smooth muscle actin (α-SMA), TGF-β and tenascin-C would have 
to be examined following intradermal injection of the cells.  
The evident limitation of such a strategy though is the small diffusion radius and inaccessibility 
of internally affected sites such as the erosions of the esophagus. Intradermal fibroblast 
administration in RDEB mice has shown cells to disperse throughout all vertical layers of the 
dermis at the injection site, although only exhibited slight overall lateral migration of ~10 mm 
(Kern et al., 2009).  
Systemic delivery of fibroblasts via intravenous administration as a way to address those 
shortcomings has shown to promote wound healing and support phenotypic amelioration by 
homing to the injured site (Woodley et al., 2007b). The precise mechanism of fibroblast 
recruitment from the periphery is unknown although it has been speculated that factors such as 
HMGB1 involved in the recruitment of MSCs to wounded sites may be common amongst cells 
of stromal origin (Woodley et al., 2007b, Tamai et al., 2011). Such recruitment has also been 
described in a subset of fibroblasts termed bone marrow derived fibroblasts (BMDFs) when 
following transplantation of bone marrow cells into the fetal circulation of mouse embryos, 
fibroblast progenitors migrate to uninjured skin and aggregate around hair follicle structures 
(Chino et al., 2008). Upon the appropriate matrix stimulation, these progenitors can give rise to 
de novo dermal fibroblasts and facilitate wound healing. Admittedly, the tissue distribution 
following systemic administration of gene corrected fibroblasts might pose a concern. Woodley 
et al. demonstrated in a mouse model, that trafficking of intravenously injected human 
fibroblasts was confined and maintained within cutaneous sites of injury for 6 weeks, with none 
detected in brain, kidney, spleen, liver and heart although small foci of the lungs showed 
positivity with no adverse effects (Woodley et al., 2007b). It is believed that in an immune 
competent patient, cells migrated to unintended sites would be rapidly cleared (Woodley et al., 
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2007b). An additional strategy for the use of gene corrected fibroblasts could potentially be 
their implementation in deeper wound remodelling. RDEB patients typically develop multiple 
sites of SCCs requiring surgical excision. Diseased fibroblasts such as those in RDEB have 
been shown to promote tumour progression, growth and metastasis by facilitating angiogenesis 
at the site highlighting the need for their removal (Flavell et al., 2008). A clinically 
bioengineered scaffold similar to Apligraf® but containing autologous gene corrected 
fibroblasts overlayed with an autologous epidermal sheet could therefore be used to “fill” the 
wound following excision of SCCs.  
With the majority of these approaches only able to target the disease topically, in this study I 
have also explored a systemic strategy based on the encouraging results of the allogeneic BMT 
trial (Wagner et al., 2010). With the design of LV-COL7 optimised for the transduction of stem 
cell populations, murine HSCs and MSCs were harvested from RDEB Col7a1null/null or 
Col7a1flNeo/flNeo hypomorphic mice for ex vivo correction and autologous systemic transplantation 
(data not shown). Although C7 was restored in the transduced cells, survival of the mice was 
not significantly extended.  
It is widely debated which stem cell population would be able to show clinical benefit in RDEB. 
MSCs in particular have been shown to migrate to wounded sites and contribute to tissue 
regeneration while also confer immunomodulatory properties (Wang et al., 2014, Fujita et al., 
2010). Supporting evidence by Tamai et al. has demonstrated a subset of MSCs with a lineage-
negative / platelet-derived growth factor receptor alpha-positive (Lin-/PDGFRα+) marker profile 
can be mobilised from the bone marrow to the site of injury through the action of HMGB1, a 
potent inflammatory regulator and chemo-attractant involved in tissue remodelling secreted by 
necrotic and apoptotic cells (Tamai et al., 2011). The fate of the recruited MSCs still remains 
somewhat unclear with reports suggesting both the exertion of restorative paracrine effects and 
the transdiferentiation to non-haematopoietic collagen secreting cells of the epithelial lineage 
(Tamai et al., 2011, Prockop, 1997). 
6.7  Personalised medicine for RDEB - genome editing as a tool for 
the correction of COL7A1 mutations 
With gene addition, the endogenous copy of the mutant gene remains intact with the potential of 
producing mutant protein. This may not always have a deleterious/negative effect. In the case of 
RDEB, it has been hypothesised that mutant endogenous C7 giving rise to rudimentary AFs can 
assemble with allogeneic introduced healthy C7, resulting in a clinically significant level of 
amelioration (Wagner et al., 2010). However, there may be adverse effects associated with the 
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combined expression of mutant and healthy protein, as the functionality of the mutant-healthy 
aggregates is unknown. This may interfere by diluting out the benefits of the healthy protein in 
a dominant negative manner. Gene manipulation executed via gene editing allows for a 
“seamless” method of correction without permanent integration of foreign genetic code into the 
host genome. Moreover, gene editing could help overcome obstacles encountered with 
conventional gene therapy, such as the delivery of full-length cDNA or the potential 
complications arising from constitutive gene expression by the LTRs or exogenous promoters 
that could potentially contribute to C7 mediated fibrosis (Perdoni et al., 2015). 
With over 600 mutations having been reported within COL7A1, a number of these sites exhibit 
hot-spot occurrence with population variants (Cuadrado-Corrales et al., 2010, Nishie et al., 
2014). Hot-spot mutations make ideal targets for correction by site-specific gene editing. For 
this study, the ZFN platform was selected as the gene-editing tool of choice for the targeted 
modification of COL7A1. Their recent emergence in a clinical setting for the targeted knockout 
of CCR5 in autologous HIV patients’ T-cells illustrates their clinical potential (NCT01252641, 
NCT02388594, NCT00842634).  
The strategy for the correction of COL7A1 mutations in RDEB cells using ZFNs presented here 
constitutes the first attempt of its kind in the field. The efficiency of ZFN delivery and nuclease 
activity within the target cell was examined initially in generating site-specific COL7A1 
knockout lines and subsequently in conferring targeted repair by homologous recombination. A 
modest degree genomic disruption was initially observed at exon 4 of COL7A1 by plasmid 
DNA transfections of the ZFN arms. Plasmid DNA-based ZFN delivery to keratinocytes, 
besides resulting in low cleavage efficiency, is also associated with a significant level of 
cytotoxicity (Hoher et al., 2012). Switching from DNA plasmid transfection to a viral delivery 
system doubled the rate of disruption. By cloning each aspect of the ZFNs into NILVs, infection 
of keratinocytes was greatly improved while ensuring their expression remained transient with 
knockout occurring in a “hit and run” fashion. Long-term persistence of ZFNs in the cell has 
been associated with an increase in off-target cleavage predominantly seen when delivered as 
DNA. Delivery of ZFNs as proteins using cell-penetrating peptides has been presented as the 
safest option (Liu et al., 2015).  
Delivery of the ZFNs by NILV provides an intermediate option between the two in terms of off-
target effects, however, genomic regions with significant homology at the target site are still 
prone to cleavage. This was reported to be the case with mutations found in the CCR2 locus 
following specific targeting of CCR5 (Gabriel et al., 2011). Nevertheless, lentiviral transfer still 
remains the most efficient method of gene delivery to epithelial cells (Kuhn et al., 2002). 
Although reports have indicated the likelihood of low level background integrations with 
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NILVs, these are thought to occur with an incidence of 103 to 104 times less than with 
integrative vectors at similar frequency as with delivery of naked DNA (Nightingale et al., 
2006, Leavitt et al., 1996). Both monoallelic and biallelic disruption of the gene was achieved in 
this study albeit the latter at a significantly lower frequency, detected by mismatches formed 
during the error-prone NHEJ and single strand annealing (SSA) models of repair to resolve 
induced DSBs. This correlated to a partial or complete reduction in C7 protein expression, 
respectively. Functionally, these clones appeared to recapitulate the in vitro characteristics of 
RDEB cells with a delayed wound closure speed associated with the lack of C7 deposition. LV-
COL7 transduction of the generated compound heterozygous COL7A1 mutant keratinocyte line 
led to the restoration of C7 expression confirming the efficiency of gene-addition and 
demonstrating the application of the generated in vitro RDEB model.  
The ability to create DSBs in targeted genomic regions can be harnessed in a therapeutic setting 
for diseases carrying a dominant pattern of inheritance. Dominant negative mutations in 
COL7A1 in ~70% of autosomal DDEB patients can lead to severe blistering at the DEJ 
(Pfendner and Lucky, 1993a). Gene editing for the monoallelic targeted disruption of the 
affected gene could therefore be a feasible treatment option. For RDEB, provision of a 
homologous donor template sequence would be required for the repair of the induced DSB and 
correction of the disease causing mutation. Designing the donor template sequence to span 6 
exons of endogenous COL7A1 was aimed at covering a wide range of mutations clustered 
around the cut site for site-specific correction. The length of the homologous regions was 
selected based on published data demonstrating the use of ≈400-800 bp on either side of the cut 
site resulted in greater recombination frequency than when shorter ≈50-100 bp homologous 
regions were used (Orlando et al., 2010). When designing nucleases and donor templates 
against a target sequence, the optimal distance at which correction can be mediated was also 
taken into consideration, shown to be within 100 bp of the cut site with a 4-fold drop in 
efficiency when the intended site is at a greater distance. Correction though has been 
demonstrated at ≈500 bp away from the cut site albeit at a frequency of below 0.1% (Elliott et 
al., 1998). The observed clustering of mutations around nearby exons in COL7A1 can therefore 
allow for the potential increase in target sites using a single ZFN pair. Template integration was 
first assessed on WT NTERT cells by co-delivery of the NILV-ZFN pair alongside NILV-
template. Co-delivery of ZFNs and template as NILVs was postulated to promote efficiency of 
HDR by 10-100 fold as donor template sequence would be available in an episomal state while 
the ZFNs underwent transcription and translation into effector nucleases initiating genomic 
DSBs (Lombardo et al., 2007). The study by Genovese et al., demonstrated sufficient gene 
correction of the IL2RG gene responsible for SCID-X1 when template was delivered by NILV 
one day prior to ZFNs (Genovese et al., 2014). The nucleases in contrast to ours were delivered 
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as mRNA allowing for their rapid protein synthesis. Co-delivery of both template and ZFNs as 
NILVs therefore aimed to synchronise the timing of DSB generation and template availability. 
When direct sequencing was performed for the detection of HDR events, template sequence 
integration was observed in the transduced cells, however deletions and substitutions were also 
detected around the ZFN cut site. This was hypothesised to have been caused by NILV-ZFN 
mediated cleavage of the template sequence containing homologous ZFN recognition regions.  
Redesign of the template by the introduction of silent mutations in both left and right ZFN 
binding regions, rectified this “off-target” effect. Sanger sequencing revealed monoallelic 
template integration in 1.17% of clones as detected by the degenerate nucleotides used for the 
silent mutations as well as the introduced KpnI site. These results further highlighted the ability 
to potentially correct mutations at least 145 bp away from the ZFN cut site. Although at a 
significantly reduced frequency, random genomic integration of template may occur when 
delivering an exogenous dsDNA sequence. To abrogate this potential adverse effect, single 
stranded oligonucleotides (ssODN) donors can be designed shown to increase knock in 
frequency, although their main limitation is their notably smaller size of a maximum of ≈100 
bp, restricting the correction distance from the cut site (Chen et al., 2011, Duda et al., 2014). As 
suitable primary RDEB patient cells carrying an exon 4 mutation were not available at the time, 
functional characterisation of restored protein expression data was not possible.  
Gene editing for COL7A1 mutations has previously been reported by using TALENs, in which a 
homozygous PTC mutation in exon 14 in RDEB patient fibroblasts was corrected (Osborn et al., 
2013).  The authors achieved monoallelic gene correction by HDR in 6 of the 18 puromycin 
selected clones. In this study, I used one of the expanded gene-corrected clones to generate 
bioengineered SEs which when grafted onto a human:murine chimeric skin graft model showed 
strong expression of C7 at the DEJ with restoration of blistering. This result presented a clear 
indication of the potential of gene editing for RDEB showing restoration of endogenous C7 
expression is sufficient in ameliorating the disease phenotype. However, this further highlights 
the limitation of gene-editing mediated repair, which occurs at a very low frequency 
necessitating the inclusion of a selectable marker. Although TALENs may offer certain 
advantages over ZFNs in terms of target availability and reduced manufacturing costs and 
expertise requirement, their delivery is restricted to DNA or mRNA transfection due to their 
highly homologous repetitive-variable domains (RVDs), resulting in rearrangement when 
delivered by lentiviral platform (Holkers et al., 2013). This is mediated by the intrinsic template 
switching mechanism of simple and complex retroviruses, which undergo obligate minus-strand 
to plus-strand transfer as a means of generating genotypic variability, shown to be increased in 
the presence of direct repeats. In addition, ZFNs having been available for over a decade, 
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further offer the benefit of having undergone rigorous evaluation by the scientific community 
exposing their possible caveats and making them a robust gene editing platform as seen by their 
recent introduction in clinical trials. 
The low incidence of HDR still remains the major limitation in the field of gene editing further 
corroborated by this study’s findings. This signifies the need for improved strategies that can 
boost the rate of homologous recombination to clinically significant levels.  
The preferential time for HDR to occur is during S/G2 phase of the cell cycle (Mohrin et al., 
2010), with a peak in repair at the mid-S cycle phase and a gradual decline in late S and G2 
phases (Karanam et al., 2012). Methods for delaying transit through the S/G2 phase have been 
shown to increase HDR in HSCs by using an aryl hydrocarbon receptor antagonist 
StemRegenin 1 preserving stemness by stalling differentiation (Genovese et al., 2014). A 
similar outcome could potentially be achieved in keratinocytes by exposing cells to hypothermic 
conditions by incubation at 30°C following ZFN delivery. This method termed “cold shock” has 
primarily been reported to increase of NHEJ levels by two to tenfold over conventional 
culturing by increasing the amount of ZFN protein in the target cell (Doyon et al., 2010). 
Besides a transient growth arrest that was restored following incubation at 37°C, temporary 
hypothermic conditions were shown to significantly reduce off-target cleavage (Doyon et al., 
2010). Based on evidence in the literature it can be speculated that an increase in the incidence 
of DSBs should also promote a higher level of HDR (Donoho et al., 1998, Taghian and 
Nickoloff, 1997). This hypothesis has now been confirmed with both ZFNs (Duda et al., 2014) 
and TALENs (Remy et al., 2014).  
The identification and selection of HDR modified clones presents a major barrier in the success 
of gene editing as a potential therapy. For in vitro assessment a fluorescent reporter could 
potentially be included within the intronic sequence of the template as direct cell sorting for 
cytoplasmic C7 would require permeabilisation of the cells. Alternatively, a floxed antibiotic 
resistance gene allowing for cre-recombinase-mediated removal post selection could be used 
(Osborn et al., 2013). My study having been carried out on WT cells ruling out the possibility of 
selection based on restoration of protein expression, relied solely on detection of HDR by PCR 
methods. This involved individual screening of genomic sequence and TA subcloned sequence 
of hundreds of individual clones for identification of ones bearing template highlighting the 
pitfalls of this approach. 
Despite the need for an improvement in HDR efficiency, an important factor to be considered is 
the limited lifespan of epithelial cells. Extended manipulation and culturing of both 
keratinocytes and fibroblasts in vitro such as during gene-editing and clonal selection can 
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rapidly lead to growth arrest, terminal differentiation and senescence of cells (Dickson et al., 
2000). A better-suited candidate for targeting would therefore have to bypass these hurdles. 
Recent studies have explored the use of iPSCs for epidermolysis bullosa with encouraging 
results (Sebastiano et al., 2014, Osborn et al., 2013, Tolar et al., 2011, Itoh et al., 2013, 
Umegaki-Arao et al., 2014). Spontaneous reversions of COL7A1 mutations described as 
revertant mosaicism or “natural gene therapy” are being increasingly detected in RDEB 
patients. Isolation of revertant patient cells presents a particularly promising application of 
iPSCs for an autologous cell therapy (Tolar et al., 2014). Of particular relevance was the work 
showing TALEN-mediated gene corrected RDEB fibroblasts being subsequently reprogrammed 
into iPSCs (Osborn et al., 2013). iPSCs derived from autologous human fibroblasts have now 
entered the first in man clinical trial led by the Riken Institute for the autologous treatment of 
macular degeneration based on pre-clinical safety studies carried out in mice and on human 
primates (Kamao et al., 2014, Kanemura et al., 2014). For inherited skin diseases like RDEB, 
the unlimited self-renewal capacity and hence the ability to genetically manipulate iPSCs 
without compromising on the passage number of the cells, coupled with the ever-growing 
expertise on the derivation of autologous iPSCs from primary patient fibroblasts, could open 
new avenues for potential treatment of the disease (Itoh et al., 2013).  
In our lab, we have initiated experiments whereby iPSCs have been generated from an RDEB 
patient carrying a homozygous exon 3 mutation in COL7A1 and subjected to our NILV-ZFN 
with NILV-template co-delivery strategy. We observed a marked increase in the rate of HDR of 
12.5% with a modest proportion of biallelic corrected clones. This was verified both by PCR 
based methods and also by restoration of C7 expression. Work is currently underway for their 
reprogramming into keratinocyte cells. We suspect the increased efficiency of HDR in iPSCs to 
be mediated by factors such as cell cycle timing, chromatin context reported to alter the balance 
between NHEJ and HDR repair pathways (van Sluis and McStay, 2015), and also the higher 
permissiveness of iPSCs to viral transduction. Furthermore, a high proportion of corrected 
clones could eliminate the need for clonal selection and instead allow for administration of a 
heterogeneous population.  
Recently, the novel CRISPR/Cas9 gene-editing technology has surfaced, demonstrating a 
remarkably high rate of targeted disruption. The bacterial Cas9 nuclease capable of recognising 
G(N19) coupled to an NGG PAM sequence can therefore maximise the potential human 
genomic targets covering over ≈40% of exons. Following recognition of the PAM sequence, 
DNA strand separation leads to RNA binding which then proceeds distally to the end of the 
target sequence and triggers Cas9 catalysis (Sternberg et al., 2014). The technology has already 
been used in number proof-of-concept experiments (Niu et al., 2014, Schwank et al., 2013). 
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Nevertheless, the advantage of the increased flexibility in available target sites also poses the 
greatest concern of the CRISPR/Cas9 system, namely high frequency of off-target cleavage. 
This emphasises the importance of diligent selection of the target sequence, which can currently 
be conducted with the aid of genome screening bioinformatics tools for off-target site 
prediction. In addition, designing of sgRNAs is remarkably cost effective and user-friendly 
thereby allowing for rapid screening of whole sgRNA libraries. In light of this, we have 
constructed a number of potential sgRNAs in close proximity to our ZFN target site and have 
incorporated them into a widely tested lentiviral delivery platform encoding a human optimised 
Cas9 gene and a selectable fluorescent reporter (Sanjana et al., 2014). This will permit the side-
by-side comparison with our NILV-ZFNs while also allowing us to explore alternative target 
sites for a wide range of mutations steering us towards a patient tailored therapy.  
6.8  Concluding remarks 
RDEB can undoubtedly be classed as one of the most devastating inherited genodermatosis with 
a detrimental quality of life and poor prognosis. Finding a cure for this disease still remains a 
distant thought with available treatment options solely relying on palliative care and wound 
management associated with an immense socioeconomic burden on the patients and their 
families. Pioneering work is being carried out globally investigating multifaceted therapeutic 
strategies for the management of RDEB with encouraging results. The accepted consensus is 
that obtaining a clinically significant outcome will require a combinatorial approach as a 
number of caveats have been exposed in present studies (Tolar and Wagner, 2015). These 
generally involve allogeneic cell clearance, short-lived protein expression, adverse 
immunogenic reactions and most importantly restriction to topical delivery. The systemic nature 
of the disease calls for a systemic treatment such as BMT although with RDEB patients being 
severely immunocompromised, this strategy can lead to the demise of individuals acquiring 
pathogenic infections following myeloablative treatment.  
In this study, I investigated a novel strategy for the correction of autologous patient cells using a 
state-of-the-art clinical viral vector. This involved rigorous assessment of its efficiency in vitro 
while exposing its potential shortcomings, and ultimately functionally correcting the disease 
phenotype in a purpose designed RDEB human:murine chimeric skin graft model.  
The positive outcome of these data formed the basis for proposal of therapeutic application in 
man. We have recently been granted MHRA approval for the initiation of a Phase I safety study 
evaluating the topical administration of autologous LV-COL7 corrected fibroblasts to RDEB 
patients (NCT02493816). Granted the success of this trial, we envisage a therapeutic strategy 
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where we can tackle the hurdle of systemic delivery and administer an autologous genetically 
corrected therapeutic capable of conferring total body disease amelioration. We hypothesize 
MSCs to offer such characteristics and have therefore initiated preliminary experiments for their 
assessment.  
Wanting to stay at the forefront of novel and groundbreaking technologies, in this study, I also 
explored the rapidly growing field of gene-editing for the site-specific correction of individual 
patients’ mutations with encouraging results. As the molecular tools available are still in their 
infancy we expect significant advances to be made in the simplification of their architecture, 
their increased efficiency and improved safety profile. Their recent admission in the clinic for 
the treatment of HIV has provided the field with firm grounding for what may in the imminent 
future become a viable patient tailored therapy.  
Attempting to develop a cure for RDEB is short of a mammoth task due to the extent of the 
damage not only affecting the total surface of the skin, but also extending to the internal organs 
and skeletal integrity. Early studies have been instrumental in the understanding of the genetic 
causes of the disease allowing the scientific community to develop strategies for its correction. 
The last 15 years have seen an enormous upsurge in the field owed to the emergence of new 
technologies. With clinical trials now in the pipeline we believe availability of treatment options 
to be imminent. It is doubtful that a one-fits-all therapy will be able to combat RDEB. It is 
imperative that we recognise the extent to which what may be considered a minor success in the 
field can provide inconceivable improvement in these patients’ otherwise agonising life. I feel 
honoured to have been part of this cause and to have hopefully contributed in the fight against 
this devastating disease.  
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Lentiviral Engineered Fibroblasts Expressing
Codon-Optimized COL7A1 Restore
Anchoring Fibrils in RDEB
Christos Georgiadis1,7, Farhatullah Syed1,7, Anastasia Petrova1, Alya Abdul-Wahab2, Su M. Lwin2,
Farzin Farzaneh4, Lucas Chan4, Sumera Ghani1, Roland A. Fleck3, Leanne Glover3, James R. McMillan5,
Mei Chen6, Adrian J. Thrasher1, John A. McGrath2, Wei-Li Di1,8 and Waseem Qasim1,8
Cells therapies, engineered to secrete replacement proteins, are being developed to ameliorate otherwise
debilitating diseases. Recessive dystrophic epidermolysis bullosa (RDEB) is caused by defects of type VII
collagen, a protein essential for anchoring fibril formation at the dermal-epidermal junction. Whereas allo-
geneic fibroblasts injected directly into the dermis can mediate transient disease modulation, autologous gene-
modified fibroblasts should evade immunological rejection and support sustained delivery of type VII collagen
at the dermal-epidermal junction. We demonstrate the feasibility of such an approach using a therapeutic
grade, self-inactivating-lentiviral vector, encoding codon-optimized COL7A1, to transduce RDEB fibroblasts
under conditions suitable for clinical application. Expression and secretion of type VII collagen was confirmed
with transduced cells exhibiting supranormal levels of protein expression, and ex vivo migration of fibroblasts
was restored in functional assays. Gene-modified RDEB fibroblasts also deposited type VII collagen at the
dermal-epidermal junction of human RDEB skin xenografts placed on NOD-scid IL2Rgammanull recipients, with
reconstruction of human epidermal structure and regeneration of anchoring fibrils at the dermal-epidermal
junction. Fibroblast-mediated restoration of protein and structural defects in this RDEB model strongly sup-
ports proposed therapeutic applications in man.
Journal of Investigative Dermatology (2016) 136, 284-292; doi:10.1038/JID.2015.364
INTRODUCTION
Recessive dystrophic epidermolysis bullosa (RDEB) is a
debilitating genodermatosis caused by loss-of-function mu-
tations in COL7A1 (Fine et al., 2014). Type VII collagen (C7)
is essential for anchoring fibril (AF) formation at the dermal-
epidermal junction (DEJ), and in RDEB, malformed,
reduced, or absent AFs are a direct consequence of COL7A1
mutations (Hovnanian et al., 1997). C7 is one of the main
contributors of dermal-epidermal adhesion, forming “wheat-
stack”-shaped, centrosymmetrically banded, semicircular
loop structures known as AFs after antiparallel dimerization
of two fibrils at their carboxyl (C)-termini (Burgeson et al.,
1990). These can be seen extending from their amino (N)-
termini that indirectly bind to hemidesmosomal a6b4 integ-
rin via the bridging activity of laminin-332 in the lamina
densa (Rousselle et al., 1997), where they protrude down to
the papillary dermis encircling dermal type I and III collagen
amongst other fibrous elements before terminating back in
the lamina densa (Shimizu et al., 1997). Loss-of-function
mutations in C7 lead to fragility of AF structures, thereby
compromising the integrity of the DEJ resulting in severe
sublamina densa blistering and tissue cleavage.
Clinically, skin blistering can follow even minor mechan-
ical stress causing skin erosions from birth in many subtypes
of RDEB. Moreover, chronic erosions with secondary in-
fections that can progress to widespread, mutilating scars and
joint contractures, and aggressive squamous cell carcinomas,
typify the severe generalized forms of RDEB (Fine and
Mellerio, 2009; Rodeck and Uitto, 2007). RDEB has a pro-
found medical and socioeconomic impact on patients and
their families (Tabolli et al., 2009). There are no curative
therapies for RDEB, and supportive care, with daily dressings,
meticulous wound care, nutritional support, and iron sup-
plementation for chronic anemia are the mainstay of clinical
management (Grocott et al., 2013; Mellerio et al., 2007).
Experimental therapies under development include re-
combinant C7 protein (Remington et al., 2008; Woodley
et al., 2004, 2013), infusion of allogeneic mesenchymal
cells (Conget et al., 2010), hematopoieticestem cell trans-
plantation (Tolar and Wagner, 2012; Wagner et al., 2010),
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and gene therapies (Droz-Georget Lathion et al., 2015;
Osborn et al., 2013; Sebastiano et al., 2014; Titeux et al.,
2010). We have investigated the feasibility of ex vivo gene-
modified cell-based delivery of C7 to restore AFs at the DEJ
of affected skin. Although both keratinocytes and fibroblasts
are involved in the production and secretion of C7, fibro-
blasts are generally more robust and easier to maintain in
culture, making them an attractive target for such an
approach (Goto et al., 2006). In addition, alternative ap-
proaches based on transduction of keratinocytes and pro-
duction of engineered skin grafts may not be suitable for
RDEB where the abnormal DEJ may compromise adhesion of
engineered epidermal sheets. In previous studies, intradermal
injections of allogeneic fibroblasts from healthy donors sup-
ported increased levels of COL7A1 expression in patients
with RDEB for several months (Nagy et al., 2011; Wong et al.,
2008). However, a recent phase II double-blind randomized
trial demonstrated the importance of intradermal control in-
jections. These comprised placebo (vehicle only) reagents
and resulted in similar levels of wound healing as with mis-
matched allogeneic fibroblasts (Venugopal et al., 2013). A
significant difference between injection of vehicle and allo-
geneic fibroblasts was only noted at day 7 (of 28 days) in a
separate trial (Petrof et al., 2013). Although the mechanism is
unclear, a localized anti-inflammatory effect and upregula-
tion of COL7A1 from intradermal inoculation of the vehicle
solution or injection needle itself (commonly used in scar
remodeling) has been postulated (Nagy et al., 2011; Petrof
et al., 2013; Venugopal et al., 2013). Irrespective of the
mechanism, a major limitation of allogeneic injections is the
immunological rejection of HLA-mismatched donor fibro-
blasts (Larcher and Del Rı´o, 2015; Venugopal et al., 2013;
Wong et al., 2008). An autologous approach using geneti-
cally modified RDEB fibroblasts should circumvent the risk of
rejection and provide a source of locally synthesized C7.
Previous reports have established the feasibility of modifying
fibroblasts with a variety of vectors, including phage (Ortiz-
Urda et al., 2003), gamma retrovirus (Goto et al., 2006;
Titeux et al., 2010; Woodley et al., 2007), and lentivirus
(Chen et al., 2002; Woodley et al., 2003), and local or sys-
temic injection into recipient mice has provided varying
degrees of evidence of restoration of skin integrity (Woodley
et al., 2004, 2007). We have developed a self-inactivating-
lentiviral (LV) platform combined with a human phospho-
glycerate kinase promoter and codon-optimized COL7A1 for
the engineering of autologous RDEB fibroblasts and have
shown definitive evidence of AF reconstruction at the DEJ in a
human:murine xenograft model. The production and valida-
tion of good-manufacturing-practice compliant reagents and
a robust process for manufacturing engineered fibroblasts
have enabled the submission of applications for regulatory
approval for first-in-man testing of this therapy.
RESULTS
Restoration of C7 expression in LV-COL7A1-transduced
RDEB primary fibroblasts
Primary fibroblasts from patients with RDEB lacking C7
expression were transduced with a third-generation
self-inactivating-LV vector encoding codon-optimized C7
(LV-COL7) under current good-manufacturing-practice
compliant conditions using a single round of exposure at a
multiplicity of infection 5 (Figure 1a). After 3 weeks of culture
and expansion, flow cytometric analysis showed 9.3e12.8%
of fibroblasts expressing C7 (Figure 1bed), and this
Figure 1. Expression of C7 in gene-corrected RDEB fibroblasts using a SIN-
LV-COL7A1 vector. (a) Configuration of pCCL-PGK-COL7A1 lentiviral
transfer plasmid shows a third-generation, split-packaging SIN vector with the
deleted U3 region of the 30LTR, internal PGK promoter, mutated woodchuck
hepatitis virus posttranscriptional regulatory element (WPRE), and central
polypurine tract (cPPT). Transgene COL7A1 was codon-optimized (co-
COL7A1) encoding the full-length COL7A1 sequence. (b, c) Average
expression of C7 in LV-COL7-transduced and untransduced (UT) primary
RDEB-1 and -2 fibroblasts by intracellular staining and flow cytometry with
corresponding mean fluorescence intensity (MFI) (d). (e) In situ expression of
C7 in RDEB-1 and -2 LV-COL7 fibroblasts using in-cell Western blotting
(ICWB). Green lanes represent C7 expression; red lanes represent loading
control (b-actin) expression with average immunoreactivity (f). LTR, long
terminal repeat; LV, lentiviral; PGK, phosphoglycerate kinase; RDEB,
recessive dystrophic epidermolysis bullosa; SD , standard deviation; SIN, self-
inactivating. Error bars represent SD of four replicates.
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corresponded to an integrated proviral copy number of
0.12e0.14 copies/cell. In-cell Western blotting showed
overexpression of C7 in transduced RDEB fibroblasts
compared with untransduced and wild-type (WT) fibroblasts
as measured by mean fluorescence intensity (Figure 1e and f).
In situ cytostaining also detected C7 protein expression in
transduced RDEB fibroblasts (Figure 2a), whereas there was
no expression in untransduced RDEB fibroblasts. These re-
sults were further confirmed by Western blot analysis using a
purified C7 antibody (a gift from Professor Mei Chen). Cell
lysates from transduced RDEB fibroblasts revealed the
expression of an approximately 290 kDa protein band cor-
responding to full-length C7 (Figure 2b) and expression was
stable when reassessed after 8 weeks. Full-length protein was
also detected in media harvested from cultured transduced
RDEB fibroblasts (Figure 2c) indicating effective secretion of
the recombinant protein. In view of previous reports that
around a quarter of gamma retroviral vector integrants,
particularly in keratinocytes, may encode truncated forms of
the COL7A1 transgene, we screened cultures for aberrant
protein forms, and found that only 3 of 49 single-cell clonal
populations expressed abnormally sized protein. This greatly
reduced frequency was attributed to our codon optimization
of the transgene, with residual low-level recombination
events during reverse transcription linked to a small number
of persisting repeat sequences.
Functional recovery in LV-COL7-transduced RDEB
fibroblasts
LV-COL7-transduced fibroblasts were assessed for viability
and metabolic activity using a water-soluble tetrazolium salt-
1 assay, with no differences observed compared with non-
corrected RDEB fibroblasts (Supplementary Figure S1 online).
In migration assays, the loss of C7 in RDEB cells has been
previously correlated with adverse functional effects on the
kinetics of wound closure compared with WT cells. Reports
have separately described both increased or decreased
migration associated with loss of C7, but with normalization
to WT levels after the reconstitution of C7 expression (Chen
et al., 2002; Martins et al., 2009; Nystrom et al., 2013).
Functional recovery in transduced RDEB fibroblasts was
examined by using a two-dimensional assay of fibroblast
migration across “wounds” created by cell-seeding stoppers
(Syed et al., 2013). RDEB fibroblasts had reduced (P < 0.05)
migration compared with WT fibroblasts, which was restored
by transduction with LV-COL7 (Figure 3a). The number of
cells within the 2 mm migration zone was analyzed using
ImageJ and revealed a significant increase in transduced
compared with nontransduced RDEB fibroblasts (P < 0.01),
with numbers similar to healthy donor fibroblasts (P > 0.05)
(Figure 3b).
Morphological correction of the DEJ in an RDEB
human:murine skin graft model
To determine whether secreted C7 produced from LV-COL7-
transduced fibroblasts can contribute toward the deposition
and incorporation of C7 into the DEJ in vivo, a modified
human:murine xenograft skin model was developed using
previously described procedures (Di et al., 2011, 2012;
Larcher et al., 2007). Primary RDEB fibroblasts were trans-
duced with LV-COL7 and seeded in a supporting fibrin matrix
composed of porcine plasma and human thrombin on which
primary keratinocytes were further seeded, generating a bio-
engineered skin graft. Control grafts carrying combinations of
primary healthy or untransduced RDEB keratinocytes and
fibroblasts were prepared alongside under the same condi-
tions. The bioengineered skin grafts were grafted onNOD-scid
IL2Rgammanull mice in duplicate for each condition and
allowed to mature over a period of 8 weeks. This provided an
opportunity to monitor two full cycles of human keratinocyte
and fibroblast development in vivo. At that point the grafts
were harvested and processed for cryosectioning and trans-
mission electron microscopy (TEM). Hematoxylin and eosin
staining showed distinct and fully differentiated human
epidermis with visible stratification and formation of a thick
cornified layer that was readily distinguishable from murine
tissue (Figure 4aec and Supplementary Figure S2aec online).
The human derivation of the grafted area was confirmed by
species-specific staining for human C7 and mitochondrial
markers (complex IV subunit II) and showed clearly demar-
cated human:murine borders (Figure 4def and gei). Human-
specific staining for desmoglein further verified the human
origin of the graft (Supplementary Figure S2dee online).
Epidermal proliferation and differentiation was confirmed by
staining of keratin 10 and involucrin in suprabasal layers and
the upper epidermal strata of terminally differentiated kerati-
nocytes, respectively (Figure 4jel and meo). Taken together,
these data support the adoption of a NOD-scid IL2Rgammanull
xenograft model for the reconstruction of human epidermal
structures pertinent to human RDEB modeling. Severe
blistering was observed in the RDEB grafts derived from
untransduced fibroblasts in combination with untransduced
keratinocytes and closely resembled the human disease
phenotype (Figure 4b). Tissue cleavage at the junction be-
tween basal keratinocytes and the underlying dermis resulted
in blister formation and epidermal sloughing uponmechanical
stress. On the contrary, there was no blistering observed using
the healthy donor fibroblast in combination with healthy
donor keratinocytes (Figure 4a). Importantly, in grafts
comprising vector-transduced RDEB fibroblasts with untrans-
duced keratinocytes, there was also no indication of blister
formation, consistent with restoration of theDEJ (Figure 4c and
Supplementary Figure S2aec) and supported by the detection
of C7 expression. Robust expression of human-specific C7was
seen only in grafts incorporating transduced fibroblasts, with
the deposition of the protein throughout the DEJ at levels
comparable with healthy donor grafts (Figure 5a and c). C7
expression could also be detected in fibroblasts in the dermis
by punctate staining in corrected RDEB grafts and healthy
donor grafts, but not in untransduced RDEB cell combinations
(Figure 5aec). Collectively, these data provide compelling
evidence that human C7 expression can be restored in vivo at
the DEJ by RDEB fibroblasts transduced with LV-COL7.
LV-COL7-mediated restoration of AFs at the DEJ of RDEB
skin grafts
To evaluate whether the C7 expression confirmed in grafts
incorporating LV-COL7-transduced RDEB fibroblasts
extended to the formation of AFs, ultrathin sections of each
graft were imaged by TEM. The micrographs revealed an
abundance sublamina densa fibrillary structures that bore the
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ultrastructural characteristics of normal AFs. These appeared
similar to the AFs seen in healthy donor control grafts,
exhibiting cross-banding and extending approximately 200
nm into the dermis, looping around type I and III dermal
collagen fibers (Figure 5d, h and f, i). The morphological
features of hemidesmosomes, subbasal dense plates, and
anchoring filaments also resembled control skin. In addition,
there was an abundance of plasmalemmal vesicles within the
finger-like protrusions of the basal keratinocytes in close
proximity to the basement membrane zone. In both control
and transduced grafts, there was no blistering or tissue
cleavage at the DEJ and a robust lamina densa throughout,
consistent with the functional correction of the DEJ with
restoration of dermal-epidermal adhesion by AFs (Figure 5d,
h and f, i). In contrast, the nonmodified RDEB grafts had a
blistering phenotype and an extensive splitting of sublamina
densa leading to complete separation of the epidermis from
the underlying dermis (Figure 5e and h). Moreover, the
hemidesmosomes were reduced in number, smaller and, in
some cases, internalized. There were no clearly discernible
AFs at the DEJ, in keeping with an absence of C7 by immu-
nofluorescent staining (Figure 5b). Overall, the data suggest
that C7 secreted by a modest proportion of engineered fi-
broblasts is sufficient for the generation of robust AFs and the
amelioration of blistering at the DEJ.
DISCUSSION
RDEB is a serious, painful, and disabling condition with
limited therapeutic options. Based on recent experience with
allogeneic fibroblasts (Wong et al., 2008), there is a strong
rationale to develop a therapy for RDEB using autologous
gene-engineered fibroblasts. Wong et al. reported allogeneic
fibroblast cell therapy for RDEB-supported twofold increases
in C7 immunostaining at the sites injected with donor fibro-
blasts, although it has been postulated that autocrine effects
exerted on recipient keratinocytes by inflammation-induced
heparin-binding EGF may also indirectly lead to increased
Figure 2. Restoration of full-length
C7 protein expression in RDEB
fibroblasts. (a) In situ
immunocytochemistry for type VII
collagen expression (C7) (red) and
nuclear stain 4’.6-diamidino-2-
phenylindole (blue) of either healthy
primary (WT) or RDEB-1 and -2
patient untransduced (UT) or LV-COL7
fibroblasts. C7 expression restored
after LV-COL7 transduction at MOI 5.
Bar ¼ 25 mm. (b) RDEB-1 and -2
fibroblast pellets were lysed before
assessment by SDS-PAGE. Restoration
of full-length C7 expression visualized
at 290 kDa in LV-COL7 and WT
fibroblasts. The complete absence of
C7 expression was seen in both RDEB-
1 and -2 UT samples. Vinculin
represents internal loading control. (c)
Culture supernatant from WT, RDEB-2
UT, and LV-COL7 fibroblasts showing
secreted C7 protein at 290 kDa after
lentiviral transduction. Ponceau S
used as internal loading control. LV,
lentiviral; MOI, multiplicity of
infection; RDEB, recessive dystrophic
epidermolysis bullosa; UT,
untransduced; WT, wild-type.
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synthesis and secretion of endogenous C7 (Nagy et al., 2011;
Wong et al., 2008). An unexpected indirect upregulation of
COL7A1was also found after intradermal injection of placebo
suspension solution alone (Nagy et al., 2011; Venugopal et al.,
2010), with further confirmation in a randomized clinical trial
(Venugopal et al., 2010), although the precise mechanism
remains unclear. In any case, such a therapy has potential
advantages over gene-modified epidermal graft approaches in
RDEB (Siprashvili et al., 2010), where there is concern that
grafts may fail because of the nature of the DEJ defects.
Localized injections of engineered fibroblasts could be used to
treat troublesome blistering lesions, and systemic delivery
may deliver more generalized benefit. The demonstration of
safety of vector-modified cells in a localized setting would
provide valuable data for subsequent systemic therapies using
the same vector platform.
Whereas allogeneic fibroblasts mediated only transient
benefits and were rejected over a matter of weeks, engi-
neered autologous cells should provide longer lasting effects.
This may be partly mediated through local effects triggered by
the intradermal injections, but more importantly by the
secretion of recombinant C7 produced in situ by a subpop-
ulation of transduced cells. Effective fibroblast transduction
has previously been reported using a variety of methods
(Chen et al., 2002; Ortiz-Urda et al., 2003; Woodley et al.,
2003) with a g-retroviral delivery developed with clinical
applications in mind, but troubled by low vector titer and
high frequency of abnormal, shortened collagen forms (Titeux
et al., 2010). Our LV platform was developed with clinical
applications in mind and includes a human phosphoglyc-
erate kinase internal promoter and co-COL7A1 transgene
with eliminated cryptic splice sites. All reagents, including
sera and enzymes, were sourced for their certificates of
analysis and transmissible spongiform encephalopathie
compliance. Vector titer was modest, reflecting the large
cargo size, and we found a greatly reduced frequency of
truncated, or variant, C7 forms arising because of recombi-
nation events during reverse transcription. Our data indicate
that ex vivo gene transfer to a modest number of fibroblasts
using this vector results in high levels of C7 expression at the
DEJ. The vector supports supranormal levels of protein
expression in transduced cells, as indicated by the high in-
tensities of C7 detected by Western blot, in-cell assays and
flow cytometry. Critically, the reconstitution of C7 at the DEJ
supported the regeneration of ultrastructural features
including AFs.
We found that the NOD-scid IL2Rgammanull immunode-
ficient mouse strain was amenable to human skin grafting
without the need for irradiation or additional immunosup-
pression. These animals are devoid of T, B, and NK cells with
additional defects of innate immunity and, thus, unable to
mount effective rejection of human xenografts. Previous
studies of human skin grafting (Di et al., 2011; Larcher et al.,
2007) adopted the Foxn1nu nude mouse strain, which is
athymic and deficient of T cells but can retain NK and other
aspects of the immune repertoire. Importantly, the grafts
recovered from our model had clearly demarcated human:-
murine junctional boundaries, and characteristic epidermal
structural features of healthy or RDEB skin, including a pre-
disposition for epidermal detachment and blistering.
Our experiments used ex vivo transduction and graft
preparation and were specifically designed to circumvent the
triggering of localized paracrine effects that may be induced
by injection into the epidermis. Whereas previous reports
suggested that residual or baseline expression of C7 by ker-
atinocytes may be necessary to secure a therapeutic effect
(Kern et al., 2009; Wagner et al., 2010; Wong et al., 2008),
we found that the restoration of C7 expression at the DEJ and
AF formation was mediated by transduced fibroblasts even in
combination with non-C7-expressing keratinocytes. This
translated to eradication of subepidermal cleavage seen in
noncorrected grafts.
With regard to future clinical translation, we have
completed the production and release of a clinical batch of
LV-COL7 and demonstrated engineering of human RDEB fi-
broblasts under good-manufacturing-practice conditions. UK
regulatory and ethics committee approval has recently been
secured for a first-in-man study, designed in the first instance
as a single-arm, open-label study to confirm the feasibility
and safety of an approach using the localized intradermal
injection of fibroblasts. If successful, comparison against
control injections will follow and further systemic therapies
Figure 3. Human RDEB fibroblasts
corrected for C7 showed improved
migration and “wound” closure
in vitro. (a) Representative
micrographs of RDEB-1 fibroblasts
corrected for C7 from three
independent experiments show the
migration pattern in a 2 mm migration
zone at 30 hours (T ¼ 30). (b) Bar
graph showing normalization of
migration of C7 corrected primary
RDEB-1 fibroblasts toward WT values
compared with uncorrected (UT)
primary RDEB fibroblasts at 30 hours.
Statistical analysis carried out using
Student’s t-test. C7, type VII collagen;
RDEB, recessive dystrophic
epidermolysis bullosa; SD, standard
deviation; WT, wild-type. Error bars
represent SD of four replicates.
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Figure 4. Visualization of human origin and epidermal cytoarchitecture of bioengineered skin sheets generated on NOD-scid IL2Rgammanull mice. (aec) H&E
staining of WT, RDEB-2 untransduced (UT), or LV-COL7 fibroblast (FB) graft combination seeded with WT or RDEB-2 UT patient keratinocytes (KC). Blistering
seen in RDEB-2 UT combination (stars). Bar ¼ 50 mm. Human-specific anti-C7 antibody showing expression in healthy and LV-COL7 grafts (d, f) but not in
untreated RDEB grafts (e). Bar ¼ 50 mm. (gei) Human-specific mitochondrial marker identifies the human:mouse junction: the border between mouse (ms) and
bioengineered human (hu) skin (dotted line). Bar ¼ 25 mm. Involucrin staining reveals cornification (jel); keratin 10 shows a later stage of KC differentiation
(meo). Epidermal-dermal tissue cleavage in RDEB-2 patient UT combination (dotted lines). C7, type VII collagen; H&E, hematoxylin and eosin; LV, lentiviral;
RDEB, recessive dystrophic epidermolysis bullosa; WT, wild-type. Bar ¼ 25 mm.
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will be envisaged using the same vector platform for the
treatment of RDEB and other debilitating skin diseases.
MATERIALS AND METHODS
RDEB skin biopsies and isolation and propagation of primary
fibroblasts
A 6-mm RDEB skin biopsy was obtained with authorization from the
National Research Ethics Services, Westminster (07/H0802/104),
and with written informed consent from patients with RDEB-1 ((þ/e)
c.1732C>T p.R578X)/(þ/e) c.2710þ2T>C IVS20þ2T.C) and RDEB-
2 ((þ/þ) c.425A>G p.K142R). Excess connective tissue was removed
using a sterile blade and the sample was incubated in neutral pro-
tease NB (1 unit/ml; SERVA Electrophoresis, Heidelberg, Germany)
at 37 C for 3 hours until the epidermis peeled off. The remaining
dermis was fragmented and treated with collagenase NB6 (0.45
units/ml; SERVA Electrophoresis). The resulting cell suspension was
seeded into a T25 flask and cultured at 37 C in a 5% CO2 incubator.
Production of third-generation COL7A1-expressing-LV
vectors with human phosphoglycerate kinase promoter
pCCL is a self-inactivating-LV vector (Figure 1a) derived from HIV-1
as described previously (Dull et al., 1998). Self-inactivation was
achieved through a 400 bp deletion in the 30HIV-1 long terminal
repeat and a 516 bp promoter sequence from human internal
phosphoglycerate kinase promoter was included as an internal
promoter (Ginn et al., 2010; Huston et al., 2011). A mutated
woodchuck hepatitis virus posttranscriptional regulatory element
sequence devoid of the hepadnaviral-X protein open reading frame
(WPREmut6) was cloned (Marangoni et al., 2009) downstream of a
full-length codon-optimized COL7A1 transgene (Geneart, Regens-
burg, Germany). The vector was pseudotyped with vesicular sto-
matitis virus glycoprotein using a split packaging system and
concentrated by ultracentrifugation. High-grade plasmids were
produced, characterized, and released (PlasmidFactory, Bielefeld,
Germany) for the production of good-manufacturing-practice vector
stocks.
Figure 5. In vivo functional correction through LV-COL7-mediated restoration of type VII collagen anchoring fibrils (AFs). C7 overexpression over WT (a)
visible in LV-COL7 RDEB-2 fibroblast (FB) containing graft (c), no protein deposition seen in untransduced (UT) graft (b). Bar ¼ 25 mm. TEM micrographs of WT
(d), RDEB-2 patient UT (e), and LV-COL7 (f) grafts. Bar ¼ 5 mm. (g) WT human keratinocyte (KC) and/or FB combination showing thick, cross-banded AFs
(arrows). (h) Loss of AFs causes extensive tissue cleavage at the dermal-epidermal junction (DEJ) of UT RDEB-2 KC and/or FB combination with lamina densa
(LD) reduplication. (i) UT RDEB-2 KC and/or LV-COL7 FB combination reveals restoration of dermal-epidermal adhesion. C, collagen type I and III; C7, type VII
collagen; HD, hemidesmosome; KF, keratin filament; LL, lamina lucida; LV, lentiviral; PV, plasmalemmal vesicle; RDEB, recessive dystrophic epidermolysis
bullosa; TEM, transmission electron microscopy; WT, wild-type. Bar ¼ 300 nm.
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Vector titer
The titer of concentrated LV-COL7 virus was determined by exposing
293 T cells with serial dilutions of concentrated LV-COL7. Three
days after transduction, cells were harvested and copies of HIV Psi
packaging element (J) were determined by quantitative polymerase
chain reaction. Proviral integrant copy number per transduced cell
was determined after normalization of J with housekeeping gene
albumin accounting for two albumin alleles per cell. Qualified
plasmid standards encodingJ and human albumin sequences were
used.
Bioengineered skin preparation and grafting on
immunodeficient mice
The methods for preparing and grafting bioengineered skin on
immunodeficient nude mice have been described previously
(Larcher et al., 2007). Our approach was similar, except the recip-
ient strain was NOD-scid IL2Rgammanull. In brief, fibrinogen solu-
tion (cryoprecipitate derived from a porcine plasma source)
containing 1.5 106 WT, RDEB-2 patient ((þ/þ) c.425A>G,
p.K142R) or RDEB-2 LV-COL7-transduced human dermal fibro-
blasts was combined with 0.025 mmol/l CaCl2 (Sigma-Aldrich,
Gillingham, UK) and 11 IU of bovine thrombin (Sigma-Aldrich). The
mixture was poured in two 35-mm wells and allowed to solidify at
37 C for 1 hour. WT or RDEB patient human keratinocytes (1.2 
106 cells per well) were then seeded on the fibrin matrix to form the
epidermal layer of the bioengineered skin. When confluent (3 days),
bioengineered skins were manually detached from tissue culture
wells and grafted onto immunodeficient mice. All animal pro-
cedures were performed in accordance with the United Kingdom
Animals Scientific Procedures Act (1986) and associated guidelines.
Grafting was performed under sterile conditions using 6-week-old
female immunodeficient mice (NOD-scid IL2Rgammanull) housed
under protective conditions. In brief, mice were aseptically
cleansed and anesthetized, and full-thickness 35-mm-diameter
circular wounds were then created on the dorsum of the mice.
Bioengineered equivalents were placed orthotopically on the
wound. The mouse skin removed to generate the wound was
devitalized by three repeated cycles of freezing and thawing and
used as a biological bandage and fixed with sutures to protect and
hold the skin substitute in place during the take process. Dead
mouse skin typically sloughed off within 15e20 days after grafting.
Eight weeks after grafting, bioengineered human skins were har-
vested postmortem preserving a surrounding border of mouse
epithelial tissue, snap frozen in LN2, embedded in optimum cutting
temperature (Sakura Finetek, Alphen aan den Rijn, The Netherlands)
and cryosectioned at 7 mm for histological and immunohisto-
chemical examinations. A central portion of the human graft was
placed in TEM fixative for ultrastructural imaging.
Immunostaining of bioengineered grafted tissue
Immunofluorescence staining was performed on frozen graft tissue
sections after 10-min fixation with ice-cold acetone and/or methanol
(7 mm thickness). Sections were blocked for 1 hour at room
temperature (RT) with 3% fetal bovine serum in phosphate buffered
saline before incubation with primary antibodies against hC7 LH7.2
(Sigma-Aldrich) in a 1:500 dilution (Supplementary Table S1 online),
desmoglein-1 (Fitzerald Industries, Acton, MA), involucrin (Sigma-
Aldrich), keratin 10 (in-house), complex IV subunit II MTCO2
(Abcam, Cambridge, UK) overnight at 4 C. Secondary antibody
incubation with Alexa Fluor goat antimouse 488 (Invitrogen, Paisley,
UK), goat antirabbit Cy3 (Life Technologies, Paisley, UK), and strep
488 was followed for 1 hour at RT. Sections were stained with 4’.6-
diamidino-2-phenylindole (5 mg/ml) and mounted using a ProLong
Gold antifade agent (Life Technologies). These were also stained by a
hematoxylin and eosin histochemical technique. Staining was
visualized and imaged using a Leica DMLB upright microscope
(Leica Microsystems CMS, Wetzlar, Germany) and a Zeiss Axiophot
2 (Zeiss, Oberkochen, Germany) and processed using Image-Pro 6.2
(MediaCybernetics, Rockville, MD). Confocal imaging was carried
out on a Zeiss LSM 510 Meta laser confocal microscope (Zeiss).
Postprocessing was carried out using ImageJ.
Preparation of skin grafts for TEM
For TEM, the central piece (approximately 3  3 mm2) of each skin
graft was dissected out and fixed with half strength Karnovsky’s
fixative (2% [v/v] paraformaldehyde, 2.5% [v/v] glutaraldehyde in
0.1 M phosphate buffer [pH 7.4]) for 3e5 hours at RT and kept at 4
C until further processing. After the initial fixation, tissue samples
were rinsed several times in phosphate buffer and postfixed with
1.3% osmium tetroxide in double distilled water for 2 hours at RT.
Samples were then washed, en bloc stained with 2% uranyl acetate
in 50% ethanol and dehydrated in a graded series of ethanols. Tissue
samples were further equilibrated with propylene oxide before
infiltration with TAAB epoxy resin, embedded, and polymerized at
70 C for 24 hours. Ultrathin sections (70e90 nm) were prepared
using a Reichert-Jung Ultracut E ultramicrotome (Eeichert-Jung,
Vienna, Austria), mounted on 150 mesh copper grids (Gilder,
Grantham, UK), contrasted using uranyl acetate and lead citrate and
examined on a FEI Tecnai 12 (FEI, Hillsboro, OR) transmission mi-
croscope operated at 120 kV. Images were acquired with an AMT
16000M camera (Advanced Microscopy Techniques, Woburn, MA).
Morphological examination and AF scoring of the TEM slides was
blinded and performed by an ultrastructural microscopy specialist.
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